{"PMC7305873": [], "a7a8c52bf8524ed9b1a7178a2a630cce32ccf4e7": [["Porcine deltacoronavirus (PDCoV) causes an enteric disease in pigs that is characterized by diarrhea and is clinically similar to porcine epidemic diarrhea (PED) and transmissible gastroenteritis (TGE) [4] .", [["PDCoV", "CHEMICAL", 26, 31], ["enteric disease", "DISEASE", 43, 58], ["diarrhea", "DISEASE", 92, 100], ["porcine epidemic diarrhea", "DISEASE", 130, 155], ["PED", "DISEASE", 157, 160], ["transmissible gastroenteritis", "DISEASE", 166, 195], ["TGE", "DISEASE", 197, 200], ["Porcine deltacoronavirus", "ORGANISM", 0, 24], ["PDCoV", "GENE_OR_GENE_PRODUCT", 26, 31], ["pigs", "ORGANISM", 62, 66], ["Porcine", "SPECIES", 0, 7], ["pigs", "SPECIES", 62, 66], ["porcine", "SPECIES", 130, 137], ["Porcine deltacoronavirus", "SPECIES", 0, 24], ["PDCoV", "SPECIES", 26, 31], ["pigs", "SPECIES", 62, 66], ["Porcine deltacoronavirus (PDCoV", "TREATMENT", 0, 31], ["an enteric disease in pigs", "PROBLEM", 40, 66], ["diarrhea", "PROBLEM", 92, 100], ["porcine epidemic diarrhea", "PROBLEM", 130, 155], ["transmissible gastroenteritis (TGE)", "PROBLEM", 166, 201], ["enteric disease", "OBSERVATION", 43, 58], ["diarrhea", "OBSERVATION", 92, 100], ["gastroenteritis", "OBSERVATION", 180, 195]]], ["PDCoV, a recently emerged RNA virus of the family Coronaviridae, genus", [["PDCoV", "CHEMICAL", 0, 5], ["PDCoV", "GENE_OR_GENE_PRODUCT", 0, 5], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 50, 63]]]], "PMC7112546": [["IntroductionTurkey coronavirus (TCoV), a member of the family Coronaviridae in the order Nidovirale, causes atrophic enteritis in infected turkeys leading to poor feed conversion, uneven body weight gain, and significant economic loss in the turkey industry in the United States (Lin et al., 2002), Canada (Dea et al., 1986, Gomaa et al., 2009), Europe (Cavanagh et al., 2001, Maurel et al., 2011), and Brazil (Teixeira et al., 2007).", [["body", "ANATOMY", 187, 191], ["atrophic enteritis", "DISEASE", 108, 126], ["weight gain", "DISEASE", 192, 203], ["IntroductionTurkey coronavirus", "ORGANISM", 0, 30], ["TCoV", "ORGANISM", 32, 36], ["turkeys", "ORGANISM", 139, 146], ["body", "ORGANISM_SUBDIVISION", 187, 191], ["coronavirus", "SPECIES", 19, 30], ["turkeys", "SPECIES", 139, 146], ["turkey", "SPECIES", 242, 248], ["IntroductionTurkey coronavirus", "SPECIES", 0, 30], ["TCoV", "SPECIES", 32, 36], ["turkeys", "SPECIES", 139, 146], ["turkey", "SPECIES", 242, 248], ["Coronaviridae", "TREATMENT", 62, 75], ["Nidovirale", "TREATMENT", 89, 99], ["atrophic enteritis", "PROBLEM", 108, 126], ["poor feed conversion", "PROBLEM", 158, 178], ["uneven body weight gain", "PROBLEM", 180, 203], ["significant economic loss", "PROBLEM", 209, 234], ["atrophic", "OBSERVATION_MODIFIER", 108, 116], ["enteritis", "OBSERVATION", 117, 126], ["infected turkeys", "OBSERVATION", 130, 146], ["significant", "OBSERVATION_MODIFIER", 209, 220], ["economic", "OBSERVATION_MODIFIER", 221, 229], ["loss", "OBSERVATION", 230, 234]]], ["Clinical signs of TCoV infection include watery diarrhea, depression, ruffled feathers, and decreased consumption of food and water.", [["TCoV infection", "DISEASE", 18, 32], ["watery diarrhea", "DISEASE", 41, 56], ["depression", "DISEASE", 58, 68], ["TCoV", "SPECIES", 18, 22], ["TCoV infection", "PROBLEM", 18, 32], ["watery diarrhea", "PROBLEM", 41, 56], ["depression", "PROBLEM", 58, 68], ["ruffled feathers", "PROBLEM", 70, 86], ["TCoV", "OBSERVATION_MODIFIER", 18, 22], ["infection", "OBSERVATION", 23, 32], ["watery", "OBSERVATION_MODIFIER", 41, 47], ["diarrhea", "OBSERVATION", 48, 56], ["depression", "OBSERVATION", 58, 68], ["ruffled feathers", "OBSERVATION", 70, 86], ["decreased", "OBSERVATION_MODIFIER", 92, 101]]], ["Distended intestines with gaseous and watery contents are the most striking gross lesions.", [["intestines", "ANATOMY", 10, 20], ["gross lesions", "ANATOMY", 76, 89], ["intestines", "ORGAN", 10, 20], ["watery", "ORGANISM_SUBDIVISION", 38, 44], ["gross lesions", "PATHOLOGICAL_FORMATION", 76, 89], ["Distended intestines", "PROBLEM", 0, 20], ["gaseous and watery contents", "PROBLEM", 26, 53], ["the most striking gross lesions", "PROBLEM", 58, 89], ["intestines", "ANATOMY", 10, 20], ["gaseous", "OBSERVATION_MODIFIER", 26, 33], ["watery contents", "OBSERVATION", 38, 53], ["most striking", "OBSERVATION_MODIFIER", 62, 75], ["gross", "OBSERVATION_MODIFIER", 76, 81], ["lesions", "OBSERVATION", 82, 89]]], ["The major histopathological changes are blunted villi, increased crypt depth, and increased width between villi (Guy, 2003, Gomaa et al., 2009).", [["villi", "ANATOMY", 48, 53], ["crypt", "ANATOMY", 65, 70], ["villi", "ANATOMY", 106, 111], ["villi", "MULTI-TISSUE_STRUCTURE", 48, 53], ["crypt depth", "TISSUE", 65, 76], ["villi", "TISSUE", 106, 111], ["blunted villi", "PROBLEM", 40, 53], ["increased crypt depth", "PROBLEM", 55, 76], ["major", "OBSERVATION_MODIFIER", 4, 9], ["histopathological", "OBSERVATION", 10, 27], ["blunted", "OBSERVATION", 40, 47], ["villi", "ANATOMY_MODIFIER", 48, 53], ["increased", "OBSERVATION_MODIFIER", 55, 64], ["crypt", "OBSERVATION_MODIFIER", 65, 70], ["depth", "OBSERVATION_MODIFIER", 71, 76], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["width", "OBSERVATION_MODIFIER", 92, 97], ["villi", "ANATOMY", 106, 111]]], ["Currently, there are no effective vaccines available to control TCoV infection.IntroductionTCoV is an enveloped virus with a liner positive-sense, single-stranded RNA genome with a size of 27 kilobases (Kb).", [["infection", "DISEASE", 69, 78], ["TCoV", "GENE_OR_GENE_PRODUCT", 64, 68], ["liner positive-sense, single-stranded RNA genome", "DNA", 125, 173], ["TCoV", "SPECIES", 64, 68], ["effective vaccines", "TREATMENT", 24, 42], ["TCoV infection", "PROBLEM", 64, 78], ["an enveloped virus", "PROBLEM", 99, 117], ["no", "UNCERTAINTY", 21, 23], ["effective", "OBSERVATION_MODIFIER", 24, 33], ["infection", "OBSERVATION", 69, 78], ["enveloped", "OBSERVATION_MODIFIER", 102, 111], ["virus", "OBSERVATION", 112, 117], ["RNA genome", "OBSERVATION", 163, 173], ["size", "OBSERVATION_MODIFIER", 181, 185], ["27 kilobases", "OBSERVATION_MODIFIER", 189, 201]]], ["Spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins are four major structure proteins of TCoV (Lin et al., 2002, Cao et al., 2008).", [["membrane", "ANATOMY", 25, 33], ["Spike (S)", "GENE_OR_GENE_PRODUCT", 0, 9], ["membrane", "CELLULAR_COMPONENT", 25, 33], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 43, 59], ["TCoV", "GENE_OR_GENE_PRODUCT", 106, 110], ["Spike (S), envelope (E), membrane (M)", "PROTEIN", 0, 37], ["nucleocapsid (N) proteins", "PROTEIN", 43, 68], ["structure proteins", "PROTEIN", 84, 102], ["TCoV", "PROTEIN", 106, 110], ["Spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins", "PROBLEM", 0, 68]]], ["The amino-terminal S1 subunit of S protein forms the globular head of the spike structure on the surface of coronaviruses and contains the receptor binding domain and neutralizing epitopes to determine host tropism and humoral immunity (Godet et al., 1994, Taguchi and Kubo, 1995, He et al., 2004, Ho et al., 2004, Lu et al., 2004, Zhou et al., 2004, Chen et al., 2011).", [["head", "ANATOMY", 62, 66], ["surface", "ANATOMY", 97, 104], ["amino-terminal", "CHEMICAL", 4, 18], ["amino", "CHEMICAL", 4, 9], ["S protein", "GENE_OR_GENE_PRODUCT", 33, 42], ["surface", "CELLULAR_COMPONENT", 97, 104], ["amino-terminal S1 subunit", "PROTEIN", 4, 29], ["S protein", "PROTEIN", 33, 42], ["globular head of the spike structure", "PROTEIN", 53, 89], ["receptor binding domain", "PROTEIN", 139, 162], ["neutralizing epitopes", "PROTEIN", 167, 188], ["The amino-terminal S1 subunit of S protein", "TEST", 0, 42], ["coronaviruses", "PROBLEM", 108, 121], ["the receptor binding domain", "TREATMENT", 135, 162], ["neutralizing epitopes", "TREATMENT", 167, 188], ["globular", "OBSERVATION_MODIFIER", 53, 61], ["head", "ANATOMY", 62, 66], ["spike", "OBSERVATION", 74, 79], ["coronaviruses", "OBSERVATION", 108, 121]]], ["The carboxyl-terminus S2 subunit of S protein constructs the stalk of the spike structure and consists of a transmembrane domain and fusion peptides to induce cell fusion and viral assembly (Spiga et al., 2003, Broer et al., 2006, Howard et al., 2008).", [["transmembrane", "ANATOMY", 108, 121], ["cell", "ANATOMY", 159, 163], ["carboxyl", "CHEMICAL", 4, 12], ["S protein", "GENE_OR_GENE_PRODUCT", 36, 45], ["cell", "CELL", 159, 163], ["carboxyl-terminus S2 subunit", "PROTEIN", 4, 32], ["S protein", "PROTEIN", 36, 45], ["transmembrane domain", "PROTEIN", 108, 128], ["The carboxyl-terminus S2 subunit of S protein", "TREATMENT", 0, 45], ["a transmembrane domain", "TREATMENT", 106, 128], ["fusion peptides", "TREATMENT", 133, 148], ["cell fusion", "TREATMENT", 159, 170], ["cell fusion", "OBSERVATION", 159, 170]]], ["Immunization by coronaviral S protein-based vaccines can produce protective neutralizing antibodies that prevent infection after challenge (Johnson et al., 2003, Zeng et al., 2004, Du et al., 2009, Shil et al., 2011).IntroductionDNA vaccine, a plasmid DNA encoding the protein from the pathogen of interest under the control of a eukaryotic cell promoter has been demonstrated to induce humoral and cellular immune responses (Laddy and Weiner, 2006).", [["plasmid", "ANATOMY", 244, 251], ["cell", "ANATOMY", 341, 345], ["cellular", "ANATOMY", 399, 407], ["infection", "DISEASE", 113, 122], ["DNA", "CELLULAR_COMPONENT", 252, 255], ["cell", "CELL", 341, 345], ["cellular", "CELL", 399, 407], ["coronaviral S protein", "PROTEIN", 16, 37], ["neutralizing antibodies", "PROTEIN", 76, 99], ["plasmid DNA", "DNA", 244, 255], ["eukaryotic cell promoter", "DNA", 330, 354], ["Immunization", "TREATMENT", 0, 12], ["coronaviral S protein-based vaccines", "TREATMENT", 16, 52], ["protective neutralizing antibodies", "TREATMENT", 65, 99], ["infection", "PROBLEM", 113, 122], ["IntroductionDNA vaccine", "TREATMENT", 217, 240], ["a plasmid DNA", "TREATMENT", 242, 255], ["a eukaryotic cell promoter", "TREATMENT", 328, 354], ["infection", "OBSERVATION", 113, 122], ["eukaryotic cell promoter", "OBSERVATION", 330, 354]]], ["Several approaches have been also investigated to improve the low immunogenicity of DNA vaccine (Barouch, 2006), including co-administration of genes encoding the immunostimulatory molecules like IL-2 (Tang et al., 2008), cytosine-phosphate-guanine (CpG) motifs (Kinman et al., 2010), or granulocyte-macrophage stimulating factor (GM-CSF) (Tan et al., 2009) to enhance immune responses.", [["cytosine-phosphate", "CHEMICAL", 222, 240], ["guanine", "CHEMICAL", 241, 248], ["CpG", "CHEMICAL", 250, 253], ["cytosine-phosphate", "CHEMICAL", 222, 240], ["guanine", "CHEMICAL", 241, 248], ["CpG", "CHEMICAL", 250, 253], ["DNA", "CELLULAR_COMPONENT", 84, 87], ["IL-2", "GENE_OR_GENE_PRODUCT", 196, 200], ["cytosine-phosphate-guanine", "SIMPLE_CHEMICAL", 222, 248], ["CpG", "SIMPLE_CHEMICAL", 250, 253], ["granulocyte-macrophage stimulating factor", "GENE_OR_GENE_PRODUCT", 288, 329], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 331, 337], ["immunostimulatory molecules", "PROTEIN", 163, 190], ["IL", "PROTEIN", 196, 198], ["granulocyte-macrophage stimulating factor", "PROTEIN", 288, 329], ["GM", "PROTEIN", 331, 333], ["CSF", "PROTEIN", 334, 337], ["DNA vaccine", "TREATMENT", 84, 95], ["co-administration of genes", "TREATMENT", 123, 149], ["cytosine-phosphate-guanine (CpG)", "TREATMENT", 222, 254], ["granulocyte", "TEST", 288, 299], ["macrophage stimulating factor", "TEST", 300, 329], ["granulocyte", "ANATOMY", 288, 299]]], ["Other approaches to improve immunogenicity of DNA vaccine included targeting DNA toward proper antigen presenting cells like dendritic cells (Kurzler and Weiner, 2004, Nchinda et al., 2008), applying prime-boost strategy by priming with DNA and boosting with a viral vector encoding the antigenic protein (Woo et al., 2005, Wang et al., 2008), and improving DNA delivery by electroporation or incorporation with nanoparticles to increase the amount and stability of DNA inside the transfected cells and thus enhance the protein expression level by transfected DNA (Otten et al., 2005, van Drunen Little-van den Hunk and Hannaman, 2010).IntroductionNanoparticles, made of cationic lipids and polymers, can protect DNA and deliver DNA to target cells.", [["cells", "ANATOMY", 114, 119], ["dendritic cells", "ANATOMY", 125, 140], ["cells", "ANATOMY", 493, 498], ["cells", "ANATOMY", 743, 748], ["DNA", "CELLULAR_COMPONENT", 46, 49], ["DNA", "CELLULAR_COMPONENT", 77, 80], ["cells", "CELL", 114, 119], ["dendritic cells", "CELL", 125, 140], ["Kurzler", "CELL", 142, 149], ["DNA", "CELLULAR_COMPONENT", 237, 240], ["DNA", "CELLULAR_COMPONENT", 358, 361], ["DNA", "CELLULAR_COMPONENT", 466, 469], ["cells", "CELL", 493, 498], ["DNA", "CELLULAR_COMPONENT", 560, 563], ["cationic lipids", "SIMPLE_CHEMICAL", 671, 686], ["DNA", "CELLULAR_COMPONENT", 713, 716], ["DNA", "CELLULAR_COMPONENT", 729, 732], ["cells", "CELL", 743, 748], ["antigen presenting cells", "CELL_TYPE", 95, 119], ["dendritic cells", "CELL_TYPE", 125, 140], ["antigenic protein", "PROTEIN", 287, 304], ["transfected cells", "CELL_LINE", 481, 498], ["target cells", "CELL_TYPE", 736, 748], ["Other approaches", "TREATMENT", 0, 16], ["DNA vaccine", "TREATMENT", 46, 57], ["targeting DNA", "PROBLEM", 67, 80], ["boost strategy", "TREATMENT", 206, 220], ["DNA", "TREATMENT", 237, 240], ["a viral vector", "TREATMENT", 259, 273], ["DNA delivery", "TREATMENT", 358, 370], ["incorporation with nanoparticles", "TREATMENT", 393, 425], ["DNA inside the transfected cells", "PROBLEM", 466, 498], ["IntroductionNanoparticles", "TREATMENT", 636, 661], ["cationic lipids", "TREATMENT", 671, 686], ["polymers", "TREATMENT", 691, 699], ["DNA", "PROBLEM", 713, 716], ["dendritic cells", "OBSERVATION", 125, 140], ["amount", "OBSERVATION_MODIFIER", 442, 448], ["stability", "OBSERVATION_MODIFIER", 453, 462], ["transfected cells", "OBSERVATION", 481, 498]]], ["Polyethyleneimine (PEI) is a widely used polymer and the size of the DNA\u2013PEI complex is suitable for endocytic uptake by non-phagocytic cells (Jeong et al., 2007).", [["endocytic", "ANATOMY", 101, 110], ["non-phagocytic cells", "ANATOMY", 121, 141], ["Polyethyleneimine", "CHEMICAL", 0, 17], ["PEI", "CHEMICAL", 19, 22], ["Polyethyleneimine", "CHEMICAL", 0, 17], ["PEI", "CHEMICAL", 19, 22], ["Polyethyleneimine", "SIMPLE_CHEMICAL", 0, 17], ["PEI", "SIMPLE_CHEMICAL", 19, 22], ["DNA\u2013PEI", "GENE_OR_GENE_PRODUCT", 69, 76], ["cells", "CELL", 136, 141], ["DNA\u2013PEI complex", "PROTEIN", 69, 84], ["non-phagocytic cells", "CELL_TYPE", 121, 141], ["Polyethyleneimine (PEI)", "TREATMENT", 0, 23], ["a widely used polymer", "TREATMENT", 27, 48], ["size", "OBSERVATION_MODIFIER", 57, 61], ["non-phagocytic cells", "OBSERVATION", 121, 141]]], ["Once inside the cells, PEI absorbs proton ions during endosome acidification, leading to osmotic rupture of endosome and DNA release to enter the nucleus of the transfected cells (Boussif et al., 1995).", [["cells", "ANATOMY", 16, 21], ["endosome", "ANATOMY", 54, 62], ["endosome", "ANATOMY", 108, 116], ["nucleus", "ANATOMY", 146, 153], ["cells", "ANATOMY", 173, 178], ["PEI", "CHEMICAL", 23, 26], ["PEI", "CHEMICAL", 23, 26], ["cells", "CELL", 16, 21], ["PEI", "SIMPLE_CHEMICAL", 23, 26], ["proton ions", "SIMPLE_CHEMICAL", 35, 46], ["endosome", "CELLULAR_COMPONENT", 54, 62], ["endosome", "CELLULAR_COMPONENT", 108, 116], ["DNA", "CELLULAR_COMPONENT", 121, 124], ["nucleus", "CELLULAR_COMPONENT", 146, 153], ["cells", "CELL", 173, 178], ["transfected cells", "CELL_LINE", 161, 178], ["PEI absorbs proton ions", "TREATMENT", 23, 46], ["endosome acidification", "PROBLEM", 54, 76], ["osmotic rupture of endosome", "PROBLEM", 89, 116], ["DNA release", "TREATMENT", 121, 132], ["endosome acidification", "OBSERVATION", 54, 76], ["rupture", "OBSERVATION", 97, 104], ["nucleus", "ANATOMY_MODIFIER", 146, 153], ["transfected cells", "OBSERVATION", 161, 178]]], ["The addition of polysaccharide-based polyanions, like hyaluronate (HA) improved the gene transfection efficiency of the DNA\u2013PEI complex by loosening up the complex to access the gene transcription machinery (Ito et al., 2006).", [["hyaluronate", "CHEMICAL", 54, 65], ["HA", "CHEMICAL", 67, 69], ["hyaluronate", "CHEMICAL", 54, 65], ["polysaccharide-based polyanions", "SIMPLE_CHEMICAL", 16, 47], ["hyaluronate", "SIMPLE_CHEMICAL", 54, 65], ["HA", "SIMPLE_CHEMICAL", 67, 69], ["DNA\u2013PEI complex", "GENE_OR_GENE_PRODUCT", 120, 135], ["DNA\u2013PEI complex", "PROTEIN", 120, 135], ["polysaccharide-based polyanions", "TREATMENT", 16, 47], ["hyaluronate (HA", "TREATMENT", 54, 69], ["the DNA\u2013PEI complex", "PROBLEM", 116, 135], ["loosening", "PROBLEM", 139, 148], ["transfection efficiency", "OBSERVATION", 89, 112], ["loosening", "OBSERVATION", 139, 148]]], ["Polycations with disulfide linkages, which could degrade in the reductive intracellular environment and release DNA more easily, achieved higher gene expression than their uncleavable counterparts (Neu et al., 2006).", [["intracellular", "ANATOMY", 74, 87], ["disulfide", "CHEMICAL", 17, 26], ["Polycations", "SIMPLE_CHEMICAL", 0, 11], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 74, 87], ["DNA", "CELLULAR_COMPONENT", 112, 115], ["Polycations with disulfide linkages", "TREATMENT", 0, 35]]], ["By applying the advantages exerted by HA and disulfide linkage, a ternary complex (DPH complex) consisting of DNA, a disulfide-crosslinked low molecular linear polyethyleneimine (CLPEI), and sodium hyaluronate was proved to enhance the transfection efficiency significantly (Xu et al., 2009).IntroductionThe 4F/4R fragment of TCoV S protein encompassing amino acid residue 482\u2013678 has been shown to contain neutralizing epitopes from a previous study (Chen et al., 2011).", [["DPH", "CHEMICAL", 83, 86], ["polyethyleneimine", "CHEMICAL", 160, 177], ["CLPEI", "CHEMICAL", 179, 184], ["sodium hyaluronate", "CHEMICAL", 191, 209], ["amino acid residue 482\u2013678", "CHEMICAL", 354, 380], ["disulfide", "CHEMICAL", 45, 54], ["DPH", "CHEMICAL", 83, 86], ["disulfide", "CHEMICAL", 117, 126], ["polyethyleneimine", "CHEMICAL", 160, 177], ["CLPEI", "CHEMICAL", 179, 184], ["sodium hyaluronate", "CHEMICAL", 191, 209], ["amino acid", "CHEMICAL", 354, 364], ["HA", "SIMPLE_CHEMICAL", 38, 40], ["DPH", "SIMPLE_CHEMICAL", 83, 86], ["DNA", "CELLULAR_COMPONENT", 110, 113], ["polyethyleneimine", "SIMPLE_CHEMICAL", 160, 177], ["CLPEI", "SIMPLE_CHEMICAL", 179, 184], ["sodium hyaluronate", "SIMPLE_CHEMICAL", 191, 209], ["TCoV S", "GENE_OR_GENE_PRODUCT", 326, 332], ["amino acid", "AMINO_ACID", 354, 364], ["residue 482\u2013678", "AMINO_ACID", 365, 380], ["ternary complex", "PROTEIN", 66, 81], ["DPH complex", "PROTEIN", 83, 94], ["4F/4R fragment", "DNA", 308, 322], ["TCoV S protein", "PROTEIN", 326, 340], ["neutralizing epitopes", "PROTEIN", 407, 428], ["a ternary complex (DPH complex", "PROBLEM", 64, 94], ["DNA", "PROBLEM", 110, 113], ["a disulfide-crosslinked low molecular linear polyethyleneimine (CLPEI)", "TREATMENT", 115, 185], ["sodium hyaluronate", "TREATMENT", 191, 209], ["the transfection efficiency", "PROBLEM", 232, 259], ["The 4F/4R fragment of TCoV S protein", "TREATMENT", 304, 340], ["amino acid residue", "TEST", 354, 372], ["a previous study", "TEST", 434, 450], ["low molecular", "OBSERVATION_MODIFIER", 139, 152], ["linear", "OBSERVATION_MODIFIER", 153, 159], ["polyethyleneimine", "OBSERVATION_MODIFIER", 160, 177], ["neutralizing", "OBSERVATION", 407, 419]]], ["To determine whether fragment of TCoV S protein could stimulate protective neutralizing antibody response, DNA vaccines encoding 4F/4R S fragment gene (DNA-4F/4R), the ternary complex composed of DNA-4F/4R, CLPEI, and HA (DPH-4F/4R), and recombinant 4F/4R S fragment protein were generated.", [["DPH", "CHEMICAL", 222, 225], ["TCoV S", "GENE_OR_GENE_PRODUCT", 33, 39], ["DNA", "CELLULAR_COMPONENT", 107, 110], ["DNA", "CELLULAR_COMPONENT", 152, 155], ["DNA", "CELLULAR_COMPONENT", 196, 199], ["4R", "SIMPLE_CHEMICAL", 203, 205], ["CLPEI", "SIMPLE_CHEMICAL", 207, 212], ["DPH-4F/4R", "SIMPLE_CHEMICAL", 222, 231], ["4R S fragment", "GENE_OR_GENE_PRODUCT", 253, 266], ["TCoV S protein", "PROTEIN", 33, 47], ["4F/4R S fragment gene", "DNA", 129, 150], ["DNA-4F/4R", "DNA", 152, 161], ["ternary complex", "PROTEIN", 168, 183], ["DNA-4F/4R", "DNA", 196, 205], ["CLPEI", "DNA", 207, 212], ["HA", "DNA", 218, 220], ["DPH", "DNA", 222, 225], ["4F", "DNA", 226, 228], ["4R", "DNA", 229, 231], ["recombinant 4F/4R S fragment protein", "PROTEIN", 238, 274], ["TCoV", "SPECIES", 33, 37], ["TCoV S protein", "TREATMENT", 33, 47], ["protective neutralizing antibody response", "TREATMENT", 64, 105], ["DNA vaccines", "TREATMENT", 107, 119], ["4F/4R S fragment gene", "TREATMENT", 129, 150], ["DNA", "TEST", 152, 155], ["the ternary complex", "PROBLEM", 164, 183], ["DNA", "TEST", 196, 199], ["CLPEI", "PROBLEM", 207, 212], ["HA", "PROBLEM", 218, 220], ["DPH", "TEST", 222, 225], ["recombinant 4F/4R S fragment protein", "TEST", 238, 274]]], ["Thus, the purpose of the present study was to determine the immune response and protection efficacy of DNA vaccination against infectious challenge in a prime-boost strategy by priming with naked DNA-4F/4R or DNA in PEI nanoparticle DPH-4F/4R, and boosting with recombinant 4F/4R S fragment protein.Virus ::: Materials and methodsTurkey coronavirus Indiana isolate 540 (TCoV 540) was propagated and titrated in 22-day-old embryonated turkey eggs as previously described (Loa et al., 2001).", [["eggs", "ANATOMY", 441, 445], ["PEI nanoparticle", "CHEMICAL", 216, 232], ["DPH-4F/4R", "CHEMICAL", 233, 242], ["TCoV 540", "CHEMICAL", 370, 378], ["PEI", "CHEMICAL", 216, 219], ["DPH", "CHEMICAL", 233, 236], ["DNA", "CELLULAR_COMPONENT", 103, 106], ["DNA", "CELLULAR_COMPONENT", 196, 199], ["DNA", "CELLULAR_COMPONENT", 209, 212], ["PEI nanoparticle DPH-4F/4R", "SIMPLE_CHEMICAL", 216, 242], ["Virus", "ORGANISM", 299, 304], ["Turkey coronavirus", "ORGANISM", 330, 348], ["TCoV 540", "ORGANISM", 370, 378], ["turkey", "ORGANISM", 434, 440], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 441, 445], ["naked DNA-4F/4R or DNA", "DNA", 190, 212], ["recombinant 4F/4R S fragment protein", "PROTEIN", 262, 298], ["Turkey coronavirus Indiana", "SPECIES", 330, 356], ["turkey", "SPECIES", 434, 440], ["Turkey coronavirus", "SPECIES", 330, 348], ["turkey", "SPECIES", 434, 440], ["the present study", "TEST", 21, 38], ["DNA vaccination", "TREATMENT", 103, 118], ["infectious challenge", "PROBLEM", 127, 147], ["a prime-boost strategy", "TREATMENT", 151, 173], ["DNA", "PROBLEM", 209, 212], ["PEI nanoparticle DPH", "TREATMENT", 216, 236], ["recombinant 4F/4R S fragment protein", "TREATMENT", 262, 298]]], ["Briefly, intestines harvested from embryonated eggs inoculated with TCoV 540 were homogenized and served as virus stock for further titration and challenge in turkeys.", [["intestines", "ANATOMY", 9, 19], ["eggs", "ANATOMY", 47, 51], ["TCoV 540", "CHEMICAL", 68, 76], ["intestines", "ORGAN", 9, 19], ["turkeys", "ORGANISM", 159, 166], ["turkeys", "SPECIES", 159, 166], ["TCoV", "SPECIES", 68, 72], ["turkeys", "SPECIES", 159, 166], ["intestines harvested", "TREATMENT", 9, 29], ["embryonated eggs", "TREATMENT", 35, 51], ["TCoV", "TREATMENT", 68, 72], ["virus stock", "TREATMENT", 108, 119], ["further titration", "TREATMENT", 124, 141], ["intestines", "ANATOMY", 9, 19], ["harvested", "OBSERVATION", 20, 29]]], ["To determine the median embryo infectious dose (EID50) of virus stock TCoV 540, 10-fold serially diluted virus stock from 10\u22123 to 10\u22127 were inoculated into five 22-day-old embryonated turkey eggs per dilution.", [["embryo", "ANATOMY", 24, 30], ["eggs", "ANATOMY", 191, 195], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 24, 30], ["turkey", "ORGANISM", 184, 190], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 191, 195], ["turkey", "SPECIES", 184, 190], ["turkey", "SPECIES", 184, 190], ["the median embryo infectious dose", "TREATMENT", 13, 46], ["virus stock TCoV", "TREATMENT", 58, 74]]], ["After 3 days of inoculation, the embryonic intestines were harvested and subjected to immunofluorescent antibody (IFA) assay with antiserum to TCoV 540 to determine the dose that infected 50% of embryos by the method of Reed and Muench (Thayer and Beard, 2008).Eggs and poults ::: Materials and methodsTurkey eggs and one-day-old turkey poults were obtained from Perdue Farm (Thorntown, Indiana, USA).", [["embryonic intestines", "ANATOMY", 33, 53], ["embryos", "ANATOMY", 195, 202], ["Eggs", "ANATOMY", 261, 265], ["eggs", "ANATOMY", 309, 313], ["embryonic intestines", "ORGAN", 33, 53], ["antiserum", "ORGANISM_SUBSTANCE", 130, 139], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 195, 202], ["Eggs", "ORGANISM_SUBSTANCE", 261, 265], ["turkey", "ORGANISM", 330, 336], ["poults", "ORGANISM", 337, 343], ["poults", "SPECIES", 270, 276], ["turkey", "SPECIES", 330, 336], ["poults", "SPECIES", 337, 343], ["turkey", "SPECIES", 330, 336], ["inoculation", "TREATMENT", 16, 27], ["the embryonic intestines", "PROBLEM", 29, 53], ["immunofluorescent antibody", "TEST", 86, 112], ["antiserum to TCoV", "TREATMENT", 130, 147], ["intestines", "ANATOMY", 43, 53]]], ["Turkey eggs were incubated in an incubator at 37.5 \u00b0C with a humidity level of 55% (Jamesway, Indian Trail, NC, USA) and turkey poults were housed in isolated floor pens.", [["eggs", "ANATOMY", 7, 11], ["poults", "ORGANISM", 128, 134], ["turkey", "SPECIES", 121, 127], ["poults", "SPECIES", 128, 134], ["turkey", "SPECIES", 121, 127], ["a humidity level", "TEST", 59, 75], ["turkey poults", "TREATMENT", 121, 134]]], ["Sera collected from one-day-old turkey poults were negative for TCoV-specific Ab.", [["Sera", "ANATOMY", 0, 4], ["TCoV", "CHEMICAL", 64, 68], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["turkey", "ORGANISM", 32, 38], ["poults", "ORGANISM", 39, 45], ["TCoV", "SIMPLE_CHEMICAL", 64, 68], ["Ab.", "ORGANISM", 78, 81], ["TCoV", "PROTEIN", 64, 68], ["turkey", "SPECIES", 32, 38], ["poults", "SPECIES", 39, 45], ["turkey", "SPECIES", 32, 38], ["TCoV", "SPECIES", 64, 68], ["Sera", "TEST", 0, 4], ["TCoV", "TEST", 64, 68]]], ["The protocol for care and use of turkey eggs and turkey poults in the present study was approved by the Purdue University Animal Care and Use Committee.Construction of DNA vaccine encoding TCoV spike protein 4F/4R fragment ::: Materials and methodsThe gene encoding amino acid residues 482\u2013678 (4F/4R) of the S protein of TCoV 540 (GenBank accession number EU022525) amplified by primer 4F, 5\u2032-GGCCATGGCGTGCCAGACAGT-3\u2032, and 4R, 5\u2032-CAAAGGTACCCAAATTAGATACAT-3\u2032 was cloned into the NcoI and KpnI sites of expression vector pTriEx3 (Novagen, Madison, WI, USA) in frame and upstream of the series of Histidine residues as construct pTriEx3-4F/4R.", [["amino acid", "CHEMICAL", 266, 276], ["Histidine", "CHEMICAL", 595, 604], ["amino acid", "CHEMICAL", 266, 276], ["Histidine", "CHEMICAL", 595, 604], ["turkey", "ORGANISM", 33, 39], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 40, 44], ["turkey", "ORGANISM", 49, 55], ["poults", "ORGANISM_SUBDIVISION", 56, 62], ["DNA", "CELLULAR_COMPONENT", 168, 171], ["TCoV spike protein 4F", "GENE_OR_GENE_PRODUCT", 189, 210], ["amino acid", "AMINO_ACID", 266, 276], ["CAAAGGTACCCAAATTAGATACAT-3", "GENE_OR_GENE_PRODUCT", 431, 457], ["NcoI", "GENE_OR_GENE_PRODUCT", 479, 483], ["KpnI", "GENE_OR_GENE_PRODUCT", 488, 492], ["Novagen", "GENE_OR_GENE_PRODUCT", 529, 536], ["pTriEx3-4F/4R", "GENE_OR_GENE_PRODUCT", 627, 640], ["TCoV spike protein 4F/4R fragment", "PROTEIN", 189, 222], ["S protein", "PROTEIN", 309, 318], ["TCoV 540", "PROTEIN", 322, 330], ["NcoI and KpnI sites", "DNA", 479, 498], ["pTriEx3", "DNA", 520, 527], ["Novagen, Madison, WI, USA) in frame", "DNA", 529, 564], ["pTriEx3-4F/4R", "DNA", 627, 640], ["turkey", "SPECIES", 33, 39], ["turkey", "SPECIES", 49, 55], ["poults", "SPECIES", 56, 62], ["turkey", "SPECIES", 33, 39], ["turkey", "SPECIES", 49, 55], ["The protocol", "TREATMENT", 0, 12], ["care", "TREATMENT", 17, 21], ["turkey eggs", "TREATMENT", 33, 44], ["DNA vaccine", "TREATMENT", 168, 179], ["amino acid residues", "TEST", 266, 285], ["the S protein", "TEST", 305, 318], ["GGCCATGGCGTGCCAGACAGT", "TEST", 394, 415], ["Histidine residues", "TREATMENT", 595, 613]]], ["Plasmid pTriEx3-4F/4R was purified by QIAfilter\u2122 plasmid Giga kit (Qiagen, Valencia, CA, USA) from the lysogeny broth (LB) culture of Escherichia coli (E. coli) strain DH5\u03b1 transformed with pTriEx3-4F/4R.", [["pTriEx3-4F/4R", "GENE_OR_GENE_PRODUCT", 8, 21], ["Escherichia coli", "ORGANISM", 134, 150], ["E. coli", "ORGANISM", 152, 159], ["DH5\u03b1", "CELL", 168, 172], ["pTriEx3-4F/4R", "GENE_OR_GENE_PRODUCT", 190, 203], ["Plasmid pTriEx3-4F/4R", "DNA", 0, 21], ["pTriEx3-4F/4R", "PROTEIN", 190, 203], ["Escherichia coli", "SPECIES", 134, 150], ["E. coli", "SPECIES", 152, 159], ["Escherichia coli", "SPECIES", 134, 150], ["E. coli", "SPECIES", 152, 159], ["Plasmid pTriEx3", "TREATMENT", 0, 15], ["the lysogeny broth", "TEST", 99, 117], ["culture", "TEST", 123, 130], ["Escherichia coli", "PROBLEM", 134, 150], ["E. coli", "TEST", 152, 159], ["Escherichia coli", "OBSERVATION", 134, 150]]], ["The expression of TCoV 4F/4R S fragment from the purified plasmid pTriEx3-4F/4R was verified by IFA with turkey anti-TCoV 540 serum on the COS-7 cells transfected with pTriEx3-4F/4R by using FuGENE\u00ae HD transfection reagent (Roche, Indianapolis, IN, USA) in the ratio of 3:2 in reagent (\u03bcl) to DNA (\u03bcg) according to the procedures described in a previous study (Chen et al., 2011).Formation of DNA-CLPEI-HA (DPH) ternary complex ::: Materials and methodsDisulfide-crosslinked polyethyleneimine was provided by Dr. Yoon Yeo and formation of DNA-CLPEI-HA (DPH) complex was prepared by Dr. Peisheng Xu.", [["plasmid", "ANATOMY", 58, 65], ["serum", "ANATOMY", 126, 131], ["COS-7 cells", "ANATOMY", 139, 150], ["DPH", "CHEMICAL", 407, 410], ["polyethyleneimine", "CHEMICAL", 475, 492], ["DPH", "CHEMICAL", 553, 556], ["DPH", "CHEMICAL", 407, 410], ["Disulfide", "CHEMICAL", 453, 462], ["polyethyleneimine", "CHEMICAL", 475, 492], ["DPH", "CHEMICAL", 553, 556], ["TCoV 4F", "GENE_OR_GENE_PRODUCT", 18, 25], ["4R S", "GENE_OR_GENE_PRODUCT", 26, 30], ["pTriEx3-4F/4R", "GENE_OR_GENE_PRODUCT", 66, 79], ["IFA", "SIMPLE_CHEMICAL", 96, 99], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["COS-7 cells", "CELL", 139, 150], ["pTriEx3-4F", "GENE_OR_GENE_PRODUCT", 168, 178], ["4R", "GENE_OR_GENE_PRODUCT", 179, 181], ["FuGENE", "ORGANISM", 191, 197], ["DNA", "CELLULAR_COMPONENT", 293, 296], ["DNA", "CELLULAR_COMPONENT", 393, 396], ["CLPEI-HA", "SIMPLE_CHEMICAL", 397, 405], ["DPH", "SIMPLE_CHEMICAL", 407, 410], ["Disulfide-crosslinked polyethyleneimine", "SIMPLE_CHEMICAL", 453, 492], ["DNA", "CELLULAR_COMPONENT", 539, 542], ["CLPEI-HA", "SIMPLE_CHEMICAL", 543, 551], ["DPH", "SIMPLE_CHEMICAL", 553, 556], ["TCoV 4F/4R S fragment", "DNA", 18, 39], ["purified plasmid pTriEx3-4F/4R", "DNA", 49, 79], ["COS-7 cells", "CELL_LINE", 139, 150], ["pTriEx3", "PROTEIN", 168, 175], ["HA (DPH) ternary complex", "PROTEIN", 403, 427], ["DNA-CLPEI-HA (DPH) complex", "PROTEIN", 539, 565], ["turkey", "SPECIES", 105, 111], ["turkey", "SPECIES", 105, 111], ["TCoV 4F/4R S fragment", "TREATMENT", 18, 39], ["IFA", "TEST", 96, 99], ["serum", "TEST", 126, 131], ["the COS", "TEST", 135, 142], ["pTriEx3", "TEST", 168, 175], ["HD transfection reagent", "TREATMENT", 199, 222], ["a previous study", "TEST", 343, 359], ["DNA", "PROBLEM", 393, 396], ["CLPEI", "PROBLEM", 397, 402], ["HA", "PROBLEM", 403, 405], ["Materials", "TREATMENT", 432, 441], ["methodsDisulfide-crosslinked polyethyleneimine", "TREATMENT", 446, 492], ["DNA", "PROBLEM", 539, 542], ["CLPEI", "PROBLEM", 543, 548], ["HA", "PROBLEM", 549, 551], ["DNA", "OBSERVATION", 393, 396]]], ["Solutions of DNA pTriEx3-4F/4R (0.05 \u03bcg/\u03bcl) and CLPEI (0.5 \u03bcg/\u03bcl) in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffered saline (HEPES, 10 mM, pH 7.2) were mixed (v/v, 1:1) and incubated at room temperature for 30 min to prepare a complex of DNA and CLPEI (DP) first.", [["CLPEI", "CHEMICAL", 48, 53], ["4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid", "CHEMICAL", 69, 119], ["CLPEI", "CHEMICAL", 48, 53], ["4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid", "CHEMICAL", 69, 119], ["HEPES", "CHEMICAL", 137, 142], ["DNA", "CELLULAR_COMPONENT", 13, 16], ["CLPEI", "SIMPLE_CHEMICAL", 48, 53], ["4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffered saline", "SIMPLE_CHEMICAL", 69, 135], ["DNA", "CELLULAR_COMPONENT", 250, 253], ["CLPEI", "SIMPLE_CHEMICAL", 258, 263], ["DNA pTriEx3", "TREATMENT", 13, 24], ["4F/4R", "TREATMENT", 25, 30], ["CLPEI", "TREATMENT", 48, 53], ["hydroxyethyl)", "TREATMENT", 74, 87], ["piperazineethanesulfonic acid buffered saline (HEPES", "TREATMENT", 90, 142], ["pH", "TEST", 151, 153]]], ["Sequentially, the DP complex was added to HA solution in HEPES buffered saline with a HA/DNA ratio (w/w) of 1 and incubated at room temperature for 10 min.", [["HEPES buffered saline", "SIMPLE_CHEMICAL", 57, 78], ["DNA", "CELLULAR_COMPONENT", 89, 92], ["DP complex", "PROTEIN", 18, 28], ["the DP complex", "TREATMENT", 14, 28], ["HA solution", "TREATMENT", 42, 53], ["HEPES buffered saline", "TREATMENT", 57, 78], ["a HA/DNA ratio (w/w)", "TREATMENT", 84, 104]]], ["The DPH complex was then frozen in liquid nitrogen and lyophilized completely.", [["DPH", "CHEMICAL", 4, 7], ["DPH", "CHEMICAL", 4, 7], ["nitrogen", "CHEMICAL", 42, 50], ["DPH", "SIMPLE_CHEMICAL", 4, 7], ["The DPH complex", "TREATMENT", 0, 15], ["liquid nitrogen", "TREATMENT", 35, 50]]], ["Before inoculation, the powder of DPH was reconstituted with sterile water to the concentration of 0.5 \u03bcg/\u03bcl for intramuscular injection.", [["intramuscular", "ANATOMY", 113, 126], ["DPH", "CHEMICAL", 34, 37], ["DPH", "CHEMICAL", 34, 37], ["DPH", "SIMPLE_CHEMICAL", 34, 37], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 113, 126], ["inoculation", "TREATMENT", 7, 18], ["the powder of DPH", "TREATMENT", 20, 37], ["sterile water", "TREATMENT", 61, 74], ["intramuscular injection", "TREATMENT", 113, 136]]], ["The expression of TCoV 4F/4R S fragment from the purified plasmid pTriEx3-4F/4R was verified by IFA with turkey anti-TCoV 540 serum on the COS-7 cells transfected with 4 \u03bcg of DPH complex consisting of pTriEx3-4F/4R without transfection reagent.Production of recombinant TCoV S protein 4F/4R fragment from E. coli ::: Materials and methodsThe construct pTriEx3-4F/4R was transformed into E. coli strain Rosetta and the expressed TCoV 4F/4R S fragment was harvested and purified according to the protocol described previously (Chen et al., 2011).", [["plasmid", "ANATOMY", 58, 65], ["serum", "ANATOMY", 126, 131], ["COS-7 cells", "ANATOMY", 139, 150], ["DPH", "CHEMICAL", 176, 179], ["pTriEx3-4F/4R", "CHEMICAL", 202, 215], ["pTriEx3-4F/4R", "CHEMICAL", 353, 366], ["DPH", "CHEMICAL", 176, 179], ["TCoV 4F", "GENE_OR_GENE_PRODUCT", 18, 25], ["4R S", "GENE_OR_GENE_PRODUCT", 26, 30], ["pTriEx3-4F/4R", "GENE_OR_GENE_PRODUCT", 66, 79], ["IFA", "SIMPLE_CHEMICAL", 96, 99], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["COS-7 cells", "CELL", 139, 150], ["DPH", "SIMPLE_CHEMICAL", 176, 179], ["pTriEx3-4F/4R", "SIMPLE_CHEMICAL", 202, 215], ["TCoV S protein 4F", "GENE_OR_GENE_PRODUCT", 271, 288], ["E. coli", "ORGANISM", 306, 313], ["pTriEx3-4F", "GENE_OR_GENE_PRODUCT", 353, 363], ["4R", "GENE_OR_GENE_PRODUCT", 364, 366], ["E. coli", "ORGANISM", 388, 395], ["strain Rosetta", "ORGANISM", 396, 410], ["4R S fragment", "GENE_OR_GENE_PRODUCT", 437, 450], ["TCoV 4F/4R S fragment", "DNA", 18, 39], ["purified plasmid pTriEx3-4F/4R", "DNA", 49, 79], ["COS-7 cells", "CELL_LINE", 139, 150], ["pTriEx3", "PROTEIN", 202, 209], ["4F", "PROTEIN", 210, 212], ["recombinant TCoV S protein 4F/4R fragment", "PROTEIN", 259, 300], ["construct pTriEx3-4F/4R", "DNA", 343, 366], ["TCoV 4F/4R S fragment", "DNA", 429, 450], ["turkey", "SPECIES", 105, 111], ["E. coli", "SPECIES", 306, 313], ["E. coli", "SPECIES", 388, 395], ["turkey", "SPECIES", 105, 111], ["E. coli", "SPECIES", 306, 313], ["E. coli", "SPECIES", 388, 395], ["TCoV 4F/4R S fragment", "TREATMENT", 18, 39], ["IFA", "TEST", 96, 99], ["serum", "TEST", 126, 131], ["the COS", "TEST", 135, 142], ["DPH complex", "PROBLEM", 176, 187], ["transfection reagent", "TREATMENT", 224, 244], ["The construct pTriEx3", "TEST", 339, 360], ["4F/4R", "TREATMENT", 361, 366], ["E. coli strain Rosetta", "TREATMENT", 388, 410], ["the expressed TCoV 4F/4R S fragment", "TREATMENT", 415, 450], ["coli", "ANATOMY", 309, 313]]], ["The size (26 kDa) and purity of the produced TCoV 4F/4R S fragment were confirmed by SDS-PAGE and Western blotting analysis.Vaccination and challenge ::: Materials and methodsOne-day-old turkey poults were used in two trials of vaccination and challenge experiments.", [["turkey", "ORGANISM", 187, 193], ["poults", "ORGANISM", 194, 200], ["TCoV 4F/4R S fragment", "DNA", 45, 66], ["turkey", "SPECIES", 187, 193], ["poults", "SPECIES", 194, 200], ["turkey", "SPECIES", 187, 193], ["The size", "TEST", 0, 8], ["TCoV 4F/4R S fragment", "TREATMENT", 45, 66], ["blotting analysis", "TEST", 106, 123], ["methods", "TEST", 168, 175], ["old turkey poults", "TREATMENT", 183, 200], ["vaccination", "TREATMENT", 228, 239], ["challenge experiments", "TREATMENT", 244, 265], ["size", "OBSERVATION_MODIFIER", 4, 8]]], ["The vaccination schedule is summarized in Table 1.", [["The vaccination schedule", "TREATMENT", 0, 24]]], ["Two vaccinations (2V) in trial 1 and three vaccinations (3V) in trial 2 were scheduled and followed by viral challenge.", [["Two vaccinations (2V)", "TREATMENT", 0, 21]]], ["There were 15 turkeys per group and every 5 turkeys in each group were sacrificed at one day before challenge, 3 days post viral inoculation (dpi), and 10 dpi in both trials.", [["turkeys", "ORGANISM", 14, 21], ["turkeys", "ORGANISM", 44, 51], ["turkeys", "SPECIES", 14, 21], ["turkeys", "SPECIES", 44, 51], ["turkeys", "SPECIES", 44, 51], ["viral inoculation (dpi)", "TREATMENT", 123, 146]]], ["Group NC-2V in trial 1 and group NC-3V in trial 2 serving as negative control that received PBS instead of DNA vaccine, protein, or virus.", [["NC-3V", "CHEMICAL", 33, 38], ["DNA", "CELLULAR_COMPONENT", 107, 110], ["Group NC", "TREATMENT", 0, 8], ["group NC", "TREATMENT", 27, 35], ["PBS", "TREATMENT", 92, 95], ["DNA vaccine", "TREATMENT", 107, 118], ["protein", "PROBLEM", 120, 127], ["virus", "PROBLEM", 132, 137]]], ["The turkeys in group VC-2V in trial 1 and group VC-3V in trial 2 were injected intramuscularly with DNA plasmid vector pTriEx3 or PBS with complete Freud's adjuvant (CFA) (Sigma\u2013Aldrich, St. Louis, MO, USA) as the vector control groups.", [["intramuscularly", "ANATOMY", 79, 94], ["VC-2V", "CHEMICAL", 21, 26], ["VC-3V", "CHEMICAL", 48, 53], ["turkeys", "ORGANISM", 4, 11], ["DNA", "CELLULAR_COMPONENT", 100, 103], ["CFA", "SIMPLE_CHEMICAL", 166, 169], ["turkeys", "SPECIES", 4, 11], ["3V in trial 2", "TREATMENT", 51, 64], ["DNA plasmid vector pTriEx3", "TREATMENT", 100, 126]]], ["These two groups became challenge control groups after oral challenge by 100 EID50 of TCoV 540, respectively.", [["oral", "ANATOMY", 55, 59], ["TCoV 540", "CHEMICAL", 86, 94], ["oral", "ORGANISM_SUBDIVISION", 55, 59], ["oral challenge", "TREATMENT", 55, 69]]], ["In trial 1, turkeys in G1-750DP were primed with one dose of 750 \u03bcg pTriEx3-4F/4R on day 1 and boosted with 200 \u03bcg of TCoV 4F/4R S protein with CFA on day 14 before viral challenge on day 28.", [["G1-750DP", "CHEMICAL", 23, 31], ["pTriEx3-4F/4R", "CHEMICAL", 68, 81], ["turkeys", "ORGANISM", 12, 19], ["G1-750DP", "CELL", 23, 31], ["CFA", "SIMPLE_CHEMICAL", 144, 147], ["TCoV 4F/4R S protein", "PROTEIN", 118, 138], ["turkeys", "SPECIES", 12, 19], ["turkeys", "SPECIES", 12, 19], ["TCoV 4F", "TREATMENT", 118, 125]]], ["In trial 2, DNA vaccine pTriEx3-4F/4R was given on day 1 and 7, TCoV 4F/4R S protein in CFA on day 21, and viral challenge on day 35.", [["pTriEx3-4F/4R", "CHEMICAL", 24, 37], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["pTriEx3-4F/4R", "SIMPLE_CHEMICAL", 24, 37], ["CFA", "SIMPLE_CHEMICAL", 88, 91], ["TCoV 4F/4R S protein", "PROTEIN", 64, 84], ["DNA vaccine pTriEx3", "TREATMENT", 12, 31], ["4F/4R", "TREATMENT", 32, 37], ["CFA", "ANATOMY", 88, 91]]], ["The turkeys in G2-100DPH received one dose of 100 \u03bcg pTriEx3-4F/4R in the DPH complex consisting of DNA, polymer CLPEI, and HA, one dose of 750 \u03bcg pTriEx3-4F/4R, and one dose of 200 \u03bcg TCoV 4F/4R S protein with CFA before viral challenge.", [["G2-100DPH", "CHEMICAL", 15, 24], ["pTriEx3-4F/4R", "CHEMICAL", 53, 66], ["DPH", "CHEMICAL", 74, 77], ["CLPEI", "CHEMICAL", 113, 118], ["HA", "CHEMICAL", 124, 126], ["pTriEx3-4F/4R", "CHEMICAL", 147, 160], ["DPH", "CHEMICAL", 74, 77], ["turkeys", "ORGANISM", 4, 11], ["pTriEx3-4F/4R", "SIMPLE_CHEMICAL", 53, 66], ["DPH", "SIMPLE_CHEMICAL", 74, 77], ["DNA", "CELLULAR_COMPONENT", 100, 103], ["polymer CLPEI", "SIMPLE_CHEMICAL", 105, 118], ["HA", "SIMPLE_CHEMICAL", 124, 126], ["4R", "SIMPLE_CHEMICAL", 158, 160], ["CFA", "SIMPLE_CHEMICAL", 211, 214], ["TCoV 4F/4R S protein", "PROTEIN", 185, 205], ["turkeys", "SPECIES", 4, 11], ["DNA", "PROBLEM", 100, 103], ["polymer CLPEI", "PROBLEM", 105, 118], ["HA", "PROBLEM", 124, 126], ["viral challenge", "TREATMENT", 222, 237], ["DNA", "OBSERVATION", 100, 103]]], ["The turkeys in G3-750DDP were vaccinated intramuscularly with two doses of 750 \u03bcg pTriEx3-4F/4R and one dose of 200 \u03bcg TCoV 4F/4R S protein with CFA before viral challenge.Clinical signs and necropsies ::: Materials and methodsIn both trials, clinical signs including depression, diarrhea, and ruffled feathers were monitored for 10 days after viral challenge.", [["intramuscularly", "ANATOMY", 41, 56], ["G3-750DDP", "CHEMICAL", 15, 24], ["pTriEx3-4F/4R", "CHEMICAL", 82, 95], ["depression", "DISEASE", 268, 278], ["diarrhea", "DISEASE", 280, 288], ["turkeys", "ORGANISM", 4, 11], ["G3-750DDP", "CELL", 15, 24], ["4R", "SIMPLE_CHEMICAL", 93, 95], ["CFA", "SIMPLE_CHEMICAL", 145, 148], ["TCoV 4F/4R S protein", "PROTEIN", 119, 139], ["turkeys", "SPECIES", 4, 11], ["viral challenge", "TREATMENT", 156, 171], ["clinical signs", "TEST", 243, 257], ["depression", "PROBLEM", 268, 278], ["diarrhea", "PROBLEM", 280, 288], ["ruffled feathers", "PROBLEM", 294, 310], ["viral challenge", "TREATMENT", 344, 359], ["ruffled feathers", "OBSERVATION", 294, 310]]], ["Turkey poults weighted to evaluate the status of decreased body weight gains caused by TCoV infection.", [["body", "ANATOMY", 59, 63], ["weight gains", "DISEASE", 64, 76], ["TCoV", "CHEMICAL", 87, 91], ["infection", "DISEASE", 92, 101], ["poults", "ORGANISM", 7, 13], ["body", "ORGANISM_SUBDIVISION", 59, 63], ["TCoV", "SIMPLE_CHEMICAL", 87, 91], ["poults", "SPECIES", 7, 13], ["TCoV", "SPECIES", 87, 91], ["decreased body weight gains", "PROBLEM", 49, 76], ["TCoV infection", "PROBLEM", 87, 101], ["infection", "OBSERVATION", 92, 101]]], ["Sera were collected before challenge, at 3 and 10 dpi to measure TCoV-specific antibody response by performing TCoV 4F/4R S fragment-based ELISA and virus neutralization (VN) assay.", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["TCoV", "GENE_OR_GENE_PRODUCT", 65, 69], ["TCoV", "PROTEIN", 65, 69], ["TCoV", "SPECIES", 65, 69], ["TCoV", "SPECIES", 111, 115], ["Sera", "TEST", 0, 4], ["TCoV", "TEST", 65, 69], ["TCoV 4F", "TREATMENT", 111, 118], ["4R S fragment", "TREATMENT", 119, 132], ["ELISA", "TEST", 139, 144], ["virus neutralization", "TREATMENT", 149, 169]]], ["At one day before challenge, 3 and 10 dpi, turkey poults from all groups were necropsied and various tissue, including thymus, spleen, ileum, jejunum, bursa, and cecal tonsil, were collected for histopathological examination.", [["tissue", "ANATOMY", 101, 107], ["thymus", "ANATOMY", 119, 125], ["spleen", "ANATOMY", 127, 133], ["ileum", "ANATOMY", 135, 140], ["jejunum", "ANATOMY", 142, 149], ["bursa", "ANATOMY", 151, 156], ["cecal tonsil", "ANATOMY", 162, 174], ["turkey", "ORGANISM", 43, 49], ["poults", "ORGANISM", 50, 56], ["tissue", "TISSUE", 101, 107], ["thymus", "ORGAN", 119, 125], ["spleen", "ORGAN", 127, 133], ["ileum", "MULTI-TISSUE_STRUCTURE", 135, 140], ["jejunum", "MULTI-TISSUE_STRUCTURE", 142, 149], ["bursa", "ORGAN", 151, 156], ["cecal tonsil", "MULTI-TISSUE_STRUCTURE", 162, 174], ["turkey", "SPECIES", 43, 49], ["poults", "SPECIES", 50, 56], ["turkey", "SPECIES", 43, 49], ["turkey poults", "TREATMENT", 43, 56], ["various tissue, including thymus, spleen, ileum, jejunum, bursa, and cecal tonsil", "PROBLEM", 93, 174], ["histopathological examination", "TEST", 195, 224], ["various tissue", "OBSERVATION", 93, 107], ["thymus", "ANATOMY", 119, 125], ["spleen", "ANATOMY", 127, 133], ["ileum", "ANATOMY", 135, 140], ["jejunum", "ANATOMY", 142, 149], ["bursa", "ANATOMY", 151, 156], ["cecal tonsil", "ANATOMY", 162, 174]]], ["The ileum and jejunum samples were subjected to IFA assay for detecting TCoV antigen.", [["ileum", "ANATOMY", 4, 9], ["jejunum samples", "ANATOMY", 14, 29], ["ileum", "MULTI-TISSUE_STRUCTURE", 4, 9], ["jejunum samples", "CANCER", 14, 29], ["TCoV antigen", "GENE_OR_GENE_PRODUCT", 72, 84], ["TCoV antigen", "PROTEIN", 72, 84], ["TCoV", "SPECIES", 72, 76], ["IFA assay", "TEST", 48, 57], ["TCoV antigen", "PROBLEM", 72, 84], ["ileum", "ANATOMY", 4, 9], ["jejunum", "ANATOMY", 14, 21]]], ["The ileum samples were used to determine TCoV viral RNA load by quantitative real-time RT-PCR (qRT-PCR).", [["ileum samples", "ANATOMY", 4, 17], ["ileum samples", "CANCER", 4, 17], ["TCoV viral RNA", "RNA", 41, 55], ["TCoV", "SPECIES", 41, 45], ["The ileum samples", "TEST", 0, 17], ["TCoV viral RNA load", "PROBLEM", 41, 60], ["PCR", "TEST", 90, 93], ["qRT", "TEST", 95, 98], ["PCR", "TEST", 99, 102], ["ileum", "ANATOMY", 4, 9]]], ["The spleen samples were processed to determine turkey IFN\u03b3 mRNA level by qRT-PCR.IFA for detecting TCoV antigen ::: Materials and methodsA 5-cm long segment of jejunum adjacent to the Merckel's diverticulum and a 5-cm long segment of ileum between the paired ceca were collected.", [["spleen samples", "ANATOMY", 4, 18], ["jejunum", "ANATOMY", 160, 167], ["Merckel's diverticulum", "ANATOMY", 184, 206], ["ileum", "ANATOMY", 234, 239], ["ceca", "ANATOMY", 259, 263], ["spleen samples", "CANCER", 4, 18], ["turkey", "ORGANISM", 47, 53], ["IFA", "SIMPLE_CHEMICAL", 81, 84], ["TCoV antigen", "GENE_OR_GENE_PRODUCT", 99, 111], ["jejunum", "ORGAN", 160, 167], ["Merckel's diverticulum", "CANCER", 184, 206], ["ileum", "MULTI-TISSUE_STRUCTURE", 234, 239], ["ceca", "ORGAN", 259, 263], ["IFN", "PROTEIN", 54, 57], ["mRNA", "RNA", 59, 63], ["TCoV antigen", "PROTEIN", 99, 111], ["turkey", "SPECIES", 47, 53], ["turkey", "SPECIES", 47, 53], ["TCoV", "SPECIES", 99, 103], ["mRNA level", "TEST", 59, 69], ["qRT", "TEST", 73, 76], ["PCR", "TEST", 77, 80], ["Materials", "TREATMENT", 116, 125], ["methodsA", "TREATMENT", 130, 138], ["the Merckel's diverticulum", "PROBLEM", 180, 206], ["a 5-cm long segment of ileum", "PROBLEM", 211, 239], ["spleen", "ANATOMY", 4, 10], ["5-cm", "OBSERVATION_MODIFIER", 139, 143], ["long segment", "ANATOMY_MODIFIER", 144, 156], ["jejunum", "ANATOMY", 160, 167], ["diverticulum", "OBSERVATION", 194, 206], ["5-cm", "OBSERVATION_MODIFIER", 213, 217], ["long segment", "ANATOMY_MODIFIER", 218, 230], ["ileum", "ANATOMY", 234, 239], ["paired", "ANATOMY_MODIFIER", 252, 258], ["ceca", "ANATOMY", 259, 263]]], ["Contents in the intestinal segments collected were rinsed away by using cold PBS.", [["intestinal segments", "ANATOMY", 16, 35], ["intestinal segments", "MULTI-TISSUE_STRUCTURE", 16, 35], ["cold PBS", "TREATMENT", 72, 80], ["intestinal segments", "ANATOMY", 16, 35]]], ["The intestinal segments were folded and wrapped in a sheet of aluminum foils and then frozen at \u221280\u00b0C. The frozen specimens were trimmed at \u221220 \u00b0C and three 6-nm sections from the ileum and three from the jejunum per sample were prepared for IFA.", [["intestinal segments", "ANATOMY", 4, 23], ["specimens", "ANATOMY", 114, 123], ["sections", "ANATOMY", 162, 170], ["ileum", "ANATOMY", 180, 185], ["jejunum", "ANATOMY", 205, 212], ["sample", "ANATOMY", 217, 223], ["aluminum", "CHEMICAL", 62, 70], ["aluminum", "CHEMICAL", 62, 70], ["intestinal segments", "MULTI-TISSUE_STRUCTURE", 4, 23], ["ileum", "MULTI-TISSUE_STRUCTURE", 180, 185], ["jejunum", "ORGAN", 205, 212], ["a sheet of aluminum foils", "TREATMENT", 51, 76], ["The frozen specimens", "TEST", 103, 123], ["IFA", "TEST", 242, 245], ["intestinal segments", "ANATOMY", 4, 23], ["folded", "OBSERVATION", 29, 35], ["ileum", "ANATOMY", 180, 185], ["jejunum", "ANATOMY", 205, 212]]], ["The antiserum to TCoV 540 as the primary Ab and FITC-conjugated goat anti-turkey IgG (H + L) Ab (KPL, Gaithersburg, MD, USA) as the secondary Ab were used to stain the acetone-fixed sections of frozen ileum and jejunum samples.", [["sections", "ANATOMY", 182, 190], ["ileum", "ANATOMY", 201, 206], ["jejunum samples", "ANATOMY", 211, 226], ["TCoV 540", "CHEMICAL", 17, 25], ["TCoV 540", "CHEMICAL", 17, 25], ["FITC", "CHEMICAL", 48, 52], ["acetone", "CHEMICAL", 168, 175], ["antiserum", "ORGANISM_SUBSTANCE", 4, 13], ["Ab", "GENE_OR_GENE_PRODUCT", 41, 43], ["FITC", "SIMPLE_CHEMICAL", 48, 52], ["Ab", "GENE_OR_GENE_PRODUCT", 142, 144], ["acetone", "SIMPLE_CHEMICAL", 168, 175], ["ileum", "MULTI-TISSUE_STRUCTURE", 201, 206], ["jejunum samples", "CANCER", 211, 226], ["primary Ab", "PROTEIN", 33, 43], ["FITC-conjugated goat anti-turkey IgG (H + L) Ab", "PROTEIN", 48, 95], ["goat", "SPECIES", 64, 68], ["goat", "SPECIES", 64, 68], ["the primary Ab", "TEST", 29, 43], ["FITC", "TEST", 48, 52], ["IgG", "TEST", 81, 84], ["ileum", "ANATOMY", 201, 206], ["jejunum", "ANATOMY", 211, 218]]], ["Each section was observed under a fluorescent microscope and IFA scores from three independent fields per section were determined.", [["a fluorescent microscope", "TEST", 32, 56], ["IFA scores", "TEST", 61, 71]]], ["The infectivity of TCoV in turkeys was determined by the sum of IFA scores presented in three categories modified from a previous study by our laboratory (Loa et al., 2001): (1) strength of positive signals scaled from negative (0), weak (1), moderate (2), to strong (3); (2) distribution of positive cells ranged from negative (0), focal (1), multifocal (2), to diffuse (3); (3) number of positive cells can be negative (0), low (1), medium (2), or high (3).ELISA and VN assay ::: Materials and methodsThe procedures of TCoV 4F/4R S fragment-based ELISA and VN assay were described previously (Chen et al., 2011).", [["cells", "ANATOMY", 301, 306], ["cells", "ANATOMY", 399, 404], ["TCoV", "CHEMICAL", 19, 23], ["TCoV", "GENE_OR_GENE_PRODUCT", 19, 23], ["turkeys", "ORGANISM", 27, 34], ["cells", "CELL", 301, 306], ["cells", "CELL", 399, 404], ["TCoV", "PROTEIN", 19, 23], ["positive cells", "CELL_TYPE", 292, 306], ["positive cells", "CELL_TYPE", 390, 404], ["VN", "PROTEIN", 469, 471], ["VN", "PROTEIN", 559, 561], ["turkeys", "SPECIES", 27, 34], ["TCoV", "SPECIES", 19, 23], ["turkeys", "SPECIES", 27, 34], ["IFA scores", "TEST", 64, 74], ["a previous study", "TEST", 119, 135], ["weak (1), moderate (2), to strong (3); (2) distribution of positive cells", "PROBLEM", 233, 306], ["focal (1), multifocal (2), to diffuse (3); (3) number of positive cells", "PROBLEM", 333, 404], ["TCoV 4F/4R S fragment", "TREATMENT", 521, 542], ["based ELISA and VN assay", "TEST", 543, 567], ["infectivity", "OBSERVATION_MODIFIER", 4, 15], ["moderate", "OBSERVATION_MODIFIER", 243, 251], ["positive cells", "OBSERVATION", 292, 306], ["focal", "OBSERVATION_MODIFIER", 333, 338], ["multifocal", "OBSERVATION_MODIFIER", 344, 354], ["diffuse", "OBSERVATION_MODIFIER", 363, 370], ["positive cells", "OBSERVATION", 390, 404]]], ["In brief, the serum samples were diluted at 1:200 and reacted to the TCoV 4F/4R S fragment coated on the plate.", [["serum samples", "ANATOMY", 14, 27], ["serum samples", "ORGANISM_SUBSTANCE", 14, 27], ["TCoV 4F/4R S fragment", "DNA", 69, 90], ["the serum samples", "TEST", 10, 27], ["4R S", "OBSERVATION", 77, 81], ["fragment", "OBSERVATION_MODIFIER", 82, 90], ["coated", "OBSERVATION_MODIFIER", 91, 97], ["plate", "ANATOMY_MODIFIER", 105, 110]]], ["Bound antibodies were detected with horseradish peroxidase (HRP)-conjugated goat anti-turkey IgG Ab diluted at 1:40,000 and the optical density at 450 nm (OD 450 nm) was read with VMax\u2122 ELISA microplate reader (Molecular Devices, Sunnyvale, CA, USA).", [["horseradish peroxidase", "SIMPLE_CHEMICAL", 36, 58], ["HRP", "SIMPLE_CHEMICAL", 60, 63], ["Bound antibodies", "PROTEIN", 0, 16], ["horseradish peroxidase (HRP)-conjugated goat anti-turkey IgG Ab", "PROTEIN", 36, 99], ["VMax", "PROTEIN", 180, 184], ["horseradish", "SPECIES", 36, 47], ["goat", "SPECIES", 76, 80], ["Bound antibodies", "TEST", 0, 16], ["horseradish peroxidase", "TEST", 36, 58], ["conjugated goat anti-turkey IgG Ab", "TREATMENT", 65, 99], ["VMax", "TEST", 180, 184]]], ["For VN assay, sera were heat-inactivated at 56 \u00b0C for 30 min and then fourfold diluted serially.", [["sera", "ANATOMY", 14, 18], ["sera", "ORGANISM_SUBSTANCE", 14, 18], ["VN", "PROTEIN", 4, 6], ["VN assay", "TEST", 4, 12]]], ["The diluted serum was incubated with 20 EID50 of TCoV 540 at 37 \u00b0C for 1 h and the mixture was subsequently inoculated into five 22-day-old turkey embryonated eggs via amniotic sac route per dilution of each serum sample.", [["serum", "ANATOMY", 12, 17], ["eggs", "ANATOMY", 159, 163], ["amniotic sac", "ANATOMY", 168, 180], ["serum sample", "ANATOMY", 208, 220], ["TCoV 540", "CHEMICAL", 49, 57], ["serum", "ORGANISM_SUBSTANCE", 12, 17], ["turkey", "ORGANISM", 140, 146], ["eggs", "ORGANISM", 159, 163], ["amniotic sac", "MULTI-TISSUE_STRUCTURE", 168, 180], ["serum", "ORGANISM_SUBSTANCE", 208, 213], ["turkey", "SPECIES", 140, 146], ["turkey", "SPECIES", 140, 146], ["The diluted serum", "TEST", 0, 17], ["TCoV", "TREATMENT", 49, 53], ["old turkey embryonated eggs", "TREATMENT", 136, 163], ["amniotic sac route", "TREATMENT", 168, 186], ["each serum sample", "TEST", 203, 220], ["amniotic sac", "ANATOMY", 168, 180]]], ["The intestines of turkey embryos were harvested after incubation for three days and examined by IFA using TCoV 540 antiserum.", [["intestines", "ANATOMY", 4, 14], ["embryos", "ANATOMY", 25, 32], ["TCoV 540", "CHEMICAL", 106, 114], ["intestines", "ORGAN", 4, 14], ["turkey", "ORGANISM", 18, 24], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 25, 32], ["antiserum", "ORGANISM_SUBSTANCE", 115, 124], ["turkey", "SPECIES", 18, 24], ["turkey", "SPECIES", 18, 24], ["intestines", "ANATOMY", 4, 14]]], ["The dilution of serum preventing the infection of TCoV 540 in 50% of inoculated eggs was calculated as VN titer by Reed and Muench method (Thayer and Beard, 2008).qRT-PCR for turkey IFN\u03b3 mRNA level ::: Materials and methodsTotal RNA was extracted from spleens in RNAlater\u00ae stabilization reagent (Qiagen, Valencia, CA, USA) by using RNeasy mini kit (Qiagen, Valencia, CA, USA).", [["serum", "ANATOMY", 16, 21], ["eggs", "ANATOMY", 80, 84], ["spleens", "ANATOMY", 252, 259], ["infection", "DISEASE", 37, 46], ["TCoV 540", "CHEMICAL", 50, 58], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["TCoV 540", "ORGANISM", 50, 58], ["turkey", "ORGANISM", 175, 181], ["spleens", "ORGAN", 252, 259], ["IFN", "PROTEIN", 182, 185], ["mRNA", "RNA", 187, 191], ["turkey", "SPECIES", 175, 181], ["TCoV", "SPECIES", 50, 54], ["turkey", "SPECIES", 175, 181], ["The dilution of serum", "TREATMENT", 0, 21], ["the infection of TCoV", "PROBLEM", 33, 54], ["inoculated eggs", "PROBLEM", 69, 84], ["mRNA level", "TEST", 187, 197], ["Total RNA", "TREATMENT", 223, 232], ["RNAlater\u00ae stabilization reagent", "TREATMENT", 263, 294], ["infection", "OBSERVATION", 37, 46], ["spleens", "ANATOMY", 252, 259]]], ["The extracted RNA was treated with RNase-free DNase (Qiagen, Valencia, CA, USA) to remove possible genomic DNA contamination.", [["RNase", "GENE_OR_GENE_PRODUCT", 35, 40], ["DNase", "GENE_OR_GENE_PRODUCT", 46, 51], ["DNA", "CELLULAR_COMPONENT", 107, 110], ["RNase", "PROTEIN", 35, 40], ["DNase", "PROTEIN", 46, 51], ["The extracted RNA", "PROBLEM", 0, 17], ["RNase-free DNase", "TREATMENT", 35, 51], ["CA, USA", "TREATMENT", 71, 78], ["genomic DNA contamination", "PROBLEM", 99, 124], ["RNA", "OBSERVATION_MODIFIER", 14, 17], ["DNA contamination", "OBSERVATION", 107, 124]]], ["Single stranded cDNA was synthesized using random primer and SuperScript III reverse transcriptase (Invitrogen, San Diego, CA, USA).", [["Single stranded cDNA", "DNA", 0, 20], ["SuperScript III reverse transcriptase", "PROTEIN", 61, 98], ["Single stranded cDNA", "TREATMENT", 0, 20], ["random primer", "TREATMENT", 43, 56]]], ["The cDNA was subjected to SYBR Green-based qRT-PCR with forward primer TKIFNGF, 5\u2032-GTGAAGAAGGTGAAAGATATCATGGA-3\u2032, and reverse primer TKIFNGR, 5\u2032-ACTTTGCGCTGGATTCTCA-3\u2032 specific to turkey IFN\u03b3 mRNA.", [["SYBR", "GENE_OR_GENE_PRODUCT", 26, 30], ["turkey", "ORGANISM", 180, 186], ["cDNA", "DNA", 4, 8], ["reverse primer TKIFNGR, 5\u2032-ACTTTGCGCTGGATTCTCA-3", "DNA", 118, 166], ["turkey IFN\u03b3", "DNA", 180, 191], ["mRNA", "RNA", 192, 196], ["turkey", "SPECIES", 180, 186], ["turkey", "SPECIES", 180, 186], ["The cDNA", "TEST", 0, 8], ["SYBR", "TEST", 26, 30], ["forward primer TKIFNGF", "TEST", 56, 78], ["GTGAAGAAGGTGAAAGATATCATGGA", "TEST", 83, 109], ["TKIFNGR", "TEST", 133, 140], ["ACTTTGCGCTGGATTCTCA", "TEST", 145, 164], ["mRNA", "PROBLEM", 192, 196]]], ["The reaction with GADPH forward primer, 5\u2032-ATCAAGAGGGTAGTGAAGGCTGCT-3\u2032, and GADPH reverse primer, 5\u2032-TCAAAGGTGGAGG AATGGCTGTCA-3\u2032, targeting GADPH mRNA was used as internal control for SYBR Green-based qRT-PCR.", [["GADPH", "SIMPLE_CHEMICAL", 18, 23], ["GADPH", "GENE_OR_GENE_PRODUCT", 141, 146], ["SYBR", "GENE_OR_GENE_PRODUCT", 185, 189], ["GADPH forward primer", "DNA", 18, 38], ["GADPH reverse primer", "DNA", 76, 96], ["GADPH mRNA", "RNA", 141, 151], ["The reaction", "PROBLEM", 0, 12], ["GADPH forward primer", "TEST", 18, 38], ["ATCAAGAGGGTAGTGAAGGCTGCT", "TEST", 43, 67], ["AATGGCTGTCA", "TEST", 115, 126], ["targeting GADPH mRNA", "TREATMENT", 131, 151], ["SYBR Green", "TEST", 185, 195]]], ["The SYBR Green-based qRT-PCR mixture containing 200 nM forward and reverse primers and 1\u00d7 EXPRESS SYBR Green qPCR universal qPCR Supermixes (Invitrogen, Carlsbad, CA, USA) were used.", [["SYBR", "GENE_OR_GENE_PRODUCT", 4, 8], ["SYBR Green-based qRT-PCR mixture", "DNA", 4, 36], ["The SYBR", "TEST", 0, 8], ["Supermixes (Invitrogen", "TREATMENT", 129, 151], ["Carlsbad", "TREATMENT", 153, 161], ["CA, USA)", "TREATMENT", 163, 171]]], ["The parameters for thermal cycling were 2 min at 50 \u00b0C, 2 min at 95 \u00b0C, 40 cycles of 95 \u00b0C for 20 s with acquiring SYBR Green signal at 60 \u00b0C for 60 s, and 5 min at 60 \u00b0C in a real-time PCR cycler (Rotor-Q, Qiagen).", [["thermal cycling", "TREATMENT", 19, 34], ["Rotor", "TEST", 198, 203]]], ["Melting curve analysis was performed from 65 \u00b0C to 95 \u00b0C, with a ramp speed of 1 \u00b0C/s.", [["Melting curve analysis", "TEST", 0, 22], ["a ramp speed", "TEST", 63, 75]]], ["The result of the melting curve analysis was used to evaluate the specificity of the amplification product.", [["the melting curve analysis", "TEST", 14, 40], ["the amplification product", "PROBLEM", 81, 106]]], ["The cycle threshold (Ct) value of IFN\u03b3 gene was normalized with the Ct value of GADPH.", [["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 34, 38], ["GADPH", "SIMPLE_CHEMICAL", 80, 85], ["IFN\u03b3 gene", "DNA", 34, 43], ["GADPH", "PROTEIN", 80, 85], ["The cycle threshold", "TEST", 0, 19], ["Ct) value", "TEST", 21, 30], ["the Ct value", "TEST", 64, 76]]], ["The mRNA level of IFN\u03b3 in group VC-2V and Group 1-750DP was compared to that in group NC-2V while the IFN\u03b3 mRNA level in group VC-3V, Group 2-100DPH, and Group 3-750DDP was compared to that in group NC-3V.", [["VC-2V", "ANATOMY", 32, 37], ["VC-2V", "CHEMICAL", 32, 37], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 18, 22], ["VC-2V", "CELL", 32, 37], ["IFN\u03b3", "PROTEIN", 18, 22], ["IFN", "PROTEIN", 102, 105], ["mRNA", "RNA", 107, 111], ["The mRNA level", "TEST", 0, 14], ["IFN", "TEST", 18, 21], ["VC", "TEST", 32, 34], ["mRNA level", "TEST", 107, 117], ["VC", "TEST", 127, 129]]], ["The fold change of IFN\u03b3 gene expression was calculated as 2\u2212\u0394\u0394Ct where \u0394CtIFN\u03b3= CtIFN\u03b3\u2212 CtGADPH and \u0394\u0394CtIFN\u03b3= each \u0394CtIFN\u03b3 in each group \u2013 average of \u0394CtIFN\u03b3 in corresponding negative control group.qRT-PCR for TCoV viral RNA load ::: Materials and methodsWith modifications from a previous study (Chen et al., 2010), the cDNA reverse transcribed from total RNA of collected ileum samples in RNAlater\u00ae stabilization reagent was subjected to TaqMan probe-based qRT-PCR with primers QS1F and QS1R, and probe QS1P specific to TCoV S2 gene.", [["ileum samples", "ANATOMY", 374, 387], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 19, 23], ["CtIFN\u03b3\u2212 CtGADPH", "GENE_OR_GENE_PRODUCT", 80, 95], ["\u0394CtIFN\u03b3", "GENE_OR_GENE_PRODUCT", 115, 122], ["\u0394CtIFN\u03b3", "GENE_OR_GENE_PRODUCT", 150, 157], ["TCoV", "GENE_OR_GENE_PRODUCT", 210, 214], ["ileum samples", "MULTI-TISSUE_STRUCTURE", 374, 387], ["RNAlater\u00ae", "SIMPLE_CHEMICAL", 391, 400], ["TCoV S2", "GENE_OR_GENE_PRODUCT", 522, 529], ["IFN\u03b3 gene", "DNA", 19, 28], ["\u0394\u0394Ct", "PROTEIN", 60, 64], ["\u0394CtIFN\u03b3", "PROTEIN", 71, 78], ["CtIFN\u03b3", "PROTEIN", 80, 86], ["CtGADPH", "PROTEIN", 88, 95], ["\u0394\u0394CtIFN\u03b3", "PROTEIN", 100, 108], ["\u0394CtIFN\u03b3", "PROTEIN", 115, 122], ["\u0394CtIFN\u03b3", "PROTEIN", 150, 157], ["TCoV viral RNA", "RNA", 210, 224], ["TaqMan probe", "DNA", 440, 452], ["QS1F", "DNA", 480, 484], ["QS1R", "DNA", 489, 493], ["QS1P", "DNA", 505, 509], ["TCoV S2 gene", "DNA", 522, 534], ["TCoV", "SPECIES", 210, 214], ["The fold change", "PROBLEM", 0, 15], ["IFN\u03b3 gene expression", "TREATMENT", 19, 39], ["qRT", "TEST", 198, 201], ["PCR", "TEST", 202, 205], ["a previous study", "TEST", 279, 295], ["RNAlater\u00ae stabilization reagent", "TREATMENT", 391, 422], ["TaqMan probe", "TEST", 440, 452], ["PCR", "TEST", 463, 466], ["primers QS1F", "TEST", 472, 484], ["fold", "OBSERVATION_MODIFIER", 4, 8], ["ileum", "ANATOMY", 374, 379]]], ["The cycling profile was 5 min of 94 \u00b0C followed by 40 cycles of 94 \u00b0C for 20 s and 61 \u00b0C for 1 min with acquiring the fluorescence FAM in a real-time PCR cycler (Rotor-Q, Qiagen).", [["FAM", "CHEMICAL", 131, 134], ["FAM", "SIMPLE_CHEMICAL", 131, 134], ["The cycling profile", "TEST", 0, 19], ["Rotor", "TEST", 162, 167]]], ["The concentration of TCoV (fg/\u03bcl) was calculated by absolute quantitative standard curve developed by 10\u22123 to 10\u22128 of 10-fold diluted plasmid pTriEx3-6F/6R (nucleotide position 2490\u20133213 from start codon of S gene from TCoV 540) with known concentration measured by GeneQuant pro RNA/DNA calculator (GE Healthcare Bioscience, Piscataway, NJ, USA).", [["plasmid", "ANATOMY", 134, 141], ["nucleotide position 2490\u20133213", "CHEMICAL", 157, 186], ["nucleotide", "CHEMICAL", 157, 167], ["TCoV", "SIMPLE_CHEMICAL", 21, 25], ["pTriEx3-6F/6R", "GENE_OR_GENE_PRODUCT", 142, 155], ["DNA", "CELLULAR_COMPONENT", 284, 287], ["TCoV", "PROTEIN", 21, 25], ["plasmid pTriEx3-6F/6R", "DNA", 134, 155], ["nucleotide position 2490\u20133213", "DNA", 157, 186], ["start codon", "DNA", 192, 203], ["S gene", "DNA", 207, 213], ["TCoV 540", "DNA", 219, 227], ["The concentration of TCoV (fg/\u03bcl)", "TREATMENT", 0, 33], ["known concentration", "PROBLEM", 234, 253]]], ["When the Ct value of the sample was larger than the Ct value of non-template control (NTC) or larger than the total cycle number of 40 or the signal was below threshold, the concentration of TCoV in the sample was considered as 0 fg/\u03bcl.Statistical analysis ::: Materials and methodsThe normality of the data was evaluated by quantile\u2013quantile (QQ) plots.", [["sample", "ANATOMY", 25, 31], ["sample", "ANATOMY", 203, 209], ["TCoV", "CHEMICAL", 191, 195], ["TCoV", "CHEMICAL", 191, 195], ["TCoV", "SIMPLE_CHEMICAL", 191, 195], ["TCoV", "PROTEIN", 191, 195], ["the Ct value", "TEST", 5, 17], ["the sample", "TEST", 21, 31], ["the Ct value", "TEST", 48, 60], ["non-template control", "TREATMENT", 64, 84], ["larger", "OBSERVATION_MODIFIER", 36, 42], ["larger", "OBSERVATION_MODIFIER", 94, 100]]], ["When the data did not distribute normally, nonparametric Mann\u2013Whitney U test was used to compare the data from two groups and Kruskal\u2013Wallis H test was used to analyze the data from three and more groups.", [["nonparametric Mann\u2013Whitney U test", "TEST", 43, 76], ["the data", "TEST", 97, 105], ["Kruskal\u2013Wallis H test", "TEST", 126, 147], ["the data", "TEST", 168, 176]]], ["The normally distributed data underwent independent t-test or one-way analysis of variance (ANOVA).", [["independent t-test", "TEST", 40, 58]]], ["All statistical analyses used SPSS 17.0 program (SPSS Inc., Chicago, IL, USA).", [["All statistical analyses", "TEST", 0, 24]]], ["Statistical significance was set at p< 0.05.Expression of plasmid pTriEx3-4F/4R in COS-7 cells ::: ResultsThe green fluorescence was seen in the cytoplasm of the COS-7 cells transfected with pTriEx3-4F/4R with transfusion reagent or DPH complex without transfusion reagent, indicating the expression of TCoV 4F/4R S fragment in COS-7 cells (Fig. 1).", [["COS-7 cells", "ANATOMY", 83, 94], ["cytoplasm", "ANATOMY", 145, 154], ["COS-7 cells", "ANATOMY", 162, 173], ["COS-7 cells", "ANATOMY", 328, 339], ["DPH", "CHEMICAL", 233, 236], ["DPH", "CHEMICAL", 233, 236], ["pTriEx3-4F/4R", "GENE_OR_GENE_PRODUCT", 66, 79], ["COS-7 cells", "CELL", 83, 94], ["cytoplasm", "ORGANISM_SUBSTANCE", 145, 154], ["COS-7 cells", "CELL", 162, 173], ["pTriEx3-4F", "GENE_OR_GENE_PRODUCT", 191, 201], ["4R", "GENE_OR_GENE_PRODUCT", 202, 204], ["DPH", "SIMPLE_CHEMICAL", 233, 236], ["TCoV 4F", "GENE_OR_GENE_PRODUCT", 303, 310], ["COS-7 cells", "CELL", 328, 339], ["pTriEx3", "DNA", 66, 73], ["4F", "DNA", 74, 76], ["4R", "DNA", 77, 79], ["COS-7 cells", "CELL_LINE", 83, 94], ["COS-7 cells", "CELL_LINE", 162, 173], ["pTriEx3", "PROTEIN", 191, 198], ["TCoV 4F/4R S fragment", "PROTEIN", 303, 324], ["COS-7 cells", "CELL_LINE", 328, 339], ["plasmid pTriEx3", "TEST", 58, 73], ["The green fluorescence", "TEST", 106, 128], ["pTriEx3", "TEST", 191, 198], ["transfusion reagent", "TREATMENT", 210, 229], ["DPH complex", "PROBLEM", 233, 244], ["transfusion reagent", "TREATMENT", 253, 272], ["TCoV 4F/4R S fragment in COS", "TREATMENT", 303, 331], ["green fluorescence", "OBSERVATION", 110, 128]]], ["Purified TCoV 4F/4R S fragment was detected by the serum collected from TCoV-infected turkey on Western blotting with a size of 26 kDa (Fig. 2).Protection efficacy against challenge by TCoV ::: ResultsIn both trials, the body weights of turkeys from each group had no significant differences (p> 0.05) before viral challenge (Table 2).", [["serum", "ANATOMY", 51, 56], ["body", "ANATOMY", 221, 225], ["TCoV", "CHEMICAL", 185, 189], ["TCoV 4F", "GENE_OR_GENE_PRODUCT", 9, 16], ["4R S fragment", "GENE_OR_GENE_PRODUCT", 17, 30], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["TCoV", "SIMPLE_CHEMICAL", 72, 76], ["turkey", "ORGANISM", 86, 92], ["body", "ORGANISM_SUBDIVISION", 221, 225], ["turkeys", "ORGANISM", 237, 244], ["TCoV 4F/4R S fragment", "DNA", 9, 30], ["turkey", "SPECIES", 86, 92], ["turkeys", "SPECIES", 237, 244], ["turkey", "SPECIES", 86, 92], ["TCoV", "SPECIES", 185, 189], ["turkeys", "SPECIES", 237, 244], ["4R S fragment", "PROBLEM", 17, 30], ["the serum", "TEST", 47, 56], ["the body weights", "TEST", 217, 233], ["infected", "OBSERVATION", 77, 85], ["size", "OBSERVATION_MODIFIER", 120, 124]]], ["After challenge by TCoV, the turkeys in G1-750DP weighed significantly heavier than those in group VC-2V (p< 0.05) but lighter than NC-2V turkeys (p< 0.05) at 3 dpi in trial 1.", [["TCoV", "SIMPLE_CHEMICAL", 19, 23], ["turkeys", "ORGANISM", 29, 36], ["turkeys", "SPECIES", 29, 36], ["turkeys", "SPECIES", 138, 145], ["TCoV", "SPECIES", 19, 23], ["turkeys", "SPECIES", 29, 36]]], ["In trial 2, the vaccinated turkeys in G2-100DPH and G3-750DDP were heavier than the non-vaccinated turkeys in groups VC-3V and NC at 3 dpi, however, there were no significant differences (p> 0.05).Protection efficacy against challenge by TCoV ::: ResultsDNA vaccination with a DNA-prime protein-boost approach targeting TCoV 4F/4R S fragment containing neutralizing epitopes reduced the number of turkeys showing clinical signs, decreased the intensity, number and distribution of IFA-positive enterocytes and diminished the viral load in the ileum of TCoV-infected turkeys (Table 3).", [["enterocytes", "ANATOMY", 494, 505], ["ileum", "ANATOMY", 543, 548], ["G2-100DPH", "CHEMICAL", 38, 47], ["G3-750DDP", "CHEMICAL", 52, 61], ["TCoV", "CHEMICAL", 552, 556], ["turkeys", "ORGANISM", 27, 34], ["G2-100DPH", "CELL", 38, 47], ["G3-750DDP", "CELL", 52, 61], ["turkeys", "ORGANISM", 99, 106], ["VC-3V", "CELL", 117, 122], ["DNA", "CELLULAR_COMPONENT", 277, 280], ["TCoV 4F", "GENE_OR_GENE_PRODUCT", 320, 327], ["turkeys", "ORGANISM", 397, 404], ["IFA", "GENE_OR_GENE_PRODUCT", 481, 484], ["ileum", "ORGAN", 543, 548], ["TCoV", "GENE_OR_GENE_PRODUCT", 552, 556], ["turkeys", "ORGANISM", 566, 573], ["TCoV 4F/4R S fragment", "PROTEIN", 320, 341], ["neutralizing epitopes", "PROTEIN", 353, 374], ["IFA", "PROTEIN", 481, 484], ["turkeys", "SPECIES", 27, 34], ["turkeys", "SPECIES", 99, 106], ["turkeys", "SPECIES", 397, 404], ["turkeys", "SPECIES", 566, 573], ["turkeys", "SPECIES", 27, 34], ["turkeys", "SPECIES", 99, 106], ["TCoV", "SPECIES", 238, 242], ["TCoV", "SPECIES", 320, 324], ["turkeys", "SPECIES", 397, 404], ["TCoV", "SPECIES", 552, 556], ["turkeys", "SPECIES", 566, 573], ["VC", "TEST", 117, 119], ["NC", "TREATMENT", 127, 129], ["ResultsDNA vaccination", "TREATMENT", 247, 269], ["a DNA", "TEST", 275, 280], ["prime protein", "TREATMENT", 281, 294], ["boost approach", "TREATMENT", 295, 309], ["TCoV 4F", "TREATMENT", 320, 327], ["4R S fragment", "TREATMENT", 328, 341], ["neutralizing epitopes", "TREATMENT", 353, 374], ["clinical signs", "TEST", 413, 427], ["decreased the intensity", "PROBLEM", 429, 452], ["IFA", "TEST", 481, 484], ["positive enterocytes", "PROBLEM", 485, 505], ["diminished the viral load", "PROBLEM", 510, 535], ["3V", "ANATOMY", 120, 122], ["no", "UNCERTAINTY", 160, 162], ["significant", "OBSERVATION_MODIFIER", 163, 174], ["decreased", "OBSERVATION_MODIFIER", 429, 438], ["intensity", "OBSERVATION_MODIFIER", 443, 452], ["positive enterocytes", "OBSERVATION", 485, 505], ["diminished", "OBSERVATION_MODIFIER", 510, 520], ["viral load", "OBSERVATION", 525, 535], ["ileum", "ANATOMY", 543, 548], ["infected", "OBSERVATION", 557, 565]]], ["In trial 1, the turkeys in G1-750DP showed less clinical signs and significantly lower IFA scores (p< 0.05) than the un-vaccinated turkeys at 3 and 10 dpi.", [["G1-750DP", "CHEMICAL", 27, 35], ["turkeys", "ORGANISM", 16, 23], ["turkeys", "ORGANISM", 131, 138], ["turkeys", "SPECIES", 16, 23], ["turkeys", "SPECIES", 131, 138], ["turkeys", "SPECIES", 16, 23], ["turkeys", "SPECIES", 131, 138], ["significantly lower IFA scores", "PROBLEM", 67, 97], ["the un-vaccinated turkeys", "TREATMENT", 113, 138]]], ["The viral RNA loads determined by qRT-PCR were also lower in the ileum of vaccinated turkeys than un-vaccinated turkeys although there was no statistical difference (p> 0.05) probably due to sample variations.", [["ileum", "ANATOMY", 65, 70], ["sample", "ANATOMY", 191, 197], ["ileum", "ORGAN", 65, 70], ["turkeys", "ORGANISM", 85, 92], ["turkeys", "ORGANISM", 112, 119], ["turkeys", "SPECIES", 85, 92], ["turkeys", "SPECIES", 112, 119], ["turkeys", "SPECIES", 85, 92], ["turkeys", "SPECIES", 112, 119], ["The viral RNA loads", "TEST", 0, 19], ["qRT-PCR", "TEST", 34, 41], ["statistical difference", "PROBLEM", 142, 164], ["sample variations", "PROBLEM", 191, 208], ["viral RNA loads", "OBSERVATION", 4, 19], ["ileum", "ANATOMY", 65, 70], ["no", "UNCERTAINTY", 139, 141], ["probably due to", "UNCERTAINTY", 175, 190], ["sample variations", "OBSERVATION", 191, 208]]], ["In trial 2, the IFA scores and viral loads were lower in turkeys from G2-100DPH and G3-750DDP than those in non-vaccinated turkeys at 3 and 10 dpi.", [["G2-100DPH", "CHEMICAL", 70, 79], ["G3-750DDP", "CHEMICAL", 84, 93], ["turkeys", "ORGANISM", 57, 64], ["G3-750DDP", "CELL", 84, 93], ["turkeys", "ORGANISM", 123, 130], ["turkeys", "SPECIES", 57, 64], ["turkeys", "SPECIES", 123, 130], ["turkeys", "SPECIES", 57, 64], ["turkeys", "SPECIES", 123, 130], ["the IFA scores", "TEST", 12, 26], ["viral loads", "TEST", 31, 42], ["viral loads", "OBSERVATION", 31, 42]]], ["The turkeys in G2-100DPH had lower viral RNA loads in the ileum than those in G3-750DDP and un-vaccinated turkeys.", [["ileum", "ANATOMY", 58, 63], ["G2-100DPH", "CHEMICAL", 15, 24], ["G3-750DDP", "CHEMICAL", 78, 87], ["turkeys", "ORGANISM", 4, 11], ["ileum", "ORGAN", 58, 63], ["G3-750DDP", "CELL", 78, 87], ["turkeys", "ORGANISM", 106, 113], ["turkeys", "SPECIES", 4, 11], ["turkeys", "SPECIES", 106, 113], ["turkeys", "SPECIES", 106, 113], ["lower viral RNA loads in the ileum", "PROBLEM", 29, 63], ["viral RNA loads", "OBSERVATION", 35, 50], ["ileum", "ANATOMY", 58, 63]]], ["Turkeys in G2-100DPH also had significantly lower IFA scores than those in the other groups at 10 dpi (p< 0.05).Antibody responses to vaccination by ELISA ::: ResultsVaccination of TCoV 4F/4R S fragment containing neutralizing epitopes induced significant antibody response in both trials (Fig. 3).", [["G2-100DPH", "CELL", 11, 20], ["TCoV 4F/4R S fragment", "PROTEIN", 181, 202], ["neutralizing epitopes", "PROTEIN", 214, 235], ["TCoV", "SPECIES", 181, 185], ["significantly lower IFA scores", "PROBLEM", 30, 60], ["Antibody responses", "TEST", 112, 130], ["vaccination", "TEST", 134, 145], ["ELISA", "TEST", 149, 154], ["ResultsVaccination", "TEST", 159, 177], ["TCoV", "TEST", 181, 185], ["4R S fragment", "PROBLEM", 189, 202], ["neutralizing epitopes", "PROBLEM", 214, 235], ["significant antibody response", "PROBLEM", 244, 273], ["significant", "OBSERVATION_MODIFIER", 244, 255], ["antibody response", "OBSERVATION", 256, 273]]], ["At one day before viral challenge, 5 out of 15 turkeys in G1-750DP, 6 out of 15 turkeys in G2-100DPH, and 11 out of 15 turkeys in G3-750DDP had the levels of antibodies over O.D. value of 0.5.", [["G1-750DP", "CHEMICAL", 58, 66], ["G2-100DPH", "CHEMICAL", 91, 100], ["G3-750DDP", "CHEMICAL", 130, 139], ["turkeys", "ORGANISM", 47, 54], ["turkeys", "ORGANISM", 80, 87], ["turkeys", "ORGANISM", 119, 126], ["G3-750DDP", "SIMPLE_CHEMICAL", 130, 139], ["antibodies", "PROTEIN", 158, 168], ["turkeys", "SPECIES", 47, 54], ["turkeys", "SPECIES", 80, 87], ["turkeys", "SPECIES", 119, 126], ["turkeys", "SPECIES", 47, 54], ["turkeys", "SPECIES", 80, 87], ["turkeys", "SPECIES", 119, 126], ["viral challenge", "TEST", 18, 33], ["antibodies", "TEST", 158, 168]]], ["Significantly increased antibody levels (p< 0.05) were detected in the turkeys in G1-750DP at 3 dpi compared to those in G1-750DP before challenge in trail 1.", [["G1-750DP", "CHEMICAL", 121, 129], ["turkeys", "SPECIES", 71, 78], ["turkeys", "SPECIES", 71, 78], ["Significantly increased antibody levels", "PROBLEM", 0, 39], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["antibody levels", "OBSERVATION", 24, 39]]], ["In trial 2, the levels of antibodies in the turkeys in G3-750DDP were higher than those in G2-100DPH before and after challenge with no statistical significance (p> 0.05).", [["G3-750DDP", "CHEMICAL", 55, 64], ["turkeys", "ORGANISM", 44, 51], ["G3-750DDP", "SIMPLE_CHEMICAL", 55, 64], ["G2-100DPH", "CELL", 91, 100], ["antibodies", "PROTEIN", 26, 36], ["turkeys", "SPECIES", 44, 51], ["the levels", "TEST", 12, 22], ["antibodies", "TEST", 26, 36]]], ["The levels of antibodies in turkeys in G2-100DPH and G3-750DDP were significantly higher (p< 0.05) than those found in un-vaccinated turkeys before and after challenge.", [["G2-100DPH", "CHEMICAL", 39, 48], ["G3-750DDP", "CHEMICAL", 53, 62], ["turkeys", "ORGANISM", 28, 35], ["G2-100DPH", "CELL", 39, 48], ["G3-750DDP", "SIMPLE_CHEMICAL", 53, 62], ["turkeys", "ORGANISM", 133, 140], ["antibodies", "PROTEIN", 14, 24], ["turkeys", "SPECIES", 28, 35], ["turkeys", "SPECIES", 133, 140], ["turkeys", "SPECIES", 28, 35], ["turkeys", "SPECIES", 133, 140], ["The levels", "TEST", 0, 10], ["antibodies", "TEST", 14, 24], ["G3", "TEST", 53, 55]]], ["With one more dose of 750 \u03bcg DNA vaccine pTriEx3-4F/4R, the turkeys in G3-750DDP produced significantly higher (p< 0.05) antibodies than those in G1-750DP before viral challenge.", [["pTriEx3-4F/4R", "CHEMICAL", 41, 54], ["G3-750DDP", "CHEMICAL", 71, 80], ["G1-750DP", "CHEMICAL", 146, 154], ["DNA", "CELLULAR_COMPONENT", 29, 32], ["pTriEx3-4F/4R", "GENE_OR_GENE_PRODUCT", 41, 54], ["turkeys", "ORGANISM", 60, 67], ["G3-750DDP", "SIMPLE_CHEMICAL", 71, 80], ["pTriEx3", "PROTEIN", 41, 48], ["turkeys", "SPECIES", 60, 67], ["turkeys", "SPECIES", 60, 67], ["antibodies", "TEST", 121, 131], ["viral challenge", "TREATMENT", 162, 177]]], ["With an extra dose of 100 \u03bcg DNA vaccine incorporated with PEI and HA, the turkeys in G2-100DPH elicited higher antibodies than those in G1-750DP before challenge although no significant differences were found (p> 0.05).", [["PEI", "CHEMICAL", 59, 62], ["G2-100DPH", "CHEMICAL", 86, 95], ["G1-750DP", "CHEMICAL", 137, 145], ["PEI", "CHEMICAL", 59, 62], ["DNA", "CELLULAR_COMPONENT", 29, 32], ["PEI", "SIMPLE_CHEMICAL", 59, 62], ["turkeys", "ORGANISM", 75, 82], ["G2-100DPH", "SIMPLE_CHEMICAL", 86, 95], ["G1-750DP", "CELL", 137, 145], ["turkeys", "SPECIES", 75, 82], ["turkeys", "SPECIES", 75, 82], ["an extra dose of 100 \u03bcg DNA vaccine", "TREATMENT", 5, 40], ["PEI", "TREATMENT", 59, 62], ["HA", "PROBLEM", 67, 69], ["higher antibodies", "PROBLEM", 105, 122]]], ["In both trials, vaccinated turkeys responded to TCoV infection much faster than non-vaccinated turkeys and had significantly increased antibody levels detected at 3 dpi (p< 0.05).VN antibody responses to vaccination ::: ResultsSignificantly higher (p< 0.05) VN antibodies against TCoV were elicited in vaccinated turkeys before and after challenge by TCoV (Fig. 4).", [["TCoV", "CHEMICAL", 48, 52], ["infection", "DISEASE", 53, 62], ["turkeys", "ORGANISM", 27, 34], ["TCoV", "ORGANISM", 48, 52], ["turkeys", "ORGANISM", 95, 102], ["VN antibody", "GENE_OR_GENE_PRODUCT", 179, 190], ["VN antibodies", "GENE_OR_GENE_PRODUCT", 258, 271], ["TCoV", "GENE_OR_GENE_PRODUCT", 280, 284], ["turkeys", "ORGANISM", 313, 320], ["VN antibody", "PROTEIN", 179, 190], ["VN antibodies", "PROTEIN", 258, 271], ["TCoV", "PROTEIN", 280, 284], ["turkeys", "SPECIES", 27, 34], ["turkeys", "SPECIES", 95, 102], ["turkeys", "SPECIES", 313, 320], ["turkeys", "SPECIES", 27, 34], ["TCoV", "SPECIES", 48, 52], ["turkeys", "SPECIES", 95, 102], ["TCoV", "SPECIES", 280, 284], ["turkeys", "SPECIES", 313, 320], ["TCoV", "SPECIES", 351, 355], ["vaccinated turkeys", "TREATMENT", 16, 34], ["TCoV infection", "PROBLEM", 48, 62], ["significantly increased antibody levels", "PROBLEM", 111, 150], ["VN antibodies", "TEST", 258, 271], ["TCoV", "PROBLEM", 280, 284], ["antibody levels", "OBSERVATION", 135, 150]]], ["In both trials, the serum collected from vector control turkeys before viral challenge could not neutralize TCoV infection in embryonated eggs and the VN titers in the serum collected from non-vaccinated turkeys at 3 and 10 dpi were from 4 to 8.", [["serum", "ANATOMY", 20, 25], ["eggs", "ANATOMY", 138, 142], ["serum", "ANATOMY", 168, 173], ["TCoV", "CHEMICAL", 108, 112], ["infection", "DISEASE", 113, 122], ["serum", "ORGANISM_SUBSTANCE", 20, 25], ["turkeys", "ORGANISM", 56, 63], ["TCoV", "GENE_OR_GENE_PRODUCT", 108, 112], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 138, 142], ["VN", "GENE_OR_GENE_PRODUCT", 151, 153], ["serum", "ORGANISM_SUBSTANCE", 168, 173], ["turkeys", "ORGANISM", 204, 211], ["turkeys", "SPECIES", 56, 63], ["turkeys", "SPECIES", 204, 211], ["turkeys", "SPECIES", 56, 63], ["TCoV", "SPECIES", 108, 112], ["turkeys", "SPECIES", 204, 211], ["the serum", "TEST", 16, 25], ["vector control turkeys", "TREATMENT", 41, 63], ["viral challenge", "TREATMENT", 71, 86], ["TCoV infection", "PROBLEM", 108, 122], ["embryonated eggs", "PROBLEM", 126, 142], ["the VN titers", "TEST", 147, 160], ["the serum", "TEST", 164, 173], ["infection", "OBSERVATION", 113, 122]]], ["At one day before viral challenge, the VN titers over 4 were detected in 2 out of 5 turkeys in G1-750DP, 1 out of 5 turkeys in G2-100DPH, and 2 out of 5 turkeys in G3-750DDP.", [["G3-750DDP", "CHEMICAL", 164, 173], ["VN", "GENE_OR_GENE_PRODUCT", 39, 41], ["turkeys", "ORGANISM", 84, 91], ["turkeys", "ORGANISM", 116, 123], ["turkeys", "ORGANISM", 153, 160], ["G3-750DDP", "SIMPLE_CHEMICAL", 164, 173], ["VN", "PROTEIN", 39, 41], ["turkeys", "SPECIES", 84, 91], ["turkeys", "SPECIES", 116, 123], ["turkeys", "SPECIES", 153, 160], ["turkeys", "SPECIES", 84, 91], ["turkeys", "SPECIES", 153, 160], ["viral challenge", "TREATMENT", 18, 33], ["the VN titers", "TEST", 35, 48]]], ["At 3 dpi, 4 out of 5 turkeys in G1-750DP, 2 out 5 turkeys in G2-100DPH, and 5 out of 5 turkeys in G 3-750DDP produced the VN titers over 4.", [["G2-100DPH", "CHEMICAL", 61, 70], ["G 3-750DDP", "CHEMICAL", 98, 108], ["turkeys", "ORGANISM", 21, 28], ["turkeys", "ORGANISM", 50, 57], ["turkeys", "ORGANISM", 87, 94], ["G 3-750DDP", "SIMPLE_CHEMICAL", 98, 108], ["VN", "GENE_OR_GENE_PRODUCT", 122, 124], ["turkeys", "SPECIES", 21, 28], ["turkeys", "SPECIES", 50, 57], ["turkeys", "SPECIES", 87, 94], ["turkeys", "SPECIES", 87, 94]]], ["At 10 dpi, all vaccinated turkeys responded to the infection of TCoV.", [["infection", "DISEASE", 51, 60], ["TCoV", "CHEMICAL", 64, 68], ["turkeys", "ORGANISM", 26, 33], ["TCoV", "CANCER", 64, 68], ["turkeys", "SPECIES", 26, 33], ["turkeys", "SPECIES", 26, 33], ["TCoV", "SPECIES", 64, 68], ["all vaccinated turkeys", "TREATMENT", 11, 33], ["the infection of TCoV", "PROBLEM", 47, 68], ["infection", "OBSERVATION", 51, 60]]], ["In trial 1, the VN titer was detectable in turkeys from G1-750DP before challenge, increased significantly at 3 dpi (p< 0.05), and declined at 10 dpi.", [["G1-750DP", "CHEMICAL", 56, 64], ["VN", "GENE_OR_GENE_PRODUCT", 16, 18], ["turkeys", "ORGANISM", 43, 50], ["G1-750DP", "CELL", 56, 64], ["VN", "PROTEIN", 16, 18], ["turkeys", "SPECIES", 43, 50], ["turkeys", "SPECIES", 43, 50], ["the VN titer", "TEST", 12, 24]]], ["In trial 2, the turkeys in G3-750DDP had higher VN titer than those in G2-100DPH and non-vaccinated turkeys before challenge.", [["G3-750DDP", "CHEMICAL", 27, 36], ["G2-100DPH", "CHEMICAL", 71, 80], ["turkeys", "ORGANISM", 16, 23], ["G3-750DDP", "SIMPLE_CHEMICAL", 27, 36], ["VN", "GENE_OR_GENE_PRODUCT", 48, 50], ["G2-100DPH", "CELL", 71, 80], ["turkeys", "ORGANISM", 100, 107], ["VN", "PROTEIN", 48, 50], ["turkeys", "SPECIES", 16, 23], ["turkeys", "SPECIES", 100, 107], ["turkeys", "SPECIES", 16, 23], ["turkeys", "SPECIES", 100, 107], ["higher VN titer", "PROBLEM", 41, 56]]], ["The turkeys in G3-750DDP had faster neutralizing antibody responses than those in G2-100DPH and VC-3V by producing significantly higher level (p< 0.05) of neutralizing antibody at 3 dpi while the turkeys in G2-100DPH did not produce significantly higher level (p> 0.05) of neutralizing antibody until 10 dpi.Turkey IFN\u03b3 transcription level ::: ResultsIn trial 1, the transcription of IFN\u03b3 gene in turkeys from G1-750DP was up-regulated 2.4-fold before viral challenge, 2.06-fold at 3 dpi, and 0.93-fold at 10 dpi (Fig. 5A).", [["G3-750DDP", "CHEMICAL", 15, 24], ["VC-3V", "CHEMICAL", 96, 101], ["G1-750DP", "CHEMICAL", 410, 418], ["turkeys", "ORGANISM", 4, 11], ["G2-100DPH", "CELL", 82, 91], ["VC-3V", "CELL", 96, 101], ["turkeys", "ORGANISM", 196, 203], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 315, 319], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 384, 388], ["turkeys", "ORGANISM", 397, 404], ["neutralizing antibody", "PROTEIN", 155, 176], ["neutralizing antibody", "PROTEIN", 273, 294], ["IFN", "PROTEIN", 315, 318], ["IFN\u03b3 gene", "DNA", 384, 393], ["turkeys", "SPECIES", 4, 11], ["turkeys", "SPECIES", 196, 203], ["turkeys", "SPECIES", 397, 404], ["VC-3V", "SPECIES", 96, 101], ["turkeys", "SPECIES", 196, 203], ["turkeys", "SPECIES", 397, 404], ["faster neutralizing antibody responses", "PROBLEM", 29, 67], ["G2", "TEST", 82, 84], ["VC", "TEST", 96, 98], ["neutralizing antibody", "TEST", 155, 176], ["neutralizing antibody", "PROBLEM", 273, 294], ["viral challenge", "TEST", 452, 467]]], ["Vector control turkeys had lower IFN\u03b3 mRNA levels compared to turkeys in G1-750DP before challenge but showed a similar pattern of IFN\u03b3 induction after viral challenge.", [["G1-750DP", "CHEMICAL", 73, 81], ["turkeys", "ORGANISM", 15, 22], ["G1-750DP", "CELL", 73, 81], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 131, 135], ["IFN", "PROTEIN", 33, 36], ["mRNA", "RNA", 38, 42], ["IFN\u03b3", "PROTEIN", 131, 135], ["turkeys", "SPECIES", 62, 69], ["turkeys", "SPECIES", 62, 69], ["Vector control turkeys", "TREATMENT", 0, 22], ["mRNA levels", "TEST", 38, 49], ["IFN\u03b3 induction", "TREATMENT", 131, 145], ["viral challenge", "TREATMENT", 152, 167]]], ["There was no statistical significance (p> 0.05) among the different concentrations of IFN\u03b3 produced by turkeys from the groups NC-2V, VC-2C, and G1-750DP before and after challenge.", [["IFN", "CHEMICAL", 86, 89], ["G1-750DP", "CHEMICAL", 145, 153], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 86, 90], ["turkeys", "ORGANISM", 103, 110], ["NC-2V", "CELL", 127, 132], ["VC-2C", "CELL", 134, 139], ["G1-750DP", "CELL", 145, 153], ["IFN\u03b3", "PROTEIN", 86, 90], ["turkeys", "SPECIES", 103, 110], ["turkeys", "SPECIES", 103, 110], ["IFN\u03b3", "TREATMENT", 86, 90], ["NC", "TEST", 127, 129], ["VC", "TEST", 134, 136], ["no", "UNCERTAINTY", 10, 12]]], ["In trial 2, the transcription of IFN\u03b3 gene in turkeys from VC-3V, G2-100DPH, and G3-750DDP was down-regulated significantly before challenge (p< 0.05) and the mRNA levels were only 41, 8, and 18% to the level found in NC-3V turkeys, respectively (Fig. 5B).", [["VC-3V", "ANATOMY", 59, 64], ["VC-3V", "CHEMICAL", 59, 64], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 33, 37], ["turkeys", "ORGANISM", 46, 53], ["VC-3V", "CELL", 59, 64], ["G2-100DPH", "CELL", 66, 75], ["G3-750DDP", "CELL", 81, 90], ["NC-3V turkeys", "ORGANISM", 218, 231], ["IFN\u03b3 gene", "DNA", 33, 42], ["turkeys", "SPECIES", 46, 53], ["turkeys", "SPECIES", 224, 231], ["turkeys", "SPECIES", 46, 53], ["NC-3V turkeys", "SPECIES", 218, 231], ["IFN", "TREATMENT", 33, 36], ["VC", "TEST", 59, 61], ["G2", "TEST", 66, 68], ["G3", "TEST", 81, 83], ["the mRNA levels", "TEST", 155, 170], ["NC", "TEST", 218, 220]]], ["After challenge, the IFN\u03b3 levels increased significantly to 2.4-fold in turkeys from G3-750DDP and VC-3V (p< 0.05).", [["G3-750DDP", "CHEMICAL", 85, 94], ["VC-3V", "CHEMICAL", 99, 104], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 21, 25], ["turkeys", "ORGANISM", 72, 79], ["G3-750DDP", "CELL", 85, 94], ["VC-3V", "CELL", 99, 104], ["IFN\u03b3", "PROTEIN", 21, 25], ["turkeys", "SPECIES", 72, 79], ["turkeys", "SPECIES", 72, 79], ["the IFN\u03b3 levels", "TEST", 17, 32], ["G3", "TEST", 85, 87], ["VC", "TEST", 99, 101]]], ["Turkeys from G2-100DPH had higher mRNA level of IFN\u03b3 at 3 dpi compared to the level detected before challenge.", [["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 48, 52], ["IFN\u03b3", "PROTEIN", 48, 52]]], ["At 10 dpi, all turkeys including NC-3V turkeys had similar transcription level of IFN\u03b3 mRNA.DiscussionThe present study has demonstrated that the neutralizing epitope-containing TCoV S fragment encompassing the carboxyl-terminus S1 and the amino-terminus S2 (amino acid residue 482\u2013678, 4F/4R fragment) can induce neutralizing antibodies and provide partial protection against infectious challenge by TCoV.", [["amino-terminus", "CHEMICAL", 240, 254], ["amino acid", "CHEMICAL", 259, 269], ["TCoV", "CHEMICAL", 401, 405], ["carboxyl", "CHEMICAL", 211, 219], ["amino", "CHEMICAL", 240, 245], ["amino acid", "CHEMICAL", 259, 269], ["turkeys", "ORGANISM", 15, 22], ["NC-3V turkeys", "ORGANISM", 33, 46], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 82, 86], ["amino-terminus S2", "AMINO_ACID", 240, 257], ["amino acid", "AMINO_ACID", 259, 269], ["TCoV", "SIMPLE_CHEMICAL", 401, 405], ["IFN\u03b3 mRNA", "RNA", 82, 91], ["TCoV S fragment", "PROTEIN", 178, 193], ["carboxyl-terminus S1", "PROTEIN", 211, 231], ["amino-terminus S2", "PROTEIN", 240, 257], ["4F", "PROTEIN", 287, 289], ["neutralizing antibodies", "PROTEIN", 314, 337], ["turkeys", "SPECIES", 15, 22], ["turkeys", "SPECIES", 39, 46], ["turkeys", "SPECIES", 15, 22], ["TCoV", "SPECIES", 401, 405], ["NC", "TREATMENT", 33, 35], ["The present study", "TEST", 102, 119], ["the neutralizing epitope", "TREATMENT", 142, 166], ["TCoV S fragment", "PROBLEM", 178, 193], ["amino acid residue", "TEST", 259, 277], ["4F/4R fragment", "TREATMENT", 287, 301], ["neutralizing antibodies", "TREATMENT", 314, 337], ["terminus", "ANATOMY_MODIFIER", 220, 228], ["S1", "ANATOMY", 229, 231], ["amino", "ANATOMY_MODIFIER", 240, 245], ["-terminus S2", "ANATOMY", 245, 257]]], ["The full-length S protein of SARS-CoV has been shown to activate cell-mediated immune responses and induce antibody production to block viral binding, fusion, and infection (He et al., 2006, Kam et al., 2007).", [["cell", "ANATOMY", 65, 69], ["SARS", "DISEASE", 29, 33], ["infection", "DISEASE", 163, 172], ["SARS-CoV", "ORGANISM", 29, 37], ["cell", "CELL", 65, 69], ["full-length S protein", "PROTEIN", 4, 25], ["SARS-CoV", "SPECIES", 29, 37], ["SARS", "PROBLEM", 29, 33], ["antibody production", "PROBLEM", 107, 126], ["block viral binding", "PROBLEM", 130, 149], ["fusion", "PROBLEM", 151, 157], ["infection", "PROBLEM", 163, 172]]], ["Most conformation-dependent neutralizing epitopes are located in the S1 subunit of IBV (Kant et al., 1992) but there are conformation-independent neutralizing epitopes found in 47 amino acids of S1 carboxyl-terminus and 20 amino acids of S2 amino-terminus (Kusters et al., 1989).", [["amino acids", "CHEMICAL", 180, 191], ["amino acids", "CHEMICAL", 223, 234], ["amino acids", "CHEMICAL", 180, 191], ["carboxyl", "CHEMICAL", 198, 206], ["amino acids", "CHEMICAL", 223, 234], ["amino", "CHEMICAL", 241, 246], ["IBV", "ORGANISM", 83, 86], ["amino acids", "AMINO_ACID", 180, 191], ["amino acids", "AMINO_ACID", 223, 234], ["amino", "AMINO_ACID", 241, 246], ["neutralizing epitopes", "PROTEIN", 28, 49], ["S1 subunit", "PROTEIN", 69, 79], ["neutralizing epitopes", "PROTEIN", 146, 167], ["S1 carboxyl-terminus", "PROTEIN", 195, 215], ["S2 amino-terminus", "PROTEIN", 238, 255], ["dependent neutralizing epitopes", "PROBLEM", 18, 49], ["independent neutralizing epitopes", "PROBLEM", 134, 167], ["amino acids", "TEST", 180, 191], ["S1 carboxyl-terminus", "TREATMENT", 195, 215], ["dependent", "OBSERVATION_MODIFIER", 18, 27], ["neutralizing", "OBSERVATION", 28, 40]]], ["Chickens inoculated with peptides with antigenic epitopes corresponding to amino acid residue 294\u2013314 (S1), 532\u2013537 (S1), or 566\u2013584 (S2) of IBV produced antibodies that provided more than 50% protection against IBV infection in kidney but no protection in trachea (Ignjatovic and Sapats, 2005).", [["kidney", "ANATOMY", 229, 235], ["trachea", "ANATOMY", 257, 264], ["amino acid", "CHEMICAL", 75, 85], ["IBV infection", "DISEASE", 212, 225], ["amino acid", "CHEMICAL", 75, 85], ["Chickens", "ORGANISM", 0, 8], ["amino acid", "AMINO_ACID", 75, 85], ["IBV", "ORGANISM", 141, 144], ["IBV", "ORGANISM", 212, 215], ["kidney", "ORGAN", 229, 235], ["trachea", "ORGAN", 257, 264], ["antigenic epitopes", "PROTEIN", 39, 57], ["antibodies", "PROTEIN", 154, 164], ["Chickens", "SPECIES", 0, 8], ["Chickens", "SPECIES", 0, 8], ["IBV", "SPECIES", 141, 144], ["IBV", "SPECIES", 212, 215], ["Chickens inoculated with peptides", "PROBLEM", 0, 33], ["antigenic epitopes", "PROBLEM", 39, 57], ["amino acid residue", "TEST", 75, 93], ["IBV produced antibodies", "PROBLEM", 141, 164], ["IBV infection in kidney", "PROBLEM", 212, 235], ["infection", "OBSERVATION", 216, 225], ["kidney", "ANATOMY", 229, 235], ["no", "UNCERTAINTY", 240, 242], ["trachea", "ANATOMY", 257, 264]]], ["An exposed domain in the S1 subunit of SARS-CoV from amino acid residue 485\u2013625 induced antibody production to inhibit viral infection (Zhou et al., 2004).", [["SARS", "DISEASE", 39, 43], ["amino acid residue 485\u2013625", "CHEMICAL", 53, 79], ["viral infection", "DISEASE", 119, 134], ["amino acid", "CHEMICAL", 53, 63], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 39, 47], ["amino acid", "AMINO_ACID", 53, 63], ["residue", "AMINO_ACID", 64, 71], ["485\u2013625", "AMINO_ACID", 72, 79], ["S1 subunit", "PROTEIN", 25, 35], ["SARS-CoV", "PROTEIN", 39, 47], ["SARS-CoV", "SPECIES", 39, 47], ["An exposed domain", "PROBLEM", 0, 17], ["SARS", "PROBLEM", 39, 43], ["amino acid residue", "PROBLEM", 53, 71], ["induced antibody production", "PROBLEM", 80, 107], ["viral infection", "PROBLEM", 119, 134], ["S1", "ANATOMY", 25, 27], ["SARS", "OBSERVATION", 39, 43]]], ["These studies suggested that the S fragment of coronavirus contains neutralizing epitopes and is capable of eliciting a protective antiviral antibody response.DiscussionDNA vaccination can generate both humoral and cellular immunity specific to protective antigens of various pathogens.", [["cellular", "ANATOMY", 215, 223], ["coronavirus", "ORGANISM", 47, 58], ["cellular", "CELL", 215, 223], ["S fragment", "DNA", 33, 43], ["neutralizing epitopes", "PROTEIN", 68, 89], ["These studies", "TEST", 0, 13], ["the S fragment of coronavirus", "PROBLEM", 29, 58], ["neutralizing epitopes", "PROBLEM", 68, 89], ["a protective antiviral antibody response", "TREATMENT", 118, 158], ["DiscussionDNA vaccination", "TREATMENT", 159, 184], ["various pathogens", "PROBLEM", 268, 285], ["coronavirus", "OBSERVATION", 47, 58], ["neutralizing epitopes", "OBSERVATION", 68, 89]]], ["After the delivery of DNA plasmids into cells, antigenic proteins are endogenously produced and presented by MHC class I, thus inducing CD8 cytotoxic T-cell responses.", [["plasmids", "ANATOMY", 26, 34], ["cells", "ANATOMY", 40, 45], ["CD8 cytotoxic T-cell", "ANATOMY", 136, 156], ["DNA", "CELLULAR_COMPONENT", 22, 25], ["cells", "CELL", 40, 45], ["MHC class I", "GENE_OR_GENE_PRODUCT", 109, 120], ["CD8", "GENE_OR_GENE_PRODUCT", 136, 139], ["T-cell", "CELL", 150, 156], ["DNA plasmids", "DNA", 22, 34], ["antigenic proteins", "PROTEIN", 47, 65], ["MHC class I", "PROTEIN", 109, 120], ["CD8", "PROTEIN", 136, 139], ["the delivery of DNA plasmids into cells", "TREATMENT", 6, 45], ["antigenic proteins", "TEST", 47, 65]]], ["Therefore, DNA vaccines have the ability to mimic the effects of live attenuated vaccine without reversion to virulence due to recombination or mutations in live attenuated pathogens.", [["DNA", "CELLULAR_COMPONENT", 11, 14], ["DNA vaccines", "TREATMENT", 11, 23], ["live attenuated vaccine", "TREATMENT", 65, 88], ["virulence", "PROBLEM", 110, 119], ["recombination", "PROBLEM", 127, 140], ["mutations", "PROBLEM", 144, 153], ["live attenuated pathogens", "PROBLEM", 157, 182]]], ["Plasmids can be easily produced in bacteria without the risk of improper folding and instability to express recombinant proteins (Laddy and Weiner, 2006, Coban et al., 2008).", [["recombinant proteins", "PROTEIN", 108, 128], ["Plasmids", "TREATMENT", 0, 8], ["bacteria", "PROBLEM", 35, 43], ["improper folding", "PROBLEM", 64, 80], ["improper folding", "OBSERVATION", 64, 80]]], ["Prime-boost strategy and the use of nanoparticles as aid in DNA delivery were undertaken to enhance the immunogenicity and protection efficacy of DNA vaccination in the present study.", [["DNA", "CELLULAR_COMPONENT", 60, 63], ["DNA", "CELLULAR_COMPONENT", 146, 149], ["boost strategy", "TREATMENT", 6, 20], ["nanoparticles", "TREATMENT", 36, 49], ["DNA delivery", "TREATMENT", 60, 72], ["DNA vaccination", "TREATMENT", 146, 161], ["the present study", "TEST", 165, 182]]], ["According to Woo's study (Woo et al., 2005), mice primed intramuscularly with S1 DNA vaccine and boosted with recombinant S1 protein produced by E. coli was shown to generate the highest neutralizing antibody titer against SARS-CoV infection compared to DNA vaccine or S1 protein alone.", [["intramuscularly", "ANATOMY", 57, 72], ["SARS-CoV infection", "DISEASE", 223, 241], ["mice", "ORGANISM", 45, 49], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["S1", "GENE_OR_GENE_PRODUCT", 122, 124], ["E. coli", "ORGANISM", 145, 152], ["SARS-CoV", "ORGANISM", 223, 231], ["DNA", "CELLULAR_COMPONENT", 254, 257], ["recombinant S1 protein", "PROTEIN", 110, 132], ["S1 protein", "PROTEIN", 269, 279], ["mice", "SPECIES", 45, 49], ["E. coli", "SPECIES", 145, 152], ["mice", "SPECIES", 45, 49], ["E. coli", "SPECIES", 145, 152], ["SARS-CoV", "SPECIES", 223, 231], ["S1 DNA vaccine", "TREATMENT", 78, 92], ["recombinant S1 protein", "TREATMENT", 110, 132], ["E. coli", "PROBLEM", 145, 152], ["the highest neutralizing antibody titer", "TEST", 175, 214], ["SARS", "PROBLEM", 223, 227], ["CoV infection", "PROBLEM", 228, 241], ["DNA vaccine", "TREATMENT", 254, 265], ["infection", "OBSERVATION", 232, 241]]], ["On the other hand, recombinant S1 protein expressed by E. coli induced high IgG levels but not high neutralizing antibody titer.", [["S1", "GENE_OR_GENE_PRODUCT", 31, 33], ["E. coli", "ORGANISM", 55, 62], ["IgG", "GENE_OR_GENE_PRODUCT", 76, 79], ["recombinant S1 protein", "PROTEIN", 19, 41], ["IgG", "PROTEIN", 76, 79], ["E. coli", "SPECIES", 55, 62], ["E. coli", "SPECIES", 55, 62], ["recombinant S1 protein", "TEST", 19, 41], ["E. coli", "PROBLEM", 55, 62], ["high IgG levels", "PROBLEM", 71, 86], ["high neutralizing antibody titer", "PROBLEM", 95, 127], ["E. coli", "OBSERVATION", 55, 62], ["IgG levels", "OBSERVATION", 76, 86]]], ["This may be due to improper conformation and lack of glycosylation from the recombinant S1 protein expressed in a prokaryotic system.", [["recombinant S1 protein", "PROTEIN", 76, 98], ["improper conformation", "PROBLEM", 19, 40], ["glycosylation", "TREATMENT", 53, 66], ["the recombinant S1 protein", "PROBLEM", 72, 98], ["may be due to", "UNCERTAINTY", 5, 18], ["improper conformation", "OBSERVATION", 19, 40]]], ["It appears that the conformation and post-translational modification of the S1 protein expressed in DNA-transfected cells is adequate to induce neutralizing antibodies.", [["cells", "ANATOMY", 116, 121], ["S1", "GENE_OR_GENE_PRODUCT", 76, 78], ["DNA", "CELLULAR_COMPONENT", 100, 103], ["cells", "CELL", 116, 121], ["S1 protein", "PROTEIN", 76, 86], ["DNA-transfected cells", "CELL_LINE", 100, 121], ["neutralizing antibodies", "PROTEIN", 144, 167], ["the S1 protein", "TEST", 72, 86], ["transfected cells", "PROBLEM", 104, 121], ["neutralizing antibodies", "PROBLEM", 144, 167]]], ["Thus, priming with DNA vaccine can overcome the issues related to conformation and glycosylation encountered in vaccination or immunization with recombinant S1 protein (Woo et al., 2005).", [["DNA", "CELLULAR_COMPONENT", 19, 22], ["recombinant S1 protein", "PROTEIN", 145, 167], ["DNA vaccine", "TREATMENT", 19, 30], ["the issues", "PROBLEM", 44, 54], ["glycosylation", "TREATMENT", 83, 96], ["vaccination", "TREATMENT", 112, 123], ["immunization", "TREATMENT", 127, 139]]], ["In addition, the use of biodegradable polymeric nanoparticles is one of the potential means to deliver DNA.", [["polymeric nanoparticles", "SIMPLE_CHEMICAL", 38, 61], ["DNA", "CELLULAR_COMPONENT", 103, 106], ["biodegradable polymeric nanoparticles", "TREATMENT", 24, 61]]], ["By combining the advantages of CLPEI and HA, the DNA-CLPEI-HA (DPH) system had a significantly higher (p< 0.05) transfection efficiency than the other polymer systems (Xu et al., 2009).", [["DPH", "CHEMICAL", 63, 66], ["DPH", "CHEMICAL", 63, 66], ["CLPEI", "SIMPLE_CHEMICAL", 31, 36], ["DNA", "CELLULAR_COMPONENT", 49, 52], ["DPH", "SIMPLE_CHEMICAL", 63, 66], ["CLPEI", "PROBLEM", 31, 36], ["HA", "PROBLEM", 41, 43], ["the DNA", "TEST", 45, 52], ["CLPEI", "TEST", 53, 58], ["HA (DPH) system", "PROBLEM", 59, 74], ["transfection efficiency", "PROBLEM", 112, 135], ["significantly", "OBSERVATION_MODIFIER", 81, 94], ["higher", "OBSERVATION_MODIFIER", 95, 101]]], ["The prime-boost regimen using 100 \u03bcg DNA in DPH complex as the first dose in the present study provided the same protection as the regimen using 750 \u03bcg DNA as the first dose at 3 and 10 dpi.", [["DPH", "CHEMICAL", 44, 47], ["DPH", "CHEMICAL", 44, 47], ["DNA", "CELLULAR_COMPONENT", 37, 40], ["DPH", "SIMPLE_CHEMICAL", 44, 47], ["DNA", "CELLULAR_COMPONENT", 152, 155], ["The prime-boost regimen", "TREATMENT", 0, 23], ["100 \u03bcg DNA in DPH complex", "TREATMENT", 30, 55], ["the regimen", "TREATMENT", 127, 138]]], ["The turkeys vaccinated with 100 \u03bcg DNA in DPH complex did not show any local tissue responses and lesions and had lower IFA scores and viral RNA loads in the ileum than the turkeys receiving 750 \u03bcg DNA as the first dose.", [["tissue", "ANATOMY", 77, 83], ["lesions", "ANATOMY", 98, 105], ["ileum", "ANATOMY", 158, 163], ["DPH", "CHEMICAL", 42, 45], ["DPH", "CHEMICAL", 42, 45], ["turkeys", "ORGANISM", 4, 11], ["DNA", "CELLULAR_COMPONENT", 35, 38], ["DPH", "SIMPLE_CHEMICAL", 42, 45], ["tissue", "TISSUE", 77, 83], ["lesions", "PATHOLOGICAL_FORMATION", 98, 105], ["ileum", "ORGAN", 158, 163], ["turkeys", "ORGANISM", 173, 180], ["DNA", "CELLULAR_COMPONENT", 198, 201], ["turkeys", "SPECIES", 4, 11], ["turkeys", "SPECIES", 173, 180], ["turkeys", "SPECIES", 4, 11], ["turkeys", "SPECIES", 173, 180], ["The turkeys vaccinated", "TREATMENT", 0, 22], ["lesions", "PROBLEM", 98, 105], ["lower IFA scores", "PROBLEM", 114, 130], ["viral RNA loads in the ileum", "PROBLEM", 135, 163], ["lesions", "OBSERVATION", 98, 105], ["viral RNA loads", "OBSERVATION", 135, 150], ["ileum", "ANATOMY", 158, 163]]], ["However, the toxicity was revealed when the chickens received 300 \u03bcg DNA in DPH complex.", [["toxicity", "DISEASE", 13, 21], ["DPH", "CHEMICAL", 76, 79], ["DPH", "CHEMICAL", 76, 79], ["chickens", "ORGANISM", 44, 52], ["DNA", "CELLULAR_COMPONENT", 69, 72], ["DPH", "SIMPLE_CHEMICAL", 76, 79], ["chickens", "SPECIES", 44, 52], ["chickens", "SPECIES", 44, 52], ["the toxicity", "PROBLEM", 9, 21]]], ["Subcutaneous edema and hemorrhage in muscle and liver were observed in the inoculated chickens (unpublished data).", [["Subcutaneous edema", "ANATOMY", 0, 18], ["muscle", "ANATOMY", 37, 43], ["liver", "ANATOMY", 48, 53], ["edema", "DISEASE", 13, 18], ["hemorrhage", "DISEASE", 23, 33], ["Subcutaneous edema", "PATHOLOGICAL_FORMATION", 0, 18], ["muscle", "ORGAN", 37, 43], ["liver", "ORGAN", 48, 53], ["chickens", "ORGANISM", 86, 94], ["chickens", "SPECIES", 86, 94], ["chickens", "SPECIES", 86, 94], ["Subcutaneous edema", "PROBLEM", 0, 18], ["hemorrhage in muscle and liver", "PROBLEM", 23, 53], ["edema", "OBSERVATION", 13, 18], ["hemorrhage", "OBSERVATION", 23, 33], ["muscle", "ANATOMY", 37, 43], ["liver", "ANATOMY", 48, 53], ["inoculated chickens", "OBSERVATION", 75, 94]]], ["Although the application of nanoparticles CLIPEI and HA can increase transfection efficiency of DNA vaccine and enhance protective immune responses triggered by DNA vaccine, but it is also critical to use the appropriate dose that does not cause any toxicity or tissue change.DiscussionPrior to challenge, stronger TCoV-specific antibody responses by TCoV S protein-based antibody-capture ELISA, higher neutralizing antibody titers, and more efficacious protection against infectious challenge by TCoV were seen in turkeys primed with two doses of 750 \u03bcg DNA vaccine than those primed with only one dose of 750 \u03bcg DNA vaccine.", [["tissue", "ANATOMY", 262, 268], ["CLIPEI", "CHEMICAL", 42, 48], ["HA", "CHEMICAL", 53, 55], ["toxicity", "DISEASE", 250, 258], ["TCoV", "CHEMICAL", 497, 501], ["nanoparticles", "SIMPLE_CHEMICAL", 28, 41], ["CLIPEI", "SIMPLE_CHEMICAL", 42, 48], ["HA", "SIMPLE_CHEMICAL", 53, 55], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["DNA", "CELLULAR_COMPONENT", 161, 164], ["tissue", "TISSUE", 262, 268], ["TCoV", "SIMPLE_CHEMICAL", 315, 319], ["TCoV S", "GENE_OR_GENE_PRODUCT", 351, 357], ["TCoV", "SIMPLE_CHEMICAL", 497, 501], ["turkeys", "ORGANISM", 515, 522], ["DNA", "CELLULAR_COMPONENT", 555, 558], ["DNA", "CELLULAR_COMPONENT", 614, 617], ["TCoV", "PROTEIN", 315, 319], ["TCoV S protein", "PROTEIN", 351, 365], ["turkeys", "SPECIES", 515, 522], ["TCoV", "SPECIES", 351, 355], ["TCoV", "SPECIES", 497, 501], ["turkeys", "SPECIES", 515, 522], ["nanoparticles CLIPEI", "TREATMENT", 28, 48], ["HA", "PROBLEM", 53, 55], ["transfection efficiency", "TREATMENT", 69, 92], ["DNA vaccine", "TREATMENT", 96, 107], ["enhance protective immune responses", "TREATMENT", 112, 147], ["DNA vaccine", "TREATMENT", 161, 172], ["any toxicity", "PROBLEM", 246, 258], ["tissue change", "PROBLEM", 262, 275], ["specific antibody responses", "TEST", 320, 347], ["TCoV S protein", "TEST", 351, 365], ["based antibody", "TEST", 366, 380], ["capture ELISA", "TEST", 381, 394], ["higher neutralizing antibody titers", "PROBLEM", 396, 431], ["infectious challenge", "PROBLEM", 473, 493], ["750 \u03bcg DNA vaccine", "TREATMENT", 548, 566], ["750 \u03bcg DNA vaccine", "TREATMENT", 607, 625], ["toxicity", "OBSERVATION", 250, 258], ["tissue", "OBSERVATION", 262, 268]]], ["Such findings indicated that the frequency of DNA vaccination affected the kinetic and magnitude of the protective antibody response.", [["DNA", "CELLULAR_COMPONENT", 46, 49], ["DNA vaccination", "TREATMENT", 46, 61], ["antibody response", "OBSERVATION", 115, 132]]], ["From the study of infectious bursal disease virus (IBDV), chickens vaccinated with one dose of DNA vaccine showed no protection 10 days after viral challenge while chickens that received 2 or 3 doses of DNA vaccine showed 50\u2013100 or 80\u2013100% protection based on IBDV-induced bursal lesion scores (Chang et al., 2002).", [["bursal lesion", "ANATOMY", 273, 286], ["infectious bursal disease", "DISEASE", 18, 43], ["bursal lesion", "DISEASE", 273, 286], ["infectious bursal disease virus", "ORGANISM", 18, 49], ["IBDV", "ORGANISM", 51, 55], ["chickens", "ORGANISM", 58, 66], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["chickens", "ORGANISM", 164, 172], ["DNA", "CELLULAR_COMPONENT", 203, 206], ["IBDV", "ORGANISM", 260, 264], ["bursal lesion", "PATHOLOGICAL_FORMATION", 273, 286], ["infectious bursal disease virus", "SPECIES", 18, 49], ["IBDV", "SPECIES", 51, 55], ["chickens", "SPECIES", 58, 66], ["chickens", "SPECIES", 164, 172], ["infectious bursal disease virus", "SPECIES", 18, 49], ["IBDV", "SPECIES", 51, 55], ["chickens", "SPECIES", 58, 66], ["chickens", "SPECIES", 164, 172], ["IBDV", "SPECIES", 260, 264], ["the study", "TEST", 5, 14], ["infectious bursal disease virus", "PROBLEM", 18, 49], ["chickens vaccinated", "TREATMENT", 58, 77], ["DNA vaccine", "TREATMENT", 95, 106], ["viral challenge", "TREATMENT", 142, 157], ["DNA vaccine", "TREATMENT", 203, 214], ["IBDV", "PROBLEM", 260, 264], ["bursal lesion scores", "PROBLEM", 273, 293], ["infectious", "OBSERVATION_MODIFIER", 18, 28], ["no", "UNCERTAINTY", 114, 116], ["bursal", "ANATOMY", 273, 279], ["lesion", "OBSERVATION", 280, 286]]], ["Additionally, DNA encoding hemagglutinin protein of influenza virus has been shown to increase hemagglutinin-specific antibody production in a dose-responsive manner with single or multiple injections of DNA (Deck et al., 1997, Robinson et al., 1997).", [["influenza virus", "DISEASE", 52, 67], ["DNA", "CELLULAR_COMPONENT", 14, 17], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 27, 40], ["influenza virus", "ORGANISM", 52, 67], ["DNA", "CELLULAR_COMPONENT", 204, 207], ["hemagglutinin protein", "PROTEIN", 27, 48], ["hemagglutinin", "PROTEIN", 95, 108], ["influenza virus", "SPECIES", 52, 67], ["influenza virus", "SPECIES", 52, 67], ["DNA encoding hemagglutinin protein", "PROBLEM", 14, 48], ["influenza virus", "PROBLEM", 52, 67], ["hemagglutinin", "TEST", 95, 108], ["influenza virus", "OBSERVATION", 52, 67]]], ["Therefore, the protective antibody response against TCoV infection can be enhanced by increasing the dosage and/or frequency of the DNA vaccine.DiscussionThe mRNA level of turkey IFN\u03b3 determined by qRT-PCR was used to evaluate the cell-mediated immune responses to vaccination and infectious challenge by TCoV because IFN\u03b3 is primarily produced by active cytotoxic CD8, Th1 CD4 T cells and natural killer cells.", [["cell", "ANATOMY", 231, 235], ["CD8", "ANATOMY", 365, 368], ["Th1 CD4 T cells", "ANATOMY", 370, 385], ["natural killer cells", "ANATOMY", 390, 410], ["TCoV", "CHEMICAL", 52, 56], ["infection", "DISEASE", 57, 66], ["TCoV", "CHEMICAL", 305, 309], ["TCoV", "SIMPLE_CHEMICAL", 52, 56], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["turkey", "ORGANISM", 172, 178], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 179, 183], ["cell", "CELL", 231, 235], ["TCoV", "SIMPLE_CHEMICAL", 305, 309], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 318, 322], ["CD8", "GENE_OR_GENE_PRODUCT", 365, 368], ["natural killer cells", "CELL", 390, 410], ["turkey IFN\u03b3", "PROTEIN", 172, 183], ["IFN\u03b3", "PROTEIN", 318, 322], ["cytotoxic CD8, Th1 CD4 T cells", "CELL_TYPE", 355, 385], ["natural killer cells", "CELL_TYPE", 390, 410], ["turkey", "SPECIES", 172, 178], ["TCoV", "SPECIES", 52, 56], ["turkey", "SPECIES", 172, 178], ["TCoV", "SPECIES", 305, 309], ["the protective antibody response", "TEST", 11, 43], ["TCoV infection", "PROBLEM", 52, 66], ["the DNA vaccine", "TREATMENT", 128, 143], ["PCR", "TEST", 202, 205], ["the cell", "TEST", 227, 235], ["vaccination", "TREATMENT", 265, 276], ["infectious challenge", "TEST", 281, 301], ["IFN", "PROBLEM", 318, 321], ["active", "OBSERVATION_MODIFIER", 348, 354], ["cytotoxic CD8", "OBSERVATION", 355, 368], ["natural killer cells", "OBSERVATION", 390, 410]]], ["No significant up-regulated transcription of IFN\u03b3 was noted after vaccination in the present study, indicating that TCoV 4F/4R S fragment containing the neutralizing epitopes was not actively involved in activation or stimulation of cell-mediated immunity but primarily induced strong humoral immune response to TCoV.", [["cell", "ANATOMY", 233, 237], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 45, 49], ["TCoV 4F", "GENE_OR_GENE_PRODUCT", 116, 123], ["4R S", "GENE_OR_GENE_PRODUCT", 124, 128], ["cell", "CELL", 233, 237], ["TCoV", "SIMPLE_CHEMICAL", 312, 316], ["IFN\u03b3", "PROTEIN", 45, 49], ["TCoV 4F/4R S fragment", "PROTEIN", 116, 137], ["neutralizing epitopes", "PROTEIN", 153, 174], ["TCoV", "PROTEIN", 312, 316], ["IFN", "PROBLEM", 45, 48], ["vaccination", "TREATMENT", 66, 77], ["the present study", "TEST", 81, 98], ["TCoV 4F/4R S fragment", "TREATMENT", 116, 137], ["the neutralizing epitopes", "PROBLEM", 149, 174], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["humoral immune response", "OBSERVATION", 285, 308]]], ["Down-regulated IFN\u03b3 level can result from the reduced number of natural killer cells, macrophages, activated Th1 CD4 T cells, and activated CD8 T cells (Franke et al., 2006) or the increased number of Th2 CD4 T cells (Zheng et al., 2011).", [["natural killer cells", "ANATOMY", 64, 84], ["macrophages", "ANATOMY", 86, 97], ["Th1 CD4 T cells", "ANATOMY", 109, 124], ["CD8 T cells", "ANATOMY", 140, 151], ["Th2 CD4 T cells", "ANATOMY", 201, 216], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 15, 19], ["natural killer cells", "CELL", 64, 84], ["macrophages", "CELL", 86, 97], ["Th1 CD4 T cells", "CELL", 109, 124], ["CD8 T cells", "CELL", 140, 151], ["IFN\u03b3", "PROTEIN", 15, 19], ["natural killer cells", "CELL_TYPE", 64, 84], ["macrophages", "CELL_TYPE", 86, 97], ["Th1 CD4 T cells", "CELL_TYPE", 109, 124], ["activated CD8 T cells", "CELL_TYPE", 130, 151], ["Th2 CD4 T cells", "CELL_TYPE", 201, 216], ["IFN\u03b3 level", "TEST", 15, 25], ["macrophages", "PROBLEM", 86, 97], ["activated Th1 CD4 T cells", "TEST", 99, 124], ["activated CD8 T cells", "PROBLEM", 130, 151], ["natural killer cells", "OBSERVATION", 64, 84], ["increased", "OBSERVATION_MODIFIER", 181, 190], ["number", "OBSERVATION_MODIFIER", 191, 197], ["Th2 CD4", "OBSERVATION", 201, 208]]], ["Physical strained and intramuscular injections may result in stress leading to immunosuppression and inhibition of IFN\u03b3 production (Greenfeld et al., 2007).", [["intramuscular", "ANATOMY", 22, 35], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 22, 35], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 115, 119], ["IFN", "PROTEIN", 115, 118], ["Physical strained and intramuscular injections", "TREATMENT", 0, 46], ["stress", "PROBLEM", 61, 67], ["immunosuppression", "TREATMENT", 79, 96]]], ["In addition, PEI may cause apoptosis and reduce the number of IFN\u03b3-producing cells even though PEI may affect all types of immune cells (Fischer et al., 1999).", [["cells", "ANATOMY", 77, 82], ["immune cells", "ANATOMY", 123, 135], ["PEI", "CHEMICAL", 13, 16], ["PEI", "CHEMICAL", 95, 98], ["PEI", "CHEMICAL", 13, 16], ["PEI", "CHEMICAL", 95, 98], ["PEI", "SIMPLE_CHEMICAL", 13, 16], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 62, 66], ["cells", "CELL", 77, 82], ["PEI", "SIMPLE_CHEMICAL", 95, 98], ["immune cells", "CELL", 123, 135], ["IFN\u03b3-producing cells", "CELL_TYPE", 62, 82], ["immune cells", "CELL_TYPE", 123, 135], ["PEI", "TREATMENT", 13, 16], ["apoptosis", "PROBLEM", 27, 36], ["IFN\u03b3-producing cells", "TREATMENT", 62, 82], ["PEI", "PROBLEM", 95, 98], ["may cause", "UNCERTAINTY", 17, 26], ["apoptosis", "OBSERVATION", 27, 36]]], ["Therefore, reducing or eliminating stress-induced immunosuppression due to vaccination is an important factor to consider in induction of immunity to DNA vaccination.DiscussionProtection provided by vaccination against coronavirus infection involved both humoral and/or cellular immune responses (Seo et al., 2000, Marten et al., 2001, Yang et al., 2004, Thirion and Coutelier, 2009).", [["cellular", "ANATOMY", 270, 278], ["coronavirus infection", "DISEASE", 219, 240], ["DNA", "CELLULAR_COMPONENT", 150, 153], ["coronavirus", "ORGANISM", 219, 230], ["cellular", "CELL", 270, 278], ["coronavirus", "SPECIES", 219, 230], ["coronavirus", "SPECIES", 219, 230], ["stress-induced immunosuppression", "TREATMENT", 35, 67], ["vaccination", "TREATMENT", 75, 86], ["DNA vaccination", "TREATMENT", 150, 165], ["DiscussionProtection", "TREATMENT", 166, 186], ["coronavirus infection", "PROBLEM", 219, 240]]], ["Vaccinated mice protected from SARS-CoV infection produced high level of IgG and neutralizing antibodies with no significant Th1-biased immune responses (Yang et al., 2004, Woo et al., 2005).", [["SARS-CoV infection", "DISEASE", 31, 49], ["mice", "ORGANISM", 11, 15], ["SARS-CoV", "ORGANISM", 31, 39], ["IgG", "GENE_OR_GENE_PRODUCT", 73, 76], ["IgG", "PROTEIN", 73, 76], ["neutralizing antibodies", "PROTEIN", 81, 104], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 11, 15], ["SARS-CoV", "SPECIES", 31, 39], ["SARS", "PROBLEM", 31, 35], ["CoV infection", "PROBLEM", 36, 49], ["IgG", "TEST", 73, 76], ["neutralizing antibodies", "TEST", 81, 104]]], ["The protection was mediated by humoral but not a T-cell dependent immune mechanism because depletion of CD4 and CD8 T cells by using specific monoclonal antibodies did not affect vaccine-induced immunity.", [["T-cell", "ANATOMY", 49, 55], ["CD4", "ANATOMY", 104, 107], ["CD8 T cells", "ANATOMY", 112, 123], ["T-cell", "CELL", 49, 55], ["CD4", "GENE_OR_GENE_PRODUCT", 104, 107], ["CD8", "GENE_OR_GENE_PRODUCT", 112, 115], ["CD4 and CD8 T cells", "CELL_TYPE", 104, 123], ["monoclonal antibodies", "PROTEIN", 142, 163], ["The protection", "TREATMENT", 0, 14], ["CD4", "TEST", 104, 107], ["CD8 T cells", "PROBLEM", 112, 123], ["specific monoclonal antibodies", "PROBLEM", 133, 163]]], ["In addition, adoptive T-cell transfer showed that donor immune T cells were unable to reduce pulmonary viral replication in recipient animals while passive transfer of purified IgG from immunized mice provided immune protection (Yang et al., 2004).", [["T-cell", "ANATOMY", 22, 28], ["immune T cells", "ANATOMY", 56, 70], ["pulmonary", "ANATOMY", 93, 102], ["T-cell", "CELL", 22, 28], ["donor immune T cells", "CELL", 50, 70], ["pulmonary", "ORGAN", 93, 102], ["animals", "ORGANISM", 134, 141], ["IgG", "GENE_OR_GENE_PRODUCT", 177, 180], ["mice", "ORGANISM", 196, 200], ["donor immune T cells", "CELL_TYPE", 50, 70], ["purified IgG", "PROTEIN", 168, 180], ["mice", "SPECIES", 196, 200], ["mice", "SPECIES", 196, 200], ["adoptive T-cell transfer", "TREATMENT", 13, 37], ["donor immune T cells", "TREATMENT", 50, 70], ["pulmonary viral replication", "PROBLEM", 93, 120], ["purified IgG", "TREATMENT", 168, 180], ["immunized mice", "TREATMENT", 186, 200], ["immune protection", "TREATMENT", 210, 227], ["pulmonary", "ANATOMY", 93, 102], ["viral replication", "OBSERVATION", 103, 120]]], ["On the other hand, adoptive transfer of IBV primed \u03b1\u03b2T cells bearing CD8 antigens protected chicks from IBV infection and passive transfer convalescent IBV serum did not protect chickens against respiratory infection although the viral replication was delayed and kidney disease was prevented (Macdonald et al., 1981, Seo et al., 2000).", [["\u03b1\u03b2T cells", "ANATOMY", 51, 60], ["serum", "ANATOMY", 156, 161], ["respiratory", "ANATOMY", 195, 206], ["kidney", "ANATOMY", 264, 270], ["IBV infection", "DISEASE", 104, 117], ["respiratory infection", "DISEASE", 195, 216], ["kidney disease", "DISEASE", 264, 278], ["IBV", "ORGANISM", 40, 43], ["\u03b1\u03b2T cells", "CELL", 51, 60], ["CD8 antigens", "GENE_OR_GENE_PRODUCT", 69, 81], ["chicks", "ORGANISM", 92, 98], ["IBV", "ORGANISM", 104, 107], ["IBV", "ORGANISM", 152, 155], ["serum", "ORGANISM_SUBSTANCE", 156, 161], ["chickens", "ORGANISM", 178, 186], ["kidney", "ORGAN", 264, 270], ["IBV primed \u03b1\u03b2T cells", "CELL_LINE", 40, 60], ["CD8 antigens", "PROTEIN", 69, 81], ["chicks", "SPECIES", 92, 98], ["chickens", "SPECIES", 178, 186], ["IBV", "SPECIES", 40, 43], ["IBV", "SPECIES", 104, 107], ["IBV", "SPECIES", 152, 155], ["chickens", "SPECIES", 178, 186], ["IBV", "TREATMENT", 40, 43], ["IBV infection", "PROBLEM", 104, 117], ["passive transfer convalescent IBV serum", "TREATMENT", 122, 161], ["respiratory infection", "PROBLEM", 195, 216], ["the viral replication", "PROBLEM", 226, 247], ["kidney disease", "PROBLEM", 264, 278], ["infection", "OBSERVATION", 108, 117], ["infection", "OBSERVATION", 207, 216], ["viral replication", "OBSERVATION", 230, 247], ["kidney", "ANATOMY", 264, 270], ["disease", "OBSERVATION", 271, 278]]], ["From studies of mouse hepatitis virus (MHV), acute infection was primarily controlled by CD8 T cells but CD4 T cells, B cells, and NK cells contributed to reduce viral replication (Marten et al., 2001, Thirion and Coutelier, 2009).", [["CD8 T cells", "ANATOMY", 89, 100], ["CD4 T cells", "ANATOMY", 105, 116], ["B cells", "ANATOMY", 118, 125], ["NK cells", "ANATOMY", 131, 139], ["mouse hepatitis virus", "DISEASE", 16, 37], ["infection", "DISEASE", 51, 60], ["mouse hepatitis virus", "ORGANISM", 16, 37], ["MHV", "ORGANISM", 39, 42], ["CD8", "GENE_OR_GENE_PRODUCT", 89, 92], ["CD4 T cells", "CELL", 105, 116], ["B cells", "CELL", 118, 125], ["NK cells", "CELL", 131, 139], ["CD8 T cells", "CELL_TYPE", 89, 100], ["CD4 T cells", "CELL_TYPE", 105, 116], ["B cells", "CELL_TYPE", 118, 125], ["NK cells", "CELL_TYPE", 131, 139], ["mouse", "SPECIES", 16, 21], ["hepatitis virus", "SPECIES", 22, 37], ["mouse hepatitis virus", "SPECIES", 16, 37], ["MHV", "SPECIES", 39, 42], ["mouse hepatitis virus", "PROBLEM", 16, 37], ["acute infection", "PROBLEM", 45, 60], ["CD8 T cells", "TEST", 89, 100], ["CD4 T cells", "TEST", 105, 116], ["B cells", "PROBLEM", 118, 125], ["NK cells", "PROBLEM", 131, 139], ["viral replication", "PROBLEM", 162, 179], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["infection", "OBSERVATION", 51, 60], ["NK cells", "OBSERVATION", 131, 139]]], ["Thus, both humoral and cellular immunities provide optimal protection against coronaviral infection.", [["cellular", "ANATOMY", 23, 31], ["coronaviral", "ANATOMY", 78, 89], ["coronaviral infection", "DISEASE", 78, 99], ["cellular", "CELL", 23, 31], ["coronaviral", "CANCER", 78, 89], ["cellular immunities", "TREATMENT", 23, 42], ["coronaviral infection", "PROBLEM", 78, 99], ["infection", "OBSERVATION", 90, 99]]], ["DNA vaccination based on N and S1 gene provided more protection against TCoV infection in turkeys than DNA vaccination based on N gene alone in a previous study, suggesting that both humoral and cellular immunities are critical for protection against TCoV in turkeys since DNA vaccine encoding N protein of TCoV can induce cellular immune responses but not antibody responses (Ababneh, 2005).", [["cellular", "ANATOMY", 195, 203], ["cellular", "ANATOMY", 323, 331], ["TCoV", "CHEMICAL", 72, 76], ["infection", "DISEASE", 77, 86], ["TCoV", "CHEMICAL", 251, 255], ["TCoV", "CHEMICAL", 307, 311], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["S1", "GENE_OR_GENE_PRODUCT", 31, 33], ["TCoV", "GENE_OR_GENE_PRODUCT", 72, 76], ["turkeys", "ORGANISM", 90, 97], ["DNA", "CELLULAR_COMPONENT", 103, 106], ["cellular", "CELL", 195, 203], ["TCoV", "GENE_OR_GENE_PRODUCT", 251, 255], ["turkeys", "ORGANISM", 259, 266], ["DNA", "CELLULAR_COMPONENT", 273, 276], ["TCoV", "GENE_OR_GENE_PRODUCT", 307, 311], ["cellular", "CELL", 323, 331], ["N and S1 gene", "DNA", 25, 38], ["N gene", "DNA", 128, 134], ["N protein", "PROTEIN", 294, 303], ["TCoV", "PROTEIN", 307, 311], ["turkeys", "SPECIES", 90, 97], ["turkeys", "SPECIES", 259, 266], ["TCoV", "SPECIES", 72, 76], ["turkeys", "SPECIES", 90, 97], ["TCoV", "SPECIES", 251, 255], ["turkeys", "SPECIES", 259, 266], ["TCoV", "SPECIES", 307, 311], ["DNA vaccination", "TREATMENT", 0, 15], ["N and S1 gene", "TREATMENT", 25, 38], ["TCoV infection", "PROBLEM", 72, 86], ["DNA vaccination", "TREATMENT", 103, 118], ["a previous study", "TEST", 144, 160], ["TCoV in turkeys", "TREATMENT", 251, 266], ["DNA vaccine", "TREATMENT", 273, 284]]], ["Therefore, future studies of DNA vaccination against TCoV infection will include DNA vaccine encoding neutralizing epitopes in S protein and T cells epitopes in N protein that should generate adequate humoral and cellular immune responses and offer optimal protection against TCoV infection.", [["T cells", "ANATOMY", 141, 148], ["cellular", "ANATOMY", 213, 221], ["TCoV infection", "DISEASE", 53, 67], ["infection", "DISEASE", 281, 290], ["DNA", "CELLULAR_COMPONENT", 29, 32], ["TCoV", "ORGANISM", 53, 57], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["T cells", "CELL", 141, 148], ["cellular", "CELL", 213, 221], ["TCoV", "ORGANISM", 276, 280], ["neutralizing epitopes", "PROTEIN", 102, 123], ["S protein and T cells epitopes", "PROTEIN", 127, 157], ["N protein", "PROTEIN", 161, 170], ["TCoV", "SPECIES", 53, 57], ["TCoV", "SPECIES", 276, 280], ["future studies", "TEST", 11, 25], ["DNA vaccination", "TREATMENT", 29, 44], ["TCoV infection", "PROBLEM", 53, 67], ["DNA vaccine", "TREATMENT", 81, 92], ["neutralizing epitopes in S protein", "PROBLEM", 102, 136], ["T cells epitopes in N protein", "TREATMENT", 141, 170], ["optimal protection", "TREATMENT", 249, 267], ["TCoV infection", "PROBLEM", 276, 290], ["infection", "OBSERVATION", 281, 290]]], ["Because oral administration of vaccine is more suitable in field application and oral vaccination can stimulate protective mucosal immune responses, further investigation on oral delivery of TCoV DNA vaccine by fowl adenovirus (Johnson et al., 2003), attenuated Salmonella (Jiao et al., 2011, Woo et al., 2005), biodegradable nanoparticles (Plapied et al., 2010), or other methods is warranted.ConclusionDNA-prime protein-boost DNA vaccination targeting TCoV S protein fragment containing neutralizing epitopes can provide partial protection against TCoV infection by eliciting protective humoral immune response to lessen or eliminate clinical signs and reduce the viral loads in the ileum from the infected turkeys.", [["oral", "ANATOMY", 8, 12], ["oral", "ANATOMY", 81, 85], ["mucosal", "ANATOMY", 123, 130], ["oral", "ANATOMY", 174, 178], ["ileum", "ANATOMY", 685, 690], ["TCoV", "CHEMICAL", 550, 554], ["infection", "DISEASE", 555, 564], ["oral", "ORGANISM_SUBDIVISION", 8, 12], ["oral", "ORGANISM_SUBDIVISION", 81, 85], ["mucosal", "ANATOMICAL_SYSTEM", 123, 130], ["oral", "ORGANISM_SUBDIVISION", 174, 178], ["TCoV", "ORGANISM", 191, 195], ["DNA", "CELLULAR_COMPONENT", 196, 199], ["fowl adenovirus", "ORGANISM", 211, 226], ["DNA", "CELLULAR_COMPONENT", 428, 431], ["TCoV S", "GENE_OR_GENE_PRODUCT", 454, 460], ["TCoV", "ORGANISM", 550, 554], ["ileum", "ORGAN", 685, 690], ["turkeys", "ORGANISM", 709, 716], ["ConclusionDNA-prime protein", "PROTEIN", 394, 421], ["TCoV S protein fragment", "PROTEIN", 454, 477], ["neutralizing epitopes", "PROTEIN", 489, 510], ["turkeys", "SPECIES", 709, 716], ["TCoV", "SPECIES", 191, 195], ["fowl", "SPECIES", 211, 215], ["TCoV", "SPECIES", 454, 458], ["TCoV", "SPECIES", 550, 554], ["turkeys", "SPECIES", 709, 716], ["oral administration of vaccine", "TREATMENT", 8, 38], ["oral vaccination", "TREATMENT", 81, 97], ["further investigation", "TEST", 149, 170], ["oral delivery of TCoV DNA vaccine", "TREATMENT", 174, 207], ["biodegradable nanoparticles", "TREATMENT", 312, 339], ["ConclusionDNA", "TEST", 394, 407], ["prime protein", "TREATMENT", 408, 421], ["boost DNA vaccination targeting TCoV S protein fragment", "TREATMENT", 422, 477], ["neutralizing epitopes", "TREATMENT", 489, 510], ["partial protection", "TREATMENT", 523, 541], ["TCoV infection", "PROBLEM", 550, 564], ["clinical signs", "PROBLEM", 636, 650], ["the viral loads in the ileum", "PROBLEM", 662, 690], ["viral loads", "OBSERVATION", 666, 677], ["ileum", "ANATOMY", 685, 690], ["infected turkeys", "OBSERVATION", 700, 716]]]], "PMC2714572": [["Pulmonary EdemaPulmonary edema is secondary to accumulation of fluid in the lung interstitium or alveolar space.", [["Pulmonary", "ANATOMY", 0, 9], ["fluid", "ANATOMY", 63, 68], ["lung interstitium", "ANATOMY", 76, 93], ["alveolar space", "ANATOMY", 97, 111], ["Pulmonary EdemaPulmonary edema", "DISEASE", 0, 30], ["fluid", "ORGANISM_SUBSTANCE", 63, 68], ["lung interstitium", "MULTI-TISSUE_STRUCTURE", 76, 93], ["alveolar space", "MULTI-TISSUE_STRUCTURE", 97, 111], ["Pulmonary EdemaPulmonary edema", "PROBLEM", 0, 30], ["fluid in the lung interstitium", "PROBLEM", 63, 93], ["alveolar space", "PROBLEM", 97, 111], ["EdemaPulmonary", "OBSERVATION_MODIFIER", 10, 24], ["edema", "OBSERVATION", 25, 30], ["accumulation", "OBSERVATION_MODIFIER", 47, 59], ["fluid", "OBSERVATION", 63, 68], ["lung", "ANATOMY", 76, 80], ["interstitium", "ANATOMY_MODIFIER", 81, 93], ["alveolar", "ANATOMY_MODIFIER", 97, 105]]], ["Pulmonary edema is frequently seen and is a common cause of oxygen desaturation in the ICU patient.", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary edema", "DISEASE", 0, 15], ["oxygen", "CHEMICAL", 60, 66], ["desaturation", "DISEASE", 67, 79], ["oxygen", "CHEMICAL", 60, 66], ["Pulmonary", "ORGAN", 0, 9], ["oxygen", "SIMPLE_CHEMICAL", 60, 66], ["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 91, 98], ["Pulmonary edema", "PROBLEM", 0, 15], ["oxygen desaturation", "PROBLEM", 60, 79], ["edema", "OBSERVATION", 10, 15], ["oxygen desaturation", "OBSERVATION", 60, 79]]], ["Several mechanisms are implicated in the genesis of pulmonary edema, including increased hydrostatic gradient, increased oncotic pressure or increased capillary permeability.", [["pulmonary", "ANATOMY", 52, 61], ["oncotic", "ANATOMY", 121, 128], ["capillary", "ANATOMY", 151, 160], ["pulmonary edema", "DISEASE", 52, 67], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 52, 67], ["oncotic", "IMMATERIAL_ANATOMICAL_ENTITY", 121, 128], ["capillary", "TISSUE", 151, 160], ["pulmonary edema", "PROBLEM", 52, 67], ["increased hydrostatic gradient", "PROBLEM", 79, 109], ["increased oncotic pressure", "PROBLEM", 111, 137], ["increased capillary permeability", "PROBLEM", 141, 173], ["pulmonary", "ANATOMY", 52, 61], ["edema", "OBSERVATION", 62, 67], ["increased", "OBSERVATION_MODIFIER", 79, 88], ["hydrostatic gradient", "OBSERVATION", 89, 109], ["increased", "OBSERVATION_MODIFIER", 111, 120], ["oncotic pressure", "OBSERVATION", 121, 137], ["increased", "OBSERVATION_MODIFIER", 141, 150], ["capillary permeability", "OBSERVATION", 151, 173]]], ["One or a combination of these mechanisms may be involved.", [["may be", "UNCERTAINTY", 41, 47]]], ["Pulmonary edema is broadly subdivided into cardiac and noncardiac.", [["Pulmonary", "ANATOMY", 0, 9], ["cardiac", "ANATOMY", 43, 50], ["Pulmonary edema", "DISEASE", 0, 15], ["Pulmonary", "ORGAN", 0, 9], ["cardiac", "ORGAN", 43, 50], ["Pulmonary edema", "PROBLEM", 0, 15], ["edema", "OBSERVATION", 10, 15], ["cardiac", "ANATOMY", 43, 50], ["noncardiac", "ANATOMY", 55, 65]]], ["Cardiac edema is usually secondary to poor cardiac function, whilst noncardiogenic pulmonary edema can result from volume overload, diminished oncotic pressure or from endothelial injury as in the patient with adult respiratory distress syndrome (ARDS).Pulmonary EdemaInterstitial edema results from fluid collection in the lung interstitial space and usually develops when the pulmonary venous pressure rises to 25-30mm Hg.", [["Cardiac", "ANATOMY", 0, 7], ["cardiac", "ANATOMY", 43, 50], ["pulmonary", "ANATOMY", 83, 92], ["oncotic", "ANATOMY", 143, 150], ["endothelial", "ANATOMY", 168, 179], ["respiratory", "ANATOMY", 216, 227], ["Pulmonary", "ANATOMY", 253, 262], ["fluid", "ANATOMY", 300, 305], ["lung interstitial space", "ANATOMY", 324, 347], ["pulmonary venous", "ANATOMY", 378, 394], ["Cardiac edema", "DISEASE", 0, 13], ["pulmonary edema", "DISEASE", 83, 98], ["volume overload", "DISEASE", 115, 130], ["endothelial injury", "DISEASE", 168, 186], ["adult respiratory distress syndrome", "DISEASE", 210, 245], ["ARDS", "DISEASE", 247, 251], ["EdemaInterstitial edema", "DISEASE", 263, 286], ["Hg", "CHEMICAL", 421, 423], ["Cardiac edema", "PATHOLOGICAL_FORMATION", 0, 13], ["cardiac", "ORGAN", 43, 50], ["pulmonary", "ORGAN", 83, 92], ["endothelial", "TISSUE", 168, 179], ["patient", "ORGANISM", 197, 204], ["fluid", "ORGANISM_SUBSTANCE", 300, 305], ["lung interstitial", "MULTI-TISSUE_STRUCTURE", 324, 341], ["pulmonary venous", "MULTI-TISSUE_STRUCTURE", 378, 394], ["patient", "SPECIES", 197, 204], ["Cardiac edema", "PROBLEM", 0, 13], ["poor cardiac function", "PROBLEM", 38, 59], ["noncardiogenic pulmonary edema", "PROBLEM", 68, 98], ["volume overload", "PROBLEM", 115, 130], ["diminished oncotic pressure", "PROBLEM", 132, 159], ["endothelial injury", "PROBLEM", 168, 186], ["adult respiratory distress syndrome", "PROBLEM", 210, 245], ["ARDS", "PROBLEM", 247, 251], ["Pulmonary EdemaInterstitial edema", "PROBLEM", 253, 286], ["fluid collection in the lung interstitial space", "PROBLEM", 300, 347], ["the pulmonary venous pressure", "TEST", 374, 403], ["edema", "OBSERVATION", 8, 13], ["cardiac", "ANATOMY", 43, 50], ["function", "OBSERVATION", 51, 59], ["noncardiogenic", "OBSERVATION_MODIFIER", 68, 82], ["pulmonary", "ANATOMY", 83, 92], ["edema", "OBSERVATION", 93, 98], ["volume overload", "OBSERVATION", 115, 130], ["diminished", "OBSERVATION_MODIFIER", 132, 142], ["oncotic pressure", "OBSERVATION", 143, 159], ["endothelial", "OBSERVATION_MODIFIER", 168, 179], ["injury", "OBSERVATION", 180, 186], ["respiratory", "ANATOMY", 216, 227], ["distress", "OBSERVATION", 228, 236], ["ARDS", "OBSERVATION", 247, 251], ["EdemaInterstitial", "OBSERVATION_MODIFIER", 263, 280], ["edema", "OBSERVATION", 281, 286], ["fluid collection", "OBSERVATION", 300, 316], ["lung", "ANATOMY", 324, 328], ["interstitial", "ANATOMY_MODIFIER", 329, 341], ["pulmonary venous", "ANATOMY", 378, 394], ["pressure", "OBSERVATION_MODIFIER", 395, 403], ["rises", "OBSERVATION_MODIFIER", 404, 409]]], ["Interstitial pulmonary edema is one condition which may be seen on a chest radiograph before symptoms develop.", [["Interstitial pulmonary edema", "ANATOMY", 0, 28], ["chest", "ANATOMY", 69, 74], ["Interstitial pulmonary edema", "DISEASE", 0, 28], ["pulmonary", "ORGAN", 13, 22], ["Interstitial pulmonary edema", "PROBLEM", 0, 28], ["a chest radiograph", "TEST", 67, 85], ["symptoms", "PROBLEM", 93, 101], ["pulmonary", "ANATOMY", 13, 22], ["edema", "OBSERVATION", 23, 28], ["may be seen", "UNCERTAINTY", 52, 63]]], ["Radiographic signs that suggest interstitial pulmonary edema include loss of definition of large pulmonary vessels, the appearances of septal lines, interlobar septal thickening, diffuse reticular pattern resembling interstitial fibrosis and peribronchial cuffing seen as bronchial wall thickening as a result of fluid retention in the lung interstitium.", [["interstitial pulmonary", "ANATOMY", 32, 54], ["pulmonary vessels", "ANATOMY", 97, 114], ["septal lines", "ANATOMY", 135, 147], ["interlobar septal", "ANATOMY", 149, 166], ["reticular", "ANATOMY", 187, 196], ["interstitial", "ANATOMY", 216, 228], ["peribronchial", "ANATOMY", 242, 255], ["bronchial wall", "ANATOMY", 272, 286], ["fluid", "ANATOMY", 313, 318], ["lung interstitium", "ANATOMY", 336, 353], ["interstitial pulmonary edema", "DISEASE", 32, 60], ["fibrosis", "DISEASE", 229, 237], ["interstitial", "PATHOLOGICAL_FORMATION", 32, 44], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 45, 60], ["pulmonary vessels", "MULTI-TISSUE_STRUCTURE", 97, 114], ["septal lines", "CELL", 135, 147], ["interlobar septal", "PATHOLOGICAL_FORMATION", 149, 166], ["interstitial", "IMMATERIAL_ANATOMICAL_ENTITY", 216, 228], ["bronchial wall", "TISSUE", 272, 286], ["fluid", "ORGANISM_SUBSTANCE", 313, 318], ["lung interstitium", "MULTI-TISSUE_STRUCTURE", 336, 353], ["Radiographic signs", "TEST", 0, 18], ["interstitial pulmonary edema", "PROBLEM", 32, 60], ["loss of definition of large pulmonary vessels", "PROBLEM", 69, 114], ["septal lines", "PROBLEM", 135, 147], ["interlobar septal thickening", "PROBLEM", 149, 177], ["diffuse reticular pattern", "PROBLEM", 179, 204], ["interstitial fibrosis", "PROBLEM", 216, 237], ["peribronchial cuffing", "PROBLEM", 242, 263], ["bronchial wall thickening", "PROBLEM", 272, 297], ["fluid retention in the lung interstitium", "PROBLEM", 313, 353], ["suggest", "UNCERTAINTY", 24, 31], ["interstitial", "ANATOMY_MODIFIER", 32, 44], ["pulmonary", "ANATOMY", 45, 54], ["edema", "OBSERVATION", 55, 60], ["loss", "OBSERVATION_MODIFIER", 69, 73], ["large", "OBSERVATION_MODIFIER", 91, 96], ["pulmonary vessels", "ANATOMY", 97, 114], ["septal lines", "OBSERVATION", 135, 147], ["interlobar", "ANATOMY_MODIFIER", 149, 159], ["septal", "ANATOMY_MODIFIER", 160, 166], ["thickening", "OBSERVATION", 167, 177], ["diffuse", "OBSERVATION_MODIFIER", 179, 186], ["reticular pattern", "OBSERVATION", 187, 204], ["interstitial", "ANATOMY_MODIFIER", 216, 228], ["fibrosis", "OBSERVATION", 229, 237], ["peribronchial", "ANATOMY_MODIFIER", 242, 255], ["cuffing", "OBSERVATION", 256, 263], ["bronchial", "ANATOMY", 272, 281], ["wall", "ANATOMY_MODIFIER", 282, 286], ["thickening", "OBSERVATION", 287, 297], ["fluid retention", "OBSERVATION", 313, 328], ["lung", "ANATOMY", 336, 340], ["interstitium", "ANATOMY_MODIFIER", 341, 353]]], ["Septal lines represent fluid in the deep septae and lymphatics and appear as[1] Kerley's A lines, which range from 5 to 10cm in length and extend from the hilum of the lung toward the periphery in a straight or slightly curved course; and[2] Kerley's B lines, approximately 2cm long, seen in the periphery of the lower lung, extending to the pleura [Figure 1].Pulmonary EdemaAlveolar pulmonary edema generally develops when the pulmonary venous pressure exceeds 30 mm Hg and is usually preceded by interstitial pulmonary edema [Figure 2].", [["Septal lines", "ANATOMY", 0, 12], ["fluid", "ANATOMY", 23, 28], ["deep septae", "ANATOMY", 36, 47], ["lymphatics", "ANATOMY", 52, 62], ["hilum", "ANATOMY", 155, 160], ["lung", "ANATOMY", 168, 172], ["B lines", "ANATOMY", 251, 258], ["lower lung", "ANATOMY", 313, 323], ["pleura", "ANATOMY", 342, 348], ["Pulmonary", "ANATOMY", 360, 369], ["pulmonary", "ANATOMY", 384, 393], ["pulmonary venous", "ANATOMY", 428, 444], ["interstitial pulmonary", "ANATOMY", 498, 520], ["EdemaAlveolar pulmonary edema", "DISEASE", 370, 399], ["interstitial pulmonary edema", "DISEASE", 498, 526], ["Hg", "CHEMICAL", 468, 470], ["Septal lines", "CELL", 0, 12], ["septae", "TISSUE", 41, 47], ["lymphatics", "MULTI-TISSUE_STRUCTURE", 52, 62], ["A lines", "CELL", 89, 96], ["hilum", "MULTI-TISSUE_STRUCTURE", 155, 160], ["lung", "ORGAN", 168, 172], ["B lines", "CELL", 251, 258], ["lower", "ORGAN", 313, 318], ["lung", "ORGAN", 319, 323], ["pleura", "ORGAN", 342, 348], ["pulmonary", "ORGAN", 384, 393], ["pulmonary venous", "MULTI-TISSUE_STRUCTURE", 428, 444], ["pulmonary", "ORGAN", 511, 520], ["Kerley's A lines", "CELL_LINE", 80, 96], ["Kerley's B lines", "CELL_LINE", 242, 258], ["Septal lines", "PROBLEM", 0, 12], ["fluid in the deep septae and lymphatics", "PROBLEM", 23, 62], ["Kerley's A lines", "TREATMENT", 80, 96], ["Kerley's B lines", "TREATMENT", 242, 258], ["Pulmonary EdemaAlveolar pulmonary edema", "PROBLEM", 360, 399], ["the pulmonary venous pressure", "TEST", 424, 453], ["interstitial pulmonary edema", "PROBLEM", 498, 526], ["lines", "OBSERVATION", 7, 12], ["fluid", "OBSERVATION", 23, 28], ["deep", "ANATOMY_MODIFIER", 36, 40], ["septae", "ANATOMY_MODIFIER", 41, 47], ["lymphatics", "ANATOMY", 52, 62], ["lines", "OBSERVATION", 91, 96], ["range", "OBSERVATION_MODIFIER", 104, 109], ["hilum", "ANATOMY", 155, 160], ["lung", "ANATOMY", 168, 172], ["periphery", "ANATOMY_MODIFIER", 184, 193], ["straight", "OBSERVATION_MODIFIER", 199, 207], ["slightly", "OBSERVATION_MODIFIER", 211, 219], ["curved", "OBSERVATION_MODIFIER", 220, 226], ["B lines", "OBSERVATION", 251, 258], ["approximately", "OBSERVATION_MODIFIER", 260, 273], ["2cm", "OBSERVATION_MODIFIER", 274, 277], ["long", "OBSERVATION_MODIFIER", 278, 282], ["periphery", "ANATOMY_MODIFIER", 296, 305], ["lower", "ANATOMY_MODIFIER", 313, 318], ["lung", "ANATOMY", 319, 323], ["pleura", "ANATOMY", 342, 348], ["EdemaAlveolar", "ANATOMY_MODIFIER", 370, 383], ["pulmonary", "ANATOMY", 384, 393], ["edema", "OBSERVATION", 394, 399], ["pulmonary venous", "ANATOMY", 428, 444], ["pressure", "OBSERVATION_MODIFIER", 445, 453], ["interstitial", "ANATOMY_MODIFIER", 498, 510], ["pulmonary", "ANATOMY", 511, 520], ["edema", "OBSERVATION", 521, 526]]], ["Chest radiographic findings include bilateral opacities that extend in a fan shape outward from the hilum in a \u2018batwing\u2019 pattern [Figure 3].", [["hilum", "ANATOMY", 100, 105], ["opacities", "DISEASE", 46, 55], ["hilum", "MULTI-TISSUE_STRUCTURE", 100, 105], ["Chest radiographic", "TEST", 0, 18], ["bilateral opacities", "PROBLEM", 36, 55], ["bilateral", "ANATOMY_MODIFIER", 36, 45], ["opacities", "OBSERVATION", 46, 55], ["fan shape", "OBSERVATION_MODIFIER", 73, 82], ["outward", "OBSERVATION_MODIFIER", 83, 90], ["hilum", "ANATOMY", 100, 105]]], ["With worsening alveolar edema, the lung opacification become increasingly homogenous.", [["alveolar edema", "ANATOMY", 15, 29], ["lung", "ANATOMY", 35, 39], ["alveolar edema", "DISEASE", 15, 29], ["alveolar edema", "PATHOLOGICAL_FORMATION", 15, 29], ["lung", "ORGAN", 35, 39], ["worsening alveolar edema", "PROBLEM", 5, 29], ["the lung opacification", "PROBLEM", 31, 53], ["worsening", "OBSERVATION_MODIFIER", 5, 14], ["alveolar", "ANATOMY_MODIFIER", 15, 23], ["edema", "OBSERVATION", 24, 29], ["lung", "ANATOMY", 35, 39], ["opacification", "OBSERVATION", 40, 53], ["increasingly", "OBSERVATION_MODIFIER", 61, 73], ["homogenous", "OBSERVATION_MODIFIER", 74, 84]]], ["Normally the bronchi in the lung periphery are not seen because of air density within the bronchi and the surrounding lung parenchyma.", [["bronchi", "ANATOMY", 13, 20], ["lung periphery", "ANATOMY", 28, 42], ["bronchi", "ANATOMY", 90, 97], ["lung parenchyma", "ANATOMY", 118, 133], ["bronchi", "MULTI-TISSUE_STRUCTURE", 13, 20], ["lung periphery", "MULTI-TISSUE_STRUCTURE", 28, 42], ["air", "TISSUE", 67, 70], ["bronchi", "MULTI-TISSUE_STRUCTURE", 90, 97], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 118, 133], ["air density within the bronchi and the surrounding lung parenchyma", "PROBLEM", 67, 133], ["bronchi", "ANATOMY", 13, 20], ["lung", "ANATOMY", 28, 32], ["periphery", "ANATOMY_MODIFIER", 33, 42], ["not seen", "UNCERTAINTY", 47, 55], ["air density", "OBSERVATION", 67, 78], ["bronchi", "ANATOMY", 90, 97], ["surrounding", "ANATOMY_MODIFIER", 106, 117], ["lung", "ANATOMY", 118, 122], ["parenchyma", "ANATOMY_MODIFIER", 123, 133]]], ["However, along with fluid-filled alveoli from pulmonary edema or infection (pneumonia), the air-filled bronchi can be easily seen, an appearance known as \u2018air bronchogram\u2019 [Figure 4].", [["alveoli", "ANATOMY", 33, 40], ["pulmonary edema", "ANATOMY", 46, 61], ["bronchi", "ANATOMY", 103, 110], ["pulmonary edema", "DISEASE", 46, 61], ["infection", "DISEASE", 65, 74], ["pneumonia", "DISEASE", 76, 85], ["alveoli", "MULTI-TISSUE_STRUCTURE", 33, 40], ["pulmonary", "ORGAN", 46, 55], ["bronchi", "MULTI-TISSUE_STRUCTURE", 103, 110], ["fluid-filled alveoli", "PROBLEM", 20, 40], ["pulmonary edema", "PROBLEM", 46, 61], ["infection", "PROBLEM", 65, 74], ["pneumonia", "PROBLEM", 76, 85], ["the air-filled bronchi", "PROBLEM", 88, 110], ["\u2018air bronchogram", "PROBLEM", 154, 170], ["fluid", "OBSERVATION", 20, 25], ["filled", "OBSERVATION_MODIFIER", 26, 32], ["alveoli", "OBSERVATION_MODIFIER", 33, 40], ["pulmonary", "ANATOMY", 46, 55], ["edema", "OBSERVATION", 56, 61], ["infection", "OBSERVATION", 65, 74], ["pneumonia", "OBSERVATION", 76, 85], ["air-filled", "OBSERVATION_MODIFIER", 92, 102], ["bronchi", "ANATOMY", 103, 110], ["air bronchogram", "OBSERVATION", 155, 170]]], ["Air bronchograms associated with congestive heart failure are usually visible in the right upper lobe.", [["heart", "ANATOMY", 44, 49], ["right upper lobe", "ANATOMY", 85, 101], ["congestive heart failure", "DISEASE", 33, 57], ["heart", "ORGAN", 44, 49], ["upper lobe", "ORGAN", 91, 101], ["Air bronchograms", "PROBLEM", 0, 16], ["congestive heart failure", "PROBLEM", 33, 57], ["bronchograms", "OBSERVATION", 4, 16], ["congestive", "OBSERVATION_MODIFIER", 33, 43], ["heart", "ANATOMY", 44, 49], ["failure", "OBSERVATION", 50, 57], ["right upper lobe", "ANATOMY", 85, 101]]], ["In pulmonary edema due to heart failure, the heart size is often enlarged.Pulmonary EdemaDiagnosis of pulmonary edema is not always straightforward, and atypical patterns can present diagnostic difficulties on radiographic findings alone.", [["pulmonary edema", "ANATOMY", 3, 18], ["heart", "ANATOMY", 26, 31], ["heart", "ANATOMY", 45, 50], ["Pulmonary", "ANATOMY", 74, 83], ["pulmonary", "ANATOMY", 102, 111], ["pulmonary edema", "DISEASE", 3, 18], ["heart failure", "DISEASE", 26, 39], ["pulmonary edema", "DISEASE", 102, 117], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 3, 18], ["heart", "ORGAN", 26, 31], ["heart", "ORGAN", 45, 50], ["Pulmonary", "ORGAN", 74, 83], ["pulmonary", "ORGAN", 102, 111], ["pulmonary edema", "PROBLEM", 3, 18], ["heart failure", "PROBLEM", 26, 39], ["pulmonary edema", "PROBLEM", 102, 117], ["radiographic findings", "TEST", 210, 231], ["pulmonary", "ANATOMY", 3, 12], ["edema", "OBSERVATION", 13, 18], ["heart", "ANATOMY", 26, 31], ["failure", "OBSERVATION", 32, 39], ["heart", "ANATOMY", 45, 50], ["size", "OBSERVATION_MODIFIER", 51, 55], ["often", "OBSERVATION_MODIFIER", 59, 64], ["enlarged", "OBSERVATION", 65, 73], ["EdemaDiagnosis", "OBSERVATION", 84, 98], ["pulmonary", "ANATOMY", 102, 111], ["edema", "OBSERVATION", 112, 117]]], ["Atypical radiographic patterns of pulmonary edema include unilateral, lobar, miliary or lower-zones edema; and other asymmetric or unusual distribution patterns [Figure 5].", [["pulmonary", "ANATOMY", 34, 43], ["lobar", "ANATOMY", 70, 75], ["lower-zones edema", "ANATOMY", 88, 105], ["pulmonary edema", "DISEASE", 34, 49], ["edema", "DISEASE", 100, 105], ["pulmonary", "ORGAN", 34, 43], ["edema", "PATHOLOGICAL_FORMATION", 100, 105], ["pulmonary edema", "PROBLEM", 34, 49], ["unilateral, lobar, miliary or lower-zones edema", "PROBLEM", 58, 105], ["other asymmetric or unusual distribution patterns", "PROBLEM", 111, 160], ["pulmonary", "ANATOMY", 34, 43], ["edema", "OBSERVATION", 44, 49], ["unilateral", "OBSERVATION_MODIFIER", 58, 68], ["lobar", "OBSERVATION_MODIFIER", 70, 75], ["miliary", "OBSERVATION_MODIFIER", 77, 84], ["lower", "ANATOMY_MODIFIER", 88, 93], ["zones", "OBSERVATION_MODIFIER", 94, 99], ["edema", "OBSERVATION", 100, 105], ["asymmetric", "OBSERVATION_MODIFIER", 117, 127], ["unusual", "OBSERVATION_MODIFIER", 131, 138], ["distribution", "OBSERVATION_MODIFIER", 139, 151]]], ["Miliary edema may precede full-blown lung edema.", [["Miliary edema", "ANATOMY", 0, 13], ["lung", "ANATOMY", 37, 41], ["edema", "DISEASE", 8, 13], ["lung edema", "DISEASE", 37, 47], ["edema", "PATHOLOGICAL_FORMATION", 8, 13], ["lung edema", "PATHOLOGICAL_FORMATION", 37, 47], ["Miliary edema", "PROBLEM", 0, 13], ["blown lung edema", "PROBLEM", 31, 47], ["edema", "OBSERVATION", 8, 13], ["blown", "OBSERVATION_MODIFIER", 31, 36], ["lung", "ANATOMY", 37, 41], ["edema", "OBSERVATION", 42, 47]]], ["Lower-zones edema and lobar pulmonary edema generally occur in patients with chronic obstructive pulmonary disease and pulmonary emphysema.Pulmonary EdemaCongestive cardiac failure causing cardiogenic pulmonary edema is usually the result of left ventricular failure, which is in turn due to poor cardiac output and increased pulmonary venous hydrostatic pressures.", [["Lower-zones edema", "ANATOMY", 0, 17], ["lobar pulmonary", "ANATOMY", 22, 37], ["pulmonary", "ANATOMY", 97, 106], ["pulmonary", "ANATOMY", 119, 128], ["Pulmonary", "ANATOMY", 139, 148], ["cardiac", "ANATOMY", 165, 172], ["pulmonary", "ANATOMY", 201, 210], ["left ventricular", "ANATOMY", 242, 258], ["cardiac", "ANATOMY", 297, 304], ["pulmonary venous", "ANATOMY", 326, 342], ["edema", "DISEASE", 12, 17], ["lobar pulmonary edema", "DISEASE", 22, 43], ["chronic obstructive pulmonary disease", "DISEASE", 77, 114], ["pulmonary emphysema", "DISEASE", 119, 138], ["Pulmonary EdemaCongestive cardiac failure", "DISEASE", 139, 180], ["cardiogenic pulmonary edema", "DISEASE", 189, 216], ["left ventricular failure", "DISEASE", 242, 266], ["pulmonary", "ORGAN", 28, 37], ["patients", "ORGANISM", 63, 71], ["pulmonary", "ORGAN", 97, 106], ["pulmonary", "ORGAN", 119, 128], ["cardiac", "ORGAN", 165, 172], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 201, 216], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 242, 258], ["cardiac", "ORGAN", 297, 304], ["pulmonary venous", "MULTI-TISSUE_STRUCTURE", 326, 342], ["patients", "SPECIES", 63, 71], ["Lower-zones edema", "PROBLEM", 0, 17], ["lobar pulmonary edema", "PROBLEM", 22, 43], ["chronic obstructive pulmonary disease", "PROBLEM", 77, 114], ["pulmonary emphysema", "PROBLEM", 119, 138], ["Pulmonary EdemaCongestive cardiac failure", "PROBLEM", 139, 180], ["cardiogenic pulmonary edema", "PROBLEM", 189, 216], ["left ventricular failure", "PROBLEM", 242, 266], ["poor cardiac output", "PROBLEM", 292, 311], ["increased pulmonary venous hydrostatic pressures", "PROBLEM", 316, 364], ["zones", "OBSERVATION_MODIFIER", 6, 11], ["edema", "OBSERVATION", 12, 17], ["lobar", "ANATOMY_MODIFIER", 22, 27], ["pulmonary", "ANATOMY", 28, 37], ["edema", "OBSERVATION", 38, 43], ["chronic", "OBSERVATION_MODIFIER", 77, 84], ["obstructive", "OBSERVATION_MODIFIER", 85, 96], ["pulmonary", "ANATOMY", 97, 106], ["disease", "OBSERVATION", 107, 114], ["pulmonary", "ANATOMY", 119, 128], ["emphysema", "OBSERVATION", 129, 138], ["EdemaCongestive", "OBSERVATION", 149, 164], ["cardiac", "ANATOMY", 165, 172], ["failure", "OBSERVATION", 173, 180], ["cardiogenic", "OBSERVATION_MODIFIER", 189, 200], ["pulmonary", "ANATOMY", 201, 210], ["edema", "OBSERVATION", 211, 216], ["left ventricular", "ANATOMY", 242, 258], ["failure", "OBSERVATION", 259, 266], ["poor cardiac output", "OBSERVATION", 292, 311], ["increased", "OBSERVATION_MODIFIER", 316, 325], ["pulmonary venous", "ANATOMY", 326, 342], ["hydrostatic pressures", "OBSERVATION", 343, 364]]], ["Generally it is a combination of a failing cardiac pump and fluid overload that tips patients into congestive heart failure.", [["cardiac", "ANATOMY", 43, 50], ["fluid", "ANATOMY", 60, 65], ["heart", "ANATOMY", 110, 115], ["congestive heart failure", "DISEASE", 99, 123], ["fluid", "ORGANISM_SUBSTANCE", 60, 65], ["patients", "ORGANISM", 85, 93], ["heart", "ORGAN", 110, 115], ["patients", "SPECIES", 85, 93], ["a failing cardiac pump", "TREATMENT", 33, 55], ["fluid overload", "PROBLEM", 60, 74], ["congestive heart failure", "PROBLEM", 99, 123], ["cardiac", "ANATOMY", 43, 50], ["pump", "OBSERVATION", 51, 55], ["fluid overload", "OBSERVATION", 60, 74], ["tips", "OBSERVATION_MODIFIER", 80, 84], ["congestive", "OBSERVATION_MODIFIER", 99, 109], ["heart", "ANATOMY", 110, 115], ["failure", "OBSERVATION", 116, 123]]], ["The chest radiograph is an important diagnostic tool in distinguishing fluid overload or congestive failure.", [["chest", "ANATOMY", 4, 9], ["fluid", "ANATOMY", 71, 76], ["fluid overload", "DISEASE", 71, 85], ["congestive failure", "DISEASE", 89, 107], ["fluid", "ORGANISM_SUBSTANCE", 71, 76], ["The chest radiograph", "TEST", 0, 20], ["fluid overload", "PROBLEM", 71, 85], ["congestive failure", "PROBLEM", 89, 107], ["chest", "ANATOMY", 4, 9], ["fluid overload", "OBSERVATION", 71, 85], ["congestive", "OBSERVATION_MODIFIER", 89, 99], ["failure", "OBSERVATION", 100, 107]]], ["This diagnosis of a left-sided cardiac failure due to an acute ischemic cardiac insult is suggested on the chest radiographs in 25% to 40% of patients before the onset of symptoms.", [["cardiac", "ANATOMY", 31, 38], ["cardiac", "ANATOMY", 72, 79], ["chest", "ANATOMY", 107, 112], ["cardiac failure", "DISEASE", 31, 46], ["ischemic cardiac insult", "DISEASE", 63, 86], ["cardiac", "ORGAN", 31, 38], ["cardiac", "ORGAN", 72, 79], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["a left-sided cardiac failure", "PROBLEM", 18, 46], ["an acute ischemic cardiac insult", "PROBLEM", 54, 86], ["the chest radiographs", "TEST", 103, 124], ["symptoms", "PROBLEM", 171, 179], ["left", "ANATOMY_MODIFIER", 20, 24], ["sided", "ANATOMY_MODIFIER", 25, 30], ["cardiac", "ANATOMY", 31, 38], ["failure", "OBSERVATION", 39, 46], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["ischemic", "OBSERVATION_MODIFIER", 63, 71], ["cardiac", "ANATOMY", 72, 79], ["insult", "OBSERVATION", 80, 86], ["chest", "ANATOMY", 107, 112]]], ["Ideally the best technique in this setting is a standard PA chest radiograph because the accuracy of detecting cardiomegaly and redistribution of pulmonary blood flow on supine AP films is poor.", [["pulmonary", "ANATOMY", 146, 155], ["blood", "ANATOMY", 156, 161], ["cardiomegaly", "DISEASE", 111, 123], ["pulmonary", "ORGAN", 146, 155], ["blood", "ORGANISM_SUBSTANCE", 156, 161], ["a standard PA chest radiograph", "TEST", 46, 76], ["cardiomegaly", "PROBLEM", 111, 123], ["pulmonary blood flow", "TEST", 146, 166], ["supine AP films", "TEST", 170, 185], ["cardiomegaly", "OBSERVATION", 111, 123], ["redistribution", "OBSERVATION_MODIFIER", 128, 142], ["pulmonary blood", "ANATOMY", 146, 161]]], ["Obtaining an erect PA radiograph may not be always possible in an ICU patient; and therefore as a compromise, semi-erect and decubitus films are recommended.", [["patient", "ORGANISM", 70, 77], ["patient", "SPECIES", 70, 77], ["an erect PA radiograph", "TEST", 10, 32], ["semi-erect and decubitus films", "TEST", 110, 140]]], ["Cardiomegaly, increased pulmonary vasculature, and pleural effusions are evident in the patient suffering from congestive heart failure.Pulmonary EdemaA chest radiograph may differentiate between cardiac and noncardiac pulmonary edema.", [["pulmonary vasculature", "ANATOMY", 24, 45], ["pleural effusions", "ANATOMY", 51, 68], ["heart", "ANATOMY", 122, 127], ["Pulmonary", "ANATOMY", 136, 145], ["cardiac", "ANATOMY", 196, 203], ["noncardiac pulmonary edema", "ANATOMY", 208, 234], ["Cardiomegaly", "DISEASE", 0, 12], ["pleural effusions", "DISEASE", 51, 68], ["congestive heart failure", "DISEASE", 111, 135], ["cardiac and noncardiac pulmonary edema", "DISEASE", 196, 234], ["pulmonary vasculature", "MULTI-TISSUE_STRUCTURE", 24, 45], ["pleural effusions", "PATHOLOGICAL_FORMATION", 51, 68], ["patient", "ORGANISM", 88, 95], ["heart", "ORGAN", 122, 127], ["Pulmonary", "ORGAN", 136, 145], ["cardiac", "ORGAN", 196, 203], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 219, 234], ["patient", "SPECIES", 88, 95], ["Cardiomegaly", "PROBLEM", 0, 12], ["increased pulmonary vasculature", "PROBLEM", 14, 45], ["pleural effusions", "PROBLEM", 51, 68], ["congestive heart failure", "PROBLEM", 111, 135], ["Pulmonary EdemaA chest radiograph", "TEST", 136, 169], ["cardiac and noncardiac pulmonary edema", "PROBLEM", 196, 234], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["pulmonary vasculature", "ANATOMY", 24, 45], ["pleural", "ANATOMY", 51, 58], ["effusions", "OBSERVATION", 59, 68], ["congestive", "OBSERVATION_MODIFIER", 111, 121], ["heart", "ANATOMY", 122, 127], ["failure", "OBSERVATION", 128, 135], ["chest", "ANATOMY", 153, 158], ["cardiac", "ANATOMY", 196, 203], ["noncardiac", "OBSERVATION_MODIFIER", 208, 218], ["pulmonary", "ANATOMY", 219, 228], ["edema", "OBSERVATION", 229, 234]]], ["The radiographic features of cardiac edema include cardiomegaly, pleural effusions, upper lobe blood diversion, septal lines, peribronchial cuffing and basal edema.", [["cardiac edema", "ANATOMY", 29, 42], ["pleural effusions", "ANATOMY", 65, 82], ["upper lobe blood", "ANATOMY", 84, 100], ["septal lines", "ANATOMY", 112, 124], ["peribronchial", "ANATOMY", 126, 139], ["basal edema", "ANATOMY", 152, 163], ["cardiac edema", "DISEASE", 29, 42], ["cardiomegaly", "DISEASE", 51, 63], ["pleural effusions", "DISEASE", 65, 82], ["basal edema", "DISEASE", 152, 163], ["cardiac edema", "PATHOLOGICAL_FORMATION", 29, 42], ["pleural effusions", "PATHOLOGICAL_FORMATION", 65, 82], ["blood", "ORGANISM_SUBSTANCE", 95, 100], ["septal lines", "CELL", 112, 124], ["basal edema", "PATHOLOGICAL_FORMATION", 152, 163], ["cardiac edema", "PROBLEM", 29, 42], ["cardiomegaly", "PROBLEM", 51, 63], ["pleural effusions", "PROBLEM", 65, 82], ["upper lobe blood diversion", "PROBLEM", 84, 110], ["septal lines", "PROBLEM", 112, 124], ["peribronchial cuffing", "PROBLEM", 126, 147], ["basal edema", "PROBLEM", 152, 163], ["cardiac", "ANATOMY", 29, 36], ["edema", "OBSERVATION", 37, 42], ["cardiomegaly", "OBSERVATION", 51, 63], ["pleural", "ANATOMY", 65, 72], ["effusions", "OBSERVATION", 73, 82], ["upper lobe", "ANATOMY", 84, 94], ["blood diversion", "OBSERVATION", 95, 110], ["septal lines", "OBSERVATION", 112, 124], ["peribronchial", "ANATOMY_MODIFIER", 126, 139], ["cuffing", "OBSERVATION", 140, 147], ["basal", "ANATOMY_MODIFIER", 152, 157], ["edema", "OBSERVATION", 158, 163]]], ["The only exception where the aforementioned changes have not had time to develop is acute myocardial infarction.", [["myocardial", "ANATOMY", 90, 100], ["myocardial infarction", "DISEASE", 90, 111], ["myocardial", "MULTI-TISSUE_STRUCTURE", 90, 100], ["acute myocardial infarction", "PROBLEM", 84, 111], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["myocardial", "ANATOMY", 90, 100], ["infarction", "OBSERVATION", 101, 111]]], ["There are a multitude of causes of noncardiogenic pulmonary edema, which include inhaled irritants causing a more mottled appearance and more peripheral distribution of lung parenchymal changes.", [["pulmonary", "ANATOMY", 50, 59], ["lung parenchymal", "ANATOMY", 169, 185], ["pulmonary edema", "DISEASE", 50, 65], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 50, 65], ["lung parenchymal", "MULTI-TISSUE_STRUCTURE", 169, 185], ["noncardiogenic pulmonary edema", "PROBLEM", 35, 65], ["inhaled irritants", "PROBLEM", 81, 98], ["a more mottled appearance", "PROBLEM", 107, 132], ["lung parenchymal changes", "PROBLEM", 169, 193], ["multitude", "OBSERVATION_MODIFIER", 12, 21], ["noncardiogenic", "OBSERVATION_MODIFIER", 35, 49], ["pulmonary", "ANATOMY", 50, 59], ["edema", "OBSERVATION", 60, 65], ["inhaled irritants", "OBSERVATION", 81, 98], ["more", "OBSERVATION_MODIFIER", 109, 113], ["mottled", "OBSERVATION_MODIFIER", 114, 121], ["more", "OBSERVATION_MODIFIER", 137, 141], ["peripheral", "OBSERVATION_MODIFIER", 142, 152], ["distribution", "OBSERVATION_MODIFIER", 153, 165], ["lung", "ANATOMY", 169, 173], ["parenchymal", "ANATOMY_MODIFIER", 174, 185]]], ["Other causes of noncardiogenic pulmonary edema include near-drowning, altitude sickness, oxygen therapy, transfusion reactions, fat embolism, central nervous system disorder, ARDS or aspiration, renal disorder or/and drug reactions, to name just a few.[1\u201315].Atelectasis ::: Adult Respiratory Distress SyndromeAtelectasis occurs when there is failure of the lung to expand (inflate) completely.", [["pulmonary", "ANATOMY", 31, 40], ["fat", "ANATOMY", 128, 131], ["central nervous system", "ANATOMY", 142, 164], ["renal", "ANATOMY", 195, 200], ["lung", "ANATOMY", 358, 362], ["pulmonary edema", "DISEASE", 31, 46], ["drowning", "DISEASE", 60, 68], ["altitude sickness", "DISEASE", 70, 87], ["oxygen", "CHEMICAL", 89, 95], ["fat embolism", "DISEASE", 128, 140], ["central nervous system disorder", "DISEASE", 142, 173], ["ARDS", "DISEASE", 175, 179], ["renal disorder", "DISEASE", 195, 209], ["Atelectasis", "DISEASE", 259, 270], ["Respiratory Distress SyndromeAtelectasis", "DISEASE", 281, 321], ["oxygen", "CHEMICAL", 89, 95], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 31, 46], ["oxygen", "SIMPLE_CHEMICAL", 89, 95], ["fat", "TISSUE", 128, 131], ["nervous system", "ANATOMICAL_SYSTEM", 150, 164], ["renal", "ORGAN", 195, 200], ["lung", "ORGAN", 358, 362], ["noncardiogenic pulmonary edema", "PROBLEM", 16, 46], ["drowning", "PROBLEM", 60, 68], ["altitude sickness", "PROBLEM", 70, 87], ["oxygen therapy", "TREATMENT", 89, 103], ["transfusion reactions", "PROBLEM", 105, 126], ["fat embolism", "PROBLEM", 128, 140], ["central nervous system disorder", "PROBLEM", 142, 173], ["ARDS", "PROBLEM", 175, 179], ["aspiration", "PROBLEM", 183, 193], ["renal disorder", "PROBLEM", 195, 209], ["drug reactions", "PROBLEM", 217, 231], ["Atelectasis", "PROBLEM", 259, 270], ["Adult Respiratory Distress SyndromeAtelectasis", "PROBLEM", 275, 321], ["failure of the lung", "PROBLEM", 343, 362], ["noncardiogenic", "OBSERVATION_MODIFIER", 16, 30], ["pulmonary", "ANATOMY", 31, 40], ["edema", "OBSERVATION", 41, 46], ["drowning", "OBSERVATION", 60, 68], ["altitude sickness", "OBSERVATION", 70, 87], ["oxygen therapy", "OBSERVATION", 89, 103], ["fat embolism", "OBSERVATION", 128, 140], ["central", "ANATOMY_MODIFIER", 142, 149], ["nervous system", "ANATOMY", 150, 164], ["ARDS", "OBSERVATION", 175, 179], ["aspiration", "OBSERVATION", 183, 193], ["renal", "ANATOMY", 195, 200], ["disorder", "OBSERVATION", 201, 209], ["Respiratory Distress", "OBSERVATION", 281, 301], ["failure", "OBSERVATION", 343, 350], ["lung", "ANATOMY", 358, 362]]], ["This may be caused by any process which reduces alveolar ventilation, including blocked airway, e.g., obstruction from mucus plugging, a tumor, general anesthesia, pneumonia, splinting from pain following surgery.[283233] Extensive alveolar hypoventilation may cause hypoxia as a result of an effective right-to-left shunt.", [["alveolar", "ANATOMY", 48, 56], ["airway", "ANATOMY", 88, 94], ["mucus", "ANATOMY", 119, 124], ["tumor", "ANATOMY", 137, 142], ["alveolar", "ANATOMY", 232, 240], ["right", "ANATOMY", 303, 308], ["obstruction", "DISEASE", 102, 113], ["tumor", "DISEASE", 137, 142], ["pneumonia", "DISEASE", 164, 173], ["pain", "DISEASE", 190, 194], ["alveolar hypoventilation", "DISEASE", 232, 256], ["hypoxia", "DISEASE", 267, 274], ["alveolar", "MULTI-TISSUE_STRUCTURE", 48, 56], ["airway", "MULTI-TISSUE_STRUCTURE", 88, 94], ["mucus", "ORGANISM_SUBSTANCE", 119, 124], ["tumor", "CANCER", 137, 142], ["alveolar", "MULTI-TISSUE_STRUCTURE", 232, 240], ["any process", "PROBLEM", 22, 33], ["alveolar ventilation", "TREATMENT", 48, 68], ["blocked airway", "PROBLEM", 80, 94], ["obstruction", "PROBLEM", 102, 113], ["mucus plugging", "PROBLEM", 119, 133], ["a tumor", "PROBLEM", 135, 142], ["general anesthesia", "TREATMENT", 144, 162], ["pneumonia", "PROBLEM", 164, 173], ["splinting from pain", "PROBLEM", 175, 194], ["surgery", "TREATMENT", 205, 212], ["Extensive alveolar hypoventilation", "PROBLEM", 222, 256], ["hypoxia", "PROBLEM", 267, 274], ["may be caused", "UNCERTAINTY", 5, 18], ["alveolar ventilation", "OBSERVATION", 48, 68], ["airway", "ANATOMY", 88, 94], ["obstruction", "OBSERVATION", 102, 113], ["mucus plugging", "OBSERVATION", 119, 133], ["tumor", "OBSERVATION", 137, 142], ["anesthesia", "OBSERVATION", 152, 162], ["pneumonia", "OBSERVATION", 164, 173], ["splinting", "OBSERVATION_MODIFIER", 175, 184], ["Extensive", "OBSERVATION_MODIFIER", 222, 231], ["alveolar hypoventilation", "OBSERVATION", 232, 256], ["may cause", "UNCERTAINTY", 257, 266], ["hypoxia", "OBSERVATION", 267, 274], ["effective", "OBSERVATION_MODIFIER", 293, 302], ["right", "ANATOMY_MODIFIER", 303, 308], ["left", "ANATOMY_MODIFIER", 312, 316], ["shunt", "OBSERVATION", 317, 322]]], ["It is a common abnormality seen on the ICU patient's chest radiograph.", [["chest", "ANATOMY", 53, 58], ["patient", "ORGANISM", 43, 50], ["chest", "ORGANISM_SUBDIVISION", 53, 58], ["patient", "SPECIES", 43, 50], ["a common abnormality", "PROBLEM", 6, 26], ["the ICU patient's chest radiograph", "TEST", 35, 69], ["common", "OBSERVATION_MODIFIER", 8, 14], ["abnormality", "OBSERVATION", 15, 26], ["chest", "ANATOMY", 53, 58]]], ["Atelectasis in ICU patients is seen most frequently in the left lower lobe.", [["left lower lobe", "ANATOMY", 59, 74], ["Atelectasis", "DISEASE", 0, 11], ["patients", "ORGANISM", 19, 27], ["lower lobe", "ORGAN", 64, 74], ["patients", "SPECIES", 19, 27], ["Atelectasis", "PROBLEM", 0, 11], ["most frequently", "OBSERVATION_MODIFIER", 36, 51], ["left lower lobe", "ANATOMY", 59, 74]]], ["It is postulated that this is due to compression of the lower lobe bronchus by the heart, in the supine patient.", [["lower lobe bronchus", "ANATOMY", 56, 75], ["heart", "ANATOMY", 83, 88], ["lower lobe bronchus", "MULTI-TISSUE_STRUCTURE", 56, 75], ["heart", "ORGAN", 83, 88], ["patient", "ORGANISM", 104, 111], ["patient", "SPECIES", 104, 111], ["compression of the lower lobe bronchus", "PROBLEM", 37, 75], ["postulated that this is due to", "UNCERTAINTY", 6, 36], ["compression", "OBSERVATION", 37, 48], ["lower lobe", "ANATOMY", 56, 66], ["bronchus", "ANATOMY_MODIFIER", 67, 75], ["heart", "ANATOMY", 83, 88]]], ["A contributory factor may be relatively difficulty of blind suctioning of the left lower lobe.", [["left lower lobe", "ANATOMY", 78, 93], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 83, 93], ["blind suctioning of the left lower lobe", "PROBLEM", 54, 93], ["contributory factor may be", "UNCERTAINTY", 2, 28], ["suctioning", "OBSERVATION", 60, 70], ["left lower lobe", "ANATOMY", 78, 93]]], ["Usually atelectasis is more extensive than is suggested by the radiograph.", [["atelectasis", "DISEASE", 8, 19], ["atelectasis", "PROBLEM", 8, 19], ["the radiograph", "TEST", 59, 73], ["atelectasis", "OBSERVATION", 8, 19], ["more", "OBSERVATION_MODIFIER", 23, 27], ["extensive", "OBSERVATION_MODIFIER", 28, 37]]], ["Atelectasis can both be reversed and prevented with the use of hyperventilation and incentive spirometry, particularly in the postoperative patient.Atelectasis ::: Adult Respiratory Distress SyndromeAtelectasis may vary from a total lung collapse to subsegmental collapse to relatively normal-appearing lungs on the chest radiograph as an acute mucus plugging may cause only a small reduction in lung volume without visible abnormality.", [["lung", "ANATOMY", 233, 237], ["lungs", "ANATOMY", 303, 308], ["chest", "ANATOMY", 316, 321], ["mucus", "ANATOMY", 345, 350], ["lung", "ANATOMY", 396, 400], ["Atelectasis", "DISEASE", 0, 11], ["Atelectasis", "DISEASE", 148, 159], ["Respiratory Distress SyndromeAtelectasis", "DISEASE", 170, 210], ["patient", "ORGANISM", 140, 147], ["lung", "ORGAN", 233, 237], ["lungs", "ORGAN", 303, 308], ["chest", "ORGAN", 316, 321], ["mucus", "ORGANISM_SUBSTANCE", 345, 350], ["lung", "ORGAN", 396, 400], ["patient", "SPECIES", 140, 147], ["Atelectasis", "PROBLEM", 0, 11], ["hyperventilation", "TREATMENT", 63, 79], ["incentive spirometry", "TREATMENT", 84, 104], ["Atelectasis", "PROBLEM", 148, 159], ["Adult Respiratory Distress SyndromeAtelectasis", "PROBLEM", 164, 210], ["a total lung collapse", "PROBLEM", 225, 246], ["subsegmental collapse", "PROBLEM", 250, 271], ["the chest radiograph", "TEST", 312, 332], ["an acute mucus plugging", "PROBLEM", 336, 359], ["a small reduction in lung volume", "PROBLEM", 375, 407], ["visible abnormality", "PROBLEM", 416, 435], ["Respiratory Distress", "OBSERVATION", 170, 190], ["total", "OBSERVATION_MODIFIER", 227, 232], ["lung", "ANATOMY", 233, 237], ["collapse", "OBSERVATION", 238, 246], ["subsegmental", "OBSERVATION_MODIFIER", 250, 262], ["collapse", "OBSERVATION", 263, 271], ["relatively", "OBSERVATION_MODIFIER", 275, 285], ["normal", "OBSERVATION", 286, 292], ["lungs", "ANATOMY", 303, 308], ["chest", "ANATOMY", 316, 321], ["acute", "OBSERVATION_MODIFIER", 339, 344], ["mucus plugging", "OBSERVATION", 345, 359], ["small", "OBSERVATION_MODIFIER", 377, 382], ["reduction", "OBSERVATION_MODIFIER", 383, 392], ["lung", "ANATOMY", 396, 400], ["volume", "OBSERVATION_MODIFIER", 401, 407], ["without", "UNCERTAINTY", 408, 415], ["visible", "OBSERVATION_MODIFIER", 416, 423], ["abnormality", "OBSERVATION", 424, 435]]], ["Notwithstanding radiographic appearances, the physiological effects may be significant.", [["may be", "UNCERTAINTY", 68, 74], ["significant", "OBSERVATION_MODIFIER", 75, 86]]], ["In a mucus plug syndrome, a sudden onset of hypoxia in the presence of a normal-looking radiograph can raise the suspicion of a pulmonary embolus and warrant an unnecessary CTPA.", [["pulmonary embolus", "ANATOMY", 128, 145], ["mucus plug syndrome", "DISEASE", 5, 24], ["hypoxia", "DISEASE", 44, 51], ["pulmonary embolus", "DISEASE", 128, 145], ["pulmonary", "ORGAN", 128, 137], ["a mucus plug syndrome", "PROBLEM", 3, 24], ["hypoxia", "PROBLEM", 44, 51], ["a pulmonary embolus", "PROBLEM", 126, 145], ["an unnecessary CTPA", "TEST", 158, 177], ["mucus plug syndrome", "OBSERVATION", 5, 24], ["hypoxia", "OBSERVATION", 44, 51], ["normal", "OBSERVATION", 73, 79], ["pulmonary", "ANATOMY", 128, 137], ["embolus", "OBSERVATION", 138, 145]]], ["The radiographic features of atelectasis are summarized in Table 1.Atelectasis ::: Adult Respiratory Distress SyndromeMinimal basal subsegmental or discoid atelectasis appearing as linear streaks is common in the ICU patient and may not be physiologically significant [Figure 11].", [["atelectasis", "DISEASE", 29, 40], ["Atelectasis", "DISEASE", 67, 78], ["atelectasis", "DISEASE", 156, 167], ["patient", "ORGANISM", 217, 224], ["patient", "SPECIES", 217, 224], ["atelectasis", "PROBLEM", 29, 40], ["Atelectasis", "PROBLEM", 67, 78], ["Adult Respiratory Distress", "PROBLEM", 83, 109], ["basal subsegmental or discoid atelectasis", "PROBLEM", 126, 167], ["linear streaks", "PROBLEM", 181, 195], ["atelectasis", "OBSERVATION", 29, 40], ["Respiratory", "ANATOMY", 89, 100], ["Distress", "OBSERVATION", 101, 109], ["basal", "ANATOMY_MODIFIER", 126, 131], ["subsegmental", "ANATOMY_MODIFIER", 132, 144], ["discoid", "OBSERVATION_MODIFIER", 148, 155], ["atelectasis", "OBSERVATION", 156, 167], ["linear", "OBSERVATION_MODIFIER", 181, 187], ["streaks", "OBSERVATION_MODIFIER", 188, 195], ["may not be", "UNCERTAINTY", 229, 239]]], ["Atelectasis may also mimic pulmonary consolidation, which may be difficult to distinguish from other causes of consolidation.", [["pulmonary", "ANATOMY", 27, 36], ["Atelectasis", "DISEASE", 0, 11], ["pulmonary", "ORGAN", 27, 36], ["Atelectasis", "PROBLEM", 0, 11], ["pulmonary consolidation", "PROBLEM", 27, 50], ["consolidation", "PROBLEM", 111, 124], ["may also mimic", "UNCERTAINTY", 12, 26], ["pulmonary", "ANATOMY", 27, 36], ["consolidation", "OBSERVATION", 37, 50], ["consolidation", "OBSERVATION", 111, 124]]], ["To distinguish between atelectasis-related consolidation and consolidations related to other causes is important, and certain distinguishing features do exist.", [["atelectasis", "DISEASE", 23, 34], ["atelectasis", "PROBLEM", 23, 34], ["consolidation", "PROBLEM", 43, 56], ["consolidations", "PROBLEM", 61, 75], ["atelectasis", "OBSERVATION", 23, 34], ["consolidation", "OBSERVATION", 43, 56], ["consolidations", "OBSERVATION", 61, 75]]], ["Atelectasis will often respond to increased ventilation while other causes of pulmonary consolidation will not.", [["pulmonary", "ANATOMY", 78, 87], ["Atelectasis", "DISEASE", 0, 11], ["pulmonary", "ORGAN", 78, 87], ["Atelectasis", "PROBLEM", 0, 11], ["increased ventilation", "TREATMENT", 34, 55], ["pulmonary consolidation", "PROBLEM", 78, 101], ["increased ventilation", "OBSERVATION", 34, 55], ["pulmonary", "ANATOMY", 78, 87], ["consolidation", "OBSERVATION", 88, 101]]], ["Other features that suggest atelectasis because of loss of volume in the involved lung include crowding of pulmonary vessels, displacement of interlobar fissures and elevation of the hemidiaphragm towards areas of atelectasis.", [["lung", "ANATOMY", 82, 86], ["pulmonary vessels", "ANATOMY", 107, 124], ["interlobar fissures", "ANATOMY", 142, 161], ["hemidiaphragm", "ANATOMY", 183, 196], ["atelectasis", "DISEASE", 28, 39], ["loss of volume", "DISEASE", 51, 65], ["atelectasis", "DISEASE", 214, 225], ["lung", "ORGAN", 82, 86], ["pulmonary vessels", "MULTI-TISSUE_STRUCTURE", 107, 124], ["interlobar fissures", "PATHOLOGICAL_FORMATION", 142, 161], ["hemidiaphragm", "ORGAN", 183, 196], ["atelectasis", "PROBLEM", 28, 39], ["loss of volume", "PROBLEM", 51, 65], ["crowding of pulmonary vessels", "PROBLEM", 95, 124], ["displacement of interlobar fissures", "PROBLEM", 126, 161], ["elevation of the hemidiaphragm", "PROBLEM", 166, 196], ["atelectasis", "PROBLEM", 214, 225], ["atelectasis", "OBSERVATION", 28, 39], ["loss", "OBSERVATION_MODIFIER", 51, 55], ["volume", "OBSERVATION_MODIFIER", 59, 65], ["lung", "ANATOMY", 82, 86], ["crowding", "OBSERVATION", 95, 103], ["pulmonary vessels", "ANATOMY", 107, 124], ["displacement", "OBSERVATION_MODIFIER", 126, 138], ["interlobar", "ANATOMY_MODIFIER", 142, 152], ["fissures", "ANATOMY_MODIFIER", 153, 161], ["elevation", "OBSERVATION_MODIFIER", 166, 175], ["hemidiaphragm", "ANATOMY", 183, 196], ["atelectasis", "OBSERVATION", 214, 225]]], ["Collapsed lung segments and lobes also follow well-recognized anatomical pathways, unlike other causes of consolidation.Atelectasis ::: Adult Respiratory Distress SyndromeThe right upper lobe collapses into a triangular opacity, with the lesser fissure migrating toward the anterior, superior and medial portion of the chest, closing like a Chinese fan.", [["lung segments", "ANATOMY", 10, 23], ["lobes", "ANATOMY", 28, 33], ["right upper lobe", "ANATOMY", 175, 191], ["anterior", "ANATOMY", 274, 282], ["superior", "ANATOMY", 284, 292], ["medial portion", "ANATOMY", 297, 311], ["chest", "ANATOMY", 319, 324], ["Atelectasis", "DISEASE", 120, 131], ["Respiratory Distress Syndrome", "DISEASE", 142, 171], ["opacity", "DISEASE", 220, 227], ["lung segments", "MULTI-TISSUE_STRUCTURE", 10, 23], ["lobes", "MULTI-TISSUE_STRUCTURE", 28, 33], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 181, 191], ["anterior", "MULTI-TISSUE_STRUCTURE", 274, 282], ["chest", "ORGAN", 319, 324], ["Collapsed lung segments and lobes", "PROBLEM", 0, 33], ["consolidation", "PROBLEM", 106, 119], ["Atelectasis", "PROBLEM", 120, 131], ["Adult Respiratory Distress Syndrome", "PROBLEM", 136, 171], ["a triangular opacity", "PROBLEM", 207, 227], ["the lesser fissure", "PROBLEM", 234, 252], ["lung", "ANATOMY", 10, 14], ["segments", "ANATOMY_MODIFIER", 15, 23], ["lobes", "ANATOMY_MODIFIER", 28, 33], ["consolidation", "OBSERVATION", 106, 119], ["Respiratory Distress", "OBSERVATION", 142, 162], ["Syndrome", "OBSERVATION", 163, 171], ["right upper lobe", "ANATOMY", 175, 191], ["triangular", "OBSERVATION_MODIFIER", 209, 219], ["opacity", "OBSERVATION", 220, 227], ["lesser", "OBSERVATION_MODIFIER", 238, 244], ["fissure", "OBSERVATION_MODIFIER", 245, 252], ["anterior", "ANATOMY_MODIFIER", 274, 282], ["superior", "ANATOMY_MODIFIER", 284, 292], ["medial", "ANATOMY_MODIFIER", 297, 303], ["portion", "ANATOMY_MODIFIER", 304, 311], ["chest", "ANATOMY", 319, 324]]], ["On an AP chest radiograph, the most striking feature is a superior and medial displacement of the minor fissure.", [["an AP chest radiograph", "TEST", 3, 25], ["a superior and medial displacement of the minor fissure", "PROBLEM", 56, 111], ["most striking", "OBSERVATION_MODIFIER", 31, 44], ["superior", "OBSERVATION_MODIFIER", 58, 66], ["medial", "OBSERVATION_MODIFIER", 71, 77], ["displacement", "OBSERVATION", 78, 90], ["minor fissure", "ANATOMY", 98, 111]]], ["On the lateral radiograph, the major fissure moves anteriorly, while the superior movement of the minor fissure is also seen [Figurea 12 and 13].Atelectasis ::: Adult Respiratory Distress SyndromeRight\u2013middle-lobe atelectasis may cause minimal changes on an AP supine chest radiograph.", [["fissure", "ANATOMY", 37, 44], ["Atelectasis", "DISEASE", 145, 156], ["Distress SyndromeRight\u2013middle-lobe atelectasis", "DISEASE", 179, 225], ["the lateral radiograph", "TEST", 3, 25], ["Figurea", "TEST", 126, 133], ["Atelectasis", "PROBLEM", 145, 156], ["Adult Respiratory Distress SyndromeRight\u2013middle-lobe atelectasis", "PROBLEM", 161, 225], ["minimal changes", "PROBLEM", 236, 251], ["an AP supine chest radiograph", "TEST", 255, 284], ["major", "OBSERVATION_MODIFIER", 31, 36], ["fissure", "OBSERVATION_MODIFIER", 37, 44], ["anteriorly", "ANATOMY_MODIFIER", 51, 61], ["superior", "OBSERVATION_MODIFIER", 73, 81], ["movement", "OBSERVATION_MODIFIER", 82, 90], ["minor fissure", "ANATOMY", 98, 111], ["Respiratory", "ANATOMY", 167, 178], ["Distress", "OBSERVATION", 179, 187], ["lobe", "ANATOMY_MODIFIER", 209, 213], ["atelectasis", "OBSERVATION", 214, 225], ["minimal", "OBSERVATION_MODIFIER", 236, 243]]], ["A constant feature is loss of definition of the right heart border.", [["right heart border", "ANATOMY", 48, 66], ["heart", "ORGAN", 54, 59], ["loss of definition of the right heart border", "PROBLEM", 22, 66], ["constant", "OBSERVATION_MODIFIER", 2, 10], ["loss", "OBSERVATION", 22, 26], ["right", "ANATOMY_MODIFIER", 48, 53], ["heart", "ANATOMY", 54, 59], ["border", "ANATOMY_MODIFIER", 60, 66]]], ["A collapsed right middle lobe is more clearly defined on lateral radiograph, which is not commonly available in the ICU patient.", [["right middle lobe", "ANATOMY", 12, 29], ["right middle lobe", "CANCER", 12, 29], ["patient", "ORGANISM", 120, 127], ["patient", "SPECIES", 120, 127], ["A collapsed right middle lobe", "PROBLEM", 0, 29], ["lateral radiograph", "TEST", 57, 75], ["collapsed", "OBSERVATION", 2, 11], ["right middle lobe", "ANATOMY", 12, 29]]], ["Attention to the fissures reveals that the horizontal and lower portions of the major fissures move towards each other resulting in a wedge of opacity pointing to the hilum.", [["lower portions", "ANATOMY", 58, 72], ["hilum", "ANATOMY", 167, 172], ["fissures", "PATHOLOGICAL_FORMATION", 17, 25], ["hilum", "MULTI-TISSUE_STRUCTURE", 167, 172], ["a wedge of opacity", "PROBLEM", 132, 150], ["fissures", "ANATOMY_MODIFIER", 17, 25], ["horizontal", "OBSERVATION_MODIFIER", 43, 53], ["lower", "ANATOMY_MODIFIER", 58, 63], ["portions", "ANATOMY_MODIFIER", 64, 72], ["major", "OBSERVATION_MODIFIER", 80, 85], ["fissures", "OBSERVATION", 86, 94], ["wedge", "OBSERVATION_MODIFIER", 134, 139], ["opacity", "OBSERVATION", 143, 150], ["hilum", "ANATOMY", 167, 172]]], ["A middle-lobe atelectasis may mimic middle-lobe pneumonic consolidation [Figure 14].Atelectasis ::: Adult Respiratory Distress SyndromeAtelectasis of either the right or left lower lobe presents a similar appearance.", [["middle-lobe", "ANATOMY", 2, 13], ["right", "ANATOMY", 161, 166], ["left lower lobe", "ANATOMY", 170, 185], ["atelectasis", "DISEASE", 14, 25], ["pneumonic", "DISEASE", 48, 57], ["Atelectasis", "DISEASE", 84, 95], ["Respiratory Distress SyndromeAtelectasis", "DISEASE", 106, 146], ["lower lobe", "ORGANISM_SUBDIVISION", 175, 185], ["A middle-lobe atelectasis", "PROBLEM", 0, 25], ["middle-lobe pneumonic consolidation", "PROBLEM", 36, 71], ["Atelectasis", "PROBLEM", 84, 95], ["Adult Respiratory Distress SyndromeAtelectasis", "PROBLEM", 100, 146], ["middle-lobe", "ANATOMY", 2, 13], ["atelectasis", "OBSERVATION", 14, 25], ["middle", "OBSERVATION_MODIFIER", 36, 42], ["lobe", "OBSERVATION_MODIFIER", 43, 47], ["pneumonic", "OBSERVATION_MODIFIER", 48, 57], ["consolidation", "OBSERVATION", 58, 71], ["Respiratory Distress", "OBSERVATION", 106, 126], ["right", "ANATOMY_MODIFIER", 161, 166], ["left lower lobe", "ANATOMY", 170, 185], ["similar", "OBSERVATION_MODIFIER", 197, 204]]], ["In right\u2013lower-lobe atelectasis the collapsing lobe moves centrally and inferiorly towards the lower dorsal spine, where it is seen as a triangular opacity.", [["right\u2013lower-lobe", "ANATOMY", 3, 19], ["lobe", "ANATOMY", 47, 51], ["lower dorsal spine", "ANATOMY", 95, 113], ["atelectasis", "DISEASE", 20, 31], ["opacity", "DISEASE", 148, 155], ["lobe", "ORGAN", 15, 19], ["lobe", "ORGAN", 47, 51], ["lower", "ORGANISM_SUBDIVISION", 95, 100], ["dorsal spine", "MULTI-TISSUE_STRUCTURE", 101, 113], ["atelectasis the collapsing lobe", "PROBLEM", 20, 51], ["a triangular opacity", "PROBLEM", 135, 155], ["right\u2013lower", "ANATOMY_MODIFIER", 3, 14], ["lobe", "ANATOMY_MODIFIER", 15, 19], ["atelectasis", "OBSERVATION", 20, 31], ["collapsing", "OBSERVATION_MODIFIER", 36, 46], ["lobe", "OBSERVATION_MODIFIER", 47, 51], ["inferiorly", "ANATOMY_MODIFIER", 72, 82], ["lower", "ANATOMY_MODIFIER", 95, 100], ["dorsal", "ANATOMY_MODIFIER", 101, 107], ["spine", "ANATOMY", 108, 113], ["triangular", "OBSERVATION_MODIFIER", 137, 147], ["opacity", "OBSERVATION", 148, 155]]], ["Silhouetting of the right hemidiaphragm and air bronchograms is a common sign of right\u2013lower-lobe atelectasis.", [["right hemidiaphragm", "ANATOMY", 20, 39], ["air bronchograms", "ANATOMY", 44, 60], ["right\u2013lower-lobe", "ANATOMY", 81, 97], ["atelectasis", "DISEASE", 98, 109], ["hemidiaphragm", "ORGAN", 26, 39], ["air bronchograms", "PROBLEM", 44, 60], ["right\u2013lower-lobe atelectasis", "PROBLEM", 81, 109], ["right", "ANATOMY_MODIFIER", 20, 25], ["hemidiaphragm", "ANATOMY", 26, 39], ["air bronchograms", "OBSERVATION", 44, 60], ["common", "OBSERVATION_MODIFIER", 66, 72], ["right\u2013lower", "ANATOMY_MODIFIER", 81, 92], ["lobe", "ANATOMY_MODIFIER", 93, 97], ["atelectasis", "OBSERVATION", 98, 109]]], ["The minor fissure shows some inferior displacement.", [["some inferior displacement", "PROBLEM", 24, 50], ["minor fissure", "ANATOMY", 4, 17], ["some", "OBSERVATION_MODIFIER", 24, 28], ["inferior", "OBSERVATION_MODIFIER", 29, 37], ["displacement", "OBSERVATION", 38, 50]]], ["As the right lower lobe collapses, part of the greater fissure may become visible on the AP radiograph.", [["right lower lobe", "ANATOMY", 7, 23], ["fissure", "ANATOMY", 55, 62], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 13, 23], ["the right lower lobe collapses", "PROBLEM", 3, 33], ["the AP radiograph", "TEST", 85, 102], ["right lower lobe", "ANATOMY", 7, 23], ["collapses", "OBSERVATION", 24, 33], ["greater", "OBSERVATION_MODIFIER", 47, 54], ["fissure", "OBSERVATION_MODIFIER", 55, 62], ["visible", "OBSERVATION_MODIFIER", 74, 81]]], ["A lateral radiograph, if obtained, may show inferior and posterior displacement of both the major and minor fissures.", [["fissures", "PATHOLOGICAL_FORMATION", 108, 116], ["A lateral radiograph", "TEST", 0, 20], ["inferior and posterior displacement of both the major and minor fissures", "PROBLEM", 44, 116], ["inferior", "ANATOMY_MODIFIER", 44, 52], ["posterior", "ANATOMY_MODIFIER", 57, 66], ["displacement", "OBSERVATION", 67, 79], ["both", "ANATOMY_MODIFIER", 83, 87], ["major", "OBSERVATION_MODIFIER", 92, 97], ["minor fissures", "ANATOMY", 102, 116]]], ["Right\u2013lower-lobe atelectasis can be differentiated from right\u2013middle-lobe atelectasis by the persistence of the right heart border [Figures 15 and 16].Atelectasis ::: Adult Respiratory Distress SyndromeA left\u2013upper-lobe atelectasis presents a different pattern compared to a right\u2013upper-lobe atelectasis as the left lung lacks a minor fissure.", [["Right\u2013lower-lobe", "ANATOMY", 0, 16], ["right\u2013middle-lobe", "ANATOMY", 56, 73], ["right heart border", "ANATOMY", 112, 130], ["right\u2013upper-lobe", "ANATOMY", 275, 291], ["left lung", "ANATOMY", 311, 320], ["atelectasis", "DISEASE", 17, 28], ["atelectasis", "DISEASE", 74, 85], ["Atelectasis", "DISEASE", 151, 162], ["atelectasis", "DISEASE", 220, 231], ["atelectasis", "DISEASE", 292, 303], ["heart", "ORGAN", 118, 123], ["lung", "ORGAN", 316, 320], ["Right\u2013lower-lobe atelectasis", "PROBLEM", 0, 28], ["right\u2013middle-lobe atelectasis", "PROBLEM", 56, 85], ["Atelectasis", "PROBLEM", 151, 162], ["Adult Respiratory Distress SyndromeA", "PROBLEM", 167, 203], ["left\u2013upper-lobe atelectasis", "PROBLEM", 204, 231], ["a right\u2013upper-lobe atelectasis", "PROBLEM", 273, 303], ["lobe", "ANATOMY_MODIFIER", 12, 16], ["atelectasis", "OBSERVATION", 17, 28], ["lobe", "ANATOMY_MODIFIER", 69, 73], ["atelectasis", "OBSERVATION", 74, 85], ["persistence", "OBSERVATION_MODIFIER", 93, 104], ["right", "ANATOMY_MODIFIER", 112, 117], ["heart", "ANATOMY", 118, 123], ["border", "ANATOMY_MODIFIER", 124, 130], ["Respiratory Distress", "OBSERVATION", 173, 193], ["lobe", "ANATOMY_MODIFIER", 215, 219], ["atelectasis", "OBSERVATION", 220, 231], ["different", "OBSERVATION_MODIFIER", 243, 252], ["pattern", "OBSERVATION_MODIFIER", 253, 260], ["lobe", "ANATOMY_MODIFIER", 287, 291], ["atelectasis", "OBSERVATION", 292, 303], ["left", "ANATOMY_MODIFIER", 311, 315], ["lung", "ANATOMY", 316, 320], ["minor", "OBSERVATION_MODIFIER", 329, 334], ["fissure", "OBSERVATION_MODIFIER", 335, 342]]], ["When the left upper lobe collapses, the lobe predominantly moves anteriorly, with loss of the left upper cardiac border.", [["left upper lobe", "ANATOMY", 9, 24], ["lobe", "ANATOMY", 40, 44], ["left upper cardiac border", "ANATOMY", 94, 119], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 14, 24], ["lobe", "ORGAN", 40, 44], ["upper", "ORGANISM_SUBDIVISION", 99, 104], ["cardiac border", "TISSUE", 105, 119], ["the left upper lobe collapses", "PROBLEM", 5, 34], ["loss of the left upper cardiac border", "PROBLEM", 82, 119], ["left upper lobe", "ANATOMY", 9, 24], ["collapses", "OBSERVATION", 25, 34], ["lobe", "ANATOMY_MODIFIER", 40, 44], ["anteriorly", "ANATOMY_MODIFIER", 65, 75], ["loss", "OBSERVATION_MODIFIER", 82, 86], ["left", "ANATOMY_MODIFIER", 94, 98], ["upper", "ANATOMY_MODIFIER", 99, 104], ["cardiac", "ANATOMY", 105, 112], ["border", "ANATOMY_MODIFIER", 113, 119]]], ["There is compensatory emphysema of the left lower lobe, which expands and migrates to a location both superior and posterior to the left upper lobe.", [["left lower lobe", "ANATOMY", 39, 54], ["superior", "ANATOMY", 102, 110], ["left upper lobe", "ANATOMY", 132, 147], ["emphysema of the left lower lobe", "DISEASE", 22, 54], ["emphysema", "PATHOLOGICAL_FORMATION", 22, 31], ["lower lobe", "ORGAN", 44, 54], ["superior", "CANCER", 102, 110], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 137, 147], ["compensatory emphysema of the left lower lobe", "PROBLEM", 9, 54], ["compensatory", "OBSERVATION_MODIFIER", 9, 21], ["emphysema", "OBSERVATION", 22, 31], ["left lower lobe", "ANATOMY", 39, 54], ["superior", "ANATOMY_MODIFIER", 102, 110], ["posterior", "ANATOMY_MODIFIER", 115, 124], ["left upper lobe", "ANATOMY", 132, 147]]], ["The left main bronchus also rotates to a nearly horizontal position.", [["left main bronchus", "ANATOMY", 4, 22], ["bronchus", "ORGAN", 14, 22], ["left main bronchus", "ANATOMY", 4, 22], ["rotates", "OBSERVATION_MODIFIER", 28, 35], ["nearly", "OBSERVATION_MODIFIER", 41, 47], ["horizontal", "OBSERVATION_MODIFIER", 48, 58], ["position", "OBSERVATION_MODIFIER", 59, 67]]], ["The AP chest radiograph reveals hazy opacification of the left hilum, elevation of the left hilum, near-horizontal course of the left main bronchus, posterior leftward rotation of the heart and the Luftsichel or air crescent sign, the name given to the appearance of aerated lung abutting the arch of the aorta, between the mediastinum and the collapsed left upper lobe [Figure 17].", [["left hilum", "ANATOMY", 58, 68], ["left hilum", "ANATOMY", 87, 97], ["left main bronchus", "ANATOMY", 129, 147], ["heart", "ANATOMY", 184, 189], ["lung", "ANATOMY", 275, 279], ["arch", "ANATOMY", 293, 297], ["aorta", "ANATOMY", 305, 310], ["mediastinum", "ANATOMY", 324, 335], ["left upper lobe", "ANATOMY", 354, 369], ["hilum", "MULTI-TISSUE_STRUCTURE", 63, 68], ["hilum", "MULTI-TISSUE_STRUCTURE", 92, 97], ["bronchus", "MULTI-TISSUE_STRUCTURE", 139, 147], ["heart", "ORGAN", 184, 189], ["lung", "ORGAN", 275, 279], ["arch", "MULTI-TISSUE_STRUCTURE", 293, 297], ["aorta", "MULTI-TISSUE_STRUCTURE", 305, 310], ["mediastinum", "ORGAN", 324, 335], ["The AP chest radiograph", "TEST", 0, 23], ["hazy opacification of the left hilum", "PROBLEM", 32, 68], ["elevation of the left hilum", "PROBLEM", 70, 97], ["posterior leftward rotation of the heart", "PROBLEM", 149, 189], ["air crescent sign", "PROBLEM", 212, 229], ["hazy", "OBSERVATION_MODIFIER", 32, 36], ["opacification", "OBSERVATION", 37, 50], ["left", "ANATOMY_MODIFIER", 58, 62], ["hilum", "ANATOMY", 63, 68], ["elevation", "OBSERVATION_MODIFIER", 70, 79], ["left", "ANATOMY_MODIFIER", 87, 91], ["hilum", "ANATOMY", 92, 97], ["horizontal", "OBSERVATION_MODIFIER", 104, 114], ["course", "OBSERVATION_MODIFIER", 115, 121], ["left main bronchus", "ANATOMY", 129, 147], ["posterior", "ANATOMY_MODIFIER", 149, 158], ["leftward", "OBSERVATION_MODIFIER", 159, 167], ["rotation", "OBSERVATION_MODIFIER", 168, 176], ["heart", "ANATOMY", 184, 189], ["air crescent", "OBSERVATION", 212, 224], ["aerated", "OBSERVATION", 267, 274], ["lung", "ANATOMY", 275, 279], ["arch", "ANATOMY_MODIFIER", 293, 297], ["aorta", "ANATOMY", 305, 310], ["mediastinum", "ANATOMY", 324, 335], ["collapsed", "OBSERVATION", 344, 353], ["left upper lobe", "ANATOMY", 354, 369]]], ["An appearance on a lateral radiograph, if available, of the ICU patient may show retrosternal opacity and displacement of the greater fissure anteriorly.Atelectasis ::: Adult Respiratory Distress SyndromeThe left lower lobe collapses medially and posteriorly to lie behind the heart.", [["fissure", "ANATOMY", 134, 141], ["left lower lobe", "ANATOMY", 208, 223], ["heart", "ANATOMY", 277, 282], ["opacity", "DISEASE", 94, 101], ["Atelectasis", "DISEASE", 153, 164], ["Respiratory Distress Syndrome", "DISEASE", 175, 204], ["patient", "ORGANISM", 64, 71], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 213, 223], ["heart", "ORGAN", 277, 282], ["patient", "SPECIES", 64, 71], ["a lateral radiograph", "TEST", 17, 37], ["retrosternal opacity", "PROBLEM", 81, 101], ["displacement of the greater fissure anteriorly", "PROBLEM", 106, 152], ["Atelectasis", "PROBLEM", 153, 164], ["Adult Respiratory Distress Syndrome", "PROBLEM", 169, 204], ["The left lower lobe collapses medially", "PROBLEM", 204, 242], ["retrosternal", "ANATOMY", 81, 93], ["opacity", "OBSERVATION", 94, 101], ["displacement", "OBSERVATION_MODIFIER", 106, 118], ["greater fissure", "ANATOMY_MODIFIER", 126, 141], ["anteriorly", "ANATOMY_MODIFIER", 142, 152], ["Respiratory Distress", "OBSERVATION", 175, 195], ["Syndrome", "OBSERVATION", 196, 204], ["left lower lobe", "ANATOMY", 208, 223], ["collapses", "OBSERVATION", 224, 233], ["medially", "ANATOMY_MODIFIER", 234, 242], ["posteriorly", "ANATOMY_MODIFIER", 247, 258], ["heart", "ANATOMY", 277, 282]]], ["It classically displays a triangular opacity, which may be visible through the cardiac shadow or may overlie it, giving the heart an unusually straight lateral border.", [["cardiac", "ANATOMY", 79, 86], ["heart", "ANATOMY", 124, 129], ["lateral border", "ANATOMY", 152, 166], ["opacity", "DISEASE", 37, 44], ["cardiac", "ORGAN", 79, 86], ["heart", "ORGAN", 124, 129], ["lateral border", "MULTI-TISSUE_STRUCTURE", 152, 166], ["a triangular opacity", "PROBLEM", 24, 44], ["triangular", "OBSERVATION_MODIFIER", 26, 36], ["opacity", "OBSERVATION", 37, 44], ["may be", "UNCERTAINTY", 52, 58], ["cardiac", "ANATOMY", 79, 86], ["shadow", "OBSERVATION", 87, 93], ["heart", "ANATOMY", 124, 129], ["unusually", "OBSERVATION_MODIFIER", 133, 142], ["straight", "OBSERVATION_MODIFIER", 143, 151], ["lateral", "OBSERVATION_MODIFIER", 152, 159], ["border", "ANATOMY_MODIFIER", 160, 166]]], ["Silhouetting of the left hemidiaphragm usually occurs, which may be associated with an air bronchogram.", [["left hemidiaphragm", "ANATOMY", 20, 38], ["hemidiaphragm", "ORGAN", 25, 38], ["an air bronchogram", "PROBLEM", 84, 102], ["left", "ANATOMY_MODIFIER", 20, 24], ["hemidiaphragm", "ANATOMY", 25, 38], ["may be", "UNCERTAINTY", 61, 67], ["air bronchogram", "OBSERVATION", 87, 102]]], ["It is also easily missed, especially on an underpenetrated film, where no detail is seen behind the heart.[18\u201336]Pneumonia in the ICUHospital-based (nosocomial) pneumonias, which by definition occur 3 days after hospital admission, differ from community-acquired pneumonias in both causation and prognosis.", [["heart", "ANATOMY", 100, 105], ["Pneumonia", "DISEASE", 113, 122], ["pneumonias", "DISEASE", 161, 171], ["pneumonias", "DISEASE", 263, 273], ["heart", "ORGAN", 100, 105], ["an underpenetrated film", "TEST", 40, 63], ["Pneumonia", "PROBLEM", 113, 122], ["the ICUHospital-based (nosocomial) pneumonias", "PROBLEM", 126, 171], ["community-acquired pneumonias", "PROBLEM", 244, 273], ["heart", "ANATOMY", 100, 105], ["Pneumonia", "OBSERVATION", 113, 122], ["nosocomial", "OBSERVATION_MODIFIER", 149, 159], ["pneumonias", "OBSERVATION", 161, 171], ["pneumonias", "OBSERVATION", 263, 273]]], ["Nosocomial pneumonia is the leading cause of death in the ICU patient.[40] The ICU patients are particularly susceptible to pneumonias as they may be immune compromised and several iatrogenic factors are at play, which increase this susceptibility.", [["pneumonia", "DISEASE", 11, 20], ["death", "DISEASE", 45, 50], ["pneumonias", "DISEASE", 124, 134], ["patient", "ORGANISM", 62, 69], ["patients", "ORGANISM", 83, 91], ["patient", "SPECIES", 62, 69], ["patients", "SPECIES", 83, 91], ["Nosocomial pneumonia", "PROBLEM", 0, 20], ["death", "PROBLEM", 45, 50], ["pneumonias", "PROBLEM", 124, 134], ["immune compromised", "PROBLEM", 150, 168], ["several iatrogenic factors", "PROBLEM", 173, 199], ["pneumonia", "OBSERVATION", 11, 20], ["pneumonias", "OBSERVATION", 124, 134], ["may be", "UNCERTAINTY", 143, 149], ["several", "OBSERVATION_MODIFIER", 173, 180], ["iatrogenic", "OBSERVATION_MODIFIER", 181, 191]]], ["Iatrogenic factors that may predispose to pneumonias include endotracheal tubes; risk of aspiration; medications used to reduce gastric acid, which may promote bacterial growth in the stomach; and the use of antibiotics, which may selectively encourage the growth of some pathogenic bacteria.", [["endotracheal", "ANATOMY", 61, 73], ["gastric", "ANATOMY", 128, 135], ["stomach", "ANATOMY", 184, 191], ["pneumonias", "DISEASE", 42, 52], ["gastric acid", "SIMPLE_CHEMICAL", 128, 140], ["stomach", "ORGAN", 184, 191], ["Iatrogenic factors", "PROBLEM", 0, 18], ["pneumonias", "PROBLEM", 42, 52], ["endotracheal tubes", "TREATMENT", 61, 79], ["aspiration", "PROBLEM", 89, 99], ["medications", "TREATMENT", 101, 112], ["gastric acid", "PROBLEM", 128, 140], ["bacterial growth in the stomach", "PROBLEM", 160, 191], ["antibiotics", "TREATMENT", 208, 219], ["some pathogenic bacteria", "PROBLEM", 267, 291], ["may predispose to", "UNCERTAINTY", 24, 41], ["pneumonias", "OBSERVATION", 42, 52], ["endotracheal tubes", "OBSERVATION", 61, 79], ["aspiration", "OBSERVATION", 89, 99], ["gastric", "ANATOMY", 128, 135], ["bacterial", "OBSERVATION_MODIFIER", 160, 169], ["growth", "OBSERVATION_MODIFIER", 170, 176], ["stomach", "ANATOMY", 184, 191], ["pathogenic", "OBSERVATION_MODIFIER", 272, 282], ["bacteria", "OBSERVATION", 283, 291]]], ["Unlike community-acquired pneumonias, which usually are caused by gram-positive species, nosocomial pneumonias are often polymicrobial and caused by gram-negative enteric pathogens.", [["pneumonias", "DISEASE", 26, 36], ["pneumonias", "DISEASE", 100, 110], ["polymicrobial", "DISEASE", 121, 134], ["community-acquired pneumonias", "PROBLEM", 7, 36], ["gram-positive species", "PROBLEM", 66, 87], ["nosocomial pneumonias", "PROBLEM", 89, 110], ["polymicrobial", "PROBLEM", 121, 134], ["gram", "TEST", 149, 153], ["negative enteric pathogens", "PROBLEM", 154, 180], ["pneumonias", "OBSERVATION", 26, 36], ["positive species", "OBSERVATION", 71, 87], ["nosocomial", "OBSERVATION_MODIFIER", 89, 99], ["pneumonias", "OBSERVATION", 100, 110], ["negative enteric pathogens", "OBSERVATION", 154, 180]]], ["Clinical and laboratory findings such as fever, leucocytosis and sputum cultures may not be useful indicators and are often masked by severe underlying disease.", [["sputum cultures", "ANATOMY", 65, 80], ["fever", "DISEASE", 41, 46], ["leucocytosis", "DISEASE", 48, 60], ["Clinical and laboratory findings", "PROBLEM", 0, 32], ["fever", "PROBLEM", 41, 46], ["leucocytosis", "PROBLEM", 48, 60], ["sputum cultures", "TEST", 65, 80], ["severe underlying disease", "PROBLEM", 134, 159], ["severe", "OBSERVATION_MODIFIER", 134, 140], ["disease", "OBSERVATION", 152, 159]]], ["The chest film must be correlated with clinical data in order to make the diagnosis of pneumonia in the ICU patient.", [["chest", "ANATOMY", 4, 9], ["pneumonia", "DISEASE", 87, 96], ["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115], ["The chest film", "TEST", 0, 14], ["clinical data", "TEST", 39, 52], ["pneumonia", "PROBLEM", 87, 96], ["chest", "ANATOMY", 4, 9], ["pneumonia", "OBSERVATION", 87, 96]]], ["Radiographically pneumonias can be difficult to differentiate from other causes of air space shadowing, including atelectasis and early ARDS.", [["pneumonias", "DISEASE", 17, 27], ["atelectasis", "DISEASE", 114, 125], ["ARDS", "DISEASE", 136, 140], ["air space", "MULTI-TISSUE_STRUCTURE", 83, 92], ["Radiographically pneumonias", "PROBLEM", 0, 27], ["air space shadowing", "PROBLEM", 83, 102], ["atelectasis", "PROBLEM", 114, 125], ["early ARDS", "PROBLEM", 130, 140], ["pneumonias", "OBSERVATION", 17, 27], ["air space shadowing", "OBSERVATION", 83, 102], ["atelectasis", "OBSERVATION", 114, 125], ["early", "OBSERVATION_MODIFIER", 130, 135], ["ARDS", "OBSERVATION", 136, 140]]], ["Usually pneumonia initially appears as patchy consolidation or ill-defined nodules [Figure 18].", [["nodules", "ANATOMY", 75, 82], ["pneumonia", "DISEASE", 8, 17], ["nodules", "PATHOLOGICAL_FORMATION", 75, 82], ["Usually pneumonia", "PROBLEM", 0, 17], ["patchy consolidation", "PROBLEM", 39, 59], ["ill-defined nodules", "PROBLEM", 63, 82], ["pneumonia", "OBSERVATION", 8, 17], ["patchy", "OBSERVATION_MODIFIER", 39, 45], ["consolidation", "OBSERVATION", 46, 59], ["ill", "OBSERVATION_MODIFIER", 63, 66], ["nodules", "OBSERVATION", 75, 82]]], ["Pneumonia is a bilateral multifocal disease and often involves gravity-dependent areas of the lung [Figure 19].", [["lung", "ANATOMY", 94, 98], ["Pneumonia", "DISEASE", 0, 9], ["lung", "ORGAN", 94, 98], ["Pneumonia", "PROBLEM", 0, 9], ["a bilateral multifocal disease", "PROBLEM", 13, 43], ["bilateral", "ANATOMY_MODIFIER", 15, 24], ["multifocal", "OBSERVATION_MODIFIER", 25, 35], ["disease", "OBSERVATION", 36, 43], ["gravity-dependent", "OBSERVATION_MODIFIER", 63, 80], ["areas", "OBSERVATION_MODIFIER", 81, 86], ["lung", "ANATOMY", 94, 98]]], ["Atelectasis and lung edema have a similar distribution, making differentiation from pneumonia difficult.", [["lung", "ANATOMY", 16, 20], ["Atelectasis", "DISEASE", 0, 11], ["lung edema", "DISEASE", 16, 26], ["pneumonia", "DISEASE", 84, 93], ["lung", "ORGAN", 16, 20], ["edema", "PATHOLOGICAL_FORMATION", 21, 26], ["Atelectasis", "PROBLEM", 0, 11], ["lung edema", "PROBLEM", 16, 26], ["pneumonia", "PROBLEM", 84, 93], ["lung", "ANATOMY", 16, 20], ["edema", "OBSERVATION", 21, 26], ["similar", "OBSERVATION_MODIFIER", 34, 41], ["distribution", "OBSERVATION_MODIFIER", 42, 54], ["pneumonia", "OBSERVATION", 84, 93]]], ["A symmetric pattern simulating pulmonary edema can occur with E-coli and pseudomonas pneumonias, which can rapidly involve the entire lungs.", [["pulmonary edema", "ANATOMY", 31, 46], ["lungs", "ANATOMY", 134, 139], ["pulmonary edema", "DISEASE", 31, 46], ["pneumonias", "DISEASE", 85, 95], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 31, 46], ["E-coli", "GENE_OR_GENE_PRODUCT", 62, 68], ["pseudomonas", "ORGANISM", 73, 84], ["lungs", "ORGAN", 134, 139], ["E-coli", "SPECIES", 62, 68], ["E-coli", "SPECIES", 62, 68], ["pulmonary edema", "PROBLEM", 31, 46], ["E-coli", "PROBLEM", 62, 68], ["pseudomonas pneumonias", "PROBLEM", 73, 95], ["symmetric", "OBSERVATION_MODIFIER", 2, 11], ["pattern", "OBSERVATION_MODIFIER", 12, 19], ["pulmonary", "ANATOMY", 31, 40], ["edema", "OBSERVATION", 41, 46], ["-coli", "OBSERVATION_MODIFIER", 63, 68], ["pseudomonas", "OBSERVATION_MODIFIER", 73, 84], ["pneumonias", "OBSERVATION", 85, 95], ["entire", "ANATOMY_MODIFIER", 127, 133], ["lungs", "ANATOMY", 134, 139]]], ["Patchy air space shadowing, ill-defined segmental consolidation or air bronchograms \u2014 either of these with associated pleural effusions supports the diagnosis of pneumonia.", [["pleural effusions", "ANATOMY", 118, 135], ["pleural effusions", "DISEASE", 118, 135], ["pneumonia", "DISEASE", 162, 171], ["pleural effusions", "PATHOLOGICAL_FORMATION", 118, 135], ["Patchy air space shadowing", "PROBLEM", 0, 26], ["ill-defined segmental consolidation", "PROBLEM", 28, 63], ["air bronchograms", "PROBLEM", 67, 83], ["associated pleural effusions", "PROBLEM", 107, 135], ["pneumonia", "PROBLEM", 162, 171], ["air space shadowing", "OBSERVATION", 7, 26], ["ill", "OBSERVATION_MODIFIER", 28, 31], ["-defined", "OBSERVATION_MODIFIER", 31, 39], ["segmental", "OBSERVATION_MODIFIER", 40, 49], ["consolidation", "OBSERVATION", 50, 63], ["air bronchograms", "OBSERVATION", 67, 83], ["pleural", "ANATOMY", 118, 125], ["effusions", "OBSERVATION", 126, 135], ["pneumonia", "OBSERVATION", 162, 171]]], ["However, unlike community-acquired pneumonia, pleural effusions caused by gram-negative organisms are more likely to represent empyema and therefore require drainage.", [["pleural effusions", "ANATOMY", 46, 63], ["pneumonia", "DISEASE", 35, 44], ["pleural effusions", "DISEASE", 46, 63], ["empyema", "DISEASE", 127, 134], ["pleural effusions", "PATHOLOGICAL_FORMATION", 46, 63], ["acquired pneumonia", "PROBLEM", 26, 44], ["pleural effusions", "PROBLEM", 46, 63], ["gram-negative organisms", "PROBLEM", 74, 97], ["empyema", "PROBLEM", 127, 134], ["drainage", "TREATMENT", 157, 165], ["community", "OBSERVATION_MODIFIER", 16, 25], ["pneumonia", "OBSERVATION", 35, 44], ["pleural", "ANATOMY", 46, 53], ["effusions", "OBSERVATION", 54, 63], ["negative organisms", "OBSERVATION", 79, 97], ["more likely to represent", "UNCERTAINTY", 102, 126], ["empyema", "OBSERVATION", 127, 134], ["drainage", "OBSERVATION", 157, 165]]], ["Other serious complications of pneumonias in the ICU patients include abscess formation and bronchopleural fistulas.[37\u201340]AspirationThe ICU patient is at a particular risk of aspiration pneumonitis, often as a result of a compromised airway.", [["abscess", "ANATOMY", 70, 77], ["bronchopleural", "ANATOMY", 92, 106], ["airway", "ANATOMY", 235, 241], ["pneumonias", "DISEASE", 31, 41], ["abscess", "DISEASE", 70, 77], ["bronchopleural fistulas", "DISEASE", 92, 115], ["pneumonitis", "DISEASE", 187, 198], ["patients", "ORGANISM", 53, 61], ["abscess", "PATHOLOGICAL_FORMATION", 70, 77], ["bronchopleural fistulas", "PATHOLOGICAL_FORMATION", 92, 115], ["patient", "ORGANISM", 141, 148], ["airway", "MULTI-TISSUE_STRUCTURE", 235, 241], ["patients", "SPECIES", 53, 61], ["patient", "SPECIES", 141, 148], ["Other serious complications", "PROBLEM", 0, 27], ["pneumonias", "PROBLEM", 31, 41], ["abscess formation", "PROBLEM", 70, 87], ["bronchopleural fistulas", "PROBLEM", 92, 115], ["Aspiration", "TREATMENT", 123, 133], ["aspiration pneumonitis", "PROBLEM", 176, 198], ["a compromised airway", "PROBLEM", 221, 241], ["serious", "OBSERVATION_MODIFIER", 6, 13], ["complications", "OBSERVATION", 14, 27], ["pneumonias", "OBSERVATION", 31, 41], ["abscess", "OBSERVATION", 70, 77], ["bronchopleural", "ANATOMY", 92, 106], ["fistulas", "OBSERVATION", 107, 115], ["aspiration", "OBSERVATION", 176, 186], ["pneumonitis", "OBSERVATION", 187, 198], ["compromised", "OBSERVATION", 223, 234], ["airway", "ANATOMY", 235, 241]]], ["Impaired consciousness, placement of ET and NG tubes are amongst many contributory factors.", [["Impaired consciousness", "DISEASE", 0, 22], ["NG", "CHEMICAL", 44, 46], ["Impaired consciousness", "PROBLEM", 0, 22], ["placement of ET and NG tubes", "TREATMENT", 24, 52], ["consciousness", "OBSERVATION", 9, 22], ["NG tubes", "OBSERVATION", 44, 52]]], ["The pulmonary response to aspiration depends on the type, pH and volume of aspirate.", [["pulmonary", "ANATOMY", 4, 13], ["pulmonary", "ORGAN", 4, 13], ["aspiration depends", "PROBLEM", 26, 44], ["aspirate", "TEST", 75, 83], ["pulmonary", "ANATOMY", 4, 13], ["aspiration", "OBSERVATION", 26, 36], ["aspirate", "OBSERVATION", 75, 83]]], ["Aspiration of gastric contents provokes a chemical pneumonitis called Mendelson's syndrome.", [["gastric", "ANATOMY", 14, 21], ["pneumonitis", "DISEASE", 51, 62], ["Mendelson's syndrome", "DISEASE", 70, 90], ["gastric", "ORGAN", 14, 21], ["Aspiration of gastric contents", "PROBLEM", 0, 30], ["a chemical pneumonitis", "PROBLEM", 40, 62], ["Mendelson's syndrome", "PROBLEM", 70, 90], ["gastric", "ANATOMY", 14, 21], ["contents", "OBSERVATION", 22, 30], ["chemical", "OBSERVATION_MODIFIER", 42, 50], ["pneumonitis", "OBSERVATION", 51, 62]]], ["The lung responds to pH <2.5 with severe bronchospasm and the release of inflammatory mediators.", [["lung", "ANATOMY", 4, 8], ["bronchospasm", "DISEASE", 41, 53], ["lung", "ORGAN", 4, 8], ["inflammatory mediators", "PROTEIN", 73, 95], ["pH", "TEST", 21, 23], ["severe bronchospasm", "PROBLEM", 34, 53], ["inflammatory mediators", "PROBLEM", 73, 95], ["lung", "ANATOMY", 4, 8], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["bronchospasm", "OBSERVATION", 41, 53], ["inflammatory", "OBSERVATION_MODIFIER", 73, 85]]], ["Patients become symptomatic almost immediately following aspiration of gastric contents, with cough, dyspnea, wheezing and diffuse crackles.", [["gastric", "ANATOMY", 71, 78], ["cough", "DISEASE", 94, 99], ["dyspnea", "DISEASE", 101, 108], ["wheezing", "DISEASE", 110, 118], ["Patients", "ORGANISM", 0, 8], ["gastric", "ORGAN", 71, 78], ["Patients", "SPECIES", 0, 8], ["symptomatic", "PROBLEM", 16, 27], ["aspiration of gastric contents", "PROBLEM", 57, 87], ["cough", "PROBLEM", 94, 99], ["dyspnea", "PROBLEM", 101, 108], ["wheezing", "PROBLEM", 110, 118], ["diffuse crackles", "PROBLEM", 123, 139], ["symptomatic", "OBSERVATION", 16, 27], ["gastric", "ANATOMY", 71, 78], ["contents", "OBSERVATION", 79, 87], ["wheezing", "OBSERVATION", 110, 118], ["diffuse", "OBSERVATION_MODIFIER", 123, 130], ["crackles", "OBSERVATION", 131, 139]]], ["Fever and leucocytosis are the norm.", [["Fever", "DISEASE", 0, 5], ["leucocytosis", "DISEASE", 10, 22], ["Fever", "PROBLEM", 0, 5], ["leucocytosis", "PROBLEM", 10, 22], ["leucocytosis", "OBSERVATION", 10, 22]]], ["The initial response is a chemical pulmonary edema.", [["pulmonary", "ANATOMY", 35, 44], ["pulmonary edema", "DISEASE", 35, 50], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 35, 50], ["a chemical pulmonary edema", "PROBLEM", 24, 50], ["chemical", "OBSERVATION_MODIFIER", 26, 34], ["pulmonary", "ANATOMY", 35, 44], ["edema", "OBSERVATION", 45, 50]]], ["Secondary infection occurs in some cases.", [["Secondary infection", "DISEASE", 0, 19], ["Secondary infection", "PROBLEM", 0, 19], ["infection", "OBSERVATION", 10, 19]]], ["Patient response to aspiration varies from shock to resolution without sequelae.", [["shock", "DISEASE", 43, 48], ["Patient", "SPECIES", 0, 7], ["aspiration varies", "PROBLEM", 20, 37], ["shock", "PROBLEM", 43, 48], ["sequelae", "PROBLEM", 71, 79], ["aspiration", "OBSERVATION", 20, 30]]], ["Patients that proceed to pneumonitis may reveal pulmonary consolidation within the first two days.", [["pulmonary", "ANATOMY", 48, 57], ["pneumonitis", "DISEASE", 25, 36], ["Patients", "ORGANISM", 0, 8], ["pulmonary", "ORGAN", 48, 57], ["Patients", "SPECIES", 0, 8], ["pneumonitis", "PROBLEM", 25, 36], ["pulmonary consolidation", "PROBLEM", 48, 71], ["pneumonitis", "OBSERVATION", 25, 36], ["pulmonary", "ANATOMY", 48, 57], ["consolidation", "OBSERVATION", 58, 71]]], ["The air space shadowing is bilateral, usually perihilar although asymmetric.", [["The air space shadowing", "PROBLEM", 0, 23], ["air space", "OBSERVATION", 4, 13], ["shadowing", "OBSERVATION_MODIFIER", 14, 23], ["bilateral", "ANATOMY_MODIFIER", 27, 36], ["perihilar", "ANATOMY_MODIFIER", 46, 55], ["asymmetric", "OBSERVATION_MODIFIER", 65, 75]]], ["Radiographically the consolidation usually begins to resolve by the third day [Figures 20 and 21].", [["Radiographically the consolidation", "PROBLEM", 0, 34], ["consolidation", "OBSERVATION", 21, 34]]], ["In some, the consolidation may worsen with added complications of lung abscesses and pleural effusion.[4142]Pulmonary EmbolismMorbidity and mortality from pulmonary embolism in the ICU remain high, and they continue to be underdiagnosed in the intensive care setting.", [["lung abscesses", "ANATOMY", 66, 80], ["pleural", "ANATOMY", 85, 92], ["pulmonary", "ANATOMY", 155, 164], ["lung abscesses", "DISEASE", 66, 80], ["pleural effusion", "DISEASE", 85, 101], ["Pulmonary EmbolismMorbidity", "DISEASE", 108, 135], ["pulmonary embolism", "DISEASE", 155, 173], ["lung abscesses", "PATHOLOGICAL_FORMATION", 66, 80], ["pleural effusion", "PATHOLOGICAL_FORMATION", 85, 101], ["pulmonary", "ORGAN", 155, 164], ["the consolidation", "PROBLEM", 9, 26], ["lung abscesses", "PROBLEM", 66, 80], ["pleural effusion", "PROBLEM", 85, 101], ["Pulmonary EmbolismMorbidity", "PROBLEM", 108, 135], ["pulmonary embolism", "PROBLEM", 155, 173], ["consolidation", "OBSERVATION", 13, 26], ["complications", "OBSERVATION_MODIFIER", 49, 62], ["lung", "ANATOMY", 66, 70], ["abscesses", "OBSERVATION", 71, 80], ["pleural", "ANATOMY", 85, 92], ["effusion", "OBSERVATION", 93, 101], ["Pulmonary", "ANATOMY", 108, 117], ["EmbolismMorbidity", "OBSERVATION", 118, 135], ["pulmonary", "ANATOMY", 155, 164], ["embolism", "OBSERVATION", 165, 173], ["high", "OBSERVATION", 192, 196]]], ["Pulmonary embolism in the ICU setting may be completely silent, but it is a cause of sudden death.", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary embolism", "DISEASE", 0, 18], ["death", "DISEASE", 92, 97], ["Pulmonary", "ORGAN", 0, 9], ["Pulmonary embolism", "PROBLEM", 0, 18], ["sudden death", "PROBLEM", 85, 97], ["embolism", "OBSERVATION", 10, 18], ["silent", "OBSERVATION", 56, 62]]], ["Symptoms are nonspecific and include dyspnea, tachypnea, hemoptysis, hypoxemia and pleuritic chest pain.", [["chest", "ANATOMY", 93, 98], ["dyspnea", "DISEASE", 37, 44], ["tachypnea", "DISEASE", 46, 55], ["hemoptysis", "DISEASE", 57, 67], ["hypoxemia", "DISEASE", 69, 78], ["chest pain", "DISEASE", 93, 103], ["chest", "ORGANISM_SUBDIVISION", 93, 98], ["Symptoms", "PROBLEM", 0, 8], ["dyspnea", "PROBLEM", 37, 44], ["tachypnea", "PROBLEM", 46, 55], ["hemoptysis", "PROBLEM", 57, 67], ["hypoxemia", "PROBLEM", 69, 78], ["pleuritic chest pain", "PROBLEM", 83, 103], ["tachypnea", "OBSERVATION", 46, 55], ["hemoptysis", "OBSERVATION", 57, 67], ["hypoxemia", "OBSERVATION", 69, 78], ["pleuritic", "OBSERVATION_MODIFIER", 83, 92], ["chest", "ANATOMY", 93, 98], ["pain", "OBSERVATION", 99, 103]]], ["Many risk factors exist, most important amongst them being a history of a previous embolic event.", [["embolic event", "DISEASE", 83, 96], ["a previous embolic event", "PROBLEM", 72, 96], ["embolic", "OBSERVATION", 83, 90]]], ["Other risk factors include immobilization, trauma, surgery, shock, obesity, pregnancy, polycythemia vera and antithrombin-III deficiency.", [["trauma", "DISEASE", 43, 49], ["shock", "DISEASE", 60, 65], ["obesity", "DISEASE", 67, 74], ["polycythemia vera", "DISEASE", 87, 104], ["antithrombin-III", "GENE_OR_GENE_PRODUCT", 109, 125], ["antithrombin", "PROTEIN", 109, 121], ["immobilization", "TREATMENT", 27, 41], ["trauma", "PROBLEM", 43, 49], ["surgery", "TREATMENT", 51, 58], ["shock", "PROBLEM", 60, 65], ["obesity", "PROBLEM", 67, 74], ["pregnancy", "PROBLEM", 76, 85], ["polycythemia vera", "PROBLEM", 87, 104], ["antithrombin-III deficiency", "PROBLEM", 109, 136], ["shock", "OBSERVATION", 60, 65], ["obesity", "OBSERVATION", 67, 74], ["polycythemia", "OBSERVATION", 87, 99], ["III deficiency", "OBSERVATION", 122, 136]]], ["The pathophysiology of pulmonary embolism consists of both hemodynamic and respiratory embarrassment.", [["pulmonary", "ANATOMY", 23, 32], ["pulmonary embolism", "DISEASE", 23, 41], ["respiratory embarrassment", "DISEASE", 75, 100], ["pulmonary", "ORGAN", 23, 32], ["pulmonary embolism", "PROBLEM", 23, 41], ["both hemodynamic and respiratory embarrassment", "PROBLEM", 54, 100], ["pulmonary", "ANATOMY", 23, 32], ["embolism", "OBSERVATION", 33, 41], ["both", "OBSERVATION_MODIFIER", 54, 58], ["hemodynamic", "OBSERVATION_MODIFIER", 59, 70], ["respiratory embarrassment", "OBSERVATION", 75, 100]]], ["Hemodynamic consequences occur when more than half the cross-sectional area of the pulmonary vascular bed is occluded by the embolic episode, leading to acute pulmonary hypertension, hypoxemia, respiratory failure and right-sided heart failure.", [["pulmonary vascular bed", "ANATOMY", 83, 105], ["pulmonary", "ANATOMY", 159, 168], ["respiratory", "ANATOMY", 194, 205], ["heart", "ANATOMY", 230, 235], ["embolic episode", "DISEASE", 125, 140], ["acute pulmonary hypertension", "DISEASE", 153, 181], ["hypoxemia", "DISEASE", 183, 192], ["respiratory failure", "DISEASE", 194, 213], ["heart failure", "DISEASE", 230, 243], ["pulmonary vascular bed", "MULTI-TISSUE_STRUCTURE", 83, 105], ["pulmonary", "ORGAN", 159, 168], ["heart", "ORGAN", 230, 235], ["Hemodynamic consequences", "PROBLEM", 0, 24], ["the embolic episode", "PROBLEM", 121, 140], ["acute pulmonary hypertension", "PROBLEM", 153, 181], ["hypoxemia", "PROBLEM", 183, 192], ["respiratory failure", "PROBLEM", 194, 213], ["right-sided heart failure", "PROBLEM", 218, 243], ["pulmonary vascular", "ANATOMY", 83, 101], ["occluded", "OBSERVATION", 109, 117], ["embolic episode", "OBSERVATION", 125, 140], ["acute", "OBSERVATION_MODIFIER", 153, 158], ["pulmonary", "ANATOMY", 159, 168], ["hypertension", "OBSERVATION", 169, 181], ["hypoxemia", "OBSERVATION", 183, 192], ["respiratory failure", "OBSERVATION", 194, 213], ["right", "ANATOMY_MODIFIER", 218, 223], ["sided", "ANATOMY_MODIFIER", 224, 229], ["heart", "ANATOMY", 230, 235], ["failure", "OBSERVATION", 236, 243]]], ["Pulmonary infarction ensues rarely in the absence of associated bronchial arterial compromise.", [["Pulmonary", "ANATOMY", 0, 9], ["bronchial arterial", "ANATOMY", 64, 82], ["Pulmonary infarction", "DISEASE", 0, 20], ["Pulmonary", "ORGAN", 0, 9], ["bronchial arterial", "MULTI-TISSUE_STRUCTURE", 64, 82], ["Pulmonary infarction", "PROBLEM", 0, 20], ["associated bronchial arterial compromise", "PROBLEM", 53, 93], ["infarction", "OBSERVATION", 10, 20], ["bronchial arterial", "ANATOMY", 64, 82], ["compromise", "OBSERVATION", 83, 93]]], ["Typically, infarctions tend to be hemorrhagic and occur in the lower lobes.Pulmonary EmbolismThe chest radiograph has poor sensitivity in establishing the diagnosis of pulmonary embolism, and the role of a chest radiograph is in ruling out other pathologies that may have a clinical presentation similar to that of pulmonary embolism.", [["lower lobes", "ANATOMY", 63, 74], ["Pulmonary", "ANATOMY", 75, 84], ["chest", "ANATOMY", 97, 102], ["pulmonary", "ANATOMY", 168, 177], ["chest", "ANATOMY", 206, 211], ["pulmonary", "ANATOMY", 315, 324], ["infarctions", "DISEASE", 11, 22], ["hemorrhagic", "DISEASE", 34, 45], ["pulmonary embolism", "DISEASE", 168, 186], ["pulmonary embolism", "DISEASE", 315, 333], ["lower lobes", "ORGAN", 63, 74], ["pulmonary", "ORGAN", 168, 177], ["pulmonary", "ORGAN", 315, 324], ["infarctions", "PROBLEM", 11, 22], ["hemorrhagic", "PROBLEM", 34, 45], ["Pulmonary Embolism", "PROBLEM", 75, 93], ["The chest radiograph", "TEST", 93, 113], ["pulmonary embolism", "PROBLEM", 168, 186], ["a chest radiograph", "TEST", 204, 222], ["other pathologies", "PROBLEM", 240, 257], ["pulmonary embolism", "PROBLEM", 315, 333], ["infarctions", "OBSERVATION", 11, 22], ["hemorrhagic", "OBSERVATION", 34, 45], ["lower lobes", "ANATOMY", 63, 74], ["Embolism", "OBSERVATION", 85, 93], ["chest", "ANATOMY", 97, 102], ["pulmonary", "ANATOMY", 168, 177], ["embolism", "OBSERVATION", 178, 186], ["chest", "ANATOMY", 206, 211], ["pathologies", "OBSERVATION", 246, 257], ["pulmonary", "ANATOMY", 315, 324], ["embolism", "OBSERVATION", 325, 333]]], ["The chest x-ray also serves a useful purpose when interpreting ventilation-perfusion scans.", [["chest", "ANATOMY", 4, 9], ["The chest x-ray", "TEST", 0, 15], ["interpreting ventilation", "TEST", 50, 74], ["perfusion scans", "TEST", 75, 90], ["chest", "ANATOMY", 4, 9]]], ["Studies have shown that the vast majority of patients with pulmonary embolism in retrospect do have abnormalities on the chest x-ray findings, but these findings are too nonspecific to be of clinical value [Figures 22\u201324].", [["pulmonary", "ANATOMY", 59, 68], ["pulmonary embolism", "DISEASE", 59, 77], ["patients", "ORGANISM", 45, 53], ["pulmonary", "ORGAN", 59, 68], ["patients", "SPECIES", 45, 53], ["Studies", "TEST", 0, 7], ["pulmonary embolism", "PROBLEM", 59, 77], ["abnormalities", "PROBLEM", 100, 113], ["the chest x-ray", "TEST", 117, 132], ["pulmonary", "ANATOMY", 59, 68], ["embolism", "OBSERVATION", 69, 77], ["chest", "ANATOMY", 121, 126]]], ["In the absence of pulmonary infarction, only a few signs of pulmonary emboli are seen on a chest radiograph, which include discoid atelectasis, elevation of the hemidiaphragm, enlargement of the main pulmonary artery into what has been described as the shape of a \u2018sausage\u2019 or a \u2018knuckle\u2019 (Palla's sign), and pulmonary oligemia beyond the point of occlusion (Westermark's sign).", [["pulmonary", "ANATOMY", 18, 27], ["pulmonary emboli", "ANATOMY", 60, 76], ["chest", "ANATOMY", 91, 96], ["hemidiaphragm", "ANATOMY", 161, 174], ["pulmonary artery", "ANATOMY", 200, 216], ["pulmonary", "ANATOMY", 309, 318], ["pulmonary infarction", "DISEASE", 18, 38], ["pulmonary emboli", "DISEASE", 60, 76], ["atelectasis", "DISEASE", 131, 142], ["elevation of the hemidiaphragm", "DISEASE", 144, 174], ["pulmonary oligemia", "DISEASE", 309, 327], ["pulmonary", "ORGAN", 18, 27], ["pulmonary emboli", "PATHOLOGICAL_FORMATION", 60, 76], ["hemidiaphragm", "ORGAN", 161, 174], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 200, 216], ["pulmonary", "ORGAN", 309, 318], ["pulmonary infarction", "PROBLEM", 18, 38], ["pulmonary emboli", "PROBLEM", 60, 76], ["a chest radiograph", "TEST", 89, 107], ["discoid atelectasis", "PROBLEM", 123, 142], ["elevation of the hemidiaphragm", "PROBLEM", 144, 174], ["enlargement of the main pulmonary artery", "PROBLEM", 176, 216], ["a \u2018knuckle\u2019 (Palla's sign", "PROBLEM", 277, 302], ["pulmonary oligemia", "PROBLEM", 309, 327], ["occlusion", "PROBLEM", 348, 357], ["pulmonary", "ANATOMY", 18, 27], ["infarction", "OBSERVATION", 28, 38], ["few", "OBSERVATION_MODIFIER", 47, 50], ["signs", "OBSERVATION_MODIFIER", 51, 56], ["pulmonary", "ANATOMY", 60, 69], ["emboli", "OBSERVATION", 70, 76], ["chest", "ANATOMY", 91, 96], ["discoid", "OBSERVATION_MODIFIER", 123, 130], ["atelectasis", "OBSERVATION", 131, 142], ["elevation", "OBSERVATION_MODIFIER", 144, 153], ["hemidiaphragm", "ANATOMY", 161, 174], ["enlargement", "OBSERVATION", 176, 187], ["main pulmonary artery", "ANATOMY", 195, 216], ["shape", "OBSERVATION_MODIFIER", 253, 258], ["pulmonary", "ANATOMY", 309, 318], ["oligemia", "OBSERVATION", 319, 327], ["occlusion", "OBSERVATION", 348, 357]]], ["A constellation of radiographic signs may be seen when pulmonary infarction complicates pulmonary embolism.", [["pulmonary", "ANATOMY", 55, 64], ["pulmonary", "ANATOMY", 88, 97], ["pulmonary infarction", "DISEASE", 55, 75], ["pulmonary embolism", "DISEASE", 88, 106], ["pulmonary", "ORGAN", 55, 64], ["pulmonary", "ORGAN", 88, 97], ["radiographic signs", "TEST", 19, 37], ["pulmonary infarction", "PROBLEM", 55, 75], ["pulmonary embolism", "PROBLEM", 88, 106], ["may be seen", "UNCERTAINTY", 38, 49], ["pulmonary", "ANATOMY", 55, 64], ["infarction", "OBSERVATION", 65, 75], ["pulmonary", "ANATOMY", 88, 97], ["embolism", "OBSERVATION", 98, 106]]], ["Multifocal consolidation may follow with established pulmonary infarctions within 12 to 24 hours following the embolic episode.", [["pulmonary", "ANATOMY", 53, 62], ["pulmonary infarctions", "DISEASE", 53, 74], ["embolic episode", "DISEASE", 111, 126], ["pulmonary", "ORGAN", 53, 62], ["Multifocal consolidation", "PROBLEM", 0, 24], ["established pulmonary infarctions", "PROBLEM", 41, 74], ["the embolic episode", "PROBLEM", 107, 126], ["consolidation", "OBSERVATION", 11, 24], ["pulmonary", "ANATOMY", 53, 62], ["infarctions", "OBSERVATION", 63, 74], ["embolic", "OBSERVATION", 111, 118]]], ["A relatively late sign of pulmonary infarction is a rounded pleural-based consolidation that is rounded centrally and is called a Hamptom's Hump.", [["pulmonary", "ANATOMY", 26, 35], ["pleural", "ANATOMY", 60, 67], ["pulmonary infarction", "DISEASE", 26, 46], ["pulmonary", "ORGAN", 26, 35], ["pulmonary infarction", "PROBLEM", 26, 46], ["a rounded pleural-based consolidation", "PROBLEM", 50, 87], ["relatively", "OBSERVATION_MODIFIER", 2, 12], ["late", "OBSERVATION_MODIFIER", 13, 17], ["pulmonary", "ANATOMY", 26, 35], ["infarction", "OBSERVATION", 36, 46], ["rounded", "OBSERVATION_MODIFIER", 52, 59], ["pleural", "ANATOMY", 60, 67], ["based", "ANATOMY_MODIFIER", 68, 73], ["consolidation", "OBSERVATION", 74, 87], ["rounded", "OBSERVATION_MODIFIER", 96, 103], ["centrally", "OBSERVATION_MODIFIER", 104, 113]]], ["A Hamptom's Hump can be differentiated from a pneumonic consolidation as the former lacks an air bronchogram.", [["pneumonic", "DISEASE", 46, 55], ["A Hamptom's Hump", "TREATMENT", 0, 16], ["a pneumonic consolidation", "PROBLEM", 44, 69], ["an air bronchogram", "PROBLEM", 90, 108], ["pneumonic", "OBSERVATION_MODIFIER", 46, 55], ["consolidation", "OBSERVATION", 56, 69], ["air bronchogram", "OBSERVATION", 93, 108]]], ["Ipsilateral or bilateral pulmonary effusions although nonspecific are associated with approximately 50% of pulmonary emboli, although these are certainly nonspecific findings.", [["pulmonary effusions", "ANATOMY", 25, 44], ["pulmonary emboli", "ANATOMY", 107, 123], ["pulmonary effusions", "DISEASE", 25, 44], ["pulmonary emboli", "DISEASE", 107, 123], ["pulmonary", "ORGAN", 25, 34], ["pulmonary emboli", "PATHOLOGICAL_FORMATION", 107, 123], ["Ipsilateral or bilateral pulmonary effusions", "PROBLEM", 0, 44], ["pulmonary emboli", "PROBLEM", 107, 123], ["bilateral", "ANATOMY_MODIFIER", 15, 24], ["pulmonary", "ANATOMY", 25, 34], ["effusions", "OBSERVATION", 35, 44], ["nonspecific", "OBSERVATION_MODIFIER", 54, 65], ["pulmonary", "ANATOMY", 107, 116], ["emboli", "OBSERVATION", 117, 123], ["nonspecific", "OBSERVATION_MODIFIER", 154, 165]]], ["Infarcts often are confused with, or are indistinguishable from, atelectasis or pneumonias on chest radiographs.Pulmonary EmbolismHowever, despite the low sensitivity of chest radiography in the diagnosis of pulmonary embolism, it remains an important first step in the diagnosis of pulmonary embolism, primarily to exclude other causes of hypoxemia and to aid in the interpretation of the ventilation/perfusion scan.[43\u201350]ConclusionTo summarize, radiography of lung pathologies common in the ICU patient is discussed, including pulmonary edema, ARDS, atelectasis, pulmonary embolism, aspiration and ICU-acquired pneumonia in terms of pathogenesis and radiographic recognition of the abnormalities.", [["chest", "ANATOMY", 94, 99], ["Pulmonary", "ANATOMY", 112, 121], ["pulmonary", "ANATOMY", 208, 217], ["pulmonary", "ANATOMY", 283, 292], ["lung", "ANATOMY", 463, 467], ["pulmonary", "ANATOMY", 530, 539], ["pulmonary", "ANATOMY", 566, 575], ["Infarcts", "DISEASE", 0, 8], ["atelectasis", "DISEASE", 65, 76], ["pneumonias", "DISEASE", 80, 90], ["pulmonary embolism", "DISEASE", 208, 226], ["pulmonary embolism", "DISEASE", 283, 301], ["hypoxemia", "DISEASE", 340, 349], ["lung pathologies", "DISEASE", 463, 479], ["pulmonary edema", "DISEASE", 530, 545], ["ARDS", "DISEASE", 547, 551], ["atelectasis", "DISEASE", 553, 564], ["pulmonary embolism", "DISEASE", 566, 584], ["pneumonia", "DISEASE", 614, 623], ["Pulmonary", "ORGAN", 112, 121], ["pulmonary", "ORGAN", 208, 217], ["pulmonary", "ORGAN", 283, 292], ["lung", "ORGAN", 463, 467], ["patient", "ORGANISM", 498, 505], ["pulmonary", "ORGAN", 530, 539], ["pulmonary", "ORGAN", 566, 575], ["patient", "SPECIES", 498, 505], ["Infarcts", "PROBLEM", 0, 8], ["confused", "PROBLEM", 19, 27], ["atelectasis", "PROBLEM", 65, 76], ["pneumonias", "PROBLEM", 80, 90], ["chest radiographs", "TEST", 94, 111], ["Pulmonary EmbolismHowever", "PROBLEM", 112, 137], ["chest radiography", "TEST", 170, 187], ["pulmonary embolism", "PROBLEM", 208, 226], ["pulmonary embolism", "PROBLEM", 283, 301], ["hypoxemia", "PROBLEM", 340, 349], ["the ventilation/perfusion scan", "TEST", 386, 416], ["radiography", "TEST", 448, 459], ["lung pathologies", "PROBLEM", 463, 479], ["pulmonary edema", "PROBLEM", 530, 545], ["ARDS", "PROBLEM", 547, 551], ["atelectasis", "PROBLEM", 553, 564], ["pulmonary embolism", "PROBLEM", 566, 584], ["aspiration", "PROBLEM", 586, 596], ["ICU-acquired pneumonia", "PROBLEM", 601, 623], ["pathogenesis", "PROBLEM", 636, 648], ["radiographic recognition", "TEST", 653, 677], ["the abnormalities", "PROBLEM", 681, 698], ["atelectasis", "OBSERVATION", 65, 76], ["pneumonias", "OBSERVATION", 80, 90], ["chest", "ANATOMY", 94, 99], ["EmbolismHowever", "OBSERVATION", 122, 137], ["chest", "ANATOMY", 170, 175], ["pulmonary", "ANATOMY", 208, 217], ["embolism", "OBSERVATION", 218, 226], ["pulmonary", "ANATOMY", 283, 292], ["embolism", "OBSERVATION", 293, 301], ["hypoxemia", "OBSERVATION", 340, 349], ["lung", "ANATOMY", 463, 467], ["pathologies", "OBSERVATION", 468, 479], ["pulmonary", "ANATOMY", 530, 539], ["edema", "OBSERVATION", 540, 545], ["ARDS", "OBSERVATION", 547, 551], ["atelectasis", "OBSERVATION", 553, 564], ["pulmonary", "ANATOMY", 566, 575], ["embolism", "OBSERVATION", 576, 584], ["aspiration", "OBSERVATION", 586, 596], ["pneumonia", "OBSERVATION", 614, 623], ["abnormalities", "OBSERVATION", 685, 698]]], ["Differential diagnosis of the radiographic signs encountered is discussed.", [["the radiographic signs", "TEST", 26, 48]]], ["Reference is made where other imaging such as CT or ultrasound is indicated.", [["other imaging", "TEST", 24, 37], ["CT or ultrasound", "TEST", 46, 62]]], ["A summary of radiographic recognition of atelectasis is presented.", [["atelectasis", "DISEASE", 41, 52], ["atelectasis", "PROBLEM", 41, 52], ["atelectasis", "OBSERVATION", 41, 52]]]], "2500ead9faf1e6d5d253ae0882053c0e2722f0a3": [], "4649c0f91b88e8dfb1f89e2157d6e3cf254faffe": [["INTRODUCTIONThe octocoral fauna of the West Indies is unique ill its profusion of gorgonian corals (also known as sea whips, sea fans, or sea plumes).t Faunistically, extensions of the West Indian region reach into the Gulf of Mexico, all the Antilles, the Bahamas, the Florida Keys, the Bermudas, the Islands of the Caribbean, and south along the northeast coast of South America to the reefs of Brazil.", [["octocoral", "OBSERVATION_MODIFIER", 16, 25], ["fauna", "OBSERVATION", 26, 31], ["gorgonian corals", "OBSERVATION", 82, 98]]], ["Although diterpenoids 13-17 did not display significant antibacterial activity, they possess strong cytotoxicity when screened against a panel of five human tumor cell lines.", [["tumor cell lines", "ANATOMY", 157, 173], ["diterpenoids 13-17", "CHEMICAL", 9, 27], ["tumor", "DISEASE", 157, 162], ["diterpenoids", "CHEMICAL", 9, 21], ["diterpenoids 13-17", "SIMPLE_CHEMICAL", 9, 27], ["human", "ORGANISM", 151, 156], ["tumor cell lines", "CELL", 157, 173], ["human tumor cell lines", "CELL_LINE", 151, 173], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 151, 156], ["diterpenoids", "TEST", 9, 21], ["significant antibacterial activity", "PROBLEM", 44, 78], ["strong cytotoxicity", "PROBLEM", 93, 112], ["a panel", "TEST", 135, 142], ["five human tumor cell lines", "TREATMENT", 146, 173], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["antibacterial activity", "OBSERVATION", 56, 78], ["tumor cell lines", "OBSERVATION", 157, 173]]], ["28 Recently, sixteen additional asbestinin diterpenes, asbestinins 11-23 (18-30) , 11acetoxy-4-deoxyasbestinin E (31), 1 l-acetoxy-4-deoxyasbestinin F (32) , and 4-deoxyasbestinin G (33), were isolated from Puerto Rican specimens of B. asbestinum and identified by interpretation of spectral data and chemical methods.", [["specimens", "ANATOMY", 220, 229], ["asbestinin diterpenes", "CHEMICAL", 32, 53], ["asbestinins 11-23 (18-30) , 11acetoxy-4-deoxyasbestinin E (31), 1 l-acetoxy-4-deoxyasbestinin F (32) , and 4-deoxyasbestinin G", "CHEMICAL", 55, 181], ["asbestinin", "CHEMICAL", 32, 42], ["diterpenes", "CHEMICAL", 43, 53], ["asbestinins 11-23", "CHEMICAL", 55, 72], ["11acetoxy-4-deoxyasbestinin E", "CHEMICAL", 83, 112], ["1 l-acetoxy-4-deoxyasbestinin F", "CHEMICAL", 119, 150], ["4-deoxyasbestinin G", "CHEMICAL", 162, 181], ["asbestinin diterpenes", "SIMPLE_CHEMICAL", 32, 53], ["asbestinins 11-23 (18-30)", "SIMPLE_CHEMICAL", 55, 80], ["11acetoxy-4-deoxyasbestinin E (31), 1 l-acetoxy-4-deoxyasbestinin F (32)", "SIMPLE_CHEMICAL", 83, 155], ["4-deoxyasbestinin G (33)", "SIMPLE_CHEMICAL", 162, 186], ["B. asbestinum", "ORGANISM", 233, 246], ["B. asbestinum", "SPECIES", 233, 246], ["B. asbestinum", "SPECIES", 233, 246], ["additional asbestinin diterpenes", "TEST", 21, 53], ["asbestinins", "TEST", 55, 66], ["11acetoxy", "TEST", 83, 92], ["spectral data", "TEST", 283, 296], ["chemical methods", "TREATMENT", 301, 317]]], ["29 That publication also includes structure revisions for asbestinin-6 (13) and asbestinin-7 (14) .", [["asbestinin-6", "CHEMICAL", 58, 70], ["asbestinin", "CHEMICAL", 80, 90], ["asbestinin-6", "CHEMICAL", 58, 70], ["asbestinin-7", "CHEMICAL", 80, 92], ["asbestinin-6 (13)", "SIMPLE_CHEMICAL", 58, 75], ["asbestinin-7", "SIMPLE_CHEMICAL", 80, 92], ["structure revisions", "TREATMENT", 34, 53], ["asbestinin", "TEST", 58, 68], ["asbestinin", "TEST", 80, 90]]], ["29 The same study also resulted in the isolation of known diterpene (4S,14S*)-4-acetoxy-9,14dihydroxydolasta-1 (15),7-diene (34) which has the dolastane carbon skeleton.", [["diterpene", "CHEMICAL", 58, 67], ["4S,14S*)-4-acetoxy-9,14dihydroxydolasta-1 (15),7-diene", "CHEMICAL", 69, 123], ["dolastane", "CHEMICAL", 143, 152], ["diterpene", "CHEMICAL", 58, 67], ["4S,14S*)-4-acetoxy-9,14dihydroxydolasta-1 (15),7-diene", "CHEMICAL", 69, 123], ["dolastane", "CHEMICAL", 143, 152], ["carbon", "CHEMICAL", 153, 159], ["diterpene (4S,14S*)-4-acetoxy-9,14dihydroxydolasta-1 (15),7-diene (34)", "SIMPLE_CHEMICAL", 58, 128], ["dolastane carbon skeleton", "SIMPLE_CHEMICAL", 143, 168], ["The same study", "TEST", 3, 17], ["*)", "TEST", 75, 77], ["skeleton", "ANATOMY", 160, 168]]], ["3\u00b0 Compound 34 represents the first dolastane to be isolated from a species of the genus Briareum and extends the structural variability for this species.", [["dolastane", "CHEMICAL", 36, 45], ["dolastane", "CHEMICAL", 36, 45], ["dolastane", "SIMPLE_CHEMICAL", 36, 45], ["this species", "PROBLEM", 141, 153], ["genus Briareum", "OBSERVATION", 83, 97], ["structural variability", "OBSERVATION", 114, 136]]], ["The hexane extract of the same specimen of B. asbestinum contained traces of a novel seco-asbestinin diterpenoid.", [["specimen", "ANATOMY", 31, 39], ["hexane extract", "CHEMICAL", 4, 18], ["asbestinum", "CHEMICAL", 46, 56], ["seco-asbestinin diterpenoid", "CHEMICAL", 85, 112], ["hexane", "CHEMICAL", 4, 10], ["seco-asbestinin", "CHEMICAL", 85, 100], ["diterpenoid", "CHEMICAL", 101, 112], ["hexane", "SIMPLE_CHEMICAL", 4, 10], ["B. asbestinum", "ORGANISM", 43, 56], ["seco-asbestinin diterpenoid", "SIMPLE_CHEMICAL", 85, 112], ["B. asbestinum", "SPECIES", 43, 56], ["B. asbestinum", "SPECIES", 43, 56], ["The hexane extract", "TREATMENT", 0, 18], ["a novel seco-asbestinin diterpenoid", "PROBLEM", 77, 112], ["seco-asbestinin diterpenoid", "OBSERVATION", 85, 112]]], ["The structure of 35, the first representative of this novel class of diterpenoids, was assigned on the basis of extensive NMR analyses and by comparison with analogous spectral data from related asbestinane diterpenoids.", [["asbestinane diterpenoids", "CHEMICAL", 195, 219], ["diterpenoids", "CHEMICAL", 69, 81], ["asbestinane", "CHEMICAL", 195, 206], ["diterpenoids", "CHEMICAL", 207, 219], ["asbestinane diterpenoids", "SIMPLE_CHEMICAL", 195, 219], ["extensive NMR analyses", "TEST", 112, 134], ["analogous spectral data", "TEST", 158, 181], ["related asbestinane diterpenoids", "PROBLEM", 187, 219], ["asbestinane diterpenoids", "OBSERVATION", 195, 219]]], ["31 Confirmation of structure 35 was achieved by partial synthesis from known asbestinin-6 (13).INTRODUCTIONInterestingly, seco-asbestinin derivative 35 was not cytotoxic against HeLa and CHO-KI cells, suggesting a possible role for the ten-membered ring in the cytotoxic properties of asbestinane diterpenes.", [["HeLa", "ANATOMY", 178, 182], ["CHO-KI cells", "ANATOMY", 187, 199], ["asbestinin-6", "CHEMICAL", 77, 89], ["seco-asbestinin derivative 35", "CHEMICAL", 122, 151], ["asbestinane diterpenes", "CHEMICAL", 285, 307], ["asbestinin-6", "CHEMICAL", 77, 89], ["seco-asbestinin", "CHEMICAL", 122, 137], ["asbestinane", "CHEMICAL", 285, 296], ["diterpenes", "CHEMICAL", 297, 307], ["asbestinin-6 (13)", "SIMPLE_CHEMICAL", 77, 94], ["seco-asbestinin derivative 35", "SIMPLE_CHEMICAL", 122, 151], ["HeLa", "CELL", 178, 182], ["CHO-KI cells", "CELL", 187, 199], ["asbestinane diterpenes", "SIMPLE_CHEMICAL", 285, 307], ["HeLa", "CELL_LINE", 178, 182], ["CHO-KI cells", "CELL_LINE", 187, 199], ["partial synthesis from known asbestinin", "PROBLEM", 48, 87], ["HeLa", "TEST", 178, 182], ["the ten-membered ring", "TREATMENT", 232, 253], ["asbestinane diterpenes", "TREATMENT", 285, 307]]], ["A collection of B. Briareum asbestinum also produces a series of interesting, highly oxidized diterpenes called briareins, which may sometimes contain chlorine, headed by briarein A (37) .", [["briareins", "CHEMICAL", 112, 121], ["chlorine", "CHEMICAL", 151, 159], ["briarein A", "CHEMICAL", 171, 181], ["diterpenes", "CHEMICAL", 94, 104], ["briareins", "CHEMICAL", 112, 121], ["chlorine", "CHEMICAL", 151, 159], ["briarein A", "CHEMICAL", 171, 181], ["B.", "ORGANISM", 16, 18], ["Briareum asbestinum", "ORGANISM", 19, 38], ["diterpenes", "SIMPLE_CHEMICAL", 94, 104], ["briareins", "SIMPLE_CHEMICAL", 112, 121], ["chlorine", "SIMPLE_CHEMICAL", 151, 159], ["briarein A", "SIMPLE_CHEMICAL", 171, 181], ["B. Briareum asbestinum", "SPECIES", 16, 38], ["B. Briareum asbestinum", "SPECIES", 16, 38], ["A collection of B. Briareum asbestinum", "PROBLEM", 0, 38], ["Briareum asbestinum", "OBSERVATION", 19, 38], ["oxidized diterpenes", "OBSERVATION", 85, 104], ["chlorine", "OBSERVATION", 151, 159]]], ["The X-ray structure of briarein A, isolated from B. asbestinum collected in Jamaica, has been reported.", [["briarein A", "CHEMICAL", 23, 33], ["briarein A", "CHEMICAL", 23, 33], ["briarein A", "SIMPLE_CHEMICAL", 23, 33], ["B. asbestinum", "ORGANISM", 49, 62], ["B. asbestinum", "SPECIES", 49, 62], ["B. asbestinum", "SPECIES", 49, 62], ["The X-ray structure", "TEST", 0, 19], ["briarein A", "PROBLEM", 23, 33]]], ["33 The physical and chemical properties of briarein A as well as those for a tetraacetate monobutyrate analog of 37, briarein B (38) , which were obtained during collections of B. asbestinum from Belize 23 and Honduras, 24 have also been reported.", [["briarein A", "CHEMICAL", 43, 53], ["tetraacetate monobutyrate", "CHEMICAL", 77, 102], ["37, briarein B", "CHEMICAL", 113, 127], ["briarein A", "CHEMICAL", 43, 53], ["tetraacetate monobutyrate", "CHEMICAL", 77, 102], ["briarein B", "CHEMICAL", 117, 127], ["briarein A", "SIMPLE_CHEMICAL", 43, 53], ["tetraacetate monobutyrate", "SIMPLE_CHEMICAL", 77, 102], ["briarein B", "SIMPLE_CHEMICAL", 117, 127], ["B. asbestinum", "ORGANISM", 177, 190], ["B. asbestinum", "SPECIES", 177, 190], ["B. asbestinum", "SPECIES", 177, 190], ["a tetraacetate monobutyrate analog", "TEST", 75, 109]]], ["24 Extracts of B. asbestinum collected off the coast of Tobago, have afforded five diterpenes 39-43 that belong to the briarane class.", [["Extracts", "ANATOMY", 3, 11], ["diterpenes 39-43", "CHEMICAL", 83, 99], ["diterpenes", "CHEMICAL", 83, 93], ["briarane", "CHEMICAL", 119, 127], ["B. asbestinum", "ORGANISM", 15, 28], ["B. asbestinum", "SPECIES", 15, 28], ["B. asbestinum", "SPECIES", 15, 28]]], ["32 The structures of briaranes 39-43 were determined spectroscopically and that of methyl briareolate (39) , a crystalline compound, was confirmed by X-ray crystal structure.", [["briaranes 39-43", "CHEMICAL", 21, 36], ["methyl briareolate", "CHEMICAL", 83, 101], ["briaranes 39-43", "CHEMICAL", 21, 36], ["methyl briareolate", "CHEMICAL", 83, 101], ["briaranes 39-43", "SIMPLE_CHEMICAL", 21, 36], ["methyl briareolate (39)", "SIMPLE_CHEMICAL", 83, 106], ["briaranes", "TEST", 21, 30], ["a crystalline compound", "PROBLEM", 109, 131]]], ["34 Brianthein V (44) is a cytotoxic and antiviral diterpene from B. asbestinum collected near Sandy Cay, Bahamas.", [["Brianthein V", "CHEMICAL", 3, 15], ["Brianthein V", "CHEMICAL", 3, 15], ["diterpene", "CHEMICAL", 50, 59], ["B. asbestinum", "ORGANISM", 65, 78], ["B. asbestinum", "SPECIES", 65, 78], ["B. asbestinum", "SPECIES", 65, 78], ["a cytotoxic and antiviral diterpene", "PROBLEM", 24, 59]]], ["X-ray analysis of a suitable crystal of 44 grown from a solution of methanol furnished the absolute structure and ring conformation.", [["methanol", "CHEMICAL", 68, 76], ["methanol", "CHEMICAL", 68, 76], ["methanol", "SIMPLE_CHEMICAL", 68, 76], ["X-ray analysis", "TEST", 0, 14], ["a suitable crystal", "TEST", 18, 36], ["a solution of methanol", "TREATMENT", 54, 76], ["ring conformation", "OBSERVATION", 114, 131]]], ["35 The variation in defensive chemistry of colonies of Briareum asbestinum, which has been recognized as one of the most ubiquitous and chemically deterrent of the Caribbean gorgonians, has been sampled.", [["colonies", "ANATOMY", 43, 51], ["Briareum asbestinum", "CHEMICAL", 55, 74], ["Briareum asbestinum", "ORGANISM", 55, 74], ["Briareum asbestinum", "SPECIES", 55, 74], ["Briareum asbestinum", "SPECIES", 55, 74], ["The variation", "PROBLEM", 3, 16], ["defensive chemistry of colonies of Briareum asbestinum", "PROBLEM", 20, 74], ["variation", "OBSERVATION_MODIFIER", 7, 16], ["defensive", "OBSERVATION_MODIFIER", 20, 29], ["chemistry", "OBSERVATION_MODIFIER", 30, 39], ["colonies", "OBSERVATION_MODIFIER", 43, 51], ["Briareum asbestinum", "ANATOMY", 55, 74], ["one of the most ubiquitous", "OBSERVATION_MODIFIER", 105, 131]]], ["The basis of deterrence appears to reside in the diverse complement of briarane and asbestinane diterpenoids found in individual colonies.", [["colonies", "ANATOMY", 129, 137], ["briarane", "CHEMICAL", 71, 79], ["asbestinane diterpenoids", "CHEMICAL", 84, 108], ["briarane", "CHEMICAL", 71, 79], ["asbestinane", "CHEMICAL", 84, 95], ["diterpenoids", "CHEMICAL", 96, 108], ["briarane", "SIMPLE_CHEMICAL", 71, 79], ["asbestinane diterpenoids", "SIMPLE_CHEMICAL", 84, 108], ["asbestinane diterpenoids", "PROBLEM", 84, 108], ["diverse", "OBSERVATION_MODIFIER", 49, 56]]], ["36 The structural variability for this species has been expanded even further with the recent discovery of five new diterpenoids possessing the eunicellin ring system from B. asbestinum collected in Puerto Rico.", [["eunicellin", "CHEMICAL", 144, 154], ["diterpenoids", "CHEMICAL", 116, 128], ["eunicellin", "CHEMICAL", 144, 154], ["eunicellin", "SIMPLE_CHEMICAL", 144, 154], ["B. asbestinum", "ORGANISM", 172, 185], ["B. asbestinum", "SPECIES", 172, 185], ["B. asbestinum", "SPECIES", 172, 185], ["this species", "PROBLEM", 34, 46], ["five new diterpenoids", "PROBLEM", 107, 128], ["the eunicellin ring system", "TREATMENT", 140, 166], ["variability", "OBSERVATION_MODIFIER", 18, 29], ["new", "OBSERVATION_MODIFIER", 112, 115], ["diterpenoids", "OBSERVATION", 116, 128]]], ["The isolation of asbestinins, briareins, and eunicellins from the same organism supports the theory that metabolites belonging to these skeleton Detailed analysis of the spectral data and chemical correlation of briantheins X and Z established the gross structures of these highly oxidized, chlorinated diterpenes.", [["asbestinins", "CHEMICAL", 17, 28], ["briareins", "CHEMICAL", 30, 39], ["eunicellins", "CHEMICAL", 45, 56], ["chlorinated diterpenes", "CHEMICAL", 291, 313], ["asbestinins", "CHEMICAL", 17, 28], ["briareins", "CHEMICAL", 30, 39], ["eunicellins", "CHEMICAL", 45, 56], ["briantheins X and Z", "CHEMICAL", 212, 231], ["diterpenes", "CHEMICAL", 303, 313], ["asbestinins", "SIMPLE_CHEMICAL", 17, 28], ["briareins", "GENE_OR_GENE_PRODUCT", 30, 39], ["eunicellins", "GENE_OR_GENE_PRODUCT", 45, 56], ["briantheins X", "GENE_OR_GENE_PRODUCT", 212, 225], ["chlorinated diterpenes", "SIMPLE_CHEMICAL", 291, 313], ["briantheins X and Z", "PROTEIN", 212, 231], ["asbestinins", "TREATMENT", 17, 28], ["briareins", "TREATMENT", 30, 39], ["eunicellins", "TREATMENT", 45, 56], ["the spectral data", "TEST", 166, 183], ["briantheins X", "TREATMENT", 212, 225], ["Z", "TREATMENT", 230, 231], ["chlorinated diterpenes", "TREATMENT", 291, 313], ["chlorinated diterpenes", "OBSERVATION", 291, 313]]], ["X-ray diffraction confirmed the placement of the butyrate ester in brianthein Y and defined the absolute configuration for all three compounds.", [["butyrate ester", "CHEMICAL", 49, 63], ["brianthein Y", "CHEMICAL", 67, 79], ["butyrate ester", "CHEMICAL", 49, 63], ["brianthein Y", "CHEMICAL", 67, 79], ["butyrate ester", "SIMPLE_CHEMICAL", 49, 63], ["brianthein Y", "SIMPLE_CHEMICAL", 67, 79], ["X-ray diffraction", "TEST", 0, 17], ["the butyrate ester", "TREATMENT", 45, 63], ["absolute configuration", "OBSERVATION", 96, 118]]], ["39 Briantheins Y (46) and Z (47) have also been found in specimens ofB. asbestinum collected in the Bahamas.", [["specimens", "ANATOMY", 57, 66], ["asbestinum", "SPECIES", 72, 82], ["asbestinum", "SPECIES", 72, 82], ["asbestinum", "TREATMENT", 72, 82], ["Bahamas", "OBSERVATION", 100, 107]]], ["35 Two additional nonchlorinated diterpenes with the briarane skeleton, brianthein-W (48) and the unnamed compound 49, were reported from the same organism shortly after.", [["briarane", "CHEMICAL", 53, 61], ["brianthein-W", "CHEMICAL", 72, 84], ["diterpenes", "CHEMICAL", 33, 43], ["briarane", "CHEMICAL", 53, 61], ["brianthein-W", "CHEMICAL", 72, 84], ["nonchlorinated diterpenes", "SIMPLE_CHEMICAL", 18, 43], ["briarane skeleton", "SIMPLE_CHEMICAL", 53, 70], ["brianthein-W (48)", "SIMPLE_CHEMICAL", 72, 89], ["skeleton", "ANATOMY", 62, 70]]], ["The structure of brianthein-W was defined from spectral data and X-ray diffraction studies.", [["brianthein", "CHEMICAL", 17, 27], ["brianthein-W", "CHEMICAL", 17, 29], ["brianthein-W", "SIMPLE_CHEMICAL", 17, 29], ["spectral data", "TEST", 47, 60], ["X-ray diffraction studies", "TEST", 65, 90]]], ["40 The structure of brianthein 49 was described in 1986, but the spectral data for this metabolite were not reported.", [["brianthein 49", "CHEMICAL", 20, 33], ["brianthein 49", "CHEMICAL", 20, 33], ["brianthein 49", "SIMPLE_CHEMICAL", 20, 33], ["the spectral data", "TEST", 61, 78], ["this metabolite", "TEST", 83, 98]]], ["41 Two of these compounds, brianthein Y (46) and brianthein W (48), have been tested to determine their effects on the feeding behavior of the grasshopper Melanoplus bivittatus, a major agricultural nuisance in the plain and plateau states.", [["brianthein", "CHEMICAL", 27, 37], ["brianthein Y", "CHEMICAL", 27, 39], ["brianthein W", "CHEMICAL", 49, 61], ["brianthein Y (46)", "SIMPLE_CHEMICAL", 27, 44], ["brianthein W", "SIMPLE_CHEMICAL", 49, 61], ["Melanoplus bivittatus", "ORGANISM", 155, 176], ["Melanoplus bivittatus", "SPECIES", 155, 176], ["Melanoplus bivittatus", "SPECIES", 155, 176], ["plateau", "ANATOMY", 225, 232]]], ["40 Brianthein Y proved toxic at a high dose but inactive at a lower dose; brianthein W produced no deleterious effect at either dose.", [["Brianthein Y", "CHEMICAL", 3, 15], ["brianthein", "CHEMICAL", 74, 84], ["brianthein W", "CHEMICAL", 74, 86], ["brianthein W", "SIMPLE_CHEMICAL", 74, 86], ["toxic", "PROBLEM", 23, 28], ["deleterious effect", "PROBLEM", 99, 117]]], ["42,43 Briantheins Y (46) and Z (47) showed viral inhibition in the in vitro mouse corona-virus assay, and 47 is also active in vitro against Herpex simplex-I virus and P338 cells.", [["P338 cells", "ANATOMY", 168, 178], ["mouse", "ORGANISM", 76, 81], ["Herpex simplex-I virus", "ORGANISM", 141, 163], ["P338 cells", "CELL", 168, 178], ["P338 cells", "CELL_LINE", 168, 178], ["mouse", "SPECIES", 76, 81], ["mouse", "SPECIES", 76, 81], ["Herpex simplex-I virus", "SPECIES", 141, 163], ["Briantheins Y", "TEST", 6, 19], ["Z", "TEST", 29, 30], ["viral inhibition", "PROBLEM", 43, 59], ["Herpex simplex", "TEST", 141, 155], ["viral inhibition", "OBSERVATION", 43, 59]]], ["35 Brianthein Y was quite toxic at 250 ppm when subjected to the tobacco hornworm assay.43 A unique antimicrobiai pyranone, bissetone (50) , was isolated from the very polar extracts of B. polyanthes.", [["extracts", "ANATOMY", 174, 182], ["Brianthein Y", "CHEMICAL", 3, 15], ["pyranone", "CHEMICAL", 114, 122], ["bissetone", "CHEMICAL", 124, 133], ["pyranone", "CHEMICAL", 114, 122], ["bissetone", "CHEMICAL", 124, 133], ["tobacco", "ORGANISM", 65, 72], ["antimicrobiai pyranone", "SIMPLE_CHEMICAL", 100, 122], ["bissetone (50)", "SIMPLE_CHEMICAL", 124, 138], ["extracts", "ORGANISM_SUBSTANCE", 174, 182], ["B. polyanthes", "ORGANISM", 186, 199], ["B. polyanthes", "SPECIES", 186, 199], ["tobacco", "SPECIES", 65, 72], ["B. polyanthes", "SPECIES", 186, 199], ["A unique antimicrobiai pyranone", "TREATMENT", 91, 122], ["bissetone", "TREATMENT", 124, 133]]], ["Spectroanalytical and chemical methods were used to develop plausible structures, but X-ray diffraction settled the correct structure and relative stereochemistry.", [["Spectroanalytical and chemical methods", "TREATMENT", 0, 38], ["plausible structures", "PROBLEM", 60, 80], ["X-ray diffraction", "TEST", 86, 103], ["stereochemistry", "OBSERVATION_MODIFIER", 147, 162]]], ["44 The (S,S) configuration of (-)-bissetone has been established by total synthesis from D-glucose.", [["bissetone", "CHEMICAL", 34, 43], ["D-glucose", "CHEMICAL", 89, 98], ["(-)-bissetone", "CHEMICAL", 30, 43], ["D-glucose", "CHEMICAL", 89, 98], ["(-)-bissetone", "SIMPLE_CHEMICAL", 30, 43], ["D-glucose", "SIMPLE_CHEMICAL", 89, 98], ["bissetone", "PROBLEM", 34, 43], ["D-glucose", "TEST", 89, 98]]], ["45 In addition, a species of Briareum from Puerto Rico, which was identified as either B. asbestinum or B. polyanthes, contained nine new briarane diterpenes, which were named briareolides A-I (51-59).", [["briarane diterpenes", "CHEMICAL", 138, 157], ["briarane", "CHEMICAL", 138, 146], ["diterpenes", "CHEMICAL", 147, 157], ["briareolides A-I", "CHEMICAL", 176, 192], ["Briareum", "ORGANISM", 29, 37], ["B. asbestinum", "ORGANISM", 87, 100], ["B. polyanthes", "ORGANISM", 104, 117], ["briarane diterpenes", "SIMPLE_CHEMICAL", 138, 157], ["briareolides A-I", "SIMPLE_CHEMICAL", 176, 192], ["B. asbestinum", "SPECIES", 87, 100], ["B. polyanthes", "SPECIES", 104, 117], ["B. asbestinum", "SPECIES", 87, 100], ["B. polyanthes", "SPECIES", 104, 117]]], ["46 Their structures were determined by spectroscopic methods, especially one-Natural products of gorgonian octocorals 4577 and two-dimensional NMR.", [["spectroscopic methods", "TEST", 39, 60], ["gorgonian octocorals", "TEST", 97, 117]]], ["The structure and absolute stereochemistry of briareolide B (52) were determined by X-ray analysis.", [["briareolide B", "CHEMICAL", 46, 59], ["briareolide B", "CHEMICAL", 46, 59], ["briareolide B (52)", "SIMPLE_CHEMICAL", 46, 64], ["X-ray analysis", "TEST", 84, 98], ["absolute stereochemistry", "OBSERVATION", 18, 42]]], ["46 Some of the briareolides [A(51), B(52), C (53), D (54) , and E (55)] display antiinflammatory activity.", [["briareolides", "CHEMICAL", 15, 27], ["briareolides", "CHEMICAL", 15, 27], ["A(51), B(52), C (53), D (54) , and E (55)", "CHEMICAL", 29, 70], ["briareolides", "SIMPLE_CHEMICAL", 15, 27], ["A(51)", "SIMPLE_CHEMICAL", 29, 34], ["B(52), C (53), D (54)", "SIMPLE_CHEMICAL", 36, 57], ["E (55)]", "SIMPLE_CHEMICAL", 64, 71], ["the briareolides", "TEST", 11, 27], ["C", "TEST", 43, 44], ["D", "TEST", 51, 52], ["antiinflammatory activity", "TREATMENT", 80, 105], ["antiinflammatory activity", "OBSERVATION", 80, 105]]], ["However, these briarein type compounds, which are all nonchlorinated and highly oxygenated, were not cytotoxic against P-388 leukemia cells.", [["P-388 leukemia cells", "ANATOMY", 119, 139], ["P-388", "CHEMICAL", 119, 124], ["leukemia", "DISEASE", 125, 133], ["P-388 leukemia cells", "CELL", 119, 139], ["P-388 leukemia cells", "CELL_LINE", 119, 139], ["P-388", "SPECIES", 119, 124], ["leukemia cells", "PROBLEM", 125, 139], ["briarein", "OBSERVATION_MODIFIER", 15, 23], ["type", "OBSERVATION_MODIFIER", 24, 28], ["compounds", "OBSERVATION_MODIFIER", 29, 38], ["leukemia cells", "OBSERVATION", 125, 139]]], ["All the briareolides except briareolide G (57), which has an unsaturated ~/-lactone, contain an ~x,13-epoxy-7-1actone, a feature found only in a few other briarane diterpenes isolated from Briareum spp.", [["briareolides", "CHEMICAL", 8, 20], ["briareolide G (57)", "CHEMICAL", 28, 46], ["13-epoxy-7-1actone", "CHEMICAL", 99, 117], ["briarane diterpenes", "CHEMICAL", 155, 174], ["briareolides", "CHEMICAL", 8, 20], ["briareolide G", "CHEMICAL", 28, 41], ["unsaturated ~/-lactone", "CHEMICAL", 61, 83], ["~x,13-epoxy-7-1actone", "CHEMICAL", 96, 117], ["briarane", "CHEMICAL", 155, 163], ["diterpenes", "CHEMICAL", 164, 174], ["briareolides", "SIMPLE_CHEMICAL", 8, 20], ["briareolide G (57)", "SIMPLE_CHEMICAL", 28, 46], ["unsaturated ~/-lactone", "SIMPLE_CHEMICAL", 61, 83], ["~x,13-epoxy-7-1actone", "SIMPLE_CHEMICAL", 96, 117], ["briarane diterpenes", "SIMPLE_CHEMICAL", 155, 174], ["Briareum spp", "ORGANISM", 189, 201], ["lactone", "TREATMENT", 76, 83], ["epoxy", "TREATMENT", 102, 107], ["a few other briarane diterpenes", "PROBLEM", 143, 174], ["Briareum spp", "PROBLEM", 189, 201], ["Briareum spp", "OBSERVATION", 189, 201]]], ["46Erythropodium (family Briareidae)Relatively uncommon, the only documented species of this genus, Erythropodium caribaeorum, can be found from southern Florida to the Virgin Islands.", [["46Erythropodium", "CHEMICAL", 0, 15], ["46Erythropodium", "ORGANISM", 0, 15], ["Erythropodium caribaeorum", "ORGANISM", 99, 124], ["Erythropodium caribaeorum", "SPECIES", 99, 124], ["Erythropodium caribaeorum", "SPECIES", 99, 124], ["Erythropodium caribaeorum", "PROBLEM", 99, 124], ["Virgin Islands", "OBSERVATION", 168, 182]]], ["E. caribaeorum specializes in the biosynthesis of diterpenoids of the briarane skeleton class.", [["diterpenoids", "CHEMICAL", 50, 62], ["briarane", "CHEMICAL", 70, 78], ["E. caribaeorum", "ORGANISM", 0, 14], ["E. caribaeorum", "SPECIES", 0, 14], ["E. caribaeorum", "SPECIES", 0, 14]]], ["These compounds, named erythrolides, are usually chlorinated at C-6 and are highly oxygenated.CH3OAc OAc H OR2 ..,--'1\"~ CH 3 . ~ CH a O,A. Erythropodium caribaeorum (Duchassaing & Michelotti)Erythrolide A (60) and erythrolide B (61), isolated from the encrusting Caribbean gorgonian coral Erythropodium caribaeorum collected in Carrie Bow Cay, Belize, are two remarkably interesting chlorinated diterpenes.", [["erythrolides", "CHEMICAL", 23, 35], ["CH3OAc", "CHEMICAL", 94, 100], ["Erythrolide", "CHEMICAL", 192, 203], ["erythrolide B", "CHEMICAL", 215, 228], ["erythrolides", "CHEMICAL", 23, 35], ["CH3OAc OAc H", "CHEMICAL", 94, 106], ["CH 3", "CHEMICAL", 121, 125], ["Erythrolide A", "CHEMICAL", 192, 205], ["erythrolide B", "CHEMICAL", 215, 228], ["diterpenes", "CHEMICAL", 396, 406], ["erythrolides", "SIMPLE_CHEMICAL", 23, 35], ["C-6", "SIMPLE_CHEMICAL", 64, 67], ["Erythropodium caribaeorum", "ORGANISM", 140, 165], ["Duchassaing & Michelotti", "ORGANISM", 167, 191], ["Erythrolide A (60)", "SIMPLE_CHEMICAL", 192, 210], ["erythrolide B (61)", "SIMPLE_CHEMICAL", 215, 233], ["Erythropodium caribaeorum", "ORGANISM", 290, 315], ["chlorinated diterpenes", "SIMPLE_CHEMICAL", 384, 406], ["Erythropodium caribaeorum", "SPECIES", 140, 165], ["Erythropodium caribaeorum", "SPECIES", 290, 315], ["Erythropodium caribaeorum", "SPECIES", 140, 165], ["Erythropodium caribaeorum", "SPECIES", 290, 315], ["erythrolides", "TREATMENT", 23, 35], ["erythrolide B", "TREATMENT", 215, 228], ["oxygenated", "OBSERVATION_MODIFIER", 83, 93], ["chlorinated diterpenes", "OBSERVATION", 384, 406]]], ["The structures of erythranes 60 and 61 were determined by X-ray analysis and from spectral data, respectively.", [["erythranes", "CHEMICAL", 18, 28], ["erythranes", "CHEMICAL", 18, 28], ["erythranes", "SIMPLE_CHEMICAL", 18, 28], ["erythranes", "TEST", 18, 28], ["X-ray analysis", "TEST", 58, 72], ["spectral data", "TEST", 82, 95]]], ["Photochemical conversion of 61 into 60, by a di-~-methane rearrangement, helped confirm their structural relationship.", [["di-~-methane", "CHEMICAL", 45, 57], ["di-~-methane", "CHEMICAL", 45, 57], ["di-~-methane", "SIMPLE_CHEMICAL", 45, 57], ["Photochemical conversion", "TREATMENT", 0, 24]]], ["47 Erythrolides A and B along with seven additional erythrolides have been isolated from E. caribaeorum collected in the U.S. Virgin Islands and Jamaica.", [["Erythrolides A and B", "CHEMICAL", 3, 23], ["erythrolides", "CHEMICAL", 52, 64], ["Erythrolides A and B", "CHEMICAL", 3, 23], ["erythrolides", "CHEMICAL", 52, 64], ["B", "GENE_OR_GENE_PRODUCT", 22, 23], ["erythrolides", "SIMPLE_CHEMICAL", 52, 64], ["E. caribaeorum", "ORGANISM", 89, 103], ["E. caribaeorum", "SPECIES", 89, 103], ["E. caribaeorum", "SPECIES", 89, 103], ["seven additional erythrolides", "TREATMENT", 35, 64], ["Virgin Islands", "OBSERVATION", 126, 140]]], ["The structures of erythrolides C-I (62-68) were elucidated from spectroscopic dam.", [["erythrolides C-I", "CHEMICAL", 18, 34], ["erythrolides C-I", "CHEMICAL", 18, 34], ["erythrolides C-I (62-68", "SIMPLE_CHEMICAL", 18, 41], ["erythrolides C", "TEST", 18, 32]]], ["46 All of these erythrolides, except erythrolide H (67) , arc chlorinated at the C-6 position.", [["erythrolides", "CHEMICAL", 16, 28], ["erythrolide H (67) , arc chlorinated", "CHEMICAL", 37, 73], ["erythrolides", "CHEMICAL", 16, 28], ["erythrolide H", "CHEMICAL", 37, 50], ["erythrolides", "SIMPLE_CHEMICAL", 16, 28], ["erythrolide H (67)", "SIMPLE_CHEMICAL", 37, 55], ["these erythrolides", "TEST", 10, 28], ["erythrolide H", "TREATMENT", 37, 50], ["arc chlorinated", "TREATMENT", 58, 73]]], ["Erythrolide H (67) is unique among the compounds in this series in having a C-5,6 double bond and a 4578 A.D. RODRIGUEZ hydroxyl substituent at C-16 instead of an exocyclic C-5,16 double bond.", [["Erythrolide H", "CHEMICAL", 0, 13], ["hydroxyl", "CHEMICAL", 120, 128], ["C-16", "CHEMICAL", 144, 148], ["Erythrolide H (67)", "CHEMICAL", 0, 18], ["hydroxyl", "CHEMICAL", 120, 128], ["C", "CHEMICAL", 173, 174], ["Erythrolide H (67)", "SIMPLE_CHEMICAL", 0, 18], ["C-5,6 double bond", "SIMPLE_CHEMICAL", 76, 93], ["RODRIGUEZ hydroxyl substituent", "SIMPLE_CHEMICAL", 110, 140], ["C-16", "SIMPLE_CHEMICAL", 144, 148], ["C-5,16 double bond", "SIMPLE_CHEMICAL", 173, 191], ["a C", "TEST", 74, 77], ["a 4578 A.D. RODRIGUEZ hydroxyl substituent", "TREATMENT", 98, 140], ["an exocyclic C", "TREATMENT", 160, 174]]], ["Erythropodium caribaeorum obtained off the coast of Tobago yielded also the diterpenes erythrolide A (60), erythrolide B (61), and erythrolide E (64) along with a new diterpene, which has been designated erythrolide J (69) .", [["erythrolide A (60), erythrolide B (61), and erythrolide E", "CHEMICAL", 87, 144], ["diterpenes", "CHEMICAL", 76, 86], ["erythrolide A", "CHEMICAL", 87, 100], ["erythrolide B", "CHEMICAL", 107, 120], ["erythrolide E", "CHEMICAL", 131, 144], ["diterpene", "CHEMICAL", 167, 176], ["erythrolide J", "CHEMICAL", 204, 217], ["Erythropodium caribaeorum", "ORGANISM", 0, 25], ["erythrolide A (60)", "SIMPLE_CHEMICAL", 87, 105], ["erythrolide B (61)", "SIMPLE_CHEMICAL", 107, 125], ["erythrolide E (64)", "SIMPLE_CHEMICAL", 131, 149], ["diterpene", "SIMPLE_CHEMICAL", 167, 176], ["erythrolide J", "SIMPLE_CHEMICAL", 204, 217], ["Erythropodium caribaeorum", "SPECIES", 0, 25], ["Erythropodium caribaeorum", "SPECIES", 0, 25], ["erythrolide B", "TREATMENT", 107, 120], ["erythrolide E", "TREATMENT", 131, 144], ["a new diterpene", "TREATMENT", 161, 176]]], ["The structure of 69 was determined by high-resolution NMR.", [["The structure", "TEST", 0, 13]]], ["48 Erythrodiene (70), a new sesquiterpene hydrocarbon of a rare structural class, has been isolated from E. caribaeorum collected at Chub Cay, Bahamas.", [["Erythrodiene", "CHEMICAL", 3, 15], ["sesquiterpene hydrocarbon", "CHEMICAL", 28, 53], ["Erythrodiene", "CHEMICAL", 3, 15], ["sesquiterpene hydrocarbon", "CHEMICAL", 28, 53], ["Erythrodiene (70)", "SIMPLE_CHEMICAL", 3, 20], ["sesquiterpene hydrocarbon", "SIMPLE_CHEMICAL", 28, 53], ["E. caribaeorum", "ORGANISM", 105, 119], ["E. caribaeorum", "SPECIES", 105, 119], ["E. caribaeorum", "SPECIES", 105, 119], ["sesquiterpene hydrocarbon", "OBSERVATION", 28, 53]]], ["The structure of 70 was assigned from spectral studies and through X-ray analysis of the diol obtained during ozonolysis of erythrodiene followed by reductive work up with NaBH4.", [["diol", "CHEMICAL", 89, 93], ["erythrodiene", "CHEMICAL", 124, 136], ["NaBH4", "CHEMICAL", 172, 177], ["diol", "CHEMICAL", 89, 93], ["erythrodiene", "CHEMICAL", 124, 136], ["NaBH4", "CHEMICAL", 172, 177], ["diol", "SIMPLE_CHEMICAL", 89, 93], ["erythrodiene", "SIMPLE_CHEMICAL", 124, 136], ["NaBH4", "SIMPLE_CHEMICAL", 172, 177], ["spectral studies", "TEST", 38, 54], ["X-ray analysis", "TEST", 67, 81], ["ozonolysis", "TREATMENT", 110, 120], ["erythrodiene", "TREATMENT", 124, 136], ["NaBH4", "TREATMENT", 172, 177]]], ["49 Erythrodiene has been synthesized from 4-isopropylcyclohexanol in 8 steps and approximately 16% overall yield.", [["Erythrodiene", "CHEMICAL", 3, 15], ["4-isopropylcyclohexanol", "CHEMICAL", 42, 65], ["Erythrodiene", "CHEMICAL", 3, 15], ["4-isopropylcyclohexanol", "CHEMICAL", 42, 65], ["Erythrodiene", "SIMPLE_CHEMICAL", 3, 15], ["4-isopropylcyclohexanol", "SIMPLE_CHEMICAL", 42, 65], ["Erythrodiene", "TREATMENT", 3, 15], ["isopropylcyclohexanol", "TREATMENT", 44, 65]]], ["The synthesis features a stereoselective intrarnolecular carbomercuration reaction as the key step.", [["a stereoselective intrarnolecular carbomercuration reaction", "PROBLEM", 23, 82], ["stereoselective", "OBSERVATION_MODIFIER", 25, 40], ["intrarnolecular carbomercuration", "OBSERVATION", 41, 73]]], ["50 When an extract of E. caribaeorum was incorporated into food strips, natural groups of fishes on the same reef from which the gorgonian had been collected were deterred from feeding.", [["extract", "ANATOMY", 11, 18], ["E. caribaeorum", "ORGANISM", 22, 36], ["E. caribaeorum", "SPECIES", 22, 36], ["E. caribaeorum", "SPECIES", 22, 36]]], ["The feeding deterrent effects were present in a sample fraction containing erythrolides, but not in a fraction containing erythrodiene (70) .", [["erythrolides", "CHEMICAL", 75, 87], ["erythrodiene", "CHEMICAL", 122, 134], ["erythrolides", "CHEMICAL", 75, 87], ["erythrodiene", "CHEMICAL", 122, 134], ["erythrolides", "SIMPLE_CHEMICAL", 75, 87], ["erythrodiene", "SIMPLE_CHEMICAL", 122, 134], ["erythrolides", "TREATMENT", 75, 87]]], ["Although the erythrolides appear to defend E. caribaeorum from reef predators, the function of sesquiterpene hydrocarbons remains unclear.", [["erythrolides", "CHEMICAL", 13, 25], ["sesquiterpene hydrocarbons", "CHEMICAL", 95, 121], ["erythrolides", "CHEMICAL", 13, 25], ["sesquiterpene hydrocarbons", "CHEMICAL", 95, 121], ["erythrolides", "SIMPLE_CHEMICAL", 13, 25], ["E. caribaeorum", "ORGANISM", 43, 57], ["sesquiterpene hydrocarbons", "SIMPLE_CHEMICAL", 95, 121], ["E. caribaeorum", "SPECIES", 43, 57], ["E. caribaeorum", "SPECIES", 43, 57], ["sesquiterpene hydrocarbons", "PROBLEM", 95, 121], ["reef predators", "OBSERVATION", 63, 77], ["sesquiterpene hydrocarbons", "OBSERVATION", 95, 121]]], ["51 2.3, Eunicea (family Plexauridae) Gorgonians of the common Caribbean genus Eunicea were among the first marine invertebrates to be investigated chemically with over fifteen species documented.", [["common Caribbean", "ANATOMY", 55, 71]]], ["Although common and abundant, the genus Eunicea is taxonomically complex with many species varying only slightly in form and color.", [["taxonomically complex", "PROBLEM", 51, 72], ["many species", "PROBLEM", 78, 90], ["abundant", "OBSERVATION_MODIFIER", 20, 28], ["genus Eunicea", "OBSERVATION", 34, 47], ["many", "OBSERVATION_MODIFIER", 78, 82], ["species", "OBSERVATION_MODIFIER", 83, 90], ["varying", "OBSERVATION_MODIFIER", 91, 98], ["slightly", "OBSERVATION_MODIFIER", 104, 112]]], ["Consequently, secure species assignments were difficult to make and over the years a comprehensive chemical evaluation of this group was impeded.", [["a comprehensive chemical evaluation", "TEST", 83, 118]]], ["Animals belonging to this genus are usually rich in cembrane diterpenoids.A. Eunicea asperula (Milne Edwards and Haime)Asperdiol (71) is an antineoplastic agent (found in both Eunicea asperula and Eunicea tourneforti collected in the Caribbean region), whose structure was elucidated by X-ray analysis.", [["antineoplastic", "ANATOMY", 140, 154], ["Asperdiol", "CHEMICAL", 119, 128], ["diterpenoids", "CHEMICAL", 61, 73], ["Animals", "ORGANISM", 0, 7], ["cembrane diterpenoids", "SIMPLE_CHEMICAL", 52, 73], ["A. Eunicea asperula", "ORGANISM", 74, 93], ["Milne Edwards", "ORGANISM", 95, 108], ["Asperdiol (71)", "ORGANISM", 119, 133], ["Eunicea asperula", "ORGANISM", 176, 192], ["Eunicea tourneforti", "ORGANISM", 197, 216], ["A.", "SPECIES", 74, 76], ["Eunicea asperula", "SPECIES", 77, 93], ["Eunicea asperula", "SPECIES", 176, 192], ["Eunicea tourneforti", "SPECIES", 197, 216], ["A. Eunicea asperula", "SPECIES", 74, 93], ["Eunicea asperula", "SPECIES", 176, 192], ["Eunicea tourneforti", "SPECIES", 197, 216], ["an antineoplastic agent", "TREATMENT", 137, 160], ["X-ray analysis", "TEST", 287, 301], ["cembrane diterpenoids", "OBSERVATION", 52, 73]]], ["52 Asperdiol is unique in that it was the first cembrane lacking the lactone function that displays significant in vitro antitumor activity in the National Cancer Institute's KB, PS, and LE test systems.", [["antitumor", "ANATOMY", 121, 130], ["Asperdiol", "CHEMICAL", 3, 12], ["lactone", "CHEMICAL", 69, 76], ["Cancer", "DISEASE", 156, 162], ["Asperdiol", "CHEMICAL", 3, 12], ["lactone", "CHEMICAL", 69, 76], ["Asperdiol", "SIMPLE_CHEMICAL", 3, 12], ["lactone", "SIMPLE_CHEMICAL", 69, 76], ["antitumor", "CANCER", 121, 130], ["the lactone function", "TEST", 65, 85], ["PS", "TEST", 179, 181], ["LE test systems", "TEST", 187, 202], ["significant", "OBSERVATION_MODIFIER", 100, 111], ["antitumor activity", "OBSERVATION", 121, 139]]], ["The I3C-NMR spectral assignments of asperdiol, 53 its synthesis, 54,55 as well as the synthesis of two plausible precursors, have been reported.", [["I3C", "CHEMICAL", 4, 7], ["asperdiol", "CHEMICAL", 36, 45], ["I3C", "CHEMICAL", 4, 7], ["asperdiol", "CHEMICAL", 36, 45], ["I3C", "SIMPLE_CHEMICAL", 4, 7], ["asperdiol", "SIMPLE_CHEMICAL", 36, 45], ["The I3C", "TEST", 0, 7], ["asperdiol", "TEST", 36, 45]]], ["56,57 Asperketals A-F (72) (73) (74) (75) (76) (77) are diterpenes isolated from the Caribbean sea whip E. asperula collected along the offshore islands of the Tobago Cays.", [["Asperketals A-F", "CHEMICAL", 6, 21], ["diterpenes", "CHEMICAL", 56, 66], ["E. asperula", "ORGANISM", 104, 115], ["E. asperula", "SPECIES", 104, 115], ["E. asperula", "SPECIES", 104, 115], ["Asperketals", "TEST", 6, 17], ["diterpenes", "PROBLEM", 56, 66], ["Tobago Cays", "OBSERVATION", 160, 171]]], ["Compounds 72-76 are ketals and hemiketals related to the dilophol class of 10-memhered-ring diterpenoids, while asperketal F (77) belongs to the fuscol class.", [["Compounds 72-76", "CHEMICAL", 0, 15], ["hemiketals", "CHEMICAL", 31, 41], ["dilophol", "CHEMICAL", 57, 65], ["10-memhered-ring diterpenoids", "CHEMICAL", 75, 104], ["asperketal", "CHEMICAL", 112, 122], ["ketals", "CHEMICAL", 20, 26], ["hemiketals", "CHEMICAL", 31, 41], ["dilophol", "CHEMICAL", 57, 65], ["diterpenoids", "CHEMICAL", 92, 104], ["asperketal F", "CHEMICAL", 112, 124], ["ketals", "SIMPLE_CHEMICAL", 20, 26], ["hemiketals", "SIMPLE_CHEMICAL", 31, 41], ["dilophol", "SIMPLE_CHEMICAL", 57, 65], ["10-memhered-ring diterpenoids", "SIMPLE_CHEMICAL", 75, 104], ["asperketal F (77)", "SIMPLE_CHEMICAL", 112, 129], ["fuscol class", "PROTEIN", 145, 157]]], ["Their structures were assigned on the basis of chemical and spectroscopic studies.", [["chemical and spectroscopic studies", "TEST", 47, 81]]], ["58 In addition, the isolation of the known diterpenoid obscuronatin (78) from the same organism was reported.", [["obscuronatin", "CHEMICAL", 55, 67], ["diterpenoid", "CHEMICAL", 43, 54], ["obscuronatin", "CHEMICAL", 55, 67], ["diterpenoid obscuronatin", "SIMPLE_CHEMICAL", 43, 67], ["the known diterpenoid obscuronatin", "PROBLEM", 33, 67], ["diterpenoid obscuronatin", "OBSERVATION", 43, 67]]], ["Further studies to determine the stereochemistry of this compound were not pursued.", [["Further studies", "TEST", 0, 15], ["this compound", "PROBLEM", 52, 65]]], ["The stereochemistry of asperketal B (73) (89) is an elemene-type diterpene that has been isolated from the gorgonian Euniceafusca collected near South Caicos, W.I. 62 Although the data collected did not permit unequivocal assignment of the stereochemistry at C-4 in fuscol, the isolation of ketone 90 from the same animal implies that the side chain should be equatorial.", [["asperketal B (73) (89)", "CHEMICAL", 23, 45], ["elemene-type diterpene", "CHEMICAL", 52, 74], ["C-4", "CHEMICAL", 259, 262], ["ketone", "CHEMICAL", 291, 297], ["asperketal B (73)", "CHEMICAL", 23, 40], ["elemene", "CHEMICAL", 52, 59], ["diterpene", "CHEMICAL", 65, 74], ["fuscol", "CHEMICAL", 266, 272], ["ketone", "CHEMICAL", 291, 297], ["asperketal B (73) (89)", "SIMPLE_CHEMICAL", 23, 45], ["elemene-type diterpene", "SIMPLE_CHEMICAL", 52, 74], ["C-4", "SIMPLE_CHEMICAL", 259, 262], ["fuscol", "SIMPLE_CHEMICAL", 266, 272], ["ketone 90", "SIMPLE_CHEMICAL", 291, 300], ["The stereochemistry of asperketal B", "TEST", 0, 35], ["an elemene-type diterpene", "PROBLEM", 49, 74], ["the isolation of ketone", "TEST", 274, 297], ["gorgonian Euniceafusca", "OBSERVATION", 107, 129]]], ["An E configuration could be assigned to the disubstituted double bond.", [["the disubstituted double bond", "TREATMENT", 40, 69]]], ["However, the geometry of the trisubstituted double bond could not be specified in the original report although it was later assigned as E. 63 Their structures were elucidated by combined spectra and chemical methods and in that study the researchers established that the structure of palominol should be revised from 97 to 102.", [["palominol", "CHEMICAL", 284, 293], ["palominol", "CHEMICAL", 284, 293], ["palominol", "SIMPLE_CHEMICAL", 284, 293], ["the trisubstituted double bond", "TREATMENT", 25, 55], ["combined spectra and chemical methods", "PROBLEM", 178, 215], ["that study", "TEST", 223, 233], ["palominol", "TREATMENT", 284, 293]]], ["68 A brine shrimp assay, which was used as a simple lethality test to screen for biological activity in palominol, produced a 0% death response at an initial concentration of 30 I.tg/mL after a 24 hour count period.", [["palominol", "CHEMICAL", 104, 113], ["death", "DISEASE", 129, 134], ["palominol", "CHEMICAL", 104, 113], ["palominol", "SIMPLE_CHEMICAL", 104, 113], ["A brine shrimp assay", "TEST", 3, 23], ["a simple lethality test", "TEST", 43, 66], ["palominol", "TREATMENT", 104, 113], ["a 0% death response", "PROBLEM", 124, 143]]], ["When screened for antimicrobial activity palominol was found to inhibit weakly the growth of Gram negative bacteria.", [["palominol", "CHEMICAL", 41, 50], ["palominol", "CHEMICAL", 41, 50], ["palominol", "SIMPLE_CHEMICAL", 41, 50], ["antimicrobial activity palominol", "TREATMENT", 18, 50], ["Gram negative bacteria", "PROBLEM", 93, 115], ["negative bacteria", "OBSERVATION", 98, 115]]], ["67 Palominol also displayed modest cytotoxic activity (IC50 = 10 I.tg/mL) against the human colon (HCT 116) cell line.", [["colon (HCT 116) cell line", "ANATOMY", 92, 117], ["Palominol", "CHEMICAL", 3, 12], ["Palominol", "CHEMICAL", 3, 12], ["Palominol", "SIMPLE_CHEMICAL", 3, 12], ["human", "ORGANISM", 86, 91], ["colon (HCT 116) cell line", "CELL", 92, 117], ["human colon (HCT 116) cell line", "CELL_LINE", 86, 117], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["modest cytotoxic activity", "PROBLEM", 28, 53], ["IC50", "TEST", 55, 59], ["HCT", "TEST", 99, 102], ["cell line", "TREATMENT", 108, 117], ["modest", "OBSERVATION_MODIFIER", 28, 34], ["cytotoxic activity", "OBSERVATION", 35, 53], ["human colon", "ANATOMY", 86, 97], ["cell line", "OBSERVATION", 108, 117]]], ["69 Isopalominol (103) Specimens collected at Jamaica and the Florida Keys contain (+)-o~-muurolene (112)A. Eunicea asperula (Milne Edwards and Haime)The structure of this y-cembranolide, which showed significant cytotoxicity against CHO-K 1 cells, was assigned on the basis of spectral analysis.", [["CHO-K 1 cells", "ANATOMY", 233, 246], ["Isopalominol", "CHEMICAL", 3, 15], ["y-cembranolide", "CHEMICAL", 171, 185], ["CHO-K", "CHEMICAL", 233, 238], ["Isopalominol", "CHEMICAL", 3, 15], ["(+)-o~-muurolene", "CHEMICAL", 82, 98], ["y-cembranolide", "CHEMICAL", 171, 185], ["(+)-o~-muurolene (112)A", "SIMPLE_CHEMICAL", 82, 105], ["y-cembranolide", "SIMPLE_CHEMICAL", 171, 185], ["CHO-K 1 cells", "CELL", 233, 246], ["CHO-K 1 cells", "CELL_LINE", 233, 246], ["Eunicea asperula", "SPECIES", 107, 123], ["CHO-K 1", "SPECIES", 233, 240], ["Isopalominol", "TREATMENT", 3, 15], ["this y-cembranolide", "TEST", 166, 185], ["significant cytotoxicity", "PROBLEM", 200, 224], ["CHO", "TEST", 233, 236], ["spectral analysis", "TEST", 277, 294], ["significant", "OBSERVATION_MODIFIER", 200, 211], ["cytotoxicity", "OBSERVATION", 212, 224]]], ["88 The structures of six additional cembrane derivatives, eupalmerone (117)14-DeoxycrassinAlso isolated from the same organism were four known (x-methylene-7-1actone derivatives, namely, euniolide137R~ =~=H 140 R=CHzF.", [["cembrane", "CHEMICAL", 36, 44], ["eupalmerone", "CHEMICAL", 58, 69], ["117)14-DeoxycrassinAlso", "CHEMICAL", 71, 94], ["x-methylene-7-1actone", "CHEMICAL", 144, 165], ["euniolide", "CHEMICAL", 187, 196], ["cembrane", "CHEMICAL", 36, 44], ["eupalmerone", "CHEMICAL", 58, 69], ["117)14-DeoxycrassinAlso", "CHEMICAL", 71, 94], ["x-methylene-7-1actone", "CHEMICAL", 144, 165], ["euniolide", "CHEMICAL", 187, 196], ["CHzF", "CHEMICAL", 213, 217], ["cembrane derivatives", "SIMPLE_CHEMICAL", 36, 56], ["eupalmerone", "SIMPLE_CHEMICAL", 58, 69], ["117)14-DeoxycrassinAlso", "SIMPLE_CHEMICAL", 71, 94], ["x-methylene-7-1actone derivatives", "SIMPLE_CHEMICAL", 144, 177], ["euniolide137R~ =~=H 140 R=CHzF", "SIMPLE_CHEMICAL", 187, 217], ["six additional cembrane derivatives", "TREATMENT", 21, 56], ["eupalmerone", "TEST", 58, 69], ["DeoxycrassinAlso", "TREATMENT", 78, 94], ["x-methylene", "TEST", 144, 155], ["1actone derivatives", "TREATMENT", 158, 177], ["euniolide", "TEST", 187, 196]]], ["Eunicea palmeri (Bayer) (Palmer's Eunicea ) Eunicea palmeri from Miami contains (+)-~-muurolene (112) and (+)-I~-copaene (141) .", [["(+)-~-muurolene", "CHEMICAL", 80, 95], ["(+)-I~-copaene", "CHEMICAL", 106, 120], ["Eunicea palmeri", "ORGANISM", 0, 15], ["Bayer)", "ORGANISM", 17, 23], ["Palmer's Eunicea", "ORGANISM", 25, 41], ["Eunicea palmeri", "ORGANISM", 44, 59], ["(+)-~-muurolene (112)", "SIMPLE_CHEMICAL", 80, 101], ["(+)-I~-copaene", "SIMPLE_CHEMICAL", 106, 120], ["Eunicea palmeri", "SPECIES", 0, 15], ["Eunicea palmeri", "SPECIES", 44, 59], ["Eunicea palmeri", "SPECIES", 0, 15], ["Eunicea palmeri", "SPECIES", 44, 59]]], ["3 E. palmeri has also been reported to contain (+)-~l-ylangene (142), 74 although this claim was later noted to be incorrect.", [["(+)-~l-ylangene", "CHEMICAL", 47, 62], ["E. palmeri", "ORGANISM", 2, 12], ["E. palmeri", "SPECIES", 2, 12], ["E. palmeri", "SPECIES", 2, 12]]], ["5 A study on a new route to the total synthesis of (+)-ct-and I~-copaene and (+)-ylangene has been reported.", [["I~-copaene", "CHEMICAL", 62, 72], ["(+)-ct-and I~-copaene", "CHEMICAL", 51, 72], ["(+)-ylangene", "CHEMICAL", 77, 89], ["(+)-ct-", "SIMPLE_CHEMICAL", 51, 58], ["I~-copaene", "SIMPLE_CHEMICAL", 62, 72], ["(+)-ylangene", "SIMPLE_CHEMICAL", 77, 89], ["A study", "TEST", 2, 9], ["the total synthesis", "TEST", 28, 47], ["ct", "TEST", 55, 57]]], ["92 The 7cembranolide eupalmerin acetate (113) (147), which occurs largely as the acetate 148.100,101 The structure of cueunicin (147) was proposed on the basis of spectral analyses and chemical degradation and that of cueunicin acetate (148) by X-ray crystallography.", [["7cembranolide", "CHEMICAL", 7, 20], ["eupalmerin acetate", "CHEMICAL", 21, 39], ["acetate", "CHEMICAL", 81, 88], ["cueunicin", "CHEMICAL", 118, 127], ["cueunicin acetate", "CHEMICAL", 218, 235], ["7cembranolide eupalmerin acetate", "CHEMICAL", 7, 39], ["acetate", "CHEMICAL", 81, 88], ["cueunicin", "CHEMICAL", 118, 127], ["cueunicin acetate", "CHEMICAL", 218, 235], ["7cembranolide eupalmerin acetate (113) (147)", "SIMPLE_CHEMICAL", 7, 51], ["acetate", "SIMPLE_CHEMICAL", 81, 88], ["cueunicin (147)", "SIMPLE_CHEMICAL", 118, 133], ["cueunicin acetate", "SIMPLE_CHEMICAL", 218, 235], ["The 7cembranolide eupalmerin acetate", "TREATMENT", 3, 39], ["the acetate", "TEST", 77, 88], ["spectral analyses", "TEST", 163, 180], ["chemical degradation", "PROBLEM", 185, 205], ["cueunicin acetate", "TREATMENT", 218, 235], ["X-ray crystallography", "TEST", 245, 266], ["chemical degradation", "OBSERVATION", 185, 205]]], ["102 A systematic fractionation of the crude extract of specimens collected in Bimini led to the discovery of (13ctH, 14~H)-jeunicin (149) .", [["extract", "ANATOMY", 44, 51], ["specimens", "ANATOMY", 55, 64], ["Bimini", "CHEMICAL", 78, 84], ["13ctH, 14~H)-jeunicin", "CHEMICAL", 110, 131], ["(13ctH, 14~H)-jeunicin", "CHEMICAL", 109, 131], ["(13ctH, 14~H)-jeunicin", "SIMPLE_CHEMICAL", 109, 131], ["A systematic fractionation", "TEST", 4, 30], ["specimens", "TEST", 55, 64], ["fractionation", "OBSERVATION_MODIFIER", 17, 30]]], ["The molecular structure and absolute configuration of 149 (also known as 13,14-bis-epijeunicin) 6 were determined by X-ray crystallography.", [["13,14-bis-epijeunicin", "CHEMICAL", 73, 94], ["13,14-bis-epijeunicin", "CHEMICAL", 73, 94], ["13,14-bis-epijeunicin) 6", "SIMPLE_CHEMICAL", 73, 97], ["absolute configuration", "TEST", 28, 50], ["X-ray crystallography", "TEST", 117, 138], ["molecular", "OBSERVATION_MODIFIER", 4, 13], ["structure", "OBSERVATION_MODIFIER", 14, 23], ["absolute configuration", "OBSERVATION", 28, 50]]], ["99 This compound displayed in vitro cytotoxicity against KB and LE cell lines.", [["KB", "ANATOMY", 57, 59], ["LE cell lines", "ANATOMY", 64, 77], ["KB", "CELL", 57, 59], ["LE cell lines", "CELL", 64, 77], ["KB and LE cell lines", "CELL_LINE", 57, 77], ["This compound", "PROBLEM", 3, 16], ["vitro cytotoxicity", "TREATMENT", 30, 48], ["LE cell lines", "TREATMENT", 64, 77], ["vitro cytotoxicity", "OBSERVATION", 30, 48], ["LE cell lines", "OBSERVATION", 64, 77]]], ["The marine cembranolide peunicin (150) was isolated as the major component from the hexane extract of E. succinea collected in Panama.", [["cembranolide", "CHEMICAL", 11, 23], ["peunicin", "CHEMICAL", 24, 32], ["cembranolide", "CHEMICAL", 11, 23], ["peunicin", "CHEMICAL", 24, 32], ["hexane", "CHEMICAL", 84, 90], ["cembranolide peunicin", "SIMPLE_CHEMICAL", 11, 32], ["hexane", "SIMPLE_CHEMICAL", 84, 90], ["E. succinea", "ORGANISM", 102, 113], ["E. succinea", "SPECIES", 102, 113], ["E. succinea", "SPECIES", 102, 113], ["The marine cembranolide peunicin", "TREATMENT", 0, 32], ["the hexane extract", "TREATMENT", 80, 98]]], ["103 The 4586 A.D. RODRIOU~ molecular structure and absolute configuration were determined from X-ray data.", [["absolute configuration", "PROBLEM", 51, 73], ["X-ray data", "TEST", 95, 105], ["absolute configuration", "OBSERVATION", 51, 73]]], ["104 Peunicin (150) is cytotoxic in vitro against KB and PS cell lines and, like eunicin (143) , jeunicin (145) , and eupalmerin acetate (113) , shows strong anticiliary action.", [["KB", "ANATOMY", 49, 51], ["PS cell lines", "ANATOMY", 56, 69], ["Peunicin", "CHEMICAL", 4, 12], ["eunicin", "CHEMICAL", 80, 87], ["jeunicin", "CHEMICAL", 96, 104], ["eupalmerin acetate", "CHEMICAL", 117, 135], ["Peunicin", "CHEMICAL", 4, 12], ["eunicin", "CHEMICAL", 80, 87], ["jeunicin", "CHEMICAL", 96, 104], ["eupalmerin acetate", "CHEMICAL", 117, 135], ["KB", "CELL", 49, 51], ["PS cell lines", "CELL", 56, 69], ["eunicin (143)", "SIMPLE_CHEMICAL", 80, 93], ["jeunicin (145)", "SIMPLE_CHEMICAL", 96, 110], ["eupalmerin acetate", "SIMPLE_CHEMICAL", 117, 135], ["KB", "CELL_LINE", 49, 51], ["PS cell lines", "CELL_LINE", 56, 69], ["Peunicin", "TREATMENT", 4, 12], ["cytotoxic", "PROBLEM", 22, 31], ["PS cell lines", "TREATMENT", 56, 69], ["jeunicin", "TEST", 96, 104], ["eupalmerin acetate", "TREATMENT", 117, 135], ["PS cell lines", "OBSERVATION", 56, 69]]], ["81-84 Epipeunicin (151) is an unstable 7-1actonic cembranolide diterpene isolated from the same specimen ofE. succinea, and its proposed structure is based on spectral data.", [["specimen", "ANATOMY", 96, 104], ["81-84", "CHEMICAL", 0, 5], ["Epipeunicin", "CHEMICAL", 6, 17], ["7-1actonic cembranolide diterpene", "CHEMICAL", 39, 72], ["Epipeunicin", "CHEMICAL", 6, 17], ["7-1actonic cembranolide diterpene", "CHEMICAL", 39, 72], ["7-1actonic cembranolide diterpene", "SIMPLE_CHEMICAL", 39, 72], ["succinea", "ORGANISM", 110, 118], ["succinea", "SPECIES", 110, 118], ["succinea", "SPECIES", 110, 118], ["1actonic cembranolide diterpene", "TREATMENT", 41, 72], ["spectral data", "TEST", 159, 172]]], ["The ~cembranolide 12,13-bisepieupalmerin (152) was isolated from specimens of E. succinea collected in St.CHa--CHaCroix, U.S. Virgin Islands, and identified by X-ray methods.", [["specimens", "ANATOMY", 65, 74], ["cembranolide 12,13-bisepieupalmerin", "CHEMICAL", 5, 40], ["cembranolide 12,13-bisepieupalmerin", "CHEMICAL", 5, 40], ["cembranolide 12,13-bisepieupalmerin", "SIMPLE_CHEMICAL", 5, 40], ["E. succinea", "ORGANISM", 78, 89], ["St.CHa", "ORGANISM", 103, 109], ["E. succinea", "SPECIES", 78, 89], ["E. succinea", "SPECIES", 78, 89], ["The ~cembranolide", "TREATMENT", 0, 17], ["Virgin Islands", "OBSERVATION", 126, 140]]], ["105 12,13-Bisepieupalmedn possesses the correct stereochemistry to be a biosynthetic precursor for the related cembranolides eunicin (143) and jeunicin (145), which were found to occur with 152 in the same organism.", [["12,13-Bisepieupalmedn", "CHEMICAL", 4, 25], ["eunicin", "CHEMICAL", 125, 132], ["jeunicin", "CHEMICAL", 143, 151], ["eunicin", "CHEMICAL", 125, 132], ["jeunicin", "CHEMICAL", 143, 151], ["12,13-Bisepieupalmedn", "SIMPLE_CHEMICAL", 4, 25], ["cembranolides", "SIMPLE_CHEMICAL", 111, 124], ["eunicin", "SIMPLE_CHEMICAL", 125, 132], ["jeunicin", "SIMPLE_CHEMICAL", 143, 151], ["a biosynthetic precursor", "PROBLEM", 70, 94], ["the related cembranolides eunicin", "TREATMENT", 99, 132], ["jeunicin", "TEST", 143, 151]]], ["Eunicin (143) (143) were also found in Puerto Rican E. succinea specimens.", [["specimens", "ANATOMY", 64, 73], ["Eunicin", "CHEMICAL", 0, 7], ["Eunicin", "CHEMICAL", 0, 7], ["Eunicin (143) (143)", "GENE_OR_GENE_PRODUCT", 0, 19], ["E. succinea", "SPECIES", 52, 63], ["E. succinea", "SPECIES", 52, 63], ["Eunicin", "TEST", 0, 7]]], ["76 During this study 12,13-bisepieupalmerin was successfully converted chemically to eunicin (143) and jeunicin (145) under acidic conditions (SiO2, I)205) and thus provided evidence to establish 152 as their logical biosynthetic precursor.", [["12,13-bisepieupalmerin", "CHEMICAL", 21, 43], ["eunicin", "CHEMICAL", 85, 92], ["jeunicin", "CHEMICAL", 103, 111], ["12,13-bisepieupalmerin", "CHEMICAL", 21, 43], ["eunicin", "CHEMICAL", 85, 92], ["jeunicin", "CHEMICAL", 103, 111], ["SiO2", "CHEMICAL", 143, 147], ["12,13-bisepieupalmerin", "SIMPLE_CHEMICAL", 21, 43], ["eunicin", "SIMPLE_CHEMICAL", 85, 92], ["jeunicin", "SIMPLE_CHEMICAL", 103, 111], ["this study", "TEST", 10, 20], ["bisepieupalmerin", "TREATMENT", 27, 43], ["eunicin", "TREATMENT", 85, 92], ["jeunicin", "TREATMENT", 103, 111]]], ["All three eembranolides 115, 143, and 152 displayed strong in vitro cytotoxicity against CHO-KI cells.", [["CHO-KI cells", "ANATOMY", 89, 101], ["eembranolides 115, 143, and 152", "CHEMICAL", 10, 41], ["eembranolides", "CHEMICAL", 10, 23], ["CHO-KI cells", "CELL", 89, 101], ["CHO-KI cells", "CELL_LINE", 89, 101], ["All three eembranolides", "TEST", 0, 23], ["vitro cytotoxicity", "TEST", 62, 80], ["KI cells", "OBSERVATION", 93, 101]]], ["76 In addition, 12,13-bisepieupalmerin and eunicin were found to be active pharmacologically on the nicotinic acetylcholine receptor (AChR).", [["12,13-bisepieupalmerin", "CHEMICAL", 16, 38], ["eunicin", "CHEMICAL", 43, 50], ["acetylcholine", "CHEMICAL", 110, 123], ["12,13-bisepieupalmerin", "CHEMICAL", 16, 38], ["eunicin", "CHEMICAL", 43, 50], ["acetylcholine", "CHEMICAL", 110, 123], ["12,13-bisepieupalmerin", "SIMPLE_CHEMICAL", 16, 38], ["eunicin", "SIMPLE_CHEMICAL", 43, 50], ["nicotinic acetylcholine receptor", "GENE_OR_GENE_PRODUCT", 100, 132], ["AChR", "GENE_OR_GENE_PRODUCT", 134, 138], ["nicotinic acetylcholine receptor", "PROTEIN", 100, 132], ["AChR", "PROTEIN", 134, 138], ["eunicin", "TREATMENT", 43, 50], ["the nicotinic acetylcholine receptor", "TREATMENT", 96, 132], ["active", "OBSERVATION", 68, 74]]], ["The researchers concluded that these compounds act as noncompetitive inhibitors of peripheral AChR.", [["AChR", "GENE_OR_GENE_PRODUCT", 94, 98], ["peripheral AChR", "PROTEIN", 83, 98], ["peripheral AChR", "TREATMENT", 83, 98], ["peripheral", "ANATOMY_MODIFIER", 83, 93], ["AChR", "ANATOMY", 94, 98]]], ["106 Extraction of a freshly collected sample of E.CHa--CHasuccinea from a different location near Puerto Rico yielded 12,13-bisepieupalmerin acetate (155), 12-epieupalmerin acetate (156) , and succinolide (157) liberates free iodine vapors.", [["sample", "ANATOMY", 38, 44], ["E.CHa", "CHEMICAL", 48, 53], ["CHasuccinea", "CHEMICAL", 55, 66], ["12,13-bisepieupalmerin acetate", "CHEMICAL", 118, 148], ["12-epieupalmerin acetate", "CHEMICAL", 156, 180], ["succinolide", "CHEMICAL", 193, 204], ["iodine", "CHEMICAL", 226, 232], ["12,13-bisepieupalmerin acetate", "CHEMICAL", 118, 148], ["12-epieupalmerin acetate", "CHEMICAL", 156, 180], ["succinolide", "CHEMICAL", 193, 204], ["iodine", "CHEMICAL", 226, 232], ["12,13-bisepieupalmerin acetate", "SIMPLE_CHEMICAL", 118, 148], ["12-epieupalmerin acetate", "SIMPLE_CHEMICAL", 156, 180], ["succinolide (157)", "SIMPLE_CHEMICAL", 193, 210], ["free iodine vapors", "SIMPLE_CHEMICAL", 221, 239], ["CHasuccinea", "PROBLEM", 55, 66], ["bisepieupalmerin acetate", "TREATMENT", 124, 148], ["12-epieupalmerin acetate", "TREATMENT", 156, 180], ["succinolide", "TREATMENT", 193, 204], ["free iodine vapors", "TREATMENT", 221, 239]]], ["The iodine probably arises from the thermal degradation of covalently bonded iodine from 3,5-diiodotyrosine (172) .", [["iodine", "CHEMICAL", 4, 10], ["iodine", "CHEMICAL", 77, 83], ["3,5-diiodotyrosine", "CHEMICAL", 89, 107], ["iodine", "CHEMICAL", 4, 10], ["iodine", "CHEMICAL", 77, 83], ["3,5-diiodotyrosine", "CHEMICAL", 89, 107], ["iodine", "SIMPLE_CHEMICAL", 4, 10], ["iodine", "SIMPLE_CHEMICAL", 77, 83], ["3,5-diiodotyrosine", "SIMPLE_CHEMICAL", 89, 107], ["The iodine", "TREATMENT", 0, 10], ["covalently bonded iodine", "TREATMENT", 59, 83], ["iodine", "OBSERVATION", 4, 10]]], ["112 Extracts of this gorgonian collected in the Bahamas were reported to contain at least a dozen nonpolar terpenoids.", [["Extracts", "ANATOMY", 4, 12], ["terpenoids", "CHEMICAL", 107, 117], ["this gorgonian", "PROBLEM", 16, 30], ["Bahamas", "ANATOMY", 48, 55], ["nonpolar terpenoids", "OBSERVATION", 98, 117]]], ["113 However, no structures were described in that report.", [["structures", "PROBLEM", 16, 26]]], ["Fractions containing these compounds reduced feeding by natural assemblages of tropical fishes by 87%; sclerites reduced feeding by fishes by 95%.", [["sclerites", "ANATOMY", 103, 112], ["tropical fishes", "TREATMENT", 79, 94], ["compounds", "OBSERVATION_MODIFIER", 27, 36], ["reduced", "OBSERVATION_MODIFIER", 37, 44], ["feeding", "OBSERVATION_MODIFIER", 45, 52], ["natural", "OBSERVATION_MODIFIER", 56, 63], ["assemblages", "OBSERVATION_MODIFIER", 64, 75]]], ["In ship-board feeding experiments, artificial diet containing G. ventalina crude extracts was consumed 49% less by Cyphoma gibbosum (the flamingo tongue snail), an ovulid predatory gastropod that specializes on gorgonians.", [["extracts", "ANATOMY", 81, 89], ["gorgonians", "ANATOMY", 211, 221], ["G. ventalina", "ORGANISM", 62, 74], ["extracts", "ORGANISM_SUBSTANCE", 81, 89], ["Cyphoma gibbosum", "ORGANISM", 115, 131], ["flamingo tongue", "ORGAN", 137, 152], ["snail", "ORGANISM", 153, 158], ["G. ventalina", "SPECIES", 62, 74], ["Cyphoma gibbosum", "SPECIES", 115, 131], ["G. ventalina", "SPECIES", 62, 74], ["Cyphoma gibbosum", "SPECIES", 115, 131], ["artificial diet containing G. ventalina crude extracts", "TREATMENT", 35, 89]]], ["113Phyllogorgia (family Gorgoniidae)Several species and varieties of these leaf-corals have been described, largely because of their extraordinary variation in growth form.", [["113Phyllogorgia", "CHEMICAL", 0, 15], ["Several species", "PROBLEM", 36, 51]]], ["There is also a wide range of variation in the spicules.", [["spicules", "ANATOMY", 47, 55], ["wide", "OBSERVATION_MODIFIER", 16, 20], ["range", "OBSERVATION_MODIFIER", 21, 26], ["variation", "OBSERVATION_MODIFIER", 30, 39], ["spicules", "OBSERVATION_MODIFIER", 47, 55]]], ["The gorgonian P. dilatata is a species endemic to Brazil.A. PhyUogorgia dilatata (Esper)A nardosinane sesquiterpene, 11,12-epoxynardosin-l(10)-ene (177) , was isolated from the Brazilian gorgonian Phyllogorgia dilatata, and its structure has been deduced from chemical evidence and spectral dam.", [["Esper", "CHEMICAL", 82, 87], ["nardosinane sesquiterpene, 11,12-epoxynardosin-l(10)-ene", "CHEMICAL", 90, 146], ["nardosinane", "CHEMICAL", 90, 101], ["sesquiterpene", "CHEMICAL", 102, 115], ["11,12-epoxynardosin-l(10)-ene", "CHEMICAL", 117, 146], ["gorgonian", "ORGANISM", 4, 13], ["P. dilatata", "ORGANISM", 14, 25], ["PhyUogorgia dilatata", "ORGANISM", 60, 80], ["Esper)A nardosinane sesquiterpene, 11,12-epoxynardosin-l(10)-ene (177)", "SIMPLE_CHEMICAL", 82, 152], ["Phyllogorgia dilatata", "ORGANISM", 197, 218], ["P. dilatata", "SPECIES", 14, 25], ["A. PhyUogorgia dilatata", "SPECIES", 57, 80], ["Phyllogorgia dilatata", "SPECIES", 197, 218], ["P. dilatata", "SPECIES", 14, 25], ["A. PhyUogorgia dilatata", "SPECIES", 57, 80], ["Phyllogorgia dilatata", "SPECIES", 197, 218], ["a species endemic", "PROBLEM", 29, 46], ["epoxynardosin", "TREATMENT", 123, 136], ["gorgonian P.", "OBSERVATION", 4, 16], ["gorgonian Phyllogorgia", "OBSERVATION", 187, 209], ["spectral dam", "OBSERVATION", 282, 294]]], ["118 Gorgonians belonging to this genus arc usually rich in cembrane diterpenes and prostanoids.A. PhyUogorgia dilatata (Esper)A. Plexaura A (spee. nov.) 119A.", [["cembrane diterpenes", "CHEMICAL", 59, 78], ["prostanoids", "CHEMICAL", 83, 94], ["diterpenes", "CHEMICAL", 68, 78], ["prostanoids", "CHEMICAL", 83, 94], ["cembrane diterpenes", "SIMPLE_CHEMICAL", 59, 78], ["prostanoids", "SIMPLE_CHEMICAL", 83, 94], ["PhyUogorgia dilatata", "ORGANISM", 98, 118], ["Esper)A", "GENE_OR_GENE_PRODUCT", 120, 127], ["A.", "SPECIES", 95, 97], ["PhyUogorgia dilatata", "SPECIES", 98, 118], ["A. PhyUogorgia dilatata", "SPECIES", 95, 118], ["cembrane diterpenes", "OBSERVATION", 59, 78], ["prostanoids", "ANATOMY", 83, 94]]], ["PhyUogorgia dilatata (Esper)Plexaurolone (178) was first discovered from an undescribed gorgonian collected in Puerto Rico that appears to be related to the genus Plexaura, and that was found subsequently in the same species collected at Bonaire, Netherlands Antilles.", [["Plexaurolone", "CHEMICAL", 28, 40], ["PhyUogorgia dilatata", "ORGANISM", 0, 20], ["Esper)Plexaurolone (178)", "GENE_OR_GENE_PRODUCT", 22, 46], ["Plexaura", "GENE_OR_GENE_PRODUCT", 163, 171], ["PhyUogorgia dilatata", "SPECIES", 0, 20], ["PhyUogorgia dilatata", "SPECIES", 0, 20], ["PhyUogorgia", "TEST", 0, 11], ["the genus Plexaura", "PROBLEM", 153, 171], ["gorgonian", "OBSERVATION", 88, 97], ["appears to be related to", "UNCERTAINTY", 128, 152], ["genus Plexaura", "OBSERVATION", 157, 171]]], ["The crystal structure and absolute configuration of the acetate derivative of plexaurolone were determined from three-dimensional X-ray diffraction data.", [["acetate", "CHEMICAL", 56, 63], ["plexaurolone", "CHEMICAL", 78, 90], ["acetate", "CHEMICAL", 56, 63], ["plexaurolone", "CHEMICAL", 78, 90], ["acetate derivative", "SIMPLE_CHEMICAL", 56, 74], ["plexaurolone", "SIMPLE_CHEMICAL", 78, 90], ["the acetate derivative of plexaurolone", "TREATMENT", 52, 90], ["crystal", "OBSERVATION_MODIFIER", 4, 11], ["structure", "OBSERVATION_MODIFIER", 12, 21], ["absolute configuration", "OBSERVATION", 26, 48]]], ["120 Plexaurolone (178) may represent the first example of a Caribbean cembranoid belonging to the or-series.", [["Plexaurolone", "CHEMICAL", 4, 16], ["Plexaurolone", "CHEMICAL", 4, 16], ["or-series", "DNA", 98, 107], ["a Caribbean cembranoid", "TREATMENT", 58, 80]]], ["Later data, however, suggested that the PGA2 of P. homomaUa is not used to compete allelopathically or to reduce fouling, but to provide protection from predators.", [["PGA2", "CHEMICAL", 40, 44], ["PGA2", "GENE_OR_GENE_PRODUCT", 40, 44], ["P. homomaUa", "ORGANISM", 48, 59], ["P. homomaUa", "SPECIES", 48, 59], ["P. homomaUa", "SPECIES", 48, 59], ["the PGA2 of P. homomaUa", "PROBLEM", 36, 59]]], ["140 Interestingly, during a re-evaluation of the ichthyodeterrent role of prostaglandins in P. homomalla, it was found that the consumption of food strips containing the acetoxy methyl ester of (15R)-PGA2 did not differ from consumption of control strips when presented to a natural assemblage of Caribbean coral reef fishes.", [["prostaglandins", "CHEMICAL", 74, 88], ["acetoxy methyl ester", "CHEMICAL", 170, 190], ["15R)-PGA2", "CHEMICAL", 195, 204], ["prostaglandins", "CHEMICAL", 74, 88], ["acetoxy methyl ester", "CHEMICAL", 170, 190], ["(15R)-PGA2", "CHEMICAL", 194, 204], ["prostaglandins", "SIMPLE_CHEMICAL", 74, 88], ["P. homomalla", "ORGANISM", 92, 104], ["acetoxy methyl ester", "SIMPLE_CHEMICAL", 170, 190], ["(15R)-PGA2", "SIMPLE_CHEMICAL", 194, 204], ["P. homomalla", "SPECIES", 92, 104], ["P. homomalla", "SPECIES", 92, 104], ["a re-evaluation", "TEST", 26, 41], ["food strips", "TREATMENT", 143, 154], ["the acetoxy methyl ester", "TREATMENT", 166, 190], ["PGA2", "TREATMENT", 200, 204], ["control strips", "TREATMENT", 240, 254]]], ["However, treatment with the acetoxy acid, hydroxy methyl ester, and hydroxy acid of (15R)-PGA2 inhibited consumption of food strips by reef fishes.", [["acetoxy acid", "CHEMICAL", 28, 40], ["hydroxy methyl ester", "CHEMICAL", 42, 62], ["hydroxy acid", "CHEMICAL", 68, 80], ["15R)-PGA2", "CHEMICAL", 85, 94], ["acetoxy acid", "CHEMICAL", 28, 40], ["hydroxy methyl ester", "CHEMICAL", 42, 62], ["hydroxy acid", "CHEMICAL", 68, 80], ["(15R)-PGA2", "CHEMICAL", 84, 94], ["acetoxy acid", "SIMPLE_CHEMICAL", 28, 40], ["hydroxy methyl ester", "SIMPLE_CHEMICAL", 42, 62], ["hydroxy acid", "SIMPLE_CHEMICAL", 68, 80], ["(15R)-PGA2", "SIMPLE_CHEMICAL", 84, 94], ["the acetoxy acid", "TREATMENT", 24, 40], ["hydroxy methyl ester", "TREATMENT", 42, 62], ["hydroxy acid", "TREATMENT", 68, 80], ["PGA2", "TREATMENT", 90, 94]]], ["Although the results of the latter study suggest that the esterified prostaglandins present in P. homomalla do not deter fish predators, these compounds may have very different effects on other potential predators of gorgonians, particularly invertebrates.", [["gorgonians", "ANATOMY", 217, 227], ["prostaglandins", "CHEMICAL", 69, 83], ["prostaglandins", "CHEMICAL", 69, 83], ["prostaglandins", "SIMPLE_CHEMICAL", 69, 83], ["P. homomalla", "ORGANISM", 95, 107], ["gorgonians", "GENE_OR_GENE_PRODUCT", 217, 227], ["P. homomalla", "SPECIES", 95, 107], ["the latter study", "TEST", 24, 40], ["the esterified prostaglandins", "TREATMENT", 54, 83]]], ["141,142 The mechanism of biosynthesis of prostaglandins of the A and E series from P. homomalla, which clearly follows a distinct pathway from the mammalian cyclooxygenase/endoperoxide route, has been the subject of intense research.", [["prostaglandins", "CHEMICAL", 41, 55], ["endoperoxide", "CHEMICAL", 172, 184], ["prostaglandins", "CHEMICAL", 41, 55], ["endoperoxide", "CHEMICAL", 172, 184], ["prostaglandins", "SIMPLE_CHEMICAL", 41, 55], ["A", "GENE_OR_GENE_PRODUCT", 63, 64], ["P. homomalla", "ORGANISM", 83, 95], ["cyclooxygenase", "GENE_OR_GENE_PRODUCT", 157, 171], ["endoperoxide", "SIMPLE_CHEMICAL", 172, 184], ["cyclooxygenase", "PROTEIN", 157, 171], ["P. homomalla", "SPECIES", 83, 95], ["P. homomalla", "SPECIES", 83, 95], ["biosynthesis of prostaglandins", "TREATMENT", 25, 55], ["P. homomalla", "PROBLEM", 83, 95], ["the mammalian cyclooxygenase/endoperoxide route", "TREATMENT", 143, 190], ["intense", "OBSERVATION_MODIFIER", 216, 223]]], ["143-147 A major discussion of the chemistry and chemical ecology of Plexaura homomalla appeared in 1992.", [["143-147", "CHEMICAL", 0, 7], ["Plexaura homomalla", "ORGANISM", 68, 86], ["Plexaura homomalla", "SPECIES", 68, 86], ["the chemistry", "TEST", 30, 43]]], ["9Plexaurella (family Plexauridae)About six species of Plexaurella have been distinguished in the West Indian region.", [["Plexaurella", "CHEMICAL", 1, 12], ["Plexaurella", "ORGANISM", 1, 12], ["Plexaurella", "ORGANISM", 54, 65], ["Plexaurella", "TREATMENT", 54, 65]]], ["Gorgonians belonging to this genus are particularly rich in acyclic and cyclic sesquiterpenes.Plexaurella (family Plexauridae)A. Plexaurella dichotoma (Esper) (Double-forked Plexaurella) PlexaureUa dichotoma from the Caribbean region has been reported to contain (+)-o~-muurolene (112), (+)-13-bisabolene (174), (-)-a-cureumene (175), (+)-a-bisabolene (194) , and (+)-I~-cureumene (195B.", [["cyclic sesquiterpenes", "CHEMICAL", 72, 93], ["Plexaurella", "CHEMICAL", 94, 105], ["muurolene", "CHEMICAL", 270, 279], ["112), (+)-13-bisabolene", "CHEMICAL", 281, 304], ["cureumene", "CHEMICAL", 318, 327], ["bisabolene", "CHEMICAL", 341, 351], ["acyclic and cyclic sesquiterpenes", "CHEMICAL", 60, 93], ["(+)-o~-muurolene", "CHEMICAL", 263, 279], ["(+)-13-bisabolene", "CHEMICAL", 287, 304], ["(-)-a-cureumene", "CHEMICAL", 312, 327], ["(+)-a-bisabolene", "CHEMICAL", 335, 351], ["(+)-I~-cureumene", "CHEMICAL", 364, 380], ["cyclic sesquiterpenes", "SIMPLE_CHEMICAL", 72, 93], ["Plexaurella", "ORGANISM", 94, 105], ["A. Plexaurella dichotoma", "ORGANISM", 126, 150], ["PlexaureUa dichotoma", "ORGANISM", 187, 207], ["(+)-o~-muurolene (112)", "SIMPLE_CHEMICAL", 263, 285], ["(+)-13-bisabolene (174)", "SIMPLE_CHEMICAL", 287, 310], ["(-)-a-cureumene (175)", "SIMPLE_CHEMICAL", 312, 333], ["(+)-a-bisabolene (194)", "SIMPLE_CHEMICAL", 335, 357], ["(+)-I~-cureumene", "SIMPLE_CHEMICAL", 364, 380], ["A.", "SPECIES", 126, 128], ["Plexaurella dichotoma", "SPECIES", 129, 150], ["PlexaureUa dichotoma", "SPECIES", 187, 207], ["Plexaurella dichotoma", "SPECIES", 129, 150], ["cyclic sesquiterpenes", "TREATMENT", 72, 93], ["Plexaurella", "TEST", 94, 105], ["Double-forked Plexaurella)", "TREATMENT", 160, 186], ["PlexaureUa dichotoma", "PROBLEM", 187, 207]]], ["PlexaureUa fusifera (Kunze)The gorgonian PlexaureUafusifera from the Caribbean region contains (+)-~-muurolene (112)Pseudoplexaura (family Plexauridae)The genus Pseudoplexaura is extremely common and abundant and can be found distributed along the Bermudas, Florida Keys, Bahamas and Antilles regions.", [["(+)-~-muurolene", "CHEMICAL", 95, 110], ["PlexaureUa fusifera", "ORGANISM", 0, 19], ["gorgonian PlexaureUafusifera", "ORGANISM", 31, 59], ["Pseudoplexaura", "GENE_OR_GENE_PRODUCT", 161, 175], ["PlexaureUa fusifera", "SPECIES", 0, 19], ["PlexaureUa fusifera", "SPECIES", 0, 19], ["gorgonian PlexaureUafusifera", "OBSERVATION", 31, 59], ["genus Pseudoplexaura", "OBSERVATION", 155, 175], ["Antilles", "ANATOMY_MODIFIER", 284, 292]]], ["Four species of Pseudoplexaura have been documented.", [["Pseudoplexaura", "CHEMICAL", 16, 30], ["Pseudoplexaura", "GENE_OR_GENE_PRODUCT", 16, 30], ["Pseudoplexaura", "PROBLEM", 16, 30]]], ["This genus is characterized by a complex mixture of sesquiterpene hydrocarbons that have been consistently found in many species from well-separated geographical locations)Pseudoplexaura (family Plexauridae)A. Pseudoplexaura crucis (spee. nov.)Pseudoplexaura (family Plexauridae)Trace quantities of the ~-lactonic cembranolide crassin acetate (200) were found to be responsible for the marginal KB activity of Pseudoplexaura crucis collected near St. Thomas, U.S. Virgin Islands.", [["sesquiterpene hydrocarbons", "CHEMICAL", 52, 78], ["Pseudoplexaura", "CHEMICAL", 244, 258], ["crassin acetate", "CHEMICAL", 327, 342], ["sesquiterpene hydrocarbons", "CHEMICAL", 52, 78], ["crassin acetate", "CHEMICAL", 327, 342], ["sesquiterpene hydrocarbons", "SIMPLE_CHEMICAL", 52, 78], ["Pseudoplexaura", "ORGANISM", 172, 186], ["A. Pseudoplexaura crucis", "ORGANISM", 207, 231], ["Pseudoplexaura", "SIMPLE_CHEMICAL", 244, 258], ["~-lactonic cembranolide crassin", "SIMPLE_CHEMICAL", 303, 334], ["acetate", "SIMPLE_CHEMICAL", 335, 342], ["KB", "CANCER", 395, 397], ["Pseudoplexaura crucis", "ORGANISM", 410, 431], ["A.", "SPECIES", 207, 209], ["Pseudoplexaura crucis", "SPECIES", 210, 231], ["Pseudoplexaura crucis", "SPECIES", 410, 431], ["Pseudoplexaura crucis", "SPECIES", 210, 231], ["Pseudoplexaura crucis", "SPECIES", 410, 431], ["sesquiterpene hydrocarbons", "PROBLEM", 52, 78], ["Pseudoplexaura (family Plexauridae", "TREATMENT", 244, 278], ["the ~-lactonic cembranolide crassin acetate", "TREATMENT", 299, 342], ["Pseudoplexaura crucis", "PROBLEM", 410, 431], ["sesquiterpene hydrocarbons", "OBSERVATION", 52, 78], ["Pseudoplexaura crucis", "OBSERVATION", 410, 431], ["Virgin Islands", "OBSERVATION", 464, 478]]], ["Crassin acetate has also been found in other gorgonians belonging to the genus Pseudoplexaura (see below).", [["Crassin acetate", "CHEMICAL", 0, 15], ["Crassin acetate", "CHEMICAL", 0, 15], ["Crassin acetate", "SIMPLE_CHEMICAL", 0, 15], ["Crassin acetate", "TREATMENT", 0, 15], ["genus Pseudoplexaura", "OBSERVATION", 73, 93]]], ["150 (203) , and alloaromadendrene (204C.", [["alloaromadendrene", "CHEMICAL", 16, 33], ["alloaromadendrene", "CHEMICAL", 16, 33], ["alloaromadendrene", "SIMPLE_CHEMICAL", 16, 33]]], ["Pseudoplexaura porosa (Houttuyn)In addition to (+)-ylangene (142), 74 Pseudoplexaura porosa (originally referred to as P. crassa) contains the same complex mixture of sesquiterpene hydrocarbons (112, 141, 154, 201, 202, 203 , and 204) described above.", [["sesquiterpene hydrocarbons", "CHEMICAL", 167, 193], ["(+)-ylangene", "CHEMICAL", 47, 59], ["sesquiterpene hydrocarbons", "CHEMICAL", 167, 193], ["Pseudoplexaura porosa", "ORGANISM", 0, 21], ["(+)-ylangene", "SIMPLE_CHEMICAL", 47, 59], ["Pseudoplexaura porosa", "ORGANISM", 70, 91], ["P. crassa", "ORGANISM", 119, 128], ["sesquiterpene hydrocarbons", "SIMPLE_CHEMICAL", 167, 193], ["Pseudoplexaura porosa", "SPECIES", 0, 21], ["Pseudoplexaura porosa", "SPECIES", 70, 91], ["P. crassa", "SPECIES", 119, 128], ["Pseudoplexaura porosa", "SPECIES", 0, 21], ["Pseudoplexaura porosa", "SPECIES", 70, 91], ["P. crassa", "SPECIES", 119, 128], ["sesquiterpene hydrocarbons", "TEST", 167, 193], ["sesquiterpene hydrocarbons", "OBSERVATION", 167, 193]]], ["3,5 (+)-Calamenene (205) , which could be an artifact, was also isolated during steam distillation of the hydrocarbon fraction of P. porosa.", [["3,5 (+)-Calamenene", "CHEMICAL", 0, 18], ["3,5 (+)-Calamenene", "CHEMICAL", 0, 18], ["hydrocarbon", "CHEMICAL", 106, 117], ["3,5 (+)-Calamenene", "SIMPLE_CHEMICAL", 0, 18], ["P. porosa", "ORGANISM", 130, 139], ["P. porosa", "SPECIES", 130, 139], ["P. porosa", "SPECIES", 130, 139], ["Calamenene", "TREATMENT", 8, 18], ["artifact", "OBSERVATION", 45, 53], ["hydrocarbon fraction", "OBSERVATION", 106, 126]]], ["5, 74, 152 The synthesis of (+)-cis-calamenene has been reported.", [["calamenene", "CHEMICAL", 36, 46], ["(+)-cis-calamenene", "CHEMICAL", 28, 46], ["(+)-cis-calamenene", "SIMPLE_CHEMICAL", 28, 46], ["The synthesis", "TEST", 11, 24]]], ["153 The gorgonian P. porosa was among the first gorgonians to be investigated and, 20 after extensive chemical studies, the structure of crassin acetate (200) Subsequently, crassin acetate was also isolated from several gorgonians of the genus Pseudoplexaura, namely P. flagellosa, P. wagenaari, and P. crucis.", [["crassin acetate", "CHEMICAL", 137, 152], ["crassin acetate", "CHEMICAL", 173, 188], ["crassin acetate", "CHEMICAL", 137, 152], ["crassin acetate", "CHEMICAL", 173, 188], ["gorgonian P. porosa", "ORGANISM", 8, 27], ["crassin acetate", "SIMPLE_CHEMICAL", 137, 152], ["crassin acetate", "SIMPLE_CHEMICAL", 173, 188], ["Pseudoplexaura", "GENE_OR_GENE_PRODUCT", 244, 258], ["P. flagellosa", "ORGANISM", 267, 280], ["P. wagenaari", "ORGANISM", 282, 294], ["P. crucis", "ORGANISM", 300, 309], ["P. porosa", "SPECIES", 18, 27], ["P. flagellosa", "SPECIES", 267, 280], ["P. wagenaari", "SPECIES", 282, 294], ["P. crucis", "SPECIES", 300, 309], ["P. porosa", "SPECIES", 18, 27], ["P. flagellosa", "SPECIES", 267, 280], ["P. wagenaari", "SPECIES", 282, 294], ["P. crucis", "SPECIES", 300, 309], ["extensive chemical studies", "TEST", 92, 118], ["crassin acetate", "TREATMENT", 137, 152], ["crassin acetate", "TREATMENT", 173, 188], ["genus Pseudoplexaura", "OBSERVATION", 238, 258]]], ["150, 157 This lactone showed substantial activity in the KB test, an in vitro bioassay against a human carcinoma of the nasopharynx, and against P-388 lymphocytic leukemia.", [["KB", "ANATOMY", 57, 59], ["carcinoma", "ANATOMY", 103, 112], ["nasopharynx", "ANATOMY", 120, 131], ["P-388 lymphocytic leukemia", "ANATOMY", 145, 171], ["lactone", "CHEMICAL", 14, 21], ["carcinoma of the nasopharynx", "DISEASE", 103, 131], ["P-388", "CHEMICAL", 145, 150], ["lymphocytic leukemia", "DISEASE", 151, 171], ["lactone", "CHEMICAL", 14, 21], ["lactone", "SIMPLE_CHEMICAL", 14, 21], ["KB", "CANCER", 57, 59], ["human", "ORGANISM", 97, 102], ["carcinoma", "CANCER", 103, 112], ["nasopharynx", "ORGAN", 120, 131], ["P-388 lymphocytic leukemia", "CANCER", 145, 171], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["P-388", "SPECIES", 145, 150], ["This lactone", "TEST", 9, 21], ["the KB test", "TEST", 53, 64], ["an in vitro bioassay", "TEST", 66, 86], ["a human carcinoma of the nasopharynx", "PROBLEM", 95, 131], ["P-388 lymphocytic leukemia", "PROBLEM", 145, 171], ["substantial", "OBSERVATION_MODIFIER", 29, 40], ["activity", "OBSERVATION_MODIFIER", 41, 49], ["carcinoma", "OBSERVATION", 103, 112], ["nasopharynx", "ANATOMY", 120, 131], ["lymphocytic leukemia", "OBSERVATION", 151, 171]]], ["150 The spectral characteristics of crassin acetate, 60 its total 13C-NMR assignment, 158 and the total synthesis of crassin (206) , obtained by saponification of crassin acetate, have been reported.", [["crassin acetate", "CHEMICAL", 36, 51], ["crassin", "CHEMICAL", 117, 124], ["crassin acetate", "CHEMICAL", 163, 178], ["crassin acetate", "CHEMICAL", 36, 51], ["13C", "CHEMICAL", 66, 69], ["crassin", "CHEMICAL", 117, 124], ["crassin acetate", "CHEMICAL", 163, 178], ["crassin acetate", "SIMPLE_CHEMICAL", 36, 51], ["13C", "SIMPLE_CHEMICAL", 66, 69], ["crassin", "SIMPLE_CHEMICAL", 117, 124], ["crassin acetate", "SIMPLE_CHEMICAL", 163, 178], ["crassin acetate", "TREATMENT", 36, 51], ["NMR assignment", "TEST", 70, 84], ["the total synthesis", "TEST", 94, 113], ["crassin acetate", "TREATMENT", 163, 178]]], ["159-161 An intramolecular alkylation of a lithioalkyne with an allylic bromide has produced the 14-membered ring of crassin acetate (2,00).", [["159-161", "CHEMICAL", 0, 7], ["lithioalkyne", "CHEMICAL", 42, 54], ["allylic bromide", "CHEMICAL", 63, 78], ["crassin acetate", "CHEMICAL", 116, 131], ["lithioalkyne", "CHEMICAL", 42, 54], ["allylic bromide", "CHEMICAL", 63, 78], ["crassin acetate", "CHEMICAL", 116, 131], ["lithioalkyne", "SIMPLE_CHEMICAL", 42, 54], ["allylic bromide", "SIMPLE_CHEMICAL", 63, 78], ["crassin acetate", "SIMPLE_CHEMICAL", 116, 131], ["An intramolecular alkylation", "TREATMENT", 8, 36], ["a lithioalkyne", "TREATMENT", 40, 54], ["an allylic bromide", "TREATMENT", 60, 78], ["the 14-membered ring of crassin acetate", "TREATMENT", 92, 131], ["intramolecular alkylation", "OBSERVATION", 11, 36]]], ["162 A nitrile oxide cycloaddition furnished the lactone and the stereocenters at C-I and C-14.", [["nitrile oxide", "CHEMICAL", 6, 19], ["lactone", "CHEMICAL", 48, 55], ["nitrile oxide", "CHEMICAL", 6, 19], ["lactone", "CHEMICAL", 48, 55], ["nitrile oxide", "SIMPLE_CHEMICAL", 6, 19], ["lactone", "SIMPLE_CHEMICAL", 48, 55], ["C-I", "SIMPLE_CHEMICAL", 81, 84], ["C-14", "SIMPLE_CHEMICAL", 89, 93], ["A nitrile oxide cycloaddition", "TREATMENT", 4, 33], ["the lactone", "TREATMENT", 44, 55], ["the stereocenters", "TREATMENT", 60, 77]]], ["The total synthesis of (+)-crassin acetate methyl ether has also been reported.", [["methyl ether", "CHEMICAL", 43, 55], ["(+)-crassin acetate methyl ether", "CHEMICAL", 23, 55], ["(+)-crassin acetate methyl ether", "SIMPLE_CHEMICAL", 23, 55], ["The total synthesis", "TEST", 0, 19], ["(+)-crassin acetate methyl ether", "TREATMENT", 23, 55]]], ["163 Crassin acetate (200) , which may constitute as much as 1.5-2% of the dry weight of the cortex of the gorgonian P. porosa, functions in the marine ecosystem, along with other related compounds, by decreasing the viability of ciliated larvae of organisms which compete with gorgonians for space.t64, 165 Recently, two additional cytotoxic antitumor diterpenoids of the cembrane class related to crassin acetate, named 14-deoxycrassin (207) and pseudoplexaurol (208) , were isolated from a specimen of P. porosa The first successful synthetic approach to a pseudopterane, viz., 213, was reported.", [["cortex", "ANATOMY", 92, 98], ["antitumor", "ANATOMY", 342, 351], ["specimen", "ANATOMY", 492, 500], ["Crassin acetate", "CHEMICAL", 4, 19], ["crassin acetate", "CHEMICAL", 398, 413], ["14-deoxycrassin", "CHEMICAL", 421, 436], ["pseudoplexaurol", "CHEMICAL", 447, 462], ["pseudopterane", "CHEMICAL", 559, 572], ["Crassin acetate", "CHEMICAL", 4, 19], ["diterpenoids", "CHEMICAL", 352, 364], ["crassin acetate", "CHEMICAL", 398, 413], ["14-deoxycrassin", "CHEMICAL", 421, 436], ["pseudoplexaurol", "CHEMICAL", 447, 462], ["pseudopterane", "CHEMICAL", 559, 572], ["Crassin acetate", "SIMPLE_CHEMICAL", 4, 19], ["cortex", "CANCER", 92, 98], ["gorgonian", "ORGANISM", 106, 115], ["P. porosa", "ORGANISM", 116, 125], ["antitumor", "CANCER", 342, 351], ["crassin acetate", "SIMPLE_CHEMICAL", 398, 413], ["14-deoxycrassin (207)", "SIMPLE_CHEMICAL", 421, 442], ["pseudoplexaurol (208)", "SIMPLE_CHEMICAL", 447, 468], ["P. porosa", "ORGANISM", 504, 513], ["pseudopterane", "SIMPLE_CHEMICAL", 559, 572], ["P. porosa", "SPECIES", 116, 125], ["P. porosa", "SPECIES", 504, 513], ["P. porosa", "SPECIES", 116, 125], ["P. porosa", "SPECIES", 504, 513], ["Crassin acetate", "TREATMENT", 4, 19], ["the dry weight", "TEST", 70, 84], ["ciliated larvae of organisms", "PROBLEM", 229, 257], ["additional cytotoxic antitumor diterpenoids", "TREATMENT", 321, 364], ["crassin acetate", "TREATMENT", 398, 413], ["deoxycrassin", "TREATMENT", 424, 436], ["pseudoplexaurol", "TREATMENT", 447, 462], ["cytotoxic", "OBSERVATION_MODIFIER", 332, 341], ["antitumor diterpenoids", "OBSERVATION", 342, 364]]], ["169 A retrosynthetic strategy for the total synthesis of pseudopterolide (212) and allied pseudopteranes has been reported.", [["pseudopterolide", "CHEMICAL", 57, 72], ["pseudopteranes", "CHEMICAL", 90, 104], ["pseudopterolide", "CHEMICAL", 57, 72], ["pseudopteranes", "CHEMICAL", 90, 104], ["pseudopterolide (212)", "SIMPLE_CHEMICAL", 57, 78], ["pseudopteranes", "SIMPLE_CHEMICAL", 90, 104], ["A retrosynthetic strategy", "TREATMENT", 4, 29], ["the total synthesis of pseudopterolide", "TREATMENT", 34, 72]]], ["170,171 Several routes to the 2,5-furanocyclic ring system of the pseudopterane family of natural products along with prototype pseudopterane and furanocembrane systems have recently been described.", [["2,5-furanocyclic", "CHEMICAL", 30, 46], ["pseudopterane", "CHEMICAL", 128, 141], ["furanocembrane", "CHEMICAL", 146, 160], ["2,5-furanocyclic", "CHEMICAL", 30, 46], ["pseudopterane", "CHEMICAL", 128, 141], ["furanocembrane", "CHEMICAL", 146, 160], ["2,5-furanocyclic ring", "SIMPLE_CHEMICAL", 30, 51], ["pseudopterane", "SIMPLE_CHEMICAL", 128, 141], ["furanocembrane", "SIMPLE_CHEMICAL", 146, 160], ["pseudopterane family", "PROTEIN", 66, 86], ["natural products", "TREATMENT", 90, 106], ["prototype pseudopterane and furanocembrane systems", "TREATMENT", 118, 168], ["natural products", "OBSERVATION", 90, 106]]], ["172-176 A collection of a Pseudopterogorgia spp. from Belize, whose spicule analyses closely related the animal to the Caribbean sea whip P. acerosa, produces exclusively the sesquiterpene 12-hydroxy-E-'pbisabolene (214) .", [["172-176", "CHEMICAL", 0, 7], ["12-hydroxy-E-'pbisabolene", "CHEMICAL", 189, 214], ["sesquiterpene", "CHEMICAL", 175, 188], ["12-hydroxy-E-'pbisabolene", "CHEMICAL", 189, 214], ["Pseudopterogorgia spp.", "ORGANISM", 26, 48], ["P. acerosa", "ORGANISM", 138, 148], ["sesquiterpene 12-hydroxy-E-'pbisabolene", "SIMPLE_CHEMICAL", 175, 214], ["Pseudopterogorgia spp.", "SPECIES", 26, 48], ["P. acerosa", "SPECIES", 138, 148], ["Pseudopterogorgia spp.", "SPECIES", 26, 48], ["P. acerosa", "SPECIES", 138, 148], ["a Pseudopterogorgia spp.", "PROBLEM", 24, 48], ["whose spicule analyses", "TEST", 62, 84]]], ["The structure of this alcohol was based upon spectral analyses and chemical interconversions.", [["alcohol", "CHEMICAL", 22, 29], ["alcohol", "CHEMICAL", 22, 29], ["alcohol", "SIMPLE_CHEMICAL", 22, 29], ["spectral analyses", "TEST", 45, 62]]], ["177 Tobagolide (215) is a nitrogenous pseudopterane derivative from a Tobago specimen of P. acerosa.", [["Tobagolide", "CHEMICAL", 4, 14], ["pseudopterane", "CHEMICAL", 38, 51], ["Tobagolide", "CHEMICAL", 4, 14], ["nitrogenous pseudopterane", "CHEMICAL", 26, 51], ["P. acerosa", "ORGANISM", 89, 99], ["P. acerosa", "SPECIES", 89, 99], ["P. acerosa", "SPECIES", 89, 99], ["a nitrogenous pseudopterane derivative", "TREATMENT", 24, 62]]], ["2D-NMR spectroscopy was used to establish the structure of tobagolide as the dimethylamino derivative 215.178 Pseudopterolide (212) can be transformed efficiently into tobagolide (215) by reaction with dimethylamine.", [["tobagolide", "CHEMICAL", 59, 69], ["dimethylamino", "CHEMICAL", 77, 90], ["Pseudopterolide", "CHEMICAL", 110, 125], ["tobagolide", "CHEMICAL", 168, 178], ["dimethylamine", "CHEMICAL", 202, 215], ["tobagolide", "CHEMICAL", 59, 69], ["dimethylamino", "CHEMICAL", 77, 90], ["Pseudopterolide", "CHEMICAL", 110, 125], ["tobagolide", "CHEMICAL", 168, 178], ["dimethylamine", "CHEMICAL", 202, 215], ["tobagolide", "SIMPLE_CHEMICAL", 59, 69], ["dimethylamino derivative 215.178 Pseudopterolide (212)", "SIMPLE_CHEMICAL", 77, 131], ["tobagolide (215)", "SIMPLE_CHEMICAL", 168, 184], ["dimethylamine", "SIMPLE_CHEMICAL", 202, 215], ["NMR spectroscopy", "TEST", 3, 19], ["tobagolide", "TREATMENT", 59, 69], ["the dimethylamino derivative", "TREATMENT", 73, 101], ["dimethylamine", "TREATMENT", 202, 215]]], ["Sequential treatment of tobagolide with methyl iodide and sodium hydride results in intramolecular SN' displacement with reconstruction of pseudopterolide.", [["tobagolide", "CHEMICAL", 24, 34], ["methyl iodide", "CHEMICAL", 40, 53], ["sodium hydride", "CHEMICAL", 58, 72], ["pseudopterolide", "CHEMICAL", 139, 154], ["tobagolide", "CHEMICAL", 24, 34], ["methyl iodide", "CHEMICAL", 40, 53], ["sodium hydride", "CHEMICAL", 58, 72], ["pseudopterolide", "CHEMICAL", 139, 154], ["tobagolide", "SIMPLE_CHEMICAL", 24, 34], ["methyl iodide", "SIMPLE_CHEMICAL", 40, 53], ["sodium hydride", "SIMPLE_CHEMICAL", 58, 72], ["pseudopterolide", "SIMPLE_CHEMICAL", 139, 154], ["tobagolide", "TREATMENT", 24, 34], ["methyl iodide", "TREATMENT", 40, 53], ["sodium hydride", "TREATMENT", 58, 72], ["intramolecular SN' displacement", "TREATMENT", 84, 115], ["reconstruction of pseudopterolide", "TREATMENT", 121, 154], ["intramolecular SN' displacement", "OBSERVATION", 84, 115]]], ["179,180 Two collections of P. acerosa from Tobago produced mixtures of acids that were esterified with diazomethane to obtain deoxypseudopterolide (216) and acerosolide (217) in the former collection and tobagolide (215) in the latter collection.", [["diazomethane", "CHEMICAL", 103, 115], ["deoxypseudopterolide", "CHEMICAL", 126, 146], ["acerosolide", "CHEMICAL", 157, 168], ["tobagolide", "CHEMICAL", 204, 214], ["diazomethane", "CHEMICAL", 103, 115], ["deoxypseudopterolide", "CHEMICAL", 126, 146], ["acerosolide", "CHEMICAL", 157, 168], ["tobagolide", "CHEMICAL", 204, 214], ["P. acerosa", "ORGANISM", 27, 37], ["diazomethane", "SIMPLE_CHEMICAL", 103, 115], ["deoxypseudopterolide", "SIMPLE_CHEMICAL", 126, 146], ["acerosolide", "SIMPLE_CHEMICAL", 157, 168], ["P. acerosa", "SPECIES", 27, 37], ["P. acerosa", "SPECIES", 27, 37], ["acids", "TREATMENT", 71, 76], ["diazomethane", "TREATMENT", 103, 115], ["deoxypseudopterolide", "TREATMENT", 126, 146], ["acerosolide", "TREATMENT", 157, 168], ["tobagolide", "TREATMENT", 204, 214], ["collections", "OBSERVATION_MODIFIER", 12, 23], ["P. acerosa", "OBSERVATION", 27, 37]]], ["The reported structural assignments for the pseudopterane 216 and the cembrane 217 were devoid of relevant stereochemistry and depended heavily on 2D-NMR spectroscopy.", [["pseudopterane 216", "CHEMICAL", 44, 61], ["pseudopterane 216", "CHEMICAL", 44, 61], ["pseudopterane 216", "SIMPLE_CHEMICAL", 44, 61], ["the pseudopterane", "TEST", 40, 57], ["the cembrane", "TEST", 66, 78], ["NMR spectroscopy", "TEST", 150, 166], ["stereochemistry", "OBSERVATION", 107, 122]]], ["181C.", [["181C", "PROTEIN", 0, 4]]], ["Pseudoplexaura porosa (Houttuyn)The relative stereochemistry shown for acerosolide (217) The structure of an additional pseudopterane, diepoxygorgiacerone (218) , isolated from the same specimen of P. acerosa, was determined by 2D-NMR methods and confirmed by X-ray analysis, which also established its relative stereochemistry.", [["specimen", "ANATOMY", 186, 194], ["acerosolide", "CHEMICAL", 71, 82], ["pseudopterane", "CHEMICAL", 120, 133], ["diepoxygorgiacerone", "CHEMICAL", 135, 154], ["acerosolide", "CHEMICAL", 71, 82], ["pseudopterane", "CHEMICAL", 120, 133], ["diepoxygorgiacerone", "CHEMICAL", 135, 154], ["Pseudoplexaura porosa", "ORGANISM", 0, 21], ["acerosolide (217)", "SIMPLE_CHEMICAL", 71, 88], ["pseudopterane", "SIMPLE_CHEMICAL", 120, 133], ["diepoxygorgiacerone (218)", "SIMPLE_CHEMICAL", 135, 160], ["P. acerosa", "ORGANISM", 198, 208], ["Pseudoplexaura porosa", "SPECIES", 0, 21], ["P. acerosa", "SPECIES", 198, 208], ["Pseudoplexaura porosa", "SPECIES", 0, 21], ["P. acerosa", "SPECIES", 198, 208], ["acerosolide", "TREATMENT", 71, 82], ["an additional pseudopterane, diepoxygorgiacerone", "TREATMENT", 106, 154], ["P. acerosa", "PROBLEM", 198, 208], ["NMR methods", "TEST", 231, 242], ["X-ray analysis", "TEST", 260, 274]]], ["This compound is an unusually stable diepoxyfuran derivative.", [["diepoxyfuran", "CHEMICAL", 37, 49], ["diepoxyfuran", "CHEMICAL", 37, 49], ["diepoxyfuran derivative", "SIMPLE_CHEMICAL", 37, 60], ["diepoxyfuran derivative", "TREATMENT", 37, 60], ["unusually", "OBSERVATION_MODIFIER", 20, 29], ["stable", "OBSERVATION_MODIFIER", 30, 36], ["diepoxyfuran derivative", "OBSERVATION", 37, 60]]], ["184 Six more pseudopteranoids, namely pseudopterolide-methanol adduct (219), gorgiacerone (220), gorgiacerodiol (221), methoxygorgiacerol (222) , isogorgiacerodiol (223) , and bis(gorgiacerol) amine (224) were also isolated from P. acerosa collected around the coast of Tobago and were identified by interpretation of spectral data.", [["pseudopteranoids", "CHEMICAL", 13, 29], ["pseudopterolide-methanol adduct", "CHEMICAL", 38, 69], ["gorgiacerone", "CHEMICAL", 77, 89], ["gorgiacerodiol", "CHEMICAL", 97, 111], ["methoxygorgiacerol", "CHEMICAL", 119, 137], ["isogorgiacerodiol", "CHEMICAL", 146, 163], ["bis", "CHEMICAL", 176, 179], ["gorgiacerol", "CHEMICAL", 180, 191], ["amine", "CHEMICAL", 193, 198], ["pseudopteranoids", "CHEMICAL", 13, 29], ["pseudopterolide", "CHEMICAL", 38, 53], ["methanol", "CHEMICAL", 54, 62], ["gorgiacerone", "CHEMICAL", 77, 89], ["gorgiacerodiol", "CHEMICAL", 97, 111], ["methoxygorgiacerol", "CHEMICAL", 119, 137], ["isogorgiacerodiol", "CHEMICAL", 146, 163], ["bis(gorgiacerol) amine", "CHEMICAL", 176, 198], ["pseudopterolide-methanol adduct", "SIMPLE_CHEMICAL", 38, 69], ["219)", "SIMPLE_CHEMICAL", 71, 75], ["gorgiacerone (220)", "SIMPLE_CHEMICAL", 77, 95], ["gorgiacerodiol (221)", "SIMPLE_CHEMICAL", 97, 117], ["methoxygorgiacerol (222)", "SIMPLE_CHEMICAL", 119, 143], ["isogorgiacerodiol (223)", "SIMPLE_CHEMICAL", 146, 169], ["bis(gorgiacerol) amine (224)", "SIMPLE_CHEMICAL", 176, 204], ["P. acerosa", "ORGANISM", 229, 239], ["P. acerosa", "SPECIES", 229, 239], ["P. acerosa", "SPECIES", 229, 239], ["namely pseudopterolide-methanol adduct", "TREATMENT", 31, 69], ["gorgiacerone", "TREATMENT", 77, 89], ["gorgiacerodiol", "TREATMENT", 97, 111], ["methoxygorgiacerol", "TREATMENT", 119, 137], ["isogorgiacerodiol", "TREATMENT", 146, 163], ["bis(gorgiacerol) amine", "TREATMENT", 176, 198], ["spectral data", "TEST", 318, 331]]], ["185 The total synthesis of gorgiacerone (220) The weU-known carotenoid peridinin (225) was isolated from a sample ofP. acerosa collected on the north coast of Tobago.", [["gorgiacerone", "CHEMICAL", 27, 39], ["peridinin", "CHEMICAL", 71, 80], ["gorgiacerone", "CHEMICAL", 27, 39], ["peridinin", "CHEMICAL", 71, 80], ["gorgiacerone (220)", "SIMPLE_CHEMICAL", 27, 45], ["carotenoid peridinin", "SIMPLE_CHEMICAL", 60, 80], ["gorgiacerone", "TEST", 27, 39]]], ["After preliminary characterization by conventional spectral methods, the unambiguous 1H-and 13C-NMR assignments of peridinin were carded out.", [["peridinin", "CHEMICAL", 115, 124], ["1H", "CHEMICAL", 85, 87], ["13C", "CHEMICAL", 92, 95], ["peridinin", "CHEMICAL", 115, 124], ["1H", "SIMPLE_CHEMICAL", 85, 87], ["13C", "SIMPLE_CHEMICAL", 92, 95], ["peridinin", "SIMPLE_CHEMICAL", 115, 124], ["the unambiguous 1H", "TEST", 69, 87], ["peridinin", "TREATMENT", 115, 124]]], ["186 The total synthesis of peridinin has been reported.", [["peridinin", "CHEMICAL", 27, 36], ["peridinin", "CHEMICAL", 27, 36], ["peridinin", "SIMPLE_CHEMICAL", 27, 36], ["The total synthesis of peridinin", "TREATMENT", 4, 36]]], ["[187] [188] [189] Further investigations of the polar extracts of this gorgonian led to the isolation and structure determination of the tetrahydroxysterol 226.", [["extracts", "ANATOMY", 54, 62], ["tetrahydroxysterol 226", "CHEMICAL", 137, 159], ["tetrahydroxysterol 226", "CHEMICAL", 137, 159], ["extracts", "ORGANISM_SUBSTANCE", 54, 62], ["tetrahydroxysterol 226", "SIMPLE_CHEMICAL", 137, 159], ["Further investigations", "TEST", 18, 40], ["this gorgonian", "PROBLEM", 66, 80], ["the isolation", "TREATMENT", 88, 101], ["the tetrahydroxysterol", "TREATMENT", 133, 155]]], ["The structure of acerosterol (226) was determined on the basis of spectral data.", [["acerosterol", "CHEMICAL", 17, 28], ["acerosterol", "CHEMICAL", 17, 28], ["acerosterol (226)", "SIMPLE_CHEMICAL", 17, 34], ["spectral data", "TEST", 66, 79]]], ["190C.", [["190C", "PROTEIN", 0, 4]]], ["Pseudoplexaura porosa (Houttuyn)Assays on coral reefs have demonstrated that the crude lipid extract of P. acerosa collected at the Grenadine Islands and Belize, deterred natural predators at concentrations below their normal levels in gorgonian tissues.C. Pseudoplexaura porosa (Houttuyn)Assays conducted with purified sclerites from P. acerosa showed that the sclerites alone also function effectively to reduce predation on otherwise palatable food.", [["gorgonian tissues", "ANATOMY", 236, 253], ["sclerites", "ANATOMY", 362, 371], ["Pseudoplexaura porosa", "ORGANISM", 0, 21], ["P. acerosa", "ORGANISM", 104, 114], ["gorgonian tissues", "TISSUE", 236, 253], ["Pseudoplexaura porosa", "ORGANISM", 257, 278], ["P. acerosa", "ORGANISM", 335, 345], ["Pseudoplexaura porosa", "SPECIES", 0, 21], ["P. acerosa", "SPECIES", 104, 114], ["C. Pseudoplexaura porosa", "SPECIES", 254, 278], ["P. acerosa", "SPECIES", 335, 345], ["Pseudoplexaura porosa", "SPECIES", 0, 21], ["P. acerosa", "SPECIES", 104, 114], ["C. Pseudoplexaura porosa", "SPECIES", 254, 278], ["P. acerosa", "SPECIES", 335, 345], ["the crude lipid extract", "TREATMENT", 77, 100], ["P. acerosa", "PROBLEM", 104, 114], ["Assays", "TEST", 289, 295], ["purified sclerites", "PROBLEM", 311, 329], ["P. acerosa", "TEST", 335, 345], ["the sclerites", "PROBLEM", 358, 371], ["normal", "OBSERVATION", 219, 225], ["gorgonian tissues", "OBSERVATION", 236, 253]]], ["191, 192 Similar results were also obtained with the crude lipid extracts of the Caribbean gorgonian P. rigida collected at the same sites.", [["extracts", "ANATOMY", 65, 73], ["lipid extracts", "ORGANISM_SUBSTANCE", 59, 73], ["P. rigida", "ORGANISM", 101, 110], ["P. rigida", "SPECIES", 101, 110], ["P. rigida", "SPECIES", 101, 110], ["the crude lipid extracts", "TREATMENT", 49, 73]]], ["(229) , and (x-chamigrene (231), a new compound, l,l-dimethyl-7-isopropylidene-l,2,3,4,5,6,7,8-octahydronaphthalene (232) .", [["x-chamigrene", "CHEMICAL", 13, 25], ["l,l-dimethyl-7-isopropylidene-l,2,3,4,5,6,7,8-octahydronaphthalene", "CHEMICAL", 49, 115], ["(x-chamigrene", "CHEMICAL", 12, 25], ["l,l-dimethyl-7-isopropylidene-l,2,3,4,5,6,7,8-octahydronaphthalene", "CHEMICAL", 49, 115], ["(x-chamigrene (231)", "SIMPLE_CHEMICAL", 12, 31], ["l,l-dimethyl-7-isopropylidene-l,2,3,4,5,6,7,8-octahydronaphthalene", "SIMPLE_CHEMICAL", 49, 115], ["a new compound", "PROBLEM", 33, 47], ["dimethyl", "TREATMENT", 53, 61], ["isopropylidene", "TREATMENT", 64, 78]]], ["The latter compound was given the trivial name caridiene.", [["caridiene", "CHEMICAL", 47, 56], ["caridiene", "CHEMICAL", 47, 56], ["caridiene", "SIMPLE_CHEMICAL", 47, 56], ["the trivial name caridiene", "TREATMENT", 30, 56]]], ["The structure of 232 was elucidated by interpretation of spectroscopic data.", [["spectroscopic data", "TEST", 57, 75]]], ["194 Two short syntheses of (+)-ct-chamigrene have been reported.", [["(+)-ct-chamigrene", "CHEMICAL", 27, 44], ["(+)-ct-chamigrene", "SIMPLE_CHEMICAL", 27, 44], ["Two short syntheses", "TEST", 4, 23], ["ct-chamigrene", "TEST", 31, 44]]], ["195, 196 Norzooanemonin (233) was isolated from the alcohol extract of P. americana (Florida Keys) by ion exchange followed by alumina chromatography.", [["195, 196 Norzooanemonin (233", "CHEMICAL", 0, 28], ["alcohol", "CHEMICAL", 52, 59], ["Norzooanemonin", "CHEMICAL", 9, 23], ["alcohol", "CHEMICAL", 52, 59], ["alumina", "CHEMICAL", 127, 134], ["Norzooanemonin (233)", "SIMPLE_CHEMICAL", 9, 29], ["alcohol", "SIMPLE_CHEMICAL", 52, 59], ["P. americana", "ORGANISM", 71, 83], ["ion", "SIMPLE_CHEMICAL", 102, 105], ["P. americana", "SPECIES", 71, 83], ["P. americana", "SPECIES", 71, 83], ["Norzooanemonin", "TEST", 9, 23], ["alumina chromatography", "TEST", 127, 149]]], ["Its structure was deduced from its elemental composition and spectral features and has been confirmed by synthesis.", [["elemental composition", "OBSERVATION_MODIFIER", 35, 56]]], ["197 In addition to norzooanemonin, the betaine fraction contained a mixture that appeared from its NMR spectrum to consist of trigonelline (N-methyl nicotinic acid betaine) and possibly homarine (N-methyl ct-picolinic acid betaine).", [["norzooanemonin", "CHEMICAL", 19, 33], ["betaine", "CHEMICAL", 39, 46], ["trigonelline", "CHEMICAL", 126, 138], ["N-methyl nicotinic acid betaine", "CHEMICAL", 140, 171], ["homarine", "CHEMICAL", 186, 194], ["N-methyl ct-picolinic acid betaine", "CHEMICAL", 196, 230], ["norzooanemonin", "CHEMICAL", 19, 33], ["betaine", "CHEMICAL", 39, 46], ["trigonelline", "CHEMICAL", 126, 138], ["N-methyl nicotinic acid betaine", "CHEMICAL", 140, 171], ["homarine", "CHEMICAL", 186, 194], ["N-methyl ct-picolinic acid betaine", "CHEMICAL", 196, 230], ["norzooanemonin", "SIMPLE_CHEMICAL", 19, 33], ["betaine", "SIMPLE_CHEMICAL", 39, 46], ["trigonelline", "SIMPLE_CHEMICAL", 126, 138], ["N-methyl nicotinic acid", "SIMPLE_CHEMICAL", 140, 163], ["betaine", "SIMPLE_CHEMICAL", 164, 171], ["homarine", "SIMPLE_CHEMICAL", 186, 194], ["N-methyl ct-picolinic acid betaine", "SIMPLE_CHEMICAL", 196, 230], ["norzooanemonin", "TREATMENT", 19, 33], ["the betaine fraction", "PROBLEM", 35, 55], ["trigonelline (N-methyl nicotinic acid betaine", "TREATMENT", 126, 171], ["homarine", "TEST", 186, 194], ["methyl ct-picolinic acid betaine", "TREATMENT", 198, 230]]], ["197 The proposed structure for furanogermacrene derivative 234, which was isolated from extracts of P.C. Pseudopterogorgia bipinnata (Verrill)(Bipinnate sea feathe0C.", [["extracts", "ANATOMY", 88, 96], ["furanogermacrene derivative 234", "CHEMICAL", 31, 62], ["furanogermacrene", "CHEMICAL", 31, 47], ["furanogermacrene derivative 234", "SIMPLE_CHEMICAL", 31, 62], ["extracts", "ORGANISM_SUBSTANCE", 88, 96], ["P.C. Pseudopterogorgia bipinnata", "ORGANISM", 100, 132], ["Bipinnate sea feathe0C", "ORGANISM", 143, 165], ["P.C.", "SPECIES", 100, 104], ["Pseudopterogorgia bipinnata", "SPECIES", 105, 132], ["Pseudopterogorgia bipinnata", "SPECIES", 105, 132], ["furanogermacrene derivative", "TREATMENT", 31, 58]]], ["Pseudopterogorgia bipinnata (Verrill)The gorgonian Pseudopterogorgia bipinnata, a widely distributed member of the genus Pseudopterogorgia, produces a large variety of cembrene derivatives somewhat dependent upon collection site.", [["cembrene", "CHEMICAL", 168, 176], ["cembrene", "CHEMICAL", 168, 176], ["Pseudopterogorgia bipinnata", "ORGANISM", 0, 27], ["gorgonian Pseudopterogorgia bipinnata", "ORGANISM", 41, 78], ["cembrene derivatives", "SIMPLE_CHEMICAL", 168, 188], ["Pseudopterogorgia bipinnata", "SPECIES", 0, 27], ["Pseudopterogorgia bipinnata", "SPECIES", 51, 78], ["Pseudopterogorgia bipinnata", "SPECIES", 0, 27], ["Pseudopterogorgia bipinnata", "SPECIES", 51, 78], ["Pseudopterogorgia bipinnata", "PROBLEM", 0, 27], ["The gorgonian Pseudopterogorgia bipinnata", "PROBLEM", 37, 78], ["cembrene derivatives", "TREATMENT", 168, 188], ["collection site", "PROBLEM", 213, 228], ["gorgonian Pseudopterogorgia", "OBSERVATION", 41, 68], ["widely", "OBSERVATION_MODIFIER", 82, 88], ["genus Pseudopterogorgia", "OBSERVATION", 115, 138], ["large", "OBSERVATION_MODIFIER", 151, 156], ["variety", "OBSERVATION_MODIFIER", 157, 164], ["cembrene derivatives", "OBSERVATION", 168, 188]]], ["The characteristic of Pseudopterogorgia cembrenes is their rather high levels of oxygenation.", [["Pseudopterogorgia cembrenes", "ORGANISM", 22, 49], ["Pseudopterogorgia cembrenes", "SPECIES", 22, 49], ["Pseudopterogorgia cembrenes", "PROBLEM", 22, 49], ["Pseudopterogorgia cembrenes", "OBSERVATION", 22, 49], ["high", "OBSERVATION_MODIFIER", 66, 70], ["levels", "OBSERVATION_MODIFIER", 71, 77], ["oxygenation", "OBSERVATION_MODIFIER", 81, 92]]], ["Two cembrene derivatives, the bipinnatolides 242 and 243, were found to have antiinflammatory activity with potency equivalent to that of indomethacin.", [["cembrene", "CHEMICAL", 4, 12], ["bipinnatolides 242 and 243", "CHEMICAL", 30, 56], ["indomethacin", "CHEMICAL", 138, 150], ["cembrene", "CHEMICAL", 4, 12], ["bipinnatolides", "CHEMICAL", 30, 44], ["indomethacin", "CHEMICAL", 138, 150], ["cembrene derivatives", "SIMPLE_CHEMICAL", 4, 24], ["bipinnatolides 242", "SIMPLE_CHEMICAL", 30, 48], ["243", "SIMPLE_CHEMICAL", 53, 56], ["indomethacin", "SIMPLE_CHEMICAL", 138, 150], ["Two cembrene derivatives", "TREATMENT", 0, 24], ["the bipinnatolides", "TEST", 26, 44], ["indomethacin", "TREATMENT", 138, 150]]], ["Their structures were established by spectroscopic, X-ray, and chemical methods.", [["spectroscopic, X-ray", "TEST", 37, 57]]], ["200 Reportedly, over fifteen cembrane derivatives have been isolated from P. bipinnata but neither their structures nor the spectral data for 242 and 243, appear to have been reported.", [["cembrane", "CHEMICAL", 29, 37], ["cembrane derivatives", "SIMPLE_CHEMICAL", 29, 49], ["P. bipinnata", "ORGANISM", 74, 86], ["P. bipinnata", "SPECIES", 74, 86], ["P. bipinnata", "SPECIES", 74, 86], ["fifteen cembrane derivatives", "TREATMENT", 21, 49], ["the spectral data", "TEST", 120, 137]]], ["T T -o=, CH3 .,~ CH3 The structure of pseudopterosin F (268) was determined by X-ray analysis, and the remaining compounds were identified by spectroscopic methods.", [["CH3", "CHEMICAL", 17, 20], ["pseudopterosin F (268", "CHEMICAL", 38, 59], ["CH3", "CHEMICAL", 17, 20], ["pseudopterosin F", "CHEMICAL", 38, 54], ["pseudopterosin F (268)", "SIMPLE_CHEMICAL", 38, 60], ["CH3", "PROTEIN", 17, 20], ["X-ray analysis", "TEST", 79, 93]]], ["217 Pseudopterosin E (267) has superior antiinflammatory properties to those of other compounds in this series, is less toxic, and appears to act by a novel mechanism.", [["Pseudopterosin E (267", "CHEMICAL", 4, 25], ["Pseudopterosin E", "CHEMICAL", 4, 20], ["Pseudopterosin E", "SIMPLE_CHEMICAL", 4, 20], ["superior antiinflammatory properties", "TREATMENT", 31, 67], ["less toxic", "OBSERVATION_MODIFIER", 115, 125]]], ["Two enantiospecific syntheses of pseudopterosin E from (1S,2R,5S)-(+)-mentho1212 and from (S)-citronella1213 have been outlined.C. Pseudopterogorgia bipinnata (Verrill)The aglycone of pseudopterosin E (267) has been synthesized from 5-methoxytetralone.", [["pseudopterosin E", "CHEMICAL", 33, 49], ["aglycone", "CHEMICAL", 172, 180], ["pseudopterosin E", "CHEMICAL", 184, 200], ["5-methoxytetralone", "CHEMICAL", 233, 251], ["pseudopterosin E", "CHEMICAL", 33, 49], ["(1S,2R,5S)-(+)-mentho1212", "CHEMICAL", 55, 80], ["(S)-citronella1213", "CHEMICAL", 90, 108], ["pseudopterosin E", "CHEMICAL", 184, 200], ["5-methoxytetralone", "CHEMICAL", 233, 251], ["pseudopterosin E", "SIMPLE_CHEMICAL", 33, 49], ["(1S,2R,5S)-(+)-mentho1212", "SIMPLE_CHEMICAL", 55, 80], ["(S)-citronella1213", "SIMPLE_CHEMICAL", 90, 108], ["C.", "ORGANISM", 128, 130], ["Pseudopterogorgia bipinnata", "ORGANISM", 131, 158], ["aglycone", "SIMPLE_CHEMICAL", 172, 180], ["pseudopterosin E (267)", "SIMPLE_CHEMICAL", 184, 206], ["5-methoxytetralone", "SIMPLE_CHEMICAL", 233, 251], ["C.", "SPECIES", 128, 130], ["Pseudopterogorgia bipinnata", "SPECIES", 131, 158], ["C. Pseudopterogorgia bipinnata", "SPECIES", 128, 158], ["pseudopterosin E", "PROBLEM", 33, 49], ["citronella", "TREATMENT", 94, 104], ["C. Pseudopterogorgia bipinnata", "PROBLEM", 128, 158], ["methoxytetralone", "TREATMENT", 235, 251], ["enantiospecific syntheses", "OBSERVATION", 4, 29]]], ["218F.", [["218F.", "CHEMICAL", 0, 5]]], ["Pseudopterogorgia rigida (Bieischowsky)The gorgonian Pseudopterogorgia rigida can be easily distinguished from the more abundant P. americana because it is non-slimy and sparsely branched.", [["Pseudopterogorgia rigida", "ORGANISM", 0, 24], ["Pseudopterogorgia rigida", "ORGANISM", 53, 77], ["P. americana", "ORGANISM", 129, 141], ["Pseudopterogorgia rigida", "SPECIES", 0, 24], ["Pseudopterogorgia rigida", "SPECIES", 53, 77], ["P. americana", "SPECIES", 129, 141], ["Pseudopterogorgia rigida", "SPECIES", 0, 24], ["Pseudopterogorgia rigida", "SPECIES", 53, 77], ["P. americana", "SPECIES", 129, 141], ["Pseudopterogorgia rigida", "PROBLEM", 0, 24], ["The gorgonian Pseudopterogorgia rigida", "PROBLEM", 39, 77], ["sparsely", "OBSERVATION_MODIFIER", 170, 178], ["branched", "OBSERVATION_MODIFIER", 179, 187]]], ["The characteristic sesquiterpene components of P. rigida are the ct, 1~, and y-bisabolenes and (-)-ct-curcumene (175) .", [["sesquiterpene", "CHEMICAL", 19, 32], ["ct, 1~, and y-bisabolenes and (-)-ct-curcumene", "CHEMICAL", 65, 111], ["sesquiterpene", "CHEMICAL", 19, 32], ["y-bisabolenes", "CHEMICAL", 77, 90], ["(-)-ct-curcumene", "CHEMICAL", 95, 111], ["P. rigida", "ORGANISM", 47, 56], ["y-bisabolenes", "SIMPLE_CHEMICAL", 77, 90], ["(-)-ct-curcumene", "SIMPLE_CHEMICAL", 95, 111], ["P. rigida", "SPECIES", 47, 56], ["P. rigida", "SPECIES", 47, 56], ["the ct", "TEST", 61, 67], ["y-bisabolenes", "TEST", 77, 90], ["sesquiterpene components", "OBSERVATION", 19, 43]]], ["223 Three derivatives of the aromatic sesquiterpene \u00a2xcurcumene, (-)-curcuphenol (282), (-)-curcuquinone (283), and (-)-cureuhydroquinone (284), are, collectively, responsible for the antibiotic properties of P. rigida.", [["aromatic sesquiterpene", "CHEMICAL", 29, 51], ["\u00a2xcurcumene", "CHEMICAL", 52, 63], ["curcuphenol", "CHEMICAL", 69, 80], ["curcuquinone", "CHEMICAL", 92, 104], ["cureuhydroquinone", "CHEMICAL", 120, 137], ["aromatic sesquiterpene", "CHEMICAL", 29, 51], ["\u00a2xcurcumene", "CHEMICAL", 52, 63], ["(-)-curcuphenol", "CHEMICAL", 65, 80], ["(-)-curcuquinone", "CHEMICAL", 88, 104], ["(-)-cureuhydroquinone", "CHEMICAL", 116, 137], ["aromatic sesquiterpene \u00a2xcurcumene", "SIMPLE_CHEMICAL", 29, 63], ["(-)-curcuphenol (282)", "SIMPLE_CHEMICAL", 65, 86], ["(-)-curcuquinone (283)", "SIMPLE_CHEMICAL", 88, 110], ["(-)-cureuhydroquinone (284)", "SIMPLE_CHEMICAL", 116, 143], ["P. rigida", "ORGANISM", 209, 218], ["P. rigida", "SPECIES", 209, 218], ["P. rigida", "SPECIES", 209, 218], ["the aromatic sesquiterpene \u00a2xcurcumene", "TEST", 25, 63], ["the antibiotic properties", "TREATMENT", 180, 205], ["P. rigida", "PROBLEM", 209, 218]]], ["The structures of these antibacterial metabolites were elucidated by spectral analysis and chemical interconversions.", [["these antibacterial metabolites", "TEST", 18, 49], ["spectral analysis", "TEST", 69, 86], ["antibacterial metabolites", "OBSERVATION", 24, 49]]], ["The branches of P. citrina are flattened, and the colony is low and sparsely branched.", [["colony", "ANATOMY", 50, 56], ["P. citrina", "ORGANISM", 16, 26], ["P. citrina", "SPECIES", 16, 26], ["P. citrina", "SPECIES", 16, 26], ["P. citrina", "TEST", 16, 26], ["branches", "ANATOMY_MODIFIER", 4, 12], ["P. citrina", "OBSERVATION", 16, 26], ["flattened", "OBSERVATION_MODIFIER", 31, 40], ["colony", "OBSERVATION_MODIFIER", 50, 56], ["low", "OBSERVATION_MODIFIER", 60, 63], ["sparsely", "OBSERVATION_MODIFIER", 68, 76], ["branched", "OBSERVATION_MODIFIER", 77, 85]]], ["The colonies of P. anceps, however, are bushy and more profusely branched, and larger.", [["colonies", "ANATOMY", 4, 12], ["P. anceps", "ORGANISM", 16, 25], ["P. anceps", "SPECIES", 16, 25], ["P. anceps", "SPECIES", 16, 25], ["P. anceps", "TEST", 16, 25], ["P. anceps", "OBSERVATION", 16, 25], ["bushy", "OBSERVATION_MODIFIER", 40, 45], ["more", "OBSERVATION_MODIFIER", 50, 54], ["profusely", "OBSERVATION_MODIFIER", 55, 64], ["branched", "OBSERVATION_MODIFIER", 65, 73], ["larger", "OBSERVATION_MODIFIER", 79, 85]]], ["Sea whips of this genus are usually rich in polymethylene butenolides.", [["polymethylene butenolides", "CHEMICAL", 44, 69], ["polymethylene butenolides", "CHEMICAL", 44, 69], ["polymethylene butenolides", "SIMPLE_CHEMICAL", 44, 69], ["polymethylene butenolides", "TREATMENT", 44, 69]]], ["On the other hand, they appear to have an insignificant hydrocarbon content.", [["hydrocarbon", "CHEMICAL", 56, 67], ["hydrocarbon", "SIMPLE_CHEMICAL", 56, 67], ["an insignificant hydrocarbon content", "PROBLEM", 39, 75], ["insignificant", "OBSERVATION_MODIFIER", 42, 55], ["hydrocarbon content", "OBSERVATION", 56, 75]]], ["Pterogorgia (Xiphigorgia)anceps (Pallas)(Angular sea whip)A. Pterogorgia (Xiphigorgia)anceps (Pallas)The major component from the pentane extracts of Pterogorgia anceps collected in Bimini, Bahamas, was identified as ancepsenolide (285).", [["extracts", "ANATOMY", 138, 146], ["Pterogorgia", "CHEMICAL", 0, 11], ["pentane", "CHEMICAL", 130, 137], ["Pterogorgia anceps", "CHEMICAL", 150, 168], ["ancepsenolide", "CHEMICAL", 217, 230], ["pentane", "CHEMICAL", 130, 137], ["ancepsenolide", "CHEMICAL", 217, 230], ["Pterogorgia", "ORGANISM", 0, 11], ["Xiphigorgia)anceps", "ORGANISM", 13, 31], ["Pallas)", "ORGANISM", 33, 40], ["Angular sea whip", "ORGANISM", 41, 57], ["A. Pterogorgia", "ORGANISM", 58, 72], ["Xiphigorgia)anceps", "ORGANISM", 74, 92], ["pentane extracts", "ORGANISM_SUBSTANCE", 130, 146], ["Pterogorgia anceps", "ORGANISM", 150, 168], ["ancepsenolide", "SIMPLE_CHEMICAL", 217, 230], ["Pterogorgia", "SPECIES", 0, 11], ["Xiphigorgia)anceps", "SPECIES", 13, 31], ["A. Pterogorgia", "SPECIES", 58, 72], ["Xiphigorgia)anceps", "SPECIES", 74, 92], ["Pterogorgia anceps", "SPECIES", 150, 168], ["Xiphigorgia)anceps", "SPECIES", 13, 31], ["Pterogorgia anceps", "SPECIES", 150, 168], ["Pterogorgia", "TEST", 0, 11], ["Xiphigorgia", "TEST", 13, 24], ["anceps", "TEST", 25, 31], ["Angular sea whip", "TEST", 41, 57], ["the pentane extracts", "TEST", 126, 146], ["Pterogorgia anceps", "TEST", 150, 168]]], ["20 The structure of this crystalline bisbutenolide was elucidated by interpretation of spectroscopic data and by chemical degradation.", [["bisbutenolide", "CHEMICAL", 37, 50], ["bisbutenolide", "CHEMICAL", 37, 50], ["bisbutenolide", "SIMPLE_CHEMICAL", 37, 50], ["this crystalline bisbutenolide", "TEST", 20, 50], ["spectroscopic data", "TEST", 87, 105]]], ["226 Three total syntheses for ancepsenolide have been reported.", [["ancepsenolide", "CHEMICAL", 30, 43], ["ancepsenolide", "CHEMICAL", 30, 43], ["ancepsenolide", "SIMPLE_CHEMICAL", 30, 43], ["Three total syntheses", "TREATMENT", 4, 25], ["ancepsenolide", "TREATMENT", 30, 43]]], ["227-229 The latest synthesis, which proceeded in 31% overall yield in seven steps, established the absolute stereochemistry of ancepsenolide as 5S, 5'S. 229 Another dilactone, hydroxyancepsenolide (286), was later isolated from this same organism and its structure was identified by spectroscopic and chemical methods.", [["227-229", "CHEMICAL", 0, 7], ["ancepsenolide", "CHEMICAL", 127, 140], ["dilactone", "CHEMICAL", 165, 174], ["hydroxyancepsenolide", "CHEMICAL", 176, 196], ["ancepsenolide", "CHEMICAL", 127, 140], ["dilactone", "CHEMICAL", 165, 174], ["hydroxyancepsenolide", "CHEMICAL", 176, 196], ["ancepsenolide", "SIMPLE_CHEMICAL", 127, 140], ["dilactone", "SIMPLE_CHEMICAL", 165, 174], ["hydroxyancepsenolide (286)", "SIMPLE_CHEMICAL", 176, 202], ["The latest synthesis", "TEST", 8, 28], ["ancepsenolide", "TREATMENT", 127, 140], ["Another dilactone", "TREATMENT", 157, 174], ["hydroxyancepsenolide", "TREATMENT", 176, 196], ["absolute stereochemistry", "OBSERVATION", 99, 123]]], ["230A.", [["230A", "CHEMICAL", 0, 4]]], ["Pterogorgia (Xiphigorgia)anceps (Pallas)Field and laboratory experiments have demonstrated the feeding-deterrent properties of lipid-soluble extracts of the octocoral P. anceps.", [["extracts", "ANATOMY", 141, 149], ["Pterogorgia", "CHEMICAL", 0, 11], ["Pterogorgia", "ORGANISM", 0, 11], ["Xiphigorgia)anceps", "ORGANISM", 13, 31], ["lipid", "SIMPLE_CHEMICAL", 127, 132], ["extracts", "ORGANISM_SUBSTANCE", 141, 149], ["P. anceps", "ORGANISM", 167, 176], ["Pterogorgia", "SPECIES", 0, 11], ["P. anceps", "SPECIES", 167, 176], ["P. anceps", "SPECIES", 167, 176], ["Pterogorgia", "TEST", 0, 11], ["laboratory experiments", "TEST", 50, 72], ["lipid-soluble extracts", "TREATMENT", 127, 149]]], ["Bioassay-directed fractionation of these extracts revealed that the deterrent property was restricted to an ancepsenolide-containing fraction.", [["extracts", "ANATOMY", 41, 49], ["ancepsenolide", "CHEMICAL", 108, 121], ["ancepsenolide", "CHEMICAL", 108, 121], ["extracts", "ORGANISM_SUBSTANCE", 41, 49], ["ancepsenolide", "SIMPLE_CHEMICAL", 108, 121], ["Bioassay", "TEST", 0, 8], ["an ancepsenolide-containing fraction", "TREATMENT", 105, 141]]], ["TM Two additional acetogenin class compounds from two collections of P. anceps, one near the reefs surrounding the Bahama Island of San Salvador and a second from 4606 A.D. RODR[GUEZ Belizian waters, have been reported.", [["acetogenin", "CHEMICAL", 18, 28], ["acetogenin", "CHEMICAL", 18, 28], ["P. anceps", "ORGANISM", 69, 78], ["P. anceps", "SPECIES", 69, 78], ["P. anceps", "SPECIES", 69, 78], ["Two additional acetogenin class compounds", "PROBLEM", 3, 44], ["P. anceps", "PROBLEM", 69, 78], ["two", "OBSERVATION_MODIFIER", 50, 53], ["collections", "OBSERVATION_MODIFIER", 54, 65], ["reefs", "OBSERVATION", 93, 98]]], ["The structures of 287 and 288, however, have not been elucidated nor their spectroscopic data reported.", [["their spectroscopic data", "TEST", 69, 93], ["structures", "ANATOMY_MODIFIER", 4, 14]]], ["231 Laboratory assays of purified metabolites isolated from P. anceps revealed a substantial feeding-inhibitory effect, which was restricted to the ancepsenolide diacetoxy derivative 288.", [["ancepsenolide diacetoxy derivative 288", "CHEMICAL", 148, 186], ["ancepsenolide diacetoxy", "CHEMICAL", 148, 171], ["P. anceps", "ORGANISM", 60, 69], ["ancepsenolide diacetoxy derivative 288", "SIMPLE_CHEMICAL", 148, 186], ["P. anceps", "SPECIES", 60, 69], ["P. anceps", "SPECIES", 60, 69], ["Laboratory assays", "TEST", 4, 21], ["purified metabolites", "TEST", 25, 45], ["P. anceps", "TEST", 60, 69], ["the ancepsenolide diacetoxy derivative", "TREATMENT", 144, 182], ["substantial", "OBSERVATION_MODIFIER", 81, 92], ["inhibitory effect", "OBSERVATION", 101, 118]]], ["The structure of 296, which has been given the trivial name guadalupensic acid diacetate, 157 was proposed on the basis of spectroscopic data and conversion to ancepsenolide.", [["guadalupensic acid diacetate", "CHEMICAL", 60, 88], ["ancepsenolide", "CHEMICAL", 160, 173], ["guadalupensic acid diacetate", "CHEMICAL", 60, 88], ["ancepsenolide", "CHEMICAL", 160, 173], ["guadalupensic acid diacetate", "SIMPLE_CHEMICAL", 60, 88], ["ancepsenolide", "SIMPLE_CHEMICAL", 160, 173], ["the trivial name guadalupensic acid diacetate", "TREATMENT", 43, 88], ["spectroscopic data", "TEST", 123, 141], ["ancepsenolide", "TREATMENT", 160, 173]]], ["Lactone 296 exhibited mild antibiotic activity against Staphylococcus aureus and Mycobacterium smegmatis.", [["Lactone 296", "CHEMICAL", 0, 11], ["Staphylococcus aureus", "DISEASE", 55, 76], ["Lactone 296", "CHEMICAL", 0, 11], ["Lactone 296", "SIMPLE_CHEMICAL", 0, 11], ["Staphylococcus aureus", "ORGANISM", 55, 76], ["Mycobacterium smegmatis", "ORGANISM", 81, 104], ["Staphylococcus aureus", "SPECIES", 55, 76], ["Mycobacterium smegmatis", "SPECIES", 81, 104], ["Staphylococcus aureus", "SPECIES", 55, 76], ["Mycobacterium smegmatis", "SPECIES", 81, 104], ["Lactone", "TEST", 0, 7], ["mild antibiotic activity", "TREATMENT", 22, 46], ["Staphylococcus aureus", "PROBLEM", 55, 76], ["Mycobacterium smegmatis", "PROBLEM", 81, 104], ["mild", "OBSERVATION_MODIFIER", 22, 26], ["antibiotic activity", "OBSERVATION_MODIFIER", 27, 46], ["Mycobacterium smegmatis", "OBSERVATION", 81, 104]]], ["In general, gorgonians from this region appear to be quite consistent in that near 89% of their metabolites are terpenoid and only 1.4% and 5.2%, respectively, contain nitrogen or chlorine.", [["nitrogen", "CHEMICAL", 168, 176], ["chlorine", "CHEMICAL", 180, 188], ["terpenoid", "CHEMICAL", 112, 121], ["nitrogen", "CHEMICAL", 168, 176], ["chlorine", "CHEMICAL", 180, 188], ["nitrogen", "SIMPLE_CHEMICAL", 168, 176], ["chlorine", "SIMPLE_CHEMICAL", 180, 188], ["nitrogen", "TREATMENT", 168, 176], ["chlorine", "TREATMENT", 180, 188]]], ["Figure 1 shows a graphical breakdown by chemical class of the total number of metabolites isolated during this thirty-seven year period.", [["a graphical breakdown", "PROBLEM", 15, 36], ["graphical breakdown", "OBSERVATION", 17, 36], ["chemical class", "OBSERVATION_MODIFIER", 40, 54]]], ["The diterpenoids, the largest division, are in turn further analyzed and the distribution by skeleton classes of compounds in this group is shown in Figure 2 .", [["diterpenoids", "CHEMICAL", 4, 16], ["diterpenoids", "OBSERVATION_MODIFIER", 4, 16], ["largest", "OBSERVATION_MODIFIER", 22, 29], ["division", "OBSERVATION_MODIFIER", 30, 38], ["distribution", "OBSERVATION_MODIFIER", 77, 89], ["compounds", "OBSERVATION_MODIFIER", 113, 122]]], ["For instance, the traditional clear dominance of cembranoid metabolites has been reduced significantly during the late 4608 A.D. RODRIGUEZ 1980's and early 1990's with the discoveries of numerous diterpenoids of the asbestinane and briarane classes.A. Pterogorgia (Xiphigorgia)anceps (Pallas)They now represent, respectively, the second and third most frequently found types of diterpenoids in gorgonians from this region.", [["cembranoid", "CHEMICAL", 49, 59], ["asbestinane", "CHEMICAL", 216, 227], ["briarane", "CHEMICAL", 232, 240], ["cembranoid", "CHEMICAL", 49, 59], ["diterpenoids", "CHEMICAL", 196, 208], ["asbestinane", "CHEMICAL", 216, 227], ["briarane", "CHEMICAL", 232, 240], ["diterpenoids", "CHEMICAL", 378, 390], ["cembranoid", "SIMPLE_CHEMICAL", 49, 59], ["asbestinane", "SIMPLE_CHEMICAL", 216, 227], ["briarane", "SIMPLE_CHEMICAL", 232, 240], ["A. Pterogorgia", "ORGANISM", 249, 263], ["Xiphigorgia)anceps", "ORGANISM", 265, 283], ["gorgonians", "CANCER", 394, 404], ["A. Pterogorgia", "SPECIES", 249, 263], ["Xiphigorgia)anceps", "SPECIES", 265, 283], ["cembranoid metabolites", "PROBLEM", 49, 71], ["diterpenoids in gorgonians", "PROBLEM", 378, 404], ["cembranoid metabolites", "OBSERVATION", 49, 71], ["reduced", "OBSERVATION_MODIFIER", 81, 88], ["significantly", "OBSERVATION_MODIFIER", 89, 102], ["diterpenoids", "OBSERVATION", 378, 390]]], ["A number of these compounds have offered special opportunities for advancing basic science and laying a foundation for new research.", [["advancing basic science", "TREATMENT", 67, 90]]], ["Most marine scientists are now convinced about the defensive roles of these compounds and many suspect that they may have contributed to the evolutionary success of the producing organisms (the ecological roles of the majority of these compounds, however, have yet to be clearly dermed).", [["the producing organisms", "PROBLEM", 165, 188]]], ["Moreover, metabolites isolated from West Indian gorgonians are frequently the subjects of biochemical and biosynthetic investigations.", [["biosynthetic investigations", "TEST", 106, 133]]], ["Some of these compounds have already found application as probes for new mechanisms of action, and a selected few may soon be found under development as pharmaceutical agents (i.e. the pseudopterosins are currently in clinical evaluation for topical skin diseases and fuscosides A (91) and B (92) are of possible interest.", [["skin", "ANATOMY", 250, 254], ["skin diseases", "DISEASE", 250, 263], ["pseudopterosins", "SIMPLE_CHEMICAL", 185, 200], ["skin", "ORGAN", 250, 254], ["B (92)", "GENE_OR_GENE_PRODUCT", 290, 296], ["pharmaceutical agents", "TREATMENT", 153, 174], ["clinical evaluation", "TEST", 218, 237], ["topical skin diseases", "PROBLEM", 242, 263], ["skin", "ANATOMY", 250, 254], ["diseases", "OBSERVATION", 255, 263]]], ["At this time, however, there are no other compounds isolated from West Indian gorgonians in preclinical study or in clinical evaluation).", [["other compounds", "PROBLEM", 36, 51], ["preclinical study", "TEST", 92, 109], ["clinical evaluation", "TEST", 116, 135]]], ["235 The majority of the species of gorgonians listed by Bayer (about 80%) 1 are not easily available as chemical targets, since they are either extremely rare or occur very deep.", [["gorgonians", "ORGANISM", 35, 45], ["majority", "OBSERVATION_MODIFIER", 8, 16]]], ["As a result, the emphasis of those already involved in the isolation of new compounds and those who may choose to enter this field, should inevitably move to the study of gorgonians that are rare or difficult to collect.", [["gorgonians", "DISEASE", 171, 181], ["gorgonians", "CANCER", 171, 181], ["the study", "TEST", 158, 167]]], ["The emphasis on new directions is well justified for it is becoming increasingly difficult to find new compounds from those specimens that are too obvious or easily collected using SCUBA.", [["specimens", "ANATOMY", 124, 133], ["specimens", "CANCER", 124, 133], ["SCUBA", "PROTEIN", 181, 186], ["new compounds from those specimens", "PROBLEM", 99, 133]]], ["Notwithstanding, the recent literature provides confidence that many gorgonian species from the West Indian region will continue to yield fascinating and previously undescribed secondary metabolites with potent pharmacological activity.", [["many gorgonian species", "PROBLEM", 64, 86], ["gorgonian species", "OBSERVATION", 69, 86]]], ["One can comfortably predict not only that the natural products isolated from these marine invertebrates will provide a rich source of biologically active compounds of medicinal importance but, even more importantly, that they will provide models on which to base extensive synthetic programs leading to still more efficacious pharmaceuticals.", [["base extensive synthetic programs", "TREATMENT", 258, 291]]]], "629c38072c1521ed9854ff7d6d5490fd39a13413": [["IntroductionAn unprecedented commitment to developing and producing vaccines against SARS-CoV-2 in record time is underway and new candidates are entering clinical testing almost weekly.", [["SARS", "DISEASE", 85, 89], ["SARS-CoV-2", "ORGANISM", 85, 95], ["SARS-CoV", "SPECIES", 85, 93], ["SARS", "PROBLEM", 85, 89], ["CoV", "TEST", 90, 93], ["clinical testing", "TEST", 155, 171]]], ["The speed at which development is unfolding has led to widespread concern among both health professionals and the public that vital steps may be skipped, in particular the assessment of safety.IntroductionVaccine development has traditionally been a long process taking an average of 10-15 years.", [["the assessment", "TEST", 168, 182], ["IntroductionVaccine", "TREATMENT", 193, 212], ["unfolding", "OBSERVATION", 34, 43]]], ["The vaccine with the shortest timeline from antigen discovery to licensure is the mumps vaccine, which took 4 years.", [["The vaccine", "TREATMENT", 0, 11], ["the mumps vaccine", "TREATMENT", 78, 95]]], ["It is the high financial cost, particularly high-risk advanced clinical development, coupled with the investment in production facilities that has, in part, hampered nimble vaccine responses to emerging infectious diseases.", [["infectious diseases", "DISEASE", 203, 222], ["emerging infectious diseases", "PROBLEM", 194, 222], ["high", "OBSERVATION_MODIFIER", 10, 14]]], ["The desperate need for an Ebola vaccine galvanised us, and in less than 12 months, 12 clinical trials ran the gamut from a \"first in man\" dosing study to a phase III efficacy trial [3] .", [["Ebola", "DISEASE", 26, 31], ["Ebola", "ORGANISM", 26, 31], ["man", "SPECIES", 133, 136], ["an Ebola vaccine", "TREATMENT", 23, 39], ["a phase III efficacy trial", "TREATMENT", 154, 180]]], ["However, while the pre-licensure clinical programme was executed in record time, fragile settings are often ill equipped for post-licensure safety surveillance.Pre-Clinical: Assessment in Animal ModelsPotential vaccine candidates need to be assessed in suitable animals for safety, immunogenicity and efficacy under challenge.", [["licensure safety surveillance", "TEST", 130, 159], ["Assessment", "TEST", 174, 184], ["vaccine candidates", "TREATMENT", 211, 229]]], ["Translating data from any single animal to humans can be problematic as the disease may not mimic human infection accurately, and therefore fail to predict vaccine effects, positive or negative.", [["infection", "DISEASE", 104, 113], ["humans", "ORGANISM", 43, 49], ["human", "ORGANISM", 98, 103], ["humans", "SPECIES", 43, 49], ["human", "SPECIES", 98, 103], ["humans", "SPECIES", 43, 49], ["human", "SPECIES", 98, 103], ["the disease", "PROBLEM", 72, 83], ["human infection", "PROBLEM", 98, 113]]], ["The models for assessing SARS-CoV-2 vaccines include mouse (transgenic for the human ACE2 receptor), hamster, ferret and non-human primates, depending on what question is being asked [6] .", [["SARS", "DISEASE", 25, 29], ["SARS-CoV-2", "ORGANISM", 25, 35], ["mouse", "ORGANISM", 53, 58], ["human", "ORGANISM", 79, 84], ["ACE2", "GENE_OR_GENE_PRODUCT", 85, 89], ["hamster", "ORGANISM", 101, 108], ["ferret", "ORGANISM", 110, 116], ["non-human primates", "ORGANISM", 121, 139], ["human ACE2 receptor", "PROTEIN", 79, 98], ["mouse", "SPECIES", 53, 58], ["human", "SPECIES", 79, 84], ["hamster", "SPECIES", 101, 108], ["ferret", "SPECIES", 110, 116], ["SARS-CoV", "SPECIES", 25, 33], ["mouse", "SPECIES", 53, 58], ["human", "SPECIES", 79, 84], ["hamster", "SPECIES", 101, 108], ["SARS", "TEST", 25, 29], ["CoV-2 vaccines", "TREATMENT", 30, 44], ["the human ACE2 receptor", "TREATMENT", 75, 98]]], ["Studies of earlier SARS vaccines in animals identified two potential safety issues; antibody-dependent enhancement and cellular immunopathology.", [["cellular", "ANATOMY", 119, 127], ["SARS", "DISEASE", 19, 23], ["cellular", "CELL", 119, 127], ["earlier SARS vaccines", "TREATMENT", 11, 32], ["antibody", "TEST", 84, 92], ["dependent enhancement", "PROBLEM", 93, 114], ["cellular immunopathology", "PROBLEM", 119, 143], ["dependent enhancement", "OBSERVATION_MODIFIER", 93, 114], ["cellular immunopathology", "OBSERVATION", 119, 143]]], ["These have not been observed in human studies but flag potential responses for close examination and highlight the importance of selecting vaccine approaches and adjuvants that drive desirable responses [7] .Pre-Licensure: Assessment in HumansClinical studies in humans generally follow three phases.", [["human", "ORGANISM", 32, 37], ["humans", "ORGANISM", 263, 269], ["human", "SPECIES", 32, 37], ["humans", "SPECIES", 263, 269], ["human", "SPECIES", 32, 37], ["humans", "SPECIES", 263, 269], ["human studies", "TEST", 32, 45], ["close examination", "TEST", 79, 96], ["selecting vaccine approaches", "TREATMENT", 129, 157], ["adjuvants", "TREATMENT", 162, 171], ["Assessment in HumansClinical studies", "TEST", 223, 259]]], ["Phase I with 10's (~ 30 to 50) of healthy volunteers assesses the safety, immunogenicity and dose ranging; phase II progresses to 100's of volunteers and assesses safety and immunogenicity; phase III includes 10,000's of volunteers and assesses safety and efficacy.", [["volunteers", "ORGANISM", 42, 52], ["volunteers", "ORGANISM", 139, 149], ["volunteers", "ORGANISM", 221, 231], ["Phase I", "TEST", 0, 7], ["phase III", "TEST", 190, 199]]], ["Normally, these phases progress sequentially after careful assessment of results of each stage before moving to the next.", [["careful assessment", "TEST", 51, 69], ["each stage", "PROBLEM", 84, 94]]], ["In the case of COVID-19 vaccines, as with recent Ebola vaccines, these stages can be expedited without skipping anything thanks to investment and collaboration [2] .", [["Ebola", "DISEASE", 49, 54], ["Ebola", "ORGANISM", 49, 54], ["Ebola", "SPECIES", 49, 54], ["COVID-19 vaccines", "TREATMENT", 15, 32], ["recent Ebola vaccines", "TREATMENT", 42, 63]]], ["Each trial will have an independent drug safety monitoring board and ideally this group will have diverse expertise, including a biostatistician.", [["a biostatistician", "TREATMENT", 127, 144]]], ["For COVID-19 vaccines, it is recommended that there be persons with expertise in rare disease epidemiology.", [["persons", "ORGANISM", 55, 62], ["persons", "SPECIES", 55, 62], ["COVID-19 vaccines", "TREATMENT", 4, 21], ["rare disease epidemiology", "PROBLEM", 81, 106]]], ["A meta-drug safety monitoring board has been established to ensure that highlevel expertise is available to support all drug safety monitoring boards [8, 9] .World Health Organization Global Advisory Committee on Vaccine SafetyEstablished in 1999, this committee of 14 experts from all regions of the world meets twice a year (and when needed) to assess the safety of vaccines.", [["vaccines", "TREATMENT", 368, 376]]], ["They provide independent, authoritative, scientific advice to the World Health Organization (WHO) on vaccine safety issues of global or regional concern.", [["vaccine", "TREATMENT", 101, 108]]], ["In May 2020, the Committee focussed on COVID-19 and discussed potential safety issues that may arise with the new vaccines being developed and deployed under the emergency conditions.", [["the new vaccines", "TREATMENT", 106, 122]]], ["The Committee also considered the work being undertaken by the Coalition for Epidemic Preparedness Innovation-funded Safety Platform for Emergency vACcines (SPEAC), issues around pharmacovigilance preparedness, and safety communication at a time when vaccine hesitancy and misinformation are growing challenges.World Health Organization Global Advisory Committee on Vaccine SafetyThe key conclusions from this first meeting on COVID-19 vaccines was that post-licensure surveillance preparedness at both country and regional levels was urgent and that managing the 'infodemic' was critical, supporting the proposed approach and roadmap to COVID-19 vaccine benefit-risk communication [10] .World Health Organization Strategic Advisory Group of ExpertsThe Strategic Advisory Group of Experts is the principal advisory group to WHO for vaccines and immunisation.", [["Emergency vACcines", "TREATMENT", 137, 155], ["vaccine hesitancy", "TREATMENT", 251, 268], ["COVID-19 vaccines", "TREATMENT", 427, 444], ["COVID", "TEST", 638, 643], ["vaccines", "TREATMENT", 832, 840], ["immunisation", "TREATMENT", 845, 857]]], ["This 15-member group advises WHO on global policies and strategies, from vaccines and technology, research and development, to delivery of immunisation and its linkages with other health interventions.", [["vaccines", "TREATMENT", 73, 81], ["delivery", "TREATMENT", 127, 135], ["immunisation", "TREATMENT", 139, 151], ["other health interventions", "TREATMENT", 174, 200]]], ["For vaccine safety, the Strategic Advisory Group of Experts takes the findings of the Global Advisory Committee on Vaccine Safety and makes recommendations.", [["vaccine safety", "TREATMENT", 4, 18]]], ["The Strategic Advisory Group of Experts are next meeting in October 2020 where COVID-19 vaccines will be considered and recommendations developed.Brighton CollaborationThe Brighton Collaboration is an international collaboration launched in 1999 and tasked with developing definitions and guidelines for potential adverse events following immunisation [11] .", [["COVID-19 vaccines", "TREATMENT", 79, 96], ["potential adverse events", "PROBLEM", 304, 328]]], ["Since 2019, the Brighton Collaboration have had a contract with the Coalition for Epidemic Preparedness Innovation to develop tools to guide developers, regulatory agencies and health authorities through safety evaluations of vaccines developed with new technologies.", [["safety evaluations", "TEST", 204, 222], ["vaccines", "TREATMENT", 226, 234]]], ["This is within the SPEAC project with the objective of harmonising safety assessments with standardised tools and definitions.", [["safety assessments", "TEST", 67, 85], ["standardised tools", "TEST", 91, 109]]], ["Since COVID-19 emerged, they have increased their activities and are developing tools to help us assess COVID-19 vaccines.", [["COVID-19", "DNA", 6, 14], ["COVID", "TEST", 104, 109]]], ["These tools include templates for the different vaccine platforms, and the development of adverse events of special interest (AESIs) likely to be pertinent to COVID-19 vaccines.Standardised Templates and Adverse Events of Special InterestThe SPEAC working groups have developed templates that can be completed by vaccine developers/sponsors that describe the key considerations for risk benefit assessment.", [["templates", "TREATMENT", 20, 29], ["the different vaccine platforms", "TREATMENT", 34, 65], ["adverse events", "PROBLEM", 90, 104], ["COVID-19 vaccines", "TREATMENT", 159, 176], ["Standardised Templates", "TREATMENT", 177, 199], ["Adverse Events", "PROBLEM", 204, 218], ["risk benefit assessment", "TEST", 382, 405]]], ["There are templates for viral vector vaccines [12] , protein vaccines [13] , nucleic acid vaccines [14] and AESIs [15] .", [["nucleic acid", "CHEMICAL", 77, 89], ["nucleic acid", "SIMPLE_CHEMICAL", 77, 89], ["viral vector vaccines", "TREATMENT", 24, 45], ["protein vaccines", "TREATMENT", 53, 69], ["nucleic acid vaccines", "TREATMENT", 77, 98], ["AESIs", "TEST", 108, 113]]], ["An AESI is defined by the Council for International Organizations of Medical Sciences as:Standardised Templates and Adverse Events of Special Interest\"An adverse event of special interest (serious or nonserious) is one of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor could be appropriate.", [["ongoing monitoring", "TEST", 309, 327]]], ["Such an event might require further investigation in order to characterize and understand it.", [["further investigation", "TEST", 28, 49]]], ["Depending on the nature of the event, rapid communication by the trial sponsor to other parties (e.g., regulators) might also be warranted.\" [16] The SPEAC project has developed a list of AESIs for COVID-19 vaccines based on: proven association with immunisation; proven association with a vaccine platform and/or adjuvant relevant to Coalition for Epidemic Preparedness Innovation vaccine development; theoretical concern based on immunopathogenesis; theoretical concern related to viral replication during wild-type disease; and theoretical concern because it has been demonstrated in an animal model with one or more candidate vaccine platforms [16] .", [["wild-type disease", "DISEASE", 508, 525], ["AESIs", "TEST", 188, 193], ["COVID-19 vaccines", "TREATMENT", 198, 215], ["immunisation", "TREATMENT", 250, 262], ["a vaccine platform", "TREATMENT", 288, 306], ["adjuvant", "TREATMENT", 314, 322], ["Epidemic Preparedness Innovation vaccine", "TREATMENT", 349, 389], ["immunopathogenesis", "PROBLEM", 432, 450], ["viral replication", "PROBLEM", 483, 500], ["type disease", "PROBLEM", 513, 525]]], ["These events and the definitions and guidelines on collecting and reporting them will be invaluable to support active safety surveillance and phase IV studies.Regulatory AgenciesRegulatory agencies are tasked with having authority over safety to protect consumers.", [["These events", "PROBLEM", 0, 12], ["active safety surveillance", "TEST", 111, 137], ["phase IV studies", "TEST", 142, 158]]], ["Examples include the US Food and Drug Administration and the European Medicines Agency.", [["Drug Administration", "TREATMENT", 33, 52], ["the European Medicines", "TREATMENT", 57, 79]]], ["Vaccines must be evaluated and approved by a national regulatory authority before they can be used.", [["Vaccines", "TREATMENT", 0, 8]]], ["The US Food and Drug Administration has issued guidance for industry on the development and licensure of vaccines to prevent COVID-19.", [["Drug Administration", "TREATMENT", 16, 35], ["licensure of vaccines", "TREATMENT", 92, 113], ["COVID", "TEST", 125, 130]]], ["It outlines key considerations needed to satisfy the regulators in their assessment of these vaccines.", [["their assessment", "TEST", 67, 83], ["these vaccines", "TREATMENT", 87, 101]]], ["This covers the chemistry, manufacturing, manufacturing facilities, non-clinical data such as toxicology studies and animal models, clinical trials and plans for post-licensure evaluation [17] .", [["non-clinical data", "TEST", 68, 85], ["toxicology studies", "TEST", 94, 112], ["animal models", "TEST", 117, 130], ["post-licensure evaluation", "TEST", 162, 187]]], ["The European Medicines Agency has also issued similar guidance [18] .", [["The European Medicines", "TREATMENT", 0, 22]]], ["These guidelines will also serve as a useful framework for other nations in their decision making.Country-Level Pharmacovigilance Systems and Passive SurveillanceMost countries have a passive surveillance system for recording and reporting on adverse events following immunisation and in turn report to the WHO pharmacovigilance centre in Uppsala, Sweden.", [["a passive surveillance system", "TEST", 182, 211], ["adverse events", "PROBLEM", 243, 257], ["immunisation", "TREATMENT", 268, 280]]], ["The WHO Global Vaccine Safety Blueprint I considers a minimum reporting rate of 10 per 100,000 population for functional adverse events following an immunisation surveillance system [19] .", [["functional adverse events", "PROBLEM", 110, 135], ["an immunisation surveillance system", "TREATMENT", 146, 181]]], ["However, while safety capacity has improved in many low-and middle-income countries, others still face challenges with low detection rates and reporting, the investigation of safety signals, lack of epidemiological tools for active surveillance, challenges at the national regulatory authority level, and a lack of information sharing between countries.", [["low detection rates", "PROBLEM", 119, 138], ["active surveillance", "TEST", 225, 244], ["improved", "OBSERVATION_MODIFIER", 35, 43]]], ["When optimised, these systems have demonstrated their value in detecting unexpected or rare events but limitations such as the lack of a denominator and reliance on voluntary reports mean they cannot be relied on for detection and they cannot be used for causality assessment.", [["these systems", "TEST", 16, 29], ["rare events", "PROBLEM", 87, 98], ["causality assessment", "TEST", 255, 275]]], ["There are also significant deficiencies in global-level reporting with over half of the total reports in 2017 received from the USA, UK, France, China and the Republic of Korea [21] .", [["significant deficiencies", "PROBLEM", 15, 39], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["deficiencies", "OBSERVATION", 27, 39], ["global", "OBSERVATION_MODIFIER", 43, 49]]], ["These limitations will clearly limit or prevent the generation of COVID-19 vaccine-related safety signals in most countries.Active Safety Surveillance and Phase IV StudiesSome countries have systems that can monitor events in at least some of their population in near real time and map to vaccine exposure.", [["COVID-19", "CHEMICAL", 66, 74], ["COVID-19 vaccine", "TREATMENT", 66, 82], ["Phase IV Studies", "TEST", 155, 171]]], ["A larger number of countries can assess potential safety events retrospectively.", [["larger", "OBSERVATION_MODIFIER", 2, 8]]], ["Examples of advanced systems include the US Vaccine Safety Datalink [22, 23] and the European ADVANCE [24] .", [["advanced systems", "PROBLEM", 12, 28], ["the US Vaccine", "TREATMENT", 37, 51]]], ["The ADVANCE project has led to a sustainability project called VAC4EU, which will support the European Medicines Agency-funded COVID-19 vaccine monitoring programme called ACCESS.", [["the European Medicines", "TREATMENT", 90, 112]]], ["While these systems have demonstrated their ability to undertake robust assessments, they are not globally representative, are restricted to locally used vaccines, and the population sizes under observation lack the power to assess very rare events such as Guillain-Barre Syndrome.", [["Guillain-Barre Syndrome", "DISEASE", 257, 280], ["Guillain-Barre", "ORGANISM", 257, 271], ["robust assessments", "TEST", 65, 83], ["vaccines", "TREATMENT", 154, 162], ["very rare events", "PROBLEM", 232, 248], ["Guillain-Barre Syndrome", "PROBLEM", 257, 280], ["Barre Syndrome", "OBSERVATION", 266, 280]]], ["These collaborations pull multiple countries together to conduct studies on huge numbers of people using administrative data and can compare the risks for very rare events between vaccinated and unvaccinated people.", [["people", "ORGANISM", 92, 98], ["people", "ORGANISM", 208, 214], ["people", "SPECIES", 92, 98], ["people", "SPECIES", 208, 214], ["administrative data", "TEST", 105, 124], ["very rare events", "PROBLEM", 155, 171]]], ["Such collaborations have occurred in the past, pooled data from several countries were used to assess measles-containing vaccines and aseptic meningitis and idiopathic thrombocytopenic purpura [26, 27] , rotavirus vaccines and intussusception [28] , and the pandemic influenza vaccine and Guillain-Barre syndrome and narcolepsy [29] .", [["meningitis", "DISEASE", 142, 152], ["idiopathic thrombocytopenic purpura", "DISEASE", 157, 192], ["intussusception", "DISEASE", 227, 242], ["influenza", "DISEASE", 267, 276], ["Guillain-Barre syndrome", "DISEASE", 289, 312], ["narcolepsy", "DISEASE", 317, 327], ["rotavirus", "ORGANISM", 204, 213], ["Guillain-Barre", "ORGANISM", 289, 303], ["pandemic influenza vaccine", "SPECIES", 258, 284], ["Guillain-Barre syndrome", "SPECIES", 289, 312], ["measles-containing vaccines", "TREATMENT", 102, 129], ["aseptic meningitis", "PROBLEM", 134, 152], ["idiopathic thrombocytopenic purpura", "PROBLEM", 157, 192], ["rotavirus vaccines", "TREATMENT", 204, 222], ["intussusception", "PROBLEM", 227, 242], ["the pandemic influenza vaccine", "TREATMENT", 254, 284], ["Barre syndrome", "PROBLEM", 298, 312], ["narcolepsy", "PROBLEM", 317, 327], ["aseptic meningitis", "OBSERVATION", 134, 152], ["idiopathic", "OBSERVATION_MODIFIER", 157, 167], ["thrombocytopenic purpura", "OBSERVATION", 168, 192], ["Barre syndrome", "OBSERVATION", 298, 312]]], ["However, all these studies were ad hoc, with no sustainable network in place.", [["all these studies", "TEST", 9, 26]]], ["The capacity exists globally to assess vaccine safety.", [["vaccine safety", "TREATMENT", 39, 53]]], ["The development of this capacity is critical for the ongoing assessment of COVID-19 vaccine safety but as yet lacks investment [25] .Challenges and Solutions for the Safe and Responsible Deployment of COVID-19 VaccinesToo few countries have high functioning pharmacovigilance systems, and far fewer are able to undertake robust signal verification and post-licensure studies on safety.", [["this capacity", "PROBLEM", 19, 32], ["the ongoing assessment", "TEST", 49, 71], ["COVID-19 vaccine safety", "TREATMENT", 75, 98], ["COVID-19 Vaccines", "TREATMENT", 201, 218], ["post-licensure studies", "TEST", 352, 374]]], ["Adverse events will coincide temporally with vaccine administration [30] .", [["Adverse events", "PROBLEM", 0, 14], ["vaccine administration", "TREATMENT", 45, 67]]], ["Prior to the use of COVID-19 vaccines, it is important to understand the background rates of conditions that may be temporally associated with vaccine administration to be able to assess observed rates vs the expected rates [31] .", [["COVID-19 vaccines", "TREATMENT", 20, 37], ["vaccine administration", "TREATMENT", 143, 165]]], ["For most events, these rates are unknown and to further complicate matters the rates of many events, such as multiple sclerosis, vary by sex and geography [32, 33] .", [["multiple sclerosis", "DISEASE", 109, 127], ["these rates", "TEST", 17, 28], ["many events", "PROBLEM", 88, 99], ["multiple sclerosis", "PROBLEM", 109, 127], ["multiple", "OBSERVATION_MODIFIER", 109, 117], ["sclerosis", "OBSERVATION", 118, 127]]], ["Developing background rates for COVID-19 vaccine AESIs for as many populations as possible is a matter of urgency.Challenges and Solutions for the Safe and Responsible Deployment of COVID-19 VaccinesDeploying any new vaccine based on data from expedited clinical trials into a population without a functioning safety monitoring system in place is reckless and irresponsible given the tools that are available.", [["COVID-19 vaccine AESIs", "TREATMENT", 32, 54], ["urgency", "PROBLEM", 106, 113], ["COVID-19 Vaccines", "TREATMENT", 182, 199], ["any new vaccine", "TREATMENT", 209, 224], ["a functioning safety monitoring system", "TEST", 296, 334]]], ["While there are international collaborations aimed at supporting coordinated efforts in COVID-19 vaccine safety assessments, vaccine nationalism and a lack of a globally coordinated vaccine safety effort could limit the potential in this space.", [["COVID-19 vaccine", "TREATMENT", 88, 104], ["safety assessments", "TEST", 105, 123], ["vaccine nationalism", "TREATMENT", 125, 144], ["a globally coordinated vaccine", "TREATMENT", 159, 189]]], ["Furthermore, deployment of vaccines before the successful completion of robust clinical programmes could threaten not only public confidence in COVID-19 vaccines but also immunisation programmes in general.Challenges and Solutions for the Safe and Responsible Deployment of COVID-19 VaccinesWhile the clinical testing of COVID-19 vaccines can be done robustly and assessment by regulatory agencies can be stringent, the vaccines are likely to be used under emergency conditions and the follow-up time from the trials will be minimal.", [["vaccines", "TREATMENT", 27, 35], ["COVID-19 vaccines", "TREATMENT", 144, 161], ["immunisation programmes", "TREATMENT", 171, 194], ["COVID-19 Vaccines", "TREATMENT", 274, 291], ["the clinical testing", "TEST", 297, 317], ["COVID-19 vaccines", "TREATMENT", 321, 338], ["assessment", "TEST", 364, 374], ["the vaccines", "TREATMENT", 416, 428]]], ["Under such conditions, it is vital that the products are monitored (in near real time) for rare adverse events until risks can be either quantified or excluded (see Box for a case study).", [["rare adverse events", "PROBLEM", 91, 110], ["a case study", "TEST", 173, 185]]], ["Only a few countries have the capability to conduct this monitoring [34] and even fewer are prepared with systems at the ready and baseline rates of AESIs established.Challenges and Solutions for the Safe and Responsible Deployment of COVID-19 VaccinesThere is an urgency to support as many sites as possible to prepare in collaboration with each other to actively monitor COVID-19 vaccines as they are deployed using common protocols so that data may be pooled, and rare events assessed in diverse populations.Challenges and Solutions for the Safe and Responsible Deployment of COVID-19 VaccinesWe have the tools to intensively monitor the safety of COVID-19 vaccines.", [["this monitoring", "TEST", 52, 67], ["AESIs", "TEST", 149, 154], ["COVID-19 Vaccines", "TREATMENT", 235, 252], ["COVID-19 vaccines", "TREATMENT", 373, 390], ["common protocols", "TREATMENT", 418, 434], ["rare events", "PROBLEM", 467, 478], ["COVID-19 Vaccines", "TREATMENT", 579, 596], ["COVID-19 vaccines", "TREATMENT", 651, 668], ["few", "OBSERVATION_MODIFIER", 7, 10]]], ["While billions are being spent on the development and scale manufacturing of vaccines that have yet to demonstrate efficacy, with the exception of the European Union, there is limited investment in the post-licensure phase yet, which is inexpensive in comparison.", [["scale manufacturing of vaccines", "TREATMENT", 54, 85], ["the post-licensure phase", "TEST", 198, 222], ["inexpensive", "OBSERVATION_MODIFIER", 237, 248]]], ["Failure to assess these vaccines for safety to our full ability is wrong.", [["Failure", "PROBLEM", 0, 7], ["these vaccines", "TREATMENT", 18, 32]]], ["As we well know from extensive experience, vaccine safety issues can threaten not only the success of any COVID-19 vaccine programme but also routine immunisation programmes.", [["vaccine", "TREATMENT", 43, 50], ["any COVID-19 vaccine programme", "TREATMENT", 102, 132], ["routine immunisation programmes", "TREATMENT", 142, 173]]], ["It is vital we get this right and we have the tools and the expertise to do so and to do it well.Rolling Out a Vaccine with Limited Clinical Data Case Study: The New Zealand MeNZB VaccineDuring the 1990s and into the 2000s, New Zealand had a devastating meningococcal B disease epidemic.", [["meningococcal B disease", "DISEASE", 254, 277], ["meningococcal B", "CANCER", 254, 269], ["a devastating meningococcal B disease epidemic", "PROBLEM", 240, 286], ["devastating", "OBSERVATION_MODIFIER", 242, 253], ["meningococcal B disease", "OBSERVATION", 254, 277]]], ["There was no suitable existing vaccine available, so a tailor-made outer-membrane vesicle vaccine was developed through a collaboration (New Zealand Government, University of Auckland, Norwegian Institute of Public Health, The Institute of Environmental and Research, and industry).", [["outer-membrane vesicle", "ANATOMY", 67, 89], ["suitable existing vaccine", "TREATMENT", 13, 38], ["a tailor-made outer-membrane vesicle vaccine", "TREATMENT", 53, 97], ["no", "UNCERTAINTY", 10, 12]]], ["It was tested in New Zealand in phase I, II and IIb trials then rolled out to the highest risk members of the New Zealand population after only a few thousand people had received the vaccines (for meningococcal vaccines, immunogenicity bridging data may be used for licensure as phase III trials are not feasible because of the rarity of the disease outcome).", [["people", "ORGANISM", 159, 165], ["people", "SPECIES", 159, 165], ["meningococcal", "SPECIES", 197, 210], ["the vaccines", "TREATMENT", 179, 191], ["meningococcal vaccines", "TREATMENT", 197, 219], ["immunogenicity bridging data", "TREATMENT", 221, 249], ["licensure as phase III trials", "TREATMENT", 266, 295], ["the disease outcome", "PROBLEM", 338, 357]]], ["All people in the age group receiving the vaccine who went to hospital were assessed for their vaccine exposure [35] .", [["people", "ORGANISM", 4, 10], ["people", "SPECIES", 4, 10], ["the vaccine", "TREATMENT", 38, 49]]], ["Additionally, a proportion of primary care practices provided data on visits so that exposure to the vaccine could be assessed [36] .", [["the vaccine", "TREATMENT", 97, 108]]], ["Weekly screening occurred against background rates (observed vs expected).", [["Weekly screening", "TEST", 0, 16], ["background rates", "TEST", 34, 50]]], ["An electronic national immunisation register made comparisons between vaccinated and unvaccinated people possible to detect any safety signals.", [["people", "ORGANISM", 98, 104], ["people", "SPECIES", 98, 104]]], ["This happened in near real time and provided high-quality data that provided reassurance about the vaccine's safety profile.", [["reassurance", "TREATMENT", 77, 88], ["the vaccine", "TREATMENT", 95, 106]]]], "PMC7252049": [["IntroductionOn January 7, 2020, a novel coronavirus was isolated from the bronchoalveolar lavage samples of 3 patients suffering from severe pneumonia of unknown cause in Wuhan, China.", [["bronchoalveolar lavage samples", "ANATOMY", 74, 104], ["pneumonia", "DISEASE", 141, 150], ["coronavirus", "ORGANISM", 40, 51], ["bronchoalveolar lavage samples", "ORGANISM_SUBSTANCE", 74, 104], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["a novel coronavirus", "PROBLEM", 32, 51], ["the bronchoalveolar lavage samples", "TEST", 70, 104], ["severe pneumonia", "PROBLEM", 134, 150], ["bronchoalveolar lavage", "OBSERVATION", 74, 96], ["severe", "OBSERVATION_MODIFIER", 134, 140], ["pneumonia", "OBSERVATION", 141, 150]]], ["The 2019-nCoV, as it was initially named, was a novel betacoronavirus belonging to the same family of the pathogens responsible for previous severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks.1 On February 11, 2020, the International Committee on Taxonomy of Viruses announced \u201csevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\u201d as the name of the new virus, and the clinical syndrome caused by SARS-CoV-2 infection was named \u201cCOVID-19\u201d by the World Health Organization (WHO).2 On March 11, 2020, with 118,000 cases in 114 countries and 4,291 deaths, coronavirus disease 2019 (COVID-19) was declared a pandemic.3", [["acute respiratory syndrome", "DISEASE", 148, 174], ["SARS", "DISEASE", 176, 180], ["Middle East respiratory syndrome (MERS) outbreaks", "DISEASE", 186, 235], ["acute respiratory syndrome coronavirus", "DISEASE", 329, 367], ["SARS-CoV-2 infection", "DISEASE", 450, 470], ["deaths", "DISEASE", 598, 604], ["coronavirus disease", "DISEASE", 606, 625], ["SARS-CoV-2", "ORGANISM", 371, 381], ["SARS-CoV-2", "ORGANISM", 450, 460], ["Middle East respiratory syndrome (MERS)", "SPECIES", 186, 225], ["severe acute respiratory syndrome coronavirus", "SPECIES", 322, 367], ["SARS-CoV-2", "SPECIES", 371, 381], ["SARS-CoV-2", "SPECIES", 450, 460], ["the pathogens", "PROBLEM", 102, 115], ["previous severe acute respiratory syndrome", "PROBLEM", 132, 174], ["SARS)", "PROBLEM", 176, 181], ["Middle East respiratory syndrome", "PROBLEM", 186, 218], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 322, 367], ["SARS", "TEST", 371, 375], ["CoV", "TEST", 376, 379], ["the new virus", "PROBLEM", 399, 412], ["the clinical syndrome", "PROBLEM", 418, 439], ["SARS", "PROBLEM", 450, 454], ["CoV-2 infection", "PROBLEM", 455, 470], ["coronavirus disease", "PROBLEM", 606, 625], ["COVID", "TEST", 632, 637], ["a pandemic", "PROBLEM", 655, 665], ["severe", "OBSERVATION_MODIFIER", 141, 147], ["acute", "OBSERVATION_MODIFIER", 148, 153], ["respiratory syndrome", "OBSERVATION", 154, 174], ["Middle", "ANATOMY_MODIFIER", 186, 192], ["respiratory syndrome", "OBSERVATION", 198, 218], ["severe", "OBSERVATION_MODIFIER", 322, 328], ["acute", "OBSERVATION_MODIFIER", 329, 334], ["respiratory syndrome", "OBSERVATION", 335, 355], ["new", "OBSERVATION_MODIFIER", 403, 406], ["virus", "OBSERVATION", 407, 412], ["coronavirus disease", "OBSERVATION", 606, 625]]]], "e296e5134829af1f01ad5840af7a619ecd199aea": [["Title page:Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient.", [["Verapamil", "CHEMICAL", 11, 20], ["status epilepticus", "DISEASE", 49, 67], ["PRES", "DISEASE", 81, 85], ["SARS-Cov-2 infected", "DISEASE", 100, 119], ["Verapamil", "CHEMICAL", 11, 20], ["Verapamil", "SIMPLE_CHEMICAL", 11, 20], ["patient", "ORGANISM", 120, 127], ["patient", "SPECIES", 120, 127], ["Verapamil", "TREATMENT", 11, 20], ["treatment", "TREATMENT", 24, 33], ["refractory status epilepticus", "PROBLEM", 38, 67], ["PRES syndrome", "PROBLEM", 81, 94], ["a SARS", "PROBLEM", 98, 104]]], ["We present the case of a 74-year-old male with an 18-year history of IgG kappa multiple myeloma who received multiple lines of treatment, including carfilzomibdexamethasone every three weeks for the last 8 months.Title page:On April 1 th , 2020, the patient presented to the outpatient clinic with asthenia, dry cough, and fever, so carfilzomib-dexamethasone was not administered.", [["myeloma", "ANATOMY", 88, 95], ["multiple myeloma", "DISEASE", 79, 95], ["carfilzomibdexamethasone", "CHEMICAL", 148, 172], ["asthenia", "DISEASE", 298, 306], ["dry cough", "DISEASE", 308, 317], ["fever", "DISEASE", 323, 328], ["carfilzomib", "CHEMICAL", 333, 344], ["dexamethasone", "CHEMICAL", 345, 358], ["carfilzomibdexamethasone", "CHEMICAL", 148, 172], ["carfilzomib", "CHEMICAL", 333, 344], ["dexamethasone", "CHEMICAL", 345, 358], ["male", "ORGANISM", 37, 41], ["myeloma", "CANCER", 88, 95], ["carfilzomibdexamethasone", "SIMPLE_CHEMICAL", 148, 172], ["patient", "ORGANISM", 250, 257], ["carfilzomib-dexamethasone", "SIMPLE_CHEMICAL", 333, 358], ["patient", "SPECIES", 250, 257], ["IgG kappa multiple myeloma", "PROBLEM", 69, 95], ["multiple lines of treatment", "TREATMENT", 109, 136], ["carfilzomibdexamethasone", "TREATMENT", 148, 172], ["asthenia", "PROBLEM", 298, 306], ["dry cough", "PROBLEM", 308, 317], ["fever", "PROBLEM", 323, 328], ["carfilzomib", "TREATMENT", 333, 344], ["dexamethasone", "TREATMENT", 345, 358], ["IgG kappa", "OBSERVATION_MODIFIER", 69, 78], ["multiple", "OBSERVATION_MODIFIER", 79, 87], ["myeloma", "OBSERVATION", 88, 95], ["cough", "OBSERVATION", 312, 317]]], ["He was diagnosed with severe bilateral pneumonia due to SARS-CoV-2 infection.", [["pneumonia", "DISEASE", 39, 48], ["SARS-CoV-2 infection", "DISEASE", 56, 76], ["He", "ORGANISM", 0, 2], ["CoV-2", "ORGANISM", 61, 66], ["SARS-CoV-2", "SPECIES", 56, 66], ["severe bilateral pneumonia", "PROBLEM", 22, 48], ["SARS", "PROBLEM", 56, 60], ["CoV", "PROBLEM", 61, 64], ["2 infection", "PROBLEM", 65, 76], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["bilateral", "ANATOMY_MODIFIER", 29, 38], ["pneumonia", "OBSERVATION", 39, 48], ["SARS", "OBSERVATION", 56, 60], ["CoV", "OBSERVATION_MODIFIER", 61, 64], ["infection", "OBSERVATION", 67, 76]]], ["Laboratory tests showed ferritin of 4242 ng/ml (30 -400), IL-6 of 85,97 pg/ml (0-7) and lymphocytes of 130 cels/\u00b5L (900-5200).", [["lymphocytes", "ANATOMY", 88, 99], ["ferritin", "GENE_OR_GENE_PRODUCT", 24, 32], ["IL-6", "GENE_OR_GENE_PRODUCT", 58, 62], ["lymphocytes", "CELL", 88, 99], ["ferritin", "PROTEIN", 24, 32], ["lymphocytes", "CELL_TYPE", 88, 99], ["Laboratory tests", "TEST", 0, 16], ["ferritin", "TEST", 24, 32], ["IL", "TEST", 58, 60], ["lymphocytes", "TEST", 88, 99], ["cels", "TEST", 107, 111], ["\u00b5L", "TEST", 112, 114]]], ["He was hospitalized initiating treatment with hydroxichloroquine 200 mg/12 hours, lopinavir/ritonavir 400-100 mg/12 hours, ceftriaxone 2g/24 hours, dexamethasone 20 mg/12 hours and enoxaparin at a prophylactic dose of 40mg/24h.", [["hydroxichloroquine", "CHEMICAL", 46, 64], ["lopinavir/ritonavir", "CHEMICAL", 82, 101], ["ceftriaxone", "CHEMICAL", 123, 134], ["dexamethasone", "CHEMICAL", 148, 161], ["enoxaparin", "CHEMICAL", 181, 191], ["hydroxichloroquine", "CHEMICAL", 46, 64], ["lopinavir", "CHEMICAL", 82, 91], ["ritonavir", "CHEMICAL", 92, 101], ["ceftriaxone", "CHEMICAL", 123, 134], ["dexamethasone", "CHEMICAL", 148, 161], ["enoxaparin", "CHEMICAL", 181, 191], ["He", "ORGANISM", 0, 2], ["hydroxichloroquine", "SIMPLE_CHEMICAL", 46, 64], ["lopinavir", "SIMPLE_CHEMICAL", 82, 91], ["ritonavir", "SIMPLE_CHEMICAL", 92, 101], ["ceftriaxone", "SIMPLE_CHEMICAL", 123, 134], ["dexamethasone", "SIMPLE_CHEMICAL", 148, 161], ["enoxaparin", "SIMPLE_CHEMICAL", 181, 191], ["treatment", "TREATMENT", 31, 40], ["hydroxichloroquine", "TREATMENT", 46, 64], ["lopinavir", "TREATMENT", 82, 91], ["ritonavir", "TREATMENT", 92, 101], ["ceftriaxone", "TREATMENT", 123, 134], ["dexamethasone", "TREATMENT", 148, 161], ["enoxaparin", "TREATMENT", 181, 191]]], ["Initially he remained stable, but despite the treatment his condition worsened quickly, developing severe lymphopenia (30-40 cels/\u00b5L) and severe anemia with haemoglobin of 7,5 g/dl.Title page:On the 15th day of hospitalization, once the infection had partially improved, he suffered two focal aware motor seizures, described as left oculocefalic deviation and clonic movements of the upper left limb, that ceased spontaneously.", [["left oculocefalic", "ANATOMY", 328, 345], ["upper left limb", "ANATOMY", 384, 399], ["lymphopenia", "DISEASE", 106, 117], ["anemia", "DISEASE", 145, 151], ["infection", "DISEASE", 237, 246], ["seizures", "DISEASE", 305, 313], ["upper", "ORGANISM_SUBDIVISION", 384, 389], ["left limb", "ORGANISM_SUBDIVISION", 390, 399], ["the treatment", "TREATMENT", 42, 55], ["severe lymphopenia", "PROBLEM", 99, 117], ["cels", "TEST", 125, 129], ["severe anemia", "PROBLEM", 138, 151], ["haemoglobin", "TEST", 157, 168], ["the infection", "PROBLEM", 233, 246], ["two focal aware motor seizures", "PROBLEM", 283, 313], ["left oculocefalic deviation and clonic movements of the upper left limb", "PROBLEM", 328, 399], ["stable", "OBSERVATION", 22, 28], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["lymphopenia", "OBSERVATION", 106, 117], ["severe", "OBSERVATION_MODIFIER", 138, 144], ["anemia", "OBSERVATION", 145, 151], ["focal", "OBSERVATION_MODIFIER", 287, 292], ["motor seizures", "OBSERVATION", 299, 313], ["left", "ANATOMY_MODIFIER", 328, 332], ["oculocefalic deviation", "OBSERVATION", 333, 355], ["clonic movements", "OBSERVATION", 360, 376], ["upper", "ANATOMY_MODIFIER", 384, 389], ["left limb", "ANATOMY", 390, 399]]], ["At that moment his systolic blood pressure was of 140-150 mmHg, higher than his usual levels of 110-120 mmHg.", [["blood", "ANATOMY", 28, 33], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["his systolic blood pressure", "TEST", 15, 42], ["his usual levels", "TEST", 76, 92]]], ["Following this episode, he presented a new focal motor onset seizure with impaired awareness.", [["seizure", "DISEASE", 61, 68], ["impaired awareness", "DISEASE", 74, 92], ["a new focal motor onset seizure", "PROBLEM", 37, 68], ["impaired awareness", "PROBLEM", 74, 92], ["new", "OBSERVATION_MODIFIER", 39, 42], ["focal", "OBSERVATION_MODIFIER", 43, 48], ["motor onset", "OBSERVATION_MODIFIER", 49, 60], ["seizure", "OBSERVATION", 61, 68]]], ["As he did not recover, progressive doses of antiepileptics were After reviewing the case, infection due to SARS-Cov-2 was proposed as the etiology of the PRES.", [["infection", "DISEASE", 90, 99], ["SARS", "DISEASE", 107, 111], ["PRES", "DISEASE", 154, 158], ["antiepileptics", "TREATMENT", 44, 58], ["infection", "PROBLEM", 90, 99], ["SARS", "PROBLEM", 107, 111], ["Cov", "TEST", 112, 115], ["the PRES", "PROBLEM", 150, 158], ["infection", "OBSERVATION", 90, 99]]], ["The new coronavirus can induce endothelial dysfunction [1] that can damage the blood-brain barrier, making it highly permeable and subsequently causing cerebral edema, the underlying mechanism of PRES.", [["endothelial", "ANATOMY", 31, 42], ["blood-brain barrier", "ANATOMY", 79, 98], ["cerebral", "ANATOMY", 152, 160], ["coronavirus", "DISEASE", 8, 19], ["endothelial dysfunction", "DISEASE", 31, 54], ["cerebral edema", "DISEASE", 152, 166], ["PRES", "DISEASE", 196, 200], ["coronavirus", "ORGANISM", 8, 19], ["endothelial", "CELL", 31, 42], ["blood-", "MULTI-TISSUE_STRUCTURE", 79, 85], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 85, 98], ["cerebral edema", "PATHOLOGICAL_FORMATION", 152, 166], ["The new coronavirus", "PROBLEM", 0, 19], ["endothelial dysfunction", "PROBLEM", 31, 54], ["cerebral edema", "PROBLEM", 152, 166], ["new", "OBSERVATION_MODIFIER", 4, 7], ["coronavirus", "OBSERVATION", 8, 19], ["brain", "ANATOMY", 85, 90], ["cerebral", "ANATOMY", 152, 160], ["edema", "OBSERVATION", 161, 166]]], ["This endothelial dysfunction determines a microvascular disturbance that may produce vasoconstriction, which can influence the development of PRES.", [["endothelial", "ANATOMY", 5, 16], ["microvascular", "ANATOMY", 42, 55], ["endothelial dysfunction", "DISEASE", 5, 28], ["PRES", "DISEASE", 142, 146], ["endothelial", "CELL", 5, 16], ["microvascular", "TISSUE", 42, 55], ["This endothelial dysfunction", "PROBLEM", 0, 28], ["a microvascular disturbance", "PROBLEM", 40, 67], ["vasoconstriction", "PROBLEM", 85, 101], ["PRES", "PROBLEM", 142, 146], ["endothelial", "ANATOMY", 5, 16], ["dysfunction", "OBSERVATION", 17, 28], ["microvascular disturbance", "OBSERVATION", 42, 67], ["vasoconstriction", "OBSERVATION", 85, 101]]], ["In addition, the infection by SARS-CoV-2 can lead to a systemic inflammatory response mediated by proinflamatory cytokines, including TNF alpha.Title page:This motivates endothelial activation, increases vascular permeability and ultimately the cerebral interstitial edema [2] .", [["endothelial", "ANATOMY", 170, 181], ["vascular", "ANATOMY", 204, 212], ["cerebral interstitial edema", "ANATOMY", 245, 272], ["infection", "DISEASE", 17, 26], ["SARS", "DISEASE", 30, 34], ["interstitial edema", "DISEASE", 254, 272], ["SARS-CoV-2", "ORGANISM", 30, 40], ["TNF alpha", "GENE_OR_GENE_PRODUCT", 134, 143], ["endothelial", "CELL", 170, 181], ["vascular", "MULTI-TISSUE_STRUCTURE", 204, 212], ["cerebral interstitial", "PATHOLOGICAL_FORMATION", 245, 266], ["proinflamatory cytokines", "PROTEIN", 98, 122], ["TNF alpha", "PROTEIN", 134, 143], ["SARS-CoV", "SPECIES", 30, 38], ["the infection", "PROBLEM", 13, 26], ["SARS", "PROBLEM", 30, 34], ["a systemic inflammatory response", "PROBLEM", 53, 85], ["proinflamatory cytokines", "PROBLEM", 98, 122], ["TNF alpha", "PROBLEM", 134, 143], ["increases vascular permeability", "PROBLEM", 194, 225], ["the cerebral interstitial edema", "PROBLEM", 241, 272], ["infection", "OBSERVATION", 17, 26], ["systemic", "OBSERVATION_MODIFIER", 55, 63], ["inflammatory", "OBSERVATION", 64, 76], ["proinflamatory cytokines", "OBSERVATION", 98, 122], ["vascular", "ANATOMY", 204, 212], ["cerebral", "ANATOMY", 245, 253], ["interstitial", "ANATOMY_MODIFIER", 254, 266], ["edema", "OBSERVATION", 267, 272]]], ["Finally, carfilzomib has been described as an etiological factor in the appearance of PRES [3] , and probably played a role in our case despite not receiving the last prescribed dose.Title page:To our knowledge, this is the first reported case of PRES on a SARS-CoV-2 infected patient.", [["carfilzomib", "CHEMICAL", 9, 20], ["PRES", "DISEASE", 86, 90], ["PRES", "DISEASE", 247, 251], ["SARS-CoV-2 infected", "DISEASE", 257, 276], ["carfilzomib", "CHEMICAL", 9, 20], ["carfilzomib", "SIMPLE_CHEMICAL", 9, 20], ["SARS-CoV-2", "ORGANISM", 257, 267], ["patient", "ORGANISM", 277, 284], ["patient", "SPECIES", 277, 284], ["carfilzomib", "TREATMENT", 9, 20]]], ["This case has a probable multifactorial origin: the basal treatment with carfilzomib and the elevation of arterial blood pressure, although not substantial, could have created a susceptible environment in which the disease caused by the new coronavirus acted as a trigger.Title page:On the other hand, verapamil, used mainly as a vasodilator, has reported good results on drug-resistant epilepsy as it inhibits P-glycoprotein, increasing the availability of antiepileptic drugs [4] .", [["arterial", "ANATOMY", 106, 114], ["blood", "ANATOMY", 115, 120], ["carfilzomib", "CHEMICAL", 73, 84], ["coronavirus", "DISEASE", 241, 252], ["verapamil", "CHEMICAL", 302, 311], ["epilepsy", "DISEASE", 387, 395], ["carfilzomib", "CHEMICAL", 73, 84], ["verapamil", "CHEMICAL", 302, 311], ["carfilzomib", "SIMPLE_CHEMICAL", 73, 84], ["arterial", "MULTI-TISSUE_STRUCTURE", 106, 114], ["blood", "ORGANISM_SUBSTANCE", 115, 120], ["coronavirus", "ORGANISM", 241, 252], ["verapamil", "SIMPLE_CHEMICAL", 302, 311], ["P-glycoprotein", "PROTEIN", 411, 425], ["the basal treatment", "TREATMENT", 48, 67], ["carfilzomib", "TREATMENT", 73, 84], ["arterial blood pressure", "TEST", 106, 129], ["the disease", "PROBLEM", 211, 222], ["the new coronavirus", "PROBLEM", 233, 252], ["verapamil", "TREATMENT", 302, 311], ["a vasodilator", "TREATMENT", 328, 341], ["resistant epilepsy", "PROBLEM", 377, 395], ["glycoprotein", "TREATMENT", 413, 425], ["antiepileptic drugs", "TREATMENT", 458, 477], ["probable", "UNCERTAINTY", 16, 24], ["multifactorial", "OBSERVATION_MODIFIER", 25, 39], ["basal", "ANATOMY_MODIFIER", 52, 57], ["elevation", "OBSERVATION", 93, 102], ["arterial", "ANATOMY_MODIFIER", 106, 114], ["new", "OBSERVATION_MODIFIER", 237, 240], ["coronavirus", "OBSERVATION", 241, 252]]], ["Moreover, similar drugs such as nimodipine have been used on the prevention of vasospasm secondary to SVCR and PRES [3] .The use of verapamil in J o u r n a l P r e -p r o o f this instance was prompt by the CT images, suggestive of PRES, ceasing the focal status epilepticus with an unequivocal temporal correlation between the administration and the clinical response.Title page:We believe this is the first reported case of verapamil as treatment for refractory epilepsy secondary to PRES.", [["nimodipine", "CHEMICAL", 32, 42], ["vasospasm", "DISEASE", 79, 88], ["SVCR", "DISEASE", 102, 106], ["PRES", "DISEASE", 111, 115], ["verapamil", "CHEMICAL", 132, 141], ["PRES", "DISEASE", 233, 237], ["status epilepticus", "DISEASE", 257, 275], ["verapamil", "CHEMICAL", 427, 436], ["epilepsy", "DISEASE", 465, 473], ["PRES", "DISEASE", 487, 491], ["nimodipine", "CHEMICAL", 32, 42], ["verapamil", "CHEMICAL", 132, 141], ["verapamil", "CHEMICAL", 427, 436], ["nimodipine", "SIMPLE_CHEMICAL", 32, 42], ["verapamil", "SIMPLE_CHEMICAL", 132, 141], ["verapamil", "SIMPLE_CHEMICAL", 427, 436], ["similar drugs", "TREATMENT", 10, 23], ["nimodipine", "TREATMENT", 32, 42], ["vasospasm", "PROBLEM", 79, 88], ["SVCR and PRES", "PROBLEM", 102, 115], ["verapamil", "TREATMENT", 132, 141], ["the CT images", "TEST", 204, 217], ["PRES", "PROBLEM", 233, 237], ["the focal status epilepticus", "PROBLEM", 247, 275], ["verapamil", "TREATMENT", 427, 436], ["treatment", "TREATMENT", 440, 449], ["refractory epilepsy", "PROBLEM", 454, 473], ["PRES", "PROBLEM", 487, 491], ["vasospasm", "OBSERVATION", 79, 88], ["suggestive of", "UNCERTAINTY", 219, 232], ["PRES", "OBSERVATION", 233, 237], ["focal", "OBSERVATION_MODIFIER", 251, 256], ["status epilepticus", "OBSERVATION", 257, 275]]], ["The effectiveness of the prescription in this case may be explained by its vasodilator effect, its adjuvant effect on refractory epilepsy, or a combination of both.", [["epilepsy", "DISEASE", 129, 137], ["its vasodilator effect", "TREATMENT", 71, 93], ["refractory epilepsy", "PROBLEM", 118, 137], ["refractory", "OBSERVATION_MODIFIER", 118, 128], ["epilepsy", "OBSERVATION", 129, 137]]]], "67f40427adfd7f712e114a8f5da4a33158fc9f37": [["~ ECRETORY and many membrane-spanning proteins are translocated across or inserted into the membrane of the endoplasmic reticulum (ER) ~ in a co-translational manner (for review see references 3, 21, 35, 50, and 51).", [["membrane", "ANATOMY", 20, 28], ["membrane", "ANATOMY", 92, 100], ["endoplasmic reticulum", "ANATOMY", 108, 129], ["ER", "ANATOMY", 131, 133], ["membrane", "CELLULAR_COMPONENT", 20, 28], ["membrane", "CELLULAR_COMPONENT", 92, 100], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 108, 129], ["ER", "GENE_OR_GENE_PRODUCT", 131, 133], ["ECRETORY", "PROTEIN", 2, 10], ["membrane-spanning proteins", "PROTEIN", 20, 46], ["ER", "PROTEIN", 131, 133], ["many membrane-spanning proteins", "PROBLEM", 15, 46], ["many", "OBSERVATION_MODIFIER", 15, 19], ["membrane", "OBSERVATION_MODIFIER", 20, 28], ["membrane", "ANATOMY_MODIFIER", 92, 100], ["endoplasmic reticulum", "ANATOMY", 108, 129]]], ["Translocation requires a signal sequence on the nascent polypeptide chain and specific receptors, the signal recognition particle (SRP) and the docking protein (DP) or SRP receptor (1, 2, 6, 18, 19, 32, 33, 38, [46] [47] [48] [49] .", [["signal recognition particle", "GENE_OR_GENE_PRODUCT", 102, 129], ["DP", "GENE_OR_GENE_PRODUCT", 161, 163], ["SRP receptor", "GENE_OR_GENE_PRODUCT", 168, 180], ["nascent polypeptide chain", "PROTEIN", 48, 73], ["specific receptors", "PROTEIN", 78, 96], ["signal recognition particle", "PROTEIN", 102, 129], ["SRP", "PROTEIN", 131, 134], ["docking protein", "PROTEIN", 144, 159], ["DP", "PROTEIN", 161, 163], ["SRP receptor", "PROTEIN", 168, 180], ["a signal sequence", "TEST", 23, 40], ["the nascent polypeptide chain", "TEST", 44, 73], ["SRP receptor", "TEST", 168, 180]]], ["SRP has been shown to interact with polysomes holding nascent preprolactin chains, and it has been proposed that SRP binds to the signal sequence (46) .", [["polysomes", "ANATOMY", 36, 45], ["SRP", "CHEMICAL", 0, 3], ["SRP", "GENE_OR_GENE_PRODUCT", 0, 3], ["polysomes", "CELLULAR_COMPONENT", 36, 45], ["preprolactin", "GENE_OR_GENE_PRODUCT", 62, 74], ["SRP", "CELLULAR_COMPONENT", 113, 116], ["SRP", "PROTEIN", 0, 3], ["preprolactin chains", "PROTEIN", 62, 81], ["SRP", "PROTEIN", 113, 116], ["nascent preprolactin chains", "TREATMENT", 54, 81], ["the signal sequence", "TEST", 126, 145]]], ["When probed in a wheat germ cell free system with prolactin or IgG light chain mRNAs, SRP arrests the peptide elongation after 70-80 amino acids have been polymerized (33, 47, 48) .", [["germ cell", "ANATOMY", 23, 32], ["amino acids", "CHEMICAL", 133, 144], ["amino acids", "CHEMICAL", 133, 144], ["germ cell", "CELL", 23, 32], ["prolactin", "GENE_OR_GENE_PRODUCT", 50, 59], ["IgG light chain", "GENE_OR_GENE_PRODUCT", 63, 78], ["SRP", "GENE_OR_GENE_PRODUCT", 86, 89], ["amino acids", "AMINO_ACID", 133, 144], ["prolactin or IgG light chain mRNAs", "RNA", 50, 84], ["wheat", "SPECIES", 17, 22], ["wheat", "SPECIES", 17, 22], ["prolactin", "TREATMENT", 50, 59], ["IgG light chain mRNAs", "TREATMENT", 63, 84], ["the peptide elongation", "PROBLEM", 98, 120], ["amino acids", "TEST", 133, 144], ["elongation", "OBSERVATION_MODIFIER", 110, 120]]], ["Elongation proceeds after SRP has bound to the DP, which is located in the ER membranes (18, 19, 33) .", [["ER membranes", "ANATOMY", 75, 87], ["SRP", "CHEMICAL", 26, 29], ["SRP", "CELLULAR_COMPONENT", 26, 29], ["DP", "GENE_OR_GENE_PRODUCT", 47, 49], ["ER membranes", "CELLULAR_COMPONENT", 75, 87], ["SRP", "PROTEIN", 26, 29], ["DP", "PROTEIN", 47, 49], ["DP", "ANATOMY_MODIFIER", 47, 49], ["ER membranes", "ANATOMY", 75, 87]]]]}